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Abstract 
Background 
Diabetes mellitus is a common chronic disease and a leading cause of morbidity, 
complications and mortality worldwide. The number of people living with diabetes is 
projected to rise sharply over the forthcoming decades. Diabetes care is complex and 
can overburden clinicians and nurses. There is a need for innovative, flexible and cost-
effective technologies to enable successful diabetes management. This thesis explores 
the opportunities and challenges of the mobile application (app) technology as a 
potential tool to support diabetes care and management. 
Purpose 
The purpose was to develop and evaluate a mobile app that supports healthcare 
professionals (HCPs) in clinical decision-making. 
Methods 
A mixed-methods approach was used following the user-centred design (UCD) 
framework for the design and implementation of all studies. Quantitative and 
qualitative systematic reviews of studies reporting the use of mobile apps to support 
diabetes management were undertaken to identify, appraise and summarise available 
research evidence. An interview study was carried out with diabetes specialist nurses 
(DSNs), to explore their experiences and views, and to identify user requirements for 
apps. Lastly, a guidelines-based mobile clinical decision-support app was developed 
and tested with junior doctors and DSNs in a controlled environment to evaluate its 
usability and impact on adherence to clinical guidelines, and to explore how 
participants experienced the app and their suggestions for improvements. 
Results 
Both reviews found that the existing evidence base for mobile apps is weak and 
inadequate to draw conclusions about the impact of their use as interventions in 
diabetes management. The interview study identified that nurses lack experience in 
using apps in clinical practice, even though they believed it could facilitate and support 
their work. ‘Diabetes & CKD’, a simple mobile decision-support app, has been designed 
and built for the study to assist HCPs in management of patients with diabetes and 
kidney disease and was tested by 39 junior doctors and 3 DSNs. It had no impact on the 
accuracy of decisions. Feedback from participants after the pilot session and usability 
testing indicated a wish to integrate such apps into their clinical practice with a strong 
willingness to use them in the future.  
Conclusions 
Application of UCD methods was efficient as the app was well-accepted by both DSNs 
and junior doctors. Despite the positive views and the strong willingness to use such 
apps, they are not widely used. There is a need to regulate the use of medical apps in 
clinical practice. Further research with rigorous methodology is required upon which 
policymakers and practitioners can base their decision-making.  
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"Healthcare is the last industry that has not adopted digital technology in 
any major way to help deliver its services. And it’s becoming challenging 
for physicians and consumers to actually manage care without those 
digital tools.” David Schlanger, Chief Executive Officer, WebMD, 2015 
 
 
 
   
1 
Overview of thesis 
This section outlines the thesis’ overall aim and objectives. The scope of the thesis and 
the rationale for focusing on mobile applications (apps) specifically are then presented, 
followed by an outline of the thesis structure, which briefly describes the content of 
each chapter. 
Aim and objectives 
Developing the aim and objectives of this thesis was an iterative process, in which the 
objectives evolved while proceeding through the several stages of this research. It 
began with a primary goal of building and testing a mobile app, and the systematic 
review findings shaped the direction of this thesis.  
The overall aim was to explore the potential role and impact of mobile apps in 
management of diabetes, with a particular focus on clinical decision-support.  
The underlying objectives are as follows: 
▪ To identify, appraise and summarise the available research evidence on the 
effectiveness of mobile apps in diabetes care and management through a 
systematic review and meta-analysis 
▪ To identify, appraise and synthesise qualitative research studies exploring 
patients’ and Healthcare Professionals’ (HCPs) use of, and perspectives on, 
mobile apps for diabetes care and management 
▪ To explore the experiences and views of Diabetes Specialist Nurses (DSNs) on 
the use of mobile apps in clinical practice, to identify needs and requirements 
of their use 
▪ To design and develop a mobile, clinical decision-support app for the 
management of patients with diabetes and Chronic Kidney Disease (CKD), 
based on the findings collected in objectives 1, 2, and 3 
▪ To test the developed mobile app in a controlled setting to evaluate its usability 
along with its impact on workflow and adherence to clinical guidelines. 
   
2 
Rationale and scope  
Mobile health (mHealth) is an emerging multidisciplinary field. Solid evidence, based 
on high-quality research, on the impact of mHealth apps in diabetes care is lacking. 
There is a paucity of quality research, i.e. research with robust study design, adequate 
descriptions of methodology and result, statistically-powered sample size and 
protected against bias and inferential errors, concerning the use of mHealth apps in 
diabetes management and their integration in healthcare. This present work aims to 
make a significant contribution to the existing knowledge. Given the potential of 
mobile apps to support diabetes management, this thesis seeks to identify the best 
available evidence on the role of mobile apps in the clinical management of diabetes, 
add new evidence on how diabetes nurses currently use and perceive the use of 
mobile apps in clinical practice, and gather further evidence on the feasibility of the 
developed mobile decision-support app.  
Diabetes was selected as the condition for this thesis for several reasons. Diabetes is 
highly prevalent and costly, and a recent study estimated that the global increase in 
numbers with diabetes from 2011 to 2030 is 50.7%, at an annual growth of 2.7% 
(Whiting et al., 2011). The global trends suggest that increases will continue because of 
population growth, ageing, and rapidly rising numbers of overweight and obese 
people.  The global health expenditure on diabetes treatment and care constitute up 
to 12% of the total expenditure (International Diabetes Federation, 2015). People with 
diabetes require at least double the healthcare resources of their peers without 
diabetes (American Diabetes Association, 1998). Additionally, diabetes care is complex 
(World Health Organization, 2016) as diabetes professionals deal with additional 
information: considering the risk of hypoglycaemia, the side effects of medications, 
comorbid conditions, dyslipidemia, obesity, age, race and gender; all combined to 
make the treatment options and decision-making even more complex (Childs, 2005). In 
particular, HCPs face many challenges in caring for patients with diabetes and 
comorbid conditions. Clinical decision-making is specifically challenging in this 
population because clinicians have to balance the evidence of benefits and risks along 
with each patient’s preferences. Current individual condition guidelines rarely address 
   
3 
multimorbidities; hence, they can be irrelevant to those with complex treatment 
regimens (Guthrie et al., 2012). For all these reasons, it is vital to find technological 
solutions that may assist HCPs in handling the prevalence and complexity of diabetes. 
Integrating mobile decision-support into a complex care workflow such as diabetes 
care is essential to enhance adherence to recommended treatments and to improve 
outcomes for people with diabetes.  
In an effort to improve the quality of care and safety of this population, an interactive 
mobile-based decision-support app for the management of patients with Type 2 
diabetes (T2D) and CKD was developed, primarily for research purposes at this stage. 
The selection of CKD was informed by the patterns of comorbidity that are most 
common in this population (Deshpande et al., 2008). Nearly three quarters of people 
with diabetes will develop some stage of kidney disease (Diabetes UK, 2016a). A more 
complex version of the app, including all the common comorbidities of diabetes, 
especially major micro- and macro-vascular complications, is planned for development 
and testing in the future. Based on the intended scope of this thesis, mobile apps 
referred to throughout this thesis are limited to those developed for, and used on, 
smart devices, i.e. smartphones, iPods and tablets (not ordinary cellular phone-based 
systems).  
Thesis structure 
The thesis has 10 chapters organised as follows: 
Chapter 1 provides an overview of the key areas relevant to the wider context of the 
thesis. It introduces the reader to diabetes status nationally and globally, the use of 
information technology (IT) to support and enhance the management of diabetes and 
the increasing global adoption of mobile devices. This will be followed by a summary of 
the potential of mobile technology in diabetes management with emphasis on the 
health and medical apps market. 
Chapter 2 presents a brief background to the potential use of mobile apps in diabetes 
care including self-management, remote monitoring and clinical practice. Then, a 
summary of previous research conditions and limitations, particularly all identified 
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related systematic reviews, is presented. The chapter concludes with a summary of the 
main issues associated with mobile apps found in the literature.  
Chapter 3 describes the background to the research methodology undertaken in the 
thesis. The User-Centred Design (UCD) framework is applied to guide the development 
and structure of thesis objectives and how best to address them. The selected mixed-
methods approach is then presented, with the rationale for the choice of quantitative 
and qualitative data collection methods.  
Chapter 4 outlines the methods for the systematic reviews: the research design, the 
reviews’ aims, objectives and rationale. The methods are then presented in three 
sections: criteria for considering studies for the reviews, search methods for 
identification of studies, and data collection and analysis.  
The following two Chapters (5 & 6) elaborate on the results and discussion of the 
quantitative and qualitative systematic reviews, respectively. Both chapters state the 
review aims and objectives, followed by a description of the data analysis strategy. The 
results are then presented and described, including a summary of included studies, 
their quality assessment, and the findings. The discussion includes a comparison with 
other reviews, strengths, limitations and implications of the review, and suggestions 
for future research.  
Chapter 7 presents the interview study methods and results, beginning with the study 
aim and objectives, and the research design and setting. Next, the ethics and research 
governance approval are described. The chapter then outlines the eligibility criteria, 
sampling and recruitment of participants, interview process and data analysis 
approach. This is followed by describing the results and discussion, including a 
summary of participant characteristics and the key themes identified. The chapter 
finishes with a comparison with other relevant studies, methodological strengths and 
weaknesses, and implications of the study results are discussed. 
Chapter 8 provides a brief description of the design and development of the mobile 
app ‘Diabetes & CKD’. This begins with an outline of the rationale for the app design, 
along with functional and non-functional design requirements. This is followed by a 
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description of the development process including the decision algorithms. The chapter 
concludes with a demonstration of the final implemented design of the app. 
The evaluation of the developed mobile app is reported in Chapter 9. It begins with a 
statement of the study’s aim and objectives, followed by research design and setting, 
ethical considerations, eligibility criteria, sampling and recruitment of participants, 
evaluation process and the data analysis approach. The second half of the chapter 
reports the results and discussion, including a summary of participant characteristics, 
followed by a summary of findings. Lastly, methodological strengths and weaknesses 
and the implications of the study results are discussed. 
Finally, the thesis concludes with Chapter 10, which brings together a summary of 
main findings of the thesis with a general discussion. This chapter then explains how 
the results from this thesis contributed to the field. It then considers the limitations 
and challenges of the research. The chapter ends with future plans and the thesis’ 
conclusions. 
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Chapter 1  Introduction  
Chapter overview 
This chapter describes the current state of key areas relevant to the wider context of 
the thesis. It introduces the reader to diabetes status nationally and globally, the use 
of IT to support and enhance management of diabetes, and the increasing global 
adoption of mobile devices. This will be followed by a summary of the potential of 
mobile technology in diabetes management with emphasis on health and medical apps 
market. 
1.1 Diabetes prevalence and influence worldwide and in the UK  
1.1.1 Diabetes in general 
Diabetes is a lifelong condition in which the blood glucose (BG) level is high as a result 
of a problem in insulin production. There are three main types: Type 1 diabetes (T1D), 
Type 2 diabetes (T2D) and Gestational diabetes (GDM). Treatment for diabetes aims to 
keep BG at normal or near-normal levels (4.0–7.0 mmol/L when fasting), and to reduce 
risk factors for developing complications, e.g. unhealthy diet, physical inactivity, 
overweight and obesity, smoking, infections and other environmental influences 
(International Diabetes Federation, 2015). 
Diabetes is one of the most common chronic diseases worldwide (International 
Diabetes Federation, 2015). The World Health Organization (WHO) estimated that 
worldwide, 422 million adults had diabetes in 2014 and 1.5 million died from it in 
2012, when it was the 8th leading cause of death (World Health Organization, 2016). 
Diabetes is a public health problem occurring in all countries regardless of their level of 
development, and its prevalence and burden to patients, families and governments is 
increasing worldwide (International Diabetes Federation, 2015). 
The International Diabetes Federation (IDF) was initiated to raise awareness of the 
increased prevalence of diabetes (International Diabetes Federation, 2015). The IDF 
recommends a management programme to provide effective diabetes care by 
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encouraging patient involvement in their treatment (International Diabetes 
Federation, 2015). Diabetes therapy is directed at control rather than cure of diabetes. 
Appropriate management of diabetes requires attention to the education of patients, 
families and communities about self-management and cooperative care skills 
(International Diabetes Federation, 2015). These require the development of 
educational and behavioural interventions and partnership 
between healthcare providers and patients. Therefore, the priority is to ensure that 
cost-effective management approaches, which reduce morbidity and mortality, are 
widely available. 
1.1.2 T2D in the UK 
In the UK, an estimated 4.5 million people have diabetes (Diabetes UK, 2016a). Public 
Health England estimated the average prevalence of diabetes in adults was 9% in 2015 
(Public Health England, 2016). T2D is the most prevalent form of diabetes, accounting 
for 90% of diabetes diagnoses (Diabetes UK, 2016a). Only 37.4% of them meet the 
recommended treatment targets to reduce their risk of developing complications 
(Diabetes UK, 2016a). Diabetes UK further projected that 5 million people in England 
are at high risk of developing T2D (Diabetes UK, 2016a). 
1.1.3 Diabetes with multimorbidity 
People with diabetes often also have other conditions (multimorbidity) (Barnett et al., 
2012). There is no standard method for the measurement of multimorbidity, however, 
number of diseases is the most commonly used measure in primary care and 
community settings (Huntley et al., 2012). Multimorbidity has a negative impact on 
patient’s self-management, psychological well-being and quality of life (QoL), and 
considerably increases the use of health services, specifically ambulatory and inpatient 
care (Marengoni et al., 2011; Smith et al., 2012). There is a strong association between 
multimorbidity and age; however, multimorbidity is not limited to older persons 
(Barnett et al., 2012).  
People with diabetes are at increased risk of developing one or more long-term 
complications, including heart disease, stroke, kidney disease, nerve damage, 
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blindness and amputations, which impact on almost every aspect of life (Diabetes UK, 
2016a). Many of these complications are avoidable with regular assessment and 
management (Diabetes UK, 2016a). However, the rate of complications is increasing as 
a result of poor management of diabetes, the ageing population and rising numbers of 
overweight and obese people (Diabetes UK, 2016a). Preventable complications caused 
by diabetes are costly. The UK National Health Service (NHS) annual spend on diabetes 
is nearly 10% of its budget (Diabetes UK, 2016a; Diabetes UK, 2016a) and 80% of NHS 
diabetes spend is for managing avoidable complications (Diabetes UK, 2016a). Good 
diabetes management reduces the incidence of complications, enhances health-
related QoL and reduces hospitalisations (World Health Organization, 2016). 
Therefore, good management of diabetes has great potential to improve diabetes care 
and reduce costs. 
To date, the number of epidemiological studies on multimorbidity in diabetes is limited 
(Luijks et al., 2012). Most randomised trials focus on a single condition and exclude 
multimorbid people (Salisbury, 2012). Additionally, clinical guidelines are essentially 
established for single diseases rather than multimorbidity (Guthrie et al., 2012). 
Although guidelines have an important role in diabetes management, co-existing 
chronic conditions may interfere with management in many ways (Luijks et al., 2012). 
Understanding the epidemiology of multimorbidity in diabetes is important to help 
develop future guidelines and design prevention programmes that meet the needs of 
the population, to improve care for people with diabetes and comorbidities (Luijks et 
al., 2012). 
1.2 The potential for IT in diabetes management 
The first step was to consider the wider context of using IT in diabetes management, 
then specifically discuss mobile technology generally and mobile apps particularly. IT 
means using digital technologies (e.g. computers, software and the Internet) to 
transmit, manipulate and store various types of information (Hersh, 2009). Health IT 
(HIT), also called electronic health (eHealth), describes the application of computers 
and technology in healthcare settings (Hersh, 2009).  
   
9 
Attempts to leverage IT in diabetes management go back to the late seventies and 
have shown promising outcomes (Diabetes UK, 2009). The use of IT to support the 
delivery of diabetes care has been widely reported (El-Gayar et al., 2013b). Numerous 
ITs have been found feasible, applicable and effective for diabetes management (Tao & 
Or, 2013). Most healthcare systems recognise the potential for IT to provide quality 
care and support for the growing number of people with diabetes which, in turn, may 
produce clinical and economic benefits.  
IT-enabled diabetes management is categorised according to the user: technologies 
used by providers or by patients. Currently, a wide range of assistive technologies are 
used by patients and providers in many areas of diabetes management. Examples 
include: videoconference systems, interactive educational programmes on computers, 
online diabetes-management resources and social networks for peer support groups; 
with all becoming vital components of quality diabetes care (El-Gayar et al., 2013b). In 
particular, the Internet is one of the most common technologies where numerous 
websites may facilitate patients’ daily diabetes care. Widespread and low cost Internet 
access is reducing geographic, demographic and economic barriers to obtaining health 
and medical assistance tools online.  
Due to changes in population size, age distribution, and ethnic diversity, patients with 
diabetes often fail to receive the recommended care. In England in 2014-2015, less 
than half of persons with diabetes met all the NICE-recommended treatment targets 
for glycated haemoglobin (HbA1c) levels, blood pressure (BP) and lipid control (41% for 
T2D and 19% for T1D) (Diabetes UK, 2016a). Effective communication between 
patients and providers is central to this process and the use of IT can improve the 
quality of care with decreased associated costs (Bellazzi, 2007; Finkelstein & Friedman, 
2000). Two reviews have evaluated the potential benefit of IT in diabetes management 
and found that IT use was associated with an improvement in measures of diabetes 
care including HbA1c, BP and lipids (El-Gayar et al., 2013b; Siriwardena et al., 2012). 
Another review investigated IT to promote access and engagement of people with 
diabetes, and IT increased the frequency of contact between patient and care team 
(Sutcliffe et al., 2011).  
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Although studies of IT have addressed some difficulties with the uptake of these 
interventions (Glasgow et al., 2010), there is, currently, limited evidence documenting 
adverse effects of IT interventions. IT is not intended to replace the role of HCPs; but 
to support and complement healthcare. Clinicians commonly use IT systems and tools, 
including computerised alerts and reminders to care providers, computerised advice on 
drug dosage, diagnostic support, medical calculators and eLearning materials. Use of 
such tools aims to help professionals cope with increased workloads. Particularly, a 
range of computer systems is available to provide help and support for HCPs in 
decision-making in some areas of diabetes management. The concept of decision-
support is highlighted throughout this thesis and, thus, a brief description of decision-
support systems is provided in the section that follows. 
1.2.1 Decision-support systems in diabetes management 
As the specific aim of the thesis is to explore the role of mobile apps in clinical 
decision-support, it was necessary to first define its concept. Decision-support is 
defined as the process of utilising medical information and clinical guidelines to 
convert patient data into decisions and recommendations (Klonoff & True, 2009). 
Computerised Clinical Decision Support System (CDSS) was defined (Wyatt, 2000) as ‘a 
computer program that provides reminders, advice or interpretation specific to a given 
patient at a particular time’. Such systems use the latest medical knowledge along with 
patient data to generate patient-specific advice, allowing clinicians to make informed 
decisions. Most CDSS were designed for use on personal computers (World Health 
Organization, 2011).  
CDSS has been widely used in diabetes management, including providing drug therapy 
recommendations; referral advice to clinicians; follow-up reminders for HbA1c, blood 
lipid measurements and eye examination; and health alerts including hyperglycaemia 
(Boren et al., 2009; Cleveringa et al., 2013; Jeffery et al., 2013). One systematic review 
of 55 clinical trials involving 51 different computer-based CDSS for chronic disease 
management showed some positive benefits including improved care processes and 
patient health (Roshanov et al., 2011). Another systematic review assessed the effects 
of computerised CDSS in ambulatory diabetes management and concluded that CDSS 
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may improve patients’ clinical outcomes, however, the evidence was considered weak 
due to the inconsistency and risk of bias in most included trials (Jeffery et al., 2013). 
Mobile clinical decision-support (mHealth DSS) is the core of the thesis. A brief account 
of mobile DSS is presented in the background chapter (Chapter 2, section 2.1.3.1), 
whereas the following section of this introduction moves on to describe in greater 
detail the adoption of mobile devices.  
1.2.2 Mobile devices market 
Mobile phones have diffused very rapidly with 7.5 billion subscriptions worldwide by 
2016 (Ericsson, 2016). This represents a penetration rate of over 100%, which means 
that there are more mobile subscriptions than the population in many countries, 
primarily due to inactive subscriptions or multiple device ownership (Ericsson, 2016). 
The vast majority of people in all countries own at least a cellular phone. However, 
subscriptions for smartphones continue to increase and currently account for 55% of 
all mobile subscriptions (Ericsson, 2016). 
Compared with cellular phones, smartphones offer more advanced functionalities and 
features such as Internet and email access, installation of a variety of applications, 
global positioning systems (GPS), Bluetooth and Wi-Fi capabilities, high quality 
cameras, powerful processers and operating systems, large internal memories and 
high-resolution touchscreens. Global smartphone ownership approached 43% in 2015, 
up from just 10% in 2011 (Pew Research Center, 2016). There are 3.9 billion 
smartphone users globally in 2016, a figure that is projected to double by 2022 
(Ericsson, 2016). The rate of smartphone adoption is rapidly increasing, even among 
low-income groups (Pew Research Center, 2016). Smartphone ownership is relatively 
high in the UK, with 68% smartphone penetration as demonstrated in Figure 1.1 (Pew 
Research Center, 2016).  
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Figure 1.1 Global divide on smartphone ownership (Source: Pew Research Centre 2016, p. 16) 
Along with cellular phones and smartphones, people own a range of other mobile 
devices such as iPod Touch, tablet computers (e.g. iPads), and personal digital 
assistants (PDAs). Since the tablet launch in 2010, it was the fastest adopted, with its 
touchscreen, light weight, and blend of smartphone and laptop (Deloitte, 2016). 
Today, roughly two-thirds of people in the UK have access to tablets (65% penetration 
of UK homes) (Deloitte, 2016). Most tablets are likely to have cellular mobile 
connections, which may offer an excellent productivity tool. 
1.2.3 HCPs’ adoption of mobile devices  
After presenting the worldwide figures of various mobile devices’ ownership, the next 
step was to specifically look over the level of mobile devices’ adoption among HCPs in 
clinical setting. HCPs are also adopting mobile devices for patient care, and generally 
have positive attitudes towards their use in the workplace due to their accessibility and 
convenience (Koehler et al., 2013). Around 80% of clinicians are adopting smartphones 
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and tablets and gaining access to mobile-based point-of-care solutions (Moyer, 2013; 
Research2Guidance, 2013). Smartphone ownership and use in clinical setting has been 
well-documented across many medical specialties (Almarri & Bhatti, 2015; Buchholz et 
al., 2016; Hadjipanayis et al., 2016; Jamal et al., 2016; Koehler et al., 2013; Liu et al., 
2016; O'Connor et al., 2014; O’Reilly et al., 2014). Clinicians use mobile technology for 
various tasks, including accessing medical research or drug information (dosage 
calculators, side effects, interactions, etc.) and communicating with nurses and other 
staff (MedData Group, 2014).  
By contrast, nurses have received limited consideration in this digital revolution 
(Sedgwick et al., 2016). Today most nurses still rely on pagers and landline 
communications, which may negatively impact patient care and work efficiency. 
Consequently, around 67% of nurses are using their own smartphones to support 
clinical communications and workflow (SpyGlass Group, 2014). BYOD, short for “bring 
your own device”, is increasingly becoming acceptable in healthcare, even though this 
violates the healthcare regulations and poses major security risks such as cyber-
attacks, data breaches and introduces malware and viruses because organisations do 
not have control of these personal devices and they may not be secured and encrypted 
(Moyer, 2013).  
The potential of various mobile interventions in diabetes management is discussed in 
the following section. 
1.2.4 Mobile health (mHealth) and diabetes management 
Mobile health was first defined by Laxminarayan and Istepanian in 2000, as unwired e-
med (Silva et al., 2015). Later, in 2003, the term mHealth emerged, referring to the use 
of mobile devices to support the practice of medicine and public health (World Health 
Organization, 2011). The WHO considers mHealth as a component of eHealth (World 
Health Organization, 2011). The main goal of mHealth technology is to support the 
delivery and management of healthcare from a distance (Akter & Ray, 2010). mHealth 
is a rapidly evolving field which has great potential to further improve quality, 
efficiency and access to healthcare.  
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The increasing use of mobile devices by clinicians and patients has led to mHealth 
solutions being broadly used in many areas such as health promotion and disease 
prevention, diagnosis, treatment and monitoring (World Health Organization, 2011). 
mHealth solutions are categorised as patient-directed or HCPs-directed solutions. The 
latter do not entail direct interactions with patients but are mainly aimed at increasing 
healthcare workforce efficiency in delivering patient care.  
Chronic conditions including diabetes have noticeably been the focus of mHealth 
research (Ali et al., 2016). Studies of mobile interventions published before 2007 
predominantly used PDAs, whereas studies published in 2007–2012 mainly used 
cellular phones as the moderator to enable data flow between patients and care 
providers (Ali et al., 2016). Studies in this category used basic phone functions as the 
primary means to manage diabetes, mostly the Short Message Service (SMS) (Holtz & 
Lauckner, 2012; Liang et al., 2011; Liu & Ogwu, 2012). Other mobile intervention 
categories included voice or video calls, cameras, media player, Bluetooth technology, 
Internet and email access (Klasnja & Pratt, 2012).  
Mobile devices are increasingly used by patients with diabetes to access relevant 
information about diabetes and obtain immediate assistance with monitoring their 
own diabetes (Conway et al., 2015; Dobson & Hall, 2015; Humble et al., 2015; Williams 
& Schroeder, 2015). The use of mHealth interventions for diabetes management has 
shown some positive effects; specifically in diabetes self-management (Kitsiou et al., 
2017). However, most interventions relied on text messaging which was examined 
more extensively in the literature and was successful in improving patients’ outcomes 
(Hamine et al., 2015; Kitsiou et al., 2017; Liu & Ogwu, 2012).   
1.2.5 Need for new technology intervention methods 
Nurses spend a lot of time directly caring for patients and are responsible for their 
quality of care. However, nurses face many daily challenges in the hospital setting, e.g. 
increased paper-based documentation and colleague interruptions, yet they are under 
increased pressure to communicate, collaborate and coordinate care. Also, there is 
often a shortage of hospital-based nursing staff; with around 46% of nurses believing 
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the shortage reduces the amount of time spent with patients (Ergotron Healthcare, 
2013). These challenges are expected to increase the risk of errors and reduce the time 
dedicated to direct patient care. A typical ten-hour nursing shift is spent as follows: up 
to 35% on documentation, 21% on care coordination, 19% on patient care, 17% on 
medication administration and 7% on patient assessment (Hendrich et al., 2008). To 
improve healthcare at the point of patient contact, hospitals need to consider ways to 
overcome the challenges and provide HCPs with access to tools to address these 
challenges and deliver top-quality patient care. There are increasing opportunities for 
mobile technology to support healthcare workers in their role and enhance care 
provision for patients with diabetes. Providing HCPs with mobile tools may allow them 
to take action wherever they are, resulting in streamlined productivity and improved 
patient care quality and safety. 
Effective management of diabetes requires multidisciplinary care and self-
management by patients, including frequent monitoring of BG levels, use of oral 
medications or insulin, and adjustment of lifestyle. Mobile technology can potentially 
offer a simple tool for assessing patients’ diabetes control that can be easily applied in 
real life. Some of the distinct features of mobile technology that make it a particularly 
promising platform for health interventions are that it is ubiquitous, primarily 
personal, always available with the person, and context awareness through embedded 
sensors such as GPS location tracking and accelerometer (Klasnja & Pratt, 2012). All of 
these allow users to collect considerable medical, physiological, lifestyle, daily activity 
and environmental data with minimal effort. 
The advent of smartphones and tablets has taken the potential for mHealth to a new 
level. As these devices have become more user-friendly, affordable and powerful, they 
became tools that are widely used to enable clinicians and patients to provide or 
receive healthcare services from anywhere (Finn, 2013). Specifically, mobile 
applications (apps), which are the focus of this thesis, are a major component of 
mHealth today that can deliver tailor-made tools that can benefit both patients and 
HCPs. A large number of apps are free of charge or available at low cost (Arnhold et al., 
2014). Thus, they provide a relatively inexpensive innovative intervention to deliver 
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better care for more people at lower cost. Since 2013, the amount of mHealth 
research directed towards the use of mobile apps on smart devices increased 
substantially, with most studies (57.8%) targeting chronic conditions (Ali et al., 2016). 
Briefly, diabetes complexity and prevalence, current mobile technology penetration, 
and shortage in healthcare workers are the key drivers for mHealth apps uptake in 
diabetes management. A more detailed account of mobile apps is given in the 
following section of this introduction. 
1.3 Current state of mobile apps  
1.3.1 Definition of mobile apps 
There is no standard definition of app found in the literature but in general it refers to 
any form of application on a computing device (Gröger et al., 2013). Therefore, a 
mobile app can be defined as software application designed to be installed and run on 
a mobile device’s operating system and often perform a specific task. They are typically 
available to the public through web-based application distribution markets called App 
Stores, for example, Apple App Store, Google Play (Android), BlackBerry App World, 
Windows App Store and Nokia Ovi Store. For the purpose of this thesis, mobile apps 
may either have one or multiple components that perform specific tasks to support 
diabetes care and management, and limited to those developed for, and used on, 
smartphones, iPods or tablets, rather than ordinary cellular phone-based systems, 
which are outside the scope of this thesis.  
The health and medical apps market is considered in the section below, particularly 
elaborating on the diabetes apps market and medical apps market for professionals. 
1.3.2 mHealth apps market 
As the global market has experienced a tremendous increase in the number of 
smartphone and tablet users, a parallel increase in the number of apps that consumers 
are using on their smart devices has been observed. Downloadable health and medical 
apps for smart devices are a fast-growing element of mHealth. In 2016 there were 
nearly 250,000 medical, health and fitness apps available in major app stores around 
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the world (Fatehi et al., 2017) and only 30% of those apps are targeted at HCPs 
(Research2Guidance, 2013). It was estimated that 500 million people used mobile apps 
for fitness, diet and chronic disease management in 2015 (Hood et al., 2016). 
1.3.3 Diabetes apps market 
Many health-related apps target diabetes (Martinez-Perez et al., 2013), with more 
than 1,100 apps for the operating systems iOS and Android that are specifically 
designed for patients with diabetes and HCPs involved in diabetes care (Garabedian et 
al., 2015; Research2Guidance, 2014). The diabetes segment is the fastest growing in 
the app market (Research2guidance, 2016) and diabetes apps constitute 42.59% of all 
chronic condition apps (MobiHealthNews, 2010). Only 7-8% of diabetes apps are 
provider-directed (Arnhold et al., 2014; Hood et al., 2016). There was a steep increase 
in the annual release of diabetes apps available on the two major app store Apple and 
Google Play, from 6 in 2008, to 267 in 2012, to 656 in 2013 (Arnhold et al., 2014). 
Further, over half (53.7%) were free apps, with €1.90 being the median price for paid 
apps (Arnhold et al., 2014). The average user rating was 3.6 stars (maximum 5), with 
no difference in rating between free and paid apps (Arnhold et al., 2014).   
On the academic side, many studies reviewed app stores to investigate commercially 
available apps for diabetes self-management. Three previous assessments reviewed 
samples of diabetes self-management apps and described issues hindering their 
usability (Arnhold et al., 2014; Demidowich et al., 2012; Househ et al., 2015), with one 
specifically evaluating usability among patients aged 50 or older. It concluded that 
apps were moderate to good in terms of usability (Arnhold et al., 2014). Patients and 
HCPs should be involved in app development to overcome usability issues (Arnhold et 
al., 2014). Another set of reviews was restricted to assessing apps’ functionalities and 
features (Brzan et al., 2016; Caburnay et al., 2015; Chomutare et al., 2011; El-Gayar et 
al., 2013a; Eng & Lee, 2013; Garcia et al., 2011; Hood et al., 2016; Li & 李潔寧, 2014; 
Martinez-Perez et al., 2013; Nie et al., 2016; Tran et al., 2012). One review showed 
that there were still gaps between the evidence-based recommendations and the 
functionalities found in online markets (Chomutare et al., 2011). However, the number 
of an app’s functions was negatively correlated with its usability (Arnhold et al., 2014). 
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Additionally, a recent study examined the content of self-management apps for the 
presence of any of the seven self-management behaviours recommended by the 
American Association of Diabetes Educators (AADE7) (Tomky et al., 2008) and found 
that most diabetes apps do not adhere to more than two AADE7 behaviours (Breland 
et al., 2013). Diabetes-related mobile apps rarely integrate clinical guidelines and best 
practice recommended by diabetes professionals, including the American Diabetes 
Association (ADA) and the IDF (Brandell & Ford, 2013).  
The medical content and safety of commercially-available apps aiming to support 
people with T1D and containing information on safe drinking of alcohol have been 
critically appraised (Tamony et al., 2015). Only ten apps were identified, most of which 
did not meet the minimal educational requirements recommended by clinical 
guidelines (Tamony et al., 2015). None could serve as an intervention to increase 
awareness of alcohol-associated risk among young adults with T1D (Tamony et al., 
2015). In an attempt to explore the likely risks associated with patient-directed 
diabetes apps, the accuracy and clinical suitability of insulin dose calculator apps 
available for iOS and Android have been assessed (Huckvale et al., 2015). Of 46 
calculators found, only one app was free of faults, and these apps may recommend an 
incorrect dose which could harm patients. Hence, HCPs should be very cautious in 
recommending unregulated dose calculator apps to patients (Huckvale et al., 2015). 
Lastly, a review examined the privacy and security standards implemented in diabetes 
apps and found that most analysed apps pose privacy and security threats to users’ 
health data (Knorr et al., 2015). Issues include, but are not limited to, lack of 
encryption, failure to provide privacy policies and the lack of basic input validation 
tests; some recommendations for app stores, app developers and consumers were 
suggested (Knorr et al., 2015). 
Of the apps reviewed, very few are considered comprehensive diabetes self-
management tools. There is a need for quality apps that support self-management 
across all skill areas. Recently, efforts have been made to support end-users in 
selecting trustworthy apps, including a framework to assist HCPs in recommending 
high-quality self-management apps and matching them to users’ needs (Hale et al.). 
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Another novel effort is the development of the Mobile App Rating Scale (MARS), which 
is a reliable and comprehensive quality assessment tool for mHealth apps that can be 
used by researchers, developers and HCPs (Stoyanov et al., 2015).  
1.3.4 Medical apps market for HCPs 
The demographics of the population necessitate the use of tools such as mobile apps 
to support HCPs in their role and enhance care provision for patients with diabetes 
(Kaufman, 2010). A systematic review classified smartphone-based medical apps for 
HCPs according to their functionalities into seven categories (Boulos et al., 2014; Mosa 
et al., 2012):  
1. Disease diagnosis and drug reference 
2. Medical calculators 
3. Clinical decision-support tools 
4. Literature search 
5. Clinical communication 
6. Hospital Information System (HIS) client applications and general healthcare 
applications 
7. Medical education and training  
The first four categories were reported as most useful by HCPs and medical or nursing 
students (Boulos et al., 2014; Mosa et al., 2012). Another recent review examined 
commercially-available apps aimed at HCPs to support hospital prescribing and found 
306 apps; 34% of them are intended for use within clinical practice (Haffey et al., 
2013). Of these identified apps, 68% are paid for, with an average price of £14.25 per 
app (range £0.62–£101.90) (Haffey et al., 2013). However, there was little information 
about any medical or professional involvement in app development (Haffey et al., 
2013).  
Several studies have examined how HCPs are using smartphones and medical apps in 
practice (Koehler et al., 2013; O'Connor et al., 2014). Up to 80% of clinicians and 
medical workers are regularly using medical apps to record and access patient 
information from anywhere, or as disease management and drug administration tools 
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(Research2Guidance, 2013). More than half of nurses who own smartphones or tablets 
have downloaded free or paid-for nursing apps (Springer Publishing, 2013). The main 
reasons for clinicians’ adoption of mHealth apps are time and cost efficiency, 
improving care quality and continuity, and improving communication with patients 
(MedData Group, 2014). Clinicians clearly take advantage of medical app availability to 
enable rapid access to clinical information and communication among clinical staff. The 
use of medical apps among clinicians has a great potential in facilitating their workflow 
and connection with their patients. 
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Chapter 2  Background  
Chapter overview 
This chapter provides a background to potential uses of mobile apps in diabetes care 
including self-management, remote monitoring and clinical practice (critical 
assessment of the literature in Chapters 5 & 6); a summary of previous research 
especially systematic reviews; and a summary of the main issues associated with 
mobile apps found in the literature.  
2.1 Use of mobile apps in diabetes care and management 
mHealth apps are becoming increasingly available and popular, especially for patients 
with long-term conditions, and diabetes was the most investigated condition in mobile 
app research (Martinez-Perez et al., 2013). They offer a highly accessible and cost-
effective approach for delivering quality, tailored care for patients with diabetes, e.g. 
education, management and prevention. However, there is a lack of systematic 
consideration around the impact and safety of using diabetes apps (Goyal & Cafazzo, 
2013; Istepanian, 2015).  
2.1.1 Mobile apps for self-management 
Self-management is the process by which a person develops the skills to manage their 
condition, which involves collecting information, reviewing it, and taking action 
independently. The five key self-management diabetes-specific components are 
education, monitoring, medication/insulin, and adjustments of diet and exercise 
(Baron et al., 2012). Successful self-management requires patient education with 
information and tools that enable active participation in self-care (Baron et al., 2012). 
Technologies have been applied to behaviours including physical activity, diet, 
medication adherence and continuous monitoring, that are facilitated by the 
ubiquitous nature of mobile devices (Baron et al., 2012; Goyal & Cafazzo, 2013), and 
allow patient self-care between provider visits, access to information, data input and 
progress tracking without location restriction.  
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Mobile apps offer low-effort data collection by tools such as electronic diaries, 
medication reminders, calculators for insulin dose/carbohydrate counting, and food 
databases for nutrient optimisation at meals. Often the main goal for diabetes self-
management is to maintain BG levels within the target range, so monitoring BG level is 
the core function in most apps. Self-monitoring of BG reduces HbA1c levels, especially 
for T1D (Tao & Or, 2013). Access to personalised self-management apps supports daily 
self-tracking activities, facilitates adherence and enhances patient involvement 
(Årsand et al., 2012). A recent study provided recommendations for diabetes self-
management app developers (Brzan et al., 2016). However, limited research has 
identified apps as a distinct intervention category for diabetes self-management.  
2.1.2 Mobile apps for remote monitoring 
Remote monitoring is the use of any form of information and communication 
technology (ICT) to enable a patient’s monitoring outside a clinical setting (World 
Health Organization, 2011). The terms telemonitoring, telehealth, telemedicine, 
telecare, teleconsultations and telenursing are interchangeably used in the literature, 
encompassing a wide definition of the delivery and management of healthcare over 
distance (Busey & Michael, 2008). Remote monitoring involves two-way professional-
patient communication; patients capture and send healthcare providers information 
required to facilitate management between scheduled clinic visits, allowing clinicians 
to monitor patients’ control of diabetes and modify care plans accordingly, offering an 
opportunity to improve patient–provider interaction and feedback.  
It especially benefits patients with barriers to healthcare e.g. distance or disability 
(Akter & Ray, 2010), and can improve quality and efficiency of diabetes care (Baron et 
al., 2012). Yet, limited research evaluates mobile apps for remote diabetes monitoring 
(Baron et al., 2012).  
2.1.3 Mobile apps for clinical practice 
The growing prevalence of diabetes will absorb more time from HCPs. Professionals 
should explore the opportunities offered by the use of mobile clinical practice apps, 
and adopt apps as innovative mobile solutions for diabetes management and support 
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(Brandell & Ford, 2013), including clinical communication and workflow, problem-
solving and decision-making in diabetes diagnosis, treatment and prognosis (MedData 
Group, 2014). Nurses, in particular, require applications that assist them to interpret 
and act on patient information rapidly.  
Prior research largely focused on the development and clinical evaluation of patient-
directed mobile diabetes apps (Okazaki et al., 2012), with limited research on apps for 
HCPs. The evidence is not robust, and predominantly used PDAs, although they have 
shown improved access to information, performance and quality of care, evidence-
based decision-making, engagement with learning, and reduced medical errors, (Free 
et al., 2013a; Free et al., 2013b; Guo et al., 2015; Moyer, 2013; Prgomet et al., 2009). 
PDAs are outdated and are being increasingly replaced by smart devices e.g. 
smartphones and tablets.  
This thesis explores the role and impact of introducing a clinical decision-support app, 
outlined here. 
2.1.3.1 Clinical decision-support apps (mHealth DSS) 
Doctors spend nearly 64% of their online time searching for information to support 
clinical decisions (Ventola, 2014). The use of mobile devices for clinical decision-
support allows HCPs to make rapid and more accurate decisions (Ventola, 2014). 
However, global adoption of mobile decision-support systems is low, with few studies 
documenting implementation and evaluation, indicating that this is an emerging field 
within mHealth (World Health Organization, 2011), although one of the most widely-
used categories of medical apps is for clinical decision-support (Boulos et al., 2014; 
Mosa et al., 2012).  
Limited studies have investigated the use and development of decision-support 
systems solely for mobile apps in diabetes care (World Health Organization, 2011). A 
recently-published study has developed a prototype for a clinical decision-support 
application for mobile devices based on the Brazilian guideline for diabetes (Klein et 
al., 2016). The prototype was tested and evaluated by three medical experts, with 
promising results (Klein et al., 2016). The development and use of mHealth DSS for 
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smoking cessation, found that this can be integrated into nurses’ workflow (86% of 
nurses used it and more than 60% perceived it as useful) (Hyun et al., 2013). 
Furthermore, the smoking tool increased patients being screened, helped nurses to 
successfully support patients quit smoking (Cato et al., 2014), helped address health 
disparities, and educated nurses about available resources (Cato et al., 2014). For 
future studies, the authors recommended evaluating the use of smartphone-based 
tools on clinical workflow and patient outcomes (Cato et al., 2014).  
2.2 Critical assessment of related work and relation to my own work 
To set the scene for the thesis, a narrative overview of the literature is presented in 
this section, including how the literature has evolved, the available systematic reviews 
and their limitations.  
A scoping search was undertaken using combinations of a few terms: ‘‘mobile app’’, 
‘‘mobile application’’, or ‘‘smartphone’’, with ‘‘diabetes’’, to explore previous research 
conducted in the field of mHealth apps and diabetes. The aim was to explore existing 
studies and the types of populations, interventions, comparisons and outcomes 
assessed. The initial search revealed that clinical effectiveness studies were 
inconsistent in study design, intervention and the purpose of the intervention. Few 
randomised controlled trials (RCTs) have been completed (Kirwan et al., 2013; Quinn et 
al., 2011), whilst pilot studies with few participants dominated (Årsand et al., 2010; 
Cafazzo et al., 2012a; Tatara et al., 2013b; Waki et al., 2012). The quality of mHealth 
research for diabetes is poor, with only 21% of published studies providing robust 
evidence about the effectiveness of mobile interventions (Garabedian et al., 2015). 
Limited small-scale quantitative efficacy studies evaluate HCPs’ use of mobile apps in 
diabetes care, although studies have become much more numerous from 2014. 
In contrast, several qualitative studies have explored diabetes patients’ perspectives 
and preferences for using mobile apps (Årsand et al., 2008; Frøisland et al., 2011; 
Harris et al., 2010; Waite et al., 2013), including usability (Holtz & Lauckner, 2012; 
Okazaki et al., 2012). Limited research has explored HCPs’ perspectives and intention 
to adopt mobile technology (Holtz & Lauckner, 2012; Okazaki et al., 2012), suggesting 
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that the perceived benefits and value are the primary predictors of physicians’ 
intention to use mobile diabetes monitoring (Okazaki et al., 2012). HCPs’ use and views 
of CDSS on mobile devices have reported positive and negative views related to their 
use in clinical practice (Wan et al., 2012; Weber, 2010). 
2.2.1 Previous systematic reviews and meta-analyses 
Several systematic reviews and meta-analyses on the use of mobile technology to 
support diabetes management were found (Baron et al., 2012; de Jongh et al., 2012; 
El-Gayar et al., 2013b; Frazetta et al., 2012; Herbert et al., 2013; Holtz & Lauckner, 
2012; Krishna & Boren, 2008; Liang et al., 2011; Liu & Ogwu, 2012; Patterson, 2013; 
Saffari et al., 2014; Tao & Or, 2013; Tatara et al., 2009). None of them was particularly 
focused on smartphone or tablet apps. Past reviews on the effectiveness of mobile 
interventions in diabetes care have produced inconsistent results. Additionally, they 
did not distinguish between different modalities of mobile technology i.e. SMS, apps, 
voice calls, games, emails and Internet, despite the differences in the intervention 
components in both diabetes management and the use of technology. Only nine out of 
24 reviews provided robust evidence about the effectiveness of mobile interventions 
and they were mostly focused on text messaging interventions rather than apps 
(Garabedian et al., 2015). Evidence from these reviews is outdated as most included 
studies were published before 2010, with interventions functioning on mobile phones 
and not smartphones or tablets (Garabedian et al., 2015).  
Reviews and meta-analyses published from 2014 are summarised in Table 2.1 and 
Table 2.2, respectively. 
Table 2.1 Identified reviews on the use of mobile apps in diabetes management. 
Study Design Intervention Population 
No. of 
studies 
Result Comments 
(Li & 李
潔寧, 
2014) 
Systematic 
review 
Mobile apps Adults with 
T1D or T2D 
5 RCTs Mixed results, 
with positive 
effects on patient 
outcomes, mainly 
with reductions in 
HbA1c similar to 
usual care 
Did not 
assess the 
quality of 
included 
trials 
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(Wang 
et al., 
2014) 
Integrative 
review 
Smartphone 
interventions 
Adults with 
long-term 
conditions 
16 studies, 
5 for 
diabetes 
With the help of 
apps, patients 
participated in 
their own health 
management 
more effectively, 
felt secure that 
their illnesses 
were closely 
monitored and 
that they were 
taken good care 
of even outside 
the hospital/clinic 
Did not 
assess the 
quality of 
included 
trials 
Most of the 
included 
trials did not 
report power 
calculations 
(Deacon 
& 
Edirippul
ige, 
2015) 
Systematic 
review 
Mobile 
interventions 
Adolescents 
with T1D 
13 studies, 
4 
examined 
mobile 
apps 
Evidence is weak 
for HbA1c, with 
limited quality in 
the included 
studies, and 
mixed result for 
other outcomes 
Most studies 
use text 
messages as 
the 
intervention 
tool 
(Garabe
dian et 
al., 
2015) 
Systematic 
review 
mHealth 
technologies  
Adults with 
T1D or T2D 
20 studies Majority of 
studied 
interventions 
showed short-
term 
improvement on 
primary 
outcomes 
including HbA1c 
Studied 16 
interventions, 
only 9 were 
smartphone-
based but 
were not 
limited to 
apps 
(Majeed-
Ariss et 
al., 
2015) 
Systematic 
review 
Mobile apps Adolescents 
with long-
term 
conditions 
4 studies, 
2 were 
targeted at 
T1D 
Result was 
inconclusive, 
dearth of studies 
and the small 
overall sample 
size emphasizes 
the need for 
future studies 
Two feasibility 
studies that 
have not been 
powered to 
detect 
statistical 
significance 
(Tamony 
et al., 
2015) 
Systematic 
review 
Mobile apps 
to support 
safe drinking 
of alcohol 
Young people 
with T1D 
7 studies There was a 
limited literature 
focusing on the 
specific research 
question with 
mixed results 
Studies either 
used 
qualitative 
approaches to 
explore app 
usability and 
user 
experience or 
focused on 
the features 
and content of 
apps 
   
27 
(Cui et 
al., 
2016) 
Systematic 
review 
Smartphone 
apps  
Adults with 
T2D 
13 RCTs Moderate 
beneficial effect 
on glycaemic 
control and no 
clinically 
relevant effects 
were found on 
BP, serum lipids, 
or weight 
Most included 
studies 
utilised mobile 
phone-based 
systems 
rather than 
apps on smart 
devices 
(Sun et 
al., 
2016) 
Systematic 
review  
Smartphone 
apps  
Adults with 
T1D 
8 studies, 
4 focused 
on stand-
alone apps 
No significant 
improvement in 
HbA1c, but two 
studies indicated 
significant 
improvements in 
adherence to BG 
monitoring 
Conference 
abstract; no 
full text 
review was 
identified 
 
Considered 
both stand-
alone apps 
and apps plus 
text 
messaging 
(Whitehe
ad & 
Seaton, 
2016) 
Systematic 
review 
Mobile apps  Adults with 
long-term 
conditions 
9 RCTs, 5 
addressed 
diabetes 
4 studies 
showed 
statistically 
significant 
improvements in 
HbA1c 
 
(Hood et 
al., 
2016) 
Systematic 
review 
Mobile apps Adults with 
T1D or T2D 
13 studies Some clinical 
benefits but 
mostly tended 
to be 
insignificant due 
to the lack of 
statistical power 
Most studies 
are 
uncontrolled 
with small 
sample sizes 
(Bonoto 
et al., 
2017) 
Systematic 
review 
Mobile apps Adults with 
T1D or T2D 
13 RCTs Moderate 
beneficial effect 
on glycaemic 
control, and no 
significant 
differences 
with respect 
to secondary 
outcomes, but 
positive impacts 
on diabetes 
perception of 
self-care and 
self-efficacy 
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(Kitsiou 
et al., 
2017) 
Overview 
of 
systematic 
reviews 
mHealth 
interventions  
Adults with 
T1D or T2D 
15 
systematic 
reviews 
Mobile 
technology 
interventions 
improve HbA1c 
by as much as 
0.8% for T2D 
and 0.3% for 
T1D, particularly 
in short term 
Most reviews 
had important 
limitations in 
methodologic
al quality 
(Greenw
ood et 
al., 
2017) 
Overview 
of 
systematic 
reviews 
Technology-
enabled 
intervention 
Adults with 
T1D or T2D 
25 
systematic 
reviews 
18 studies 
reported 
significant 
reduction in 
HbA1c 
Reviews 
evaluated 
multiple types 
of technology, 
and mobile 
phones and 
secure 
messaging 
dominated 
The pooled effect size on HbA1c ranged between -0.36% and -0.49% (Table 2.2). This is 
a clinically significant difference, especially because the intervention, in some of the 
included trials, was the mHealth technology alone whereas the control was usual care 
by a clinician. Therefore, the equivalence of outcome would be a good result. mHealth 
apps have a potential role to play when compared to the effect of medications, 
specifically, if they were improved further to give more clinical effect. 
Table 2.2 Identified meta-analyses on the effect of mobile apps on HbA1c (%). 
Study Intervention Population No. of studies Pooled effect size Comments 
(Cui et 
al., 
2016) 
Smartphone 
apps for self-
management 
T2D 6 RCTs -0.40% (CI: -0.69 
to -0.11%; 
p=0.007)  
Most studies utilised 
mobile phone-based 
systems rather than apps 
on smart devices 
(Hou et 
al., 
2016) 
Mobile apps 
for self-
management 
T1D and 
T2D 
14 RCTs T2D: -0.49% (CI: -
0.30 to -0.68%; 
p<0.01) 
 
T1D: -0.36% (CI: -
0.87 to 0.14%; 
p=0.16) 
 
4 studies targeted T1D, 
therefore, inadequate 
data to describe the 
effectiveness of apps  
 
Moderate GRADE of 
evidence 
 
Subgroup analyses 
indicated that younger 
patients were more 
likely to benefit, and the 
effect size was enhanced 
with HCP feedback 
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(Bonoto 
et al., 
2017) 
Mobile apps 
for self-
management 
T1D and 
T2D 
12 RCTs -0.44% (CI: -0.59 
to -0.29%; 
p<0.001) 
Subgroup analysis was 
performed according to 
diabetes type, and both 
subgroups showed 
favourable results of 
HbA1c control to 
intervention compared 
with control  
A systematic review being planned (Huckvale et al., 2011) on the use of mobile apps 
for diabetes self-care aims to examine the clinical, informational, behavioural and 
economical facets. Yet, it is restricted to the aspect of self-management, limited to 
patients’ use and excluded diabetes during pregnancy. 
In regard to HCPs’ use of mobile apps, a systematic review aimed to assess the effect 
of mHealth interventions on healthcare delivery processes (all specialities, not 
specifically diabetes) and concluded that trials investigating mobile interventions for 
HCPs’ support have reported some promising results for clinical management, 
appropriate testing, referral, screening, diagnosis, treatment and triage (Free et al., 
2013b). Another systematic review explored classification of smartphone-based 
healthcare apps (not solely diabetes-related) according to their functionalities, but was 
limited to MEDLINE literature (Mosa et al., 2012). Thus, the use of mobile apps to 
support HCPs involved in diabetes care has not yet been explored in a systematic 
review.   
2.2.2 Limitations of current systematic reviews and meta-analyses 
To date, there is no robust evidence on the effect of mobile apps specifically, rather 
than mobile interventions more generally. Most previous reviews and meta-analyses 
have found inconclusive and heterogeneous evidence of clinical effectiveness or other 
outcomes, and they did not distinguish between the different functionality of mobile 
apps in calculation of the overall effect size.  
Limited reviews specifically focused on smartphone or tablet apps’ effectiveness, as 
distinct from mobile apps, which may include mobile phone-based systems, for 
diabetes management and care. As mHealth is an emerging field, most mobile app 
studies were published after 2013 and, although some existing reviews covered 
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publications up to 2016, they were limited to studies with such robust research design 
as RCTs. Moreover, many included studies in these reviews were published prior to 
2010 when the mHealth industry was significantly different from today, while even 
those published between 2010 and mid-2013 evaluated mobile phone systems rather 
than smartphone or tablet apps.  
Existing systematic reviews largely examined self-management of diabetes, mostly in 
patients with T2D and fewer T1D, but none with GDM. 
Additionally, past reviews have limitations in transparency of methods and rigour. No 
qualitative systematic review was identified that particularly considered the quality 
impact of using mobile apps in diabetes management and care, and no reviews 
considered the cost-benefits of mobile apps. Little is known about the uses of mHealth 
apps by diabetes care-providers since no review considered their use in clinical 
practice and decision-making.  
To conclude, the number, sample size and quality of clinical effectiveness trials so far 
provide inadequate evidence of mobile apps as an effective means of delivering 
healthcare within the care pathways for people with diabetes. All reviews helped to 
enrich the discussion part of the systematic review result reported in Chapters 5. 
The final section of the background chapter addresses issues and concerns about 
existing apps documented in the literature, and the need for regulatory control due to 
new technology.  
2.3 Issues associated with mobile apps in the literature 
There is limited evidence documenting adverse effects of mobile interventions. Yet, 
there have been well-established concerns over the accuracy and safety of the medical 
content of mobile apps (Lewis & Wyatt, 2014). The information source is unclear in 
many apps, which might question the credibility and reliability of those apps and the 
consequences for patient safety, as some may provide patients with conflicting advice 
or incorrect management practice. The National Health Service (NHS) in England has 
launched an online library of approved mobile health apps in response to concerns 
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about the quality of mHealth apps (Boulos et al., 2014). The IMS Institute for 
Healthcare Informatics analysed over 40,000 consumer health apps currently available 
to download from the U.S. Apple App Store, which can be used as a reference to assist 
consumers deciding which app to use (IMS Institute for Healthcare Informatics, 2013). 
Additionally, Lewis & Wyatt have developed a generic risk framework that helps 
consumers and stakeholders assess the potential risks of medical apps (Lewis & Wyatt, 
2014).  
mHealth apps are not regulated by specific guidelines in many countries, raising 
uncertainty about their quality and validity. There is a need to establish appropriate 
regulatory guidelines by government health authorities on mHealth apps for clinical 
use to promote accountability, best practice and quality in patient care. Some 
regulatory bodies do regulate mobile medical apps, e.g. the U.S. Food and Drug 
Administration (FDA) Medical App Guidance (U.S. Food & Drug Administration, 2013), 
for medical apps that convert a mobile platform into a medical device, and the 
European Commission has also issued legislation aiming to certify the compliance of 
medical app developers with those regulations (European Commission, 2010). 
Happtique, a U.S. mHealth solutions company, released a voluntary app certification 
scheme ‘Happtique Health App Certification Program’ (HACP) but only for apps 
available in the U.S. market (Boulos et al., 2014). Considerations regarding safety and 
reliability must be balanced by a timely certification and approval process. Buijink et al. 
proposed a number of strategies that could control the medical app market and 
minimise unnecessary procedures that may hinder app development (Buijink et al., 
2013). 
Further concerns arise around data protection, including the privacy and security of 
health data. The transfer of patient data, electronically, through mobile apps may risk 
hacking or data breaches e.g. if the device is lost or stolen. 
Mobile solutions aim to support and complement healthcare beyond traditional 
settings such as hospitals and clinicians’ offices. However, remote-care technological 
interventions, although not specific to mobile apps, may introduce new risks for 
patients and/or providers. Some possible adverse effects of this technology were 
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discussed by Finkelstein and Friedman (Finkelstein & Friedman, 2000), including the 
following: 
▪ Where manual data input is used, there is a risk of inaccurate data entry and 
the patient taking the wrong action accordingly 
▪ Patient receiving wrong advice or misinterpreting the information and guidance 
▪ Risks related to technical issues of the technology; e.g. limitations of coverage 
area, delayed or lost messages 
▪ Patient inability to use the technology, e.g. due to visual or literacy problems 
▪ Breaking down the healthcare practitioner-patient relationship due to reduced 
contact 
▪ Data generated by remote monitoring may create an additional workload for 
HCPs and increase the proportion of time clinicians spend on daily care. 
Still, compliance can be made possible and some of these risks may be overcome. 
Manual data entry, for example, can be replaced with automatic or wireless 
transmission. Further, basic security safeguarding techniques such as encryption of 
data and appropriate authentication mechanisms can easily be implemented to ensure 
patient safety and confidentiality.  
The development of medical apps is ad-hoc and is often undertaken without involving 
end-users in their design (Boulos et al., 2014). An assessment of expert involvement in 
mHealth app design and development found a low level of medical professionals’ 
involvement in development and content (Subhi et al., 2015). Moreover, it is crucial 
that medical apps are updated when new clinical evidence arises. Therefore, it has 
been suggested that medical apps should be peer-reviewed by clinicians and that the 
established guidelines should be used by app developers and reviewers to ensure their 
quality and reliability. 
A report on mHealth apps classifies the growing health and medical app market into 
three phases: an initial trial phase, a commercialisation phase and an integration phase 
(Research2Guidance, 2013). The current commercialisation phase requires regulations 
on mHealth in order to enter into the integration phase where apps are projected to 
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be integrated into treatment plans and paid for by health insurance companies 
(Research2Guidance, 2013). Medical app regulation is one of the main issues in 
mHealth field that needs to be addressed for mHealth apps to meet their potential and 
become an integral component of healthcare in the future.  
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Chapter 3  Background to thesis methodology 
Chapter overview 
This chapter provides the background to the methodological approach used in this 
thesis: The User-Centred Design (UCD) framework and justification for its use, 
application of the UCD for developing thesis objectives, the mixed-methods approach, 
and quantitative and qualitative data collection methods. 
3.1 Research framework 
mHealth is an interdisciplinary research field, primarily at the intersection of Health 
Sciences and Computer Science. As the goal is to design and develop a mobile app, a 
well-accepted framework widely used in the field of Human-Computer Interaction 
(HCI) was utilised. HCI is a discipline which emerged in the early 1980s. It studies how 
people interface with computers (Lazar et al., 2010). The User-Centred Design (UCD) 
framework is a generic, multi-disciplinary, iterative, user-oriented approach to 
software development (Noyes & Baber, 1999), putting the intended users, their needs 
and requirements at the centre (Gulliksen et al., 2003; Noyes & Baber, 1999). Its 
utilisation in healthcare has gained an increased interest over the years. 
The term User-Centered Design was first coined by Norman and Drapers in 1986 
(Norman & Draper, 1986). Several definitions of UCD have been proposed over the 
years. For instance, a simple definition was proposed by Karat in 1996 (Karat, 1996): 
“For me, UCD is an iterative process whose goal is the development of usable systems, 
achieved through involvement of potential users of a system in system design.” 
Key principles that underlie the UCD process are (Gulliksen et al., 2003): 
▪ The design should be guided from the beginning by understanding users, tasks 
and environments 
▪ Users should be actively involved throughout the entire design and 
development process 
▪ The design is refined by user-centred evaluation 
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▪ The development process is iterative where the software design is modified 
and tested repeatedly 
▪ The resulting design should address the whole user experience 
▪ A multidisciplinary team should be involved throughout the design and 
development process. 
Medical app developers may not fully understand the medical context (Boulos et al., 
2014), and app development may not involve end-users (Boulos et al., 2014). UCD can 
improve design quality and increase user acceptance and usage of the tool (Gulliksen 
et al., 2003). A design process study was considered important in the current thesis to 
guide the design and development of an app that drew upon the clinical experience 
and needs of HCPs.  
The UCD framework involves three key stages of the design process (Gulliksen et al., 
2003). Figure 2.1 illustrates the phases of UCD and the data collection methods in each 
phase.  
1. Requirements gathering: Identify the primary users of the tool, their 
requirements, tasks and the context of use 
2. Design and development: An iterative process of software design and 
development based on the specified user’s needs and requirements; building 
from a simple prototype to complete executable software 
3. Evaluation: User-based assessment of the software usability, functionality, and 
acceptability to gather critical data that feed back into the overall design 
process. 
These stages are repeated until software usability objectives have been attained.   
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Design & 
development
* Executable 
decision-support 
app
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* Controlled 
experiment
* Usability testing
* Satisfaction 
questionnaire
Feedback
Suggestions for 
changes
Requirements 
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* Qualitative 
systematic review
* Semi-structured 
interview
 
 
 
 
 
 
 
 
 
Figure 3.1 User-Centred Design stages as applied in this project with the data collections methods used in each 
stage (Adapted from Gulliksen et al. 2003, p. 5). 
3.1.1 Application of UCD framework for developing thesis objectives 
UCD is a design philosophy which aims to develop software fulfilling users’ 
requirements, without forcing them to change their behaviour to fit around the 
product (Noyes & Baber, 1999). Using the UCD framework to guide the objectives and 
methods ensures that the development of the mobile app is systematic and that the 
results could help further development and evaluation of mobile apps. This section 
describes the application of UCD methods to the process of developing and evaluating 
a decision-support mobile app. Although multiple UCD cycles are needed, only one 
cycle was feasible within the timeframe of this research project. 
Five objectives were developed to address the thesis aim. The first objective was 
devised following the need for a systematic review that was outlined in the 
background chapter (Chapter 2, section 2.2.2). Furthermore, identifying the extent of 
the evidence base concerning mobile apps in diabetes management was proposed as a 
starting point to help further in deciding the purpose and functional specifications of 
the app planned to be developed. This was addressed by carrying out a systematic 
review and meta-analysis.  
  Plan for next 
iteration 
 Initial design 
concept… 
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1. To identify and summarise the available research evidence on the effectiveness 
of mobile apps in diabetes care and management through undertaking a 
systematic review and meta-analysis. 
The guidance provided by the UCD framework concerns the planning, development 
and evaluation stages (Noyes & Baber, 1999). An initial design concept for a mobile 
decision-support app was proposed, with a goal to build an app that is evidence-based, 
user-oriented and well-suited to practice, with high potential for adoption (in this case 
by HCPs). This involves researching about users (HCPs) and their tasks and needs, and 
using the findings to help design and refine the software; investigative methods 
include focus groups and interviews (Noyes & Baber, 1999). The UCD guidance relating 
to the ‘requirements gathering’ stage helped in deciding on the second and third 
objectives, which were addressed using qualitative systematic review, and semi-
structured interview. 
2. To identify and synthesise qualitative research studies that have explored 
patients’ and HCPs’ use of, and perspectives on, mobile apps for diabetes care 
and management 
3. To explore the experiences and views of DSNs on the use of mobile apps in 
clinical practice, with a view to identifying needs and requirements of their use. 
The fourth objective relates to the ‘design & development’ stage and was addressed by 
developing decision pathways and using programming technologies.   
4. To design and develop a mobile, clinical decision-support app for the 
management of patients with diabetes and CKD, based on the findings collected 
in objectives 1, 2, and 3. 
Finally, objective five relates to the ‘evaluation’ stage, and was addressed using a 
randomised controlled experiment, usability testing and a satisfaction questionnaire. 
5. To test the developed mobile app in a controlled setting to evaluate its usability 
along with its impact on workflow and adherence to clinical guidelines. 
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Research methods addressing the objectives are outlined in the next section 
(textbooks referred to as sources are cited at the end of individual paragraphs). 
3.2 Research methods 
3.2.1 Using mixed-methods research design 
There are three empirical components, illustrated in Figure 2.2, using a mixed-methods 
design, as neither quantitative nor qualitative methods are adequate alone (Cameron, 
2009). Qualitative methods are prioritised to understand end-users’ needs and 
experiences (Gulliksen et al., 2003).  
There are a variety of designs for mixed-methods research. Triangulation of methods 
(QUAN + QUAL) is one of the most common approaches, where one method is 
combined with another in attempt to confirm, cross-validate, or discard findings within 
a study. Another approach is the complementary (QUAN + QUAL), which involves 
combining two different methods to seek elaboration, enhancement, or clarification of 
results from one method with results from another. A nested approach (QUAN (qual) 
or QUAL (quan)) involves one method embedded into another giving priority to one 
method to guide the project. This approach is typically used to seek information from 
different levels. An increasingly used approach is the sequential (QUAN      qual or 
QUAL       quan), whereby two or more methods are implemented sequentially, as one 
method is used to facilitate and inform the development of another. This strategy is 
useful when developing and testing a new instrument (Cameron, 2009; Creswell, 2014; 
Pope & Mays, 2006). Therefore, this thesis has applied a combination of 
complementary, sequential and nested designs, where the findings obtained from the 
quantitative and qualitative components assisted in designing and developing the app, 
which then was evaluated both quantitatively and qualitatively. The overall research 
design is demonstrated in Figure 2.2.      
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Figure 3.2 Mixed-methods design applied in this project along with the associated research components. 
3.2.2 Methods of data collection 
The UCD process uses several quantitative and qualitative data collection methods 
(Maguire, 2001), described next with the rationale for their selection and in later 
chapters in greater detail. As UCD falls within HCI, it is crucial to ensure consistency 
with HCI guidance, which further assisted in selecting the most appropriate methods 
to address the objectives (Lazar et al., 2010).  
3.2.2.1 Using quantitative methods  
Quantitative research is used to measure variables, test hypotheses, predict future 
results, or investigate causal relationships. It is an objective approach where the 
researchers take a neutral position in conducting the research. Quantitative methods 
try to answer a clearly-defined question and have a structured, replicable design. 
Quantitative data are in numerical format and, thus, use statistical and mathematical 
methods for analysis. Findings can be generalised across groups of people to explain a 
particular phenomenon (Creswell, 2014; Robson & McCartan, 2016). 
Quantitative research design has been broadly classified into two categories: 
descriptive and experimental. Descriptive studies may include large samples with 
hundreds or thousands of subjects who are usually measured once, with attempt to 
establish associations between variables. Experimental studies involve small samples 
of subjects who are generally measured before and after a particular intervention, to 
establish causality between variables (Creswell, 2014). 
The quantitative methods used in this thesis include systematic review, meta-analysis 
and a randomised controlled experiment. 
(QUAN + QUAL) QUAL ((QUAN (qual)) + QUAL) 
Systematic 
reviews 
Chapters 4 - 6 
Interview 
study 
Chapter 7 
App 
evaluation 
Chapter 9 
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Systematic review & meta-analysis 
A systematic review is a secondary research method that aims to identify, evaluate, 
and summarise all the existing research evidence relevant to a particular research 
question or topic area. It is possible to combine results of separate but similar 
quantitative studies using meta-analysis to produce a more reliable and precise 
numerical estimate of the overall effect of an intervention than from single studies. 
Well-designed systematic reviews are at the top of the traditional hierarchy of 
evidence for intervention studies, and examine the best available research evidence 
about a particular intervention, or identify any gaps in knowledge, and thus suggest 
areas for future research (Glasziou et al., 2001; Tacconelli, 2010). 
However, systematic reviews are more reliable and comprehensive than traditional 
literature reviews (Creswell, 2014), as they follow pre-specified, standardised and 
reproducible methods that limit any potential source of bias. They are typically 
conducted according to a predefined protocol that describes the research question, 
inclusion/exclusion criteria and the search strategy, that aims to detect as much 
relevant literature as possible. Additionally, they use critical appraisal tools to assess 
the quality of evidence in each individual study (Glasziou et al., 2001; Tacconelli, 2010). 
The systematic review for this thesis was carried out following rigorous guidelines for 
undertaking systematic reviews (Higgins & Green, 2011; Tacconelli, 2010). This 
systematic review assessed all the available evidence on mobile apps for diabetes 
management and was not restricted to any study design. However, it was split into two 
systematic reviews, a quantitative review with meta-analysis and a qualitative 
narrative review. The method for both reviews is detailed in Chapter 4, including the 
methods and criteria for identifying and selecting relevant studies, extracting and 
analysing data. 
Randomised controlled experiment 
An ‘experimental’ design tests hypotheses or theories. It is used to assess the 
quantitative impact of introducing a treatment or intervention on an outcome, while 
controlling for all other factors. A controlled experiment is a trial that includes 
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a control group to increase the reliability of the results through direct comparison 
between groups (Creswell, 2014; Lazar et al., 2010).  
One weakness of the experimental design is the inability to control, completely, for all 
other confounders that might influence the outcome. Findings can be misinterpreted 
as the experiment may additionally measure something different. The overall effect 
could exceed the treatment effect. One method to control confounders is to randomly 
assign individuals to groups. Well-designed and executed controlled experiments with 
complete randomisation can give confidence in the findings (Creswell, 2014; Lazar et 
al., 2010).  
The UCD framework supports a range of methods in the ‘evaluation’ stage, mostly 
qualitative (described below) (Maguire, 2001). Other quantitative methods were 
considered in deciding how best to measure the impact of using the app. However, it 
was important to make use of the randomised controlled experiment to ensure 
reliable and valid assessment. The randomised controlled experiment conducted with 
junior doctors, a major group of targeted users, to assess the effect of using the app on 
performance measures, is described in Chapter 9 (section 9.2.1). 
3.2.2.2 Using qualitative methods  
Qualitative research is primarily exploratory. It aims to provide insights into a problem, 
gain an in-depth understanding of a context, or develop hypotheses for potential 
quantitative research. It is a more subjective approach and the results may be 
researcher-dependent. Qualitative methods ask broad questions, focus on meanings 
and the sample size is typically small. The collected data often involve text but may 
also include pictures or observations. Qualitative methods mostly use unstructured or 
semi-structured techniques to generate rich and detailed data. Data analysis mostly 
involves structuring and coding data into groups and themes. Findings can be 
transferred to other contexts or settings (Creswell, 2014; Robson & McCartan, 2016). 
Suitable qualitative approaches for this thesis include qualitative systematic review, 
semi-structured interviews, usability testing and satisfaction questionnaires.  
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Qualitative systematic review 
Traditionally, systematic reviews rely on evidence from quantitative studies only. 
There is an argument around the feasibility of synthesising qualitative evidence despite 
the increasing utilisation of qualitative research in healthcare decision-making 
processes. Consequently, there has been a rise in efforts to include qualitative 
research in systematic reviews when appropriate (Pope & Mays, 2006).  
Qualitative research may be expressed using narrative synthesis (a “story-telling” 
approach), using words and text to summarise and explain the findings from multiple 
quantitative or qualitative studies, one after another (Pope & Mays, 2006; Rodgers et 
al., 2009). Narrative synthesis helps gather insights about the topic area and identify 
key themes that served as evidence, infer user needs and requirements for mobile 
apps in clinical practice, and then use them to inform app design and development. 
Also, narrative synthesis produces straightforward findings that are directly relevant to 
policymakers, practitioners and designers of the interventions (Barnett-Page & 
Thomas, 2009). The method for the qualitative review is outlined in Chapter 4. 
Semi-structured interviews 
Capturing user perspectives in healthcare decision-making is growing in importance. 
Qualitative feedback from potential users is a critical component, which provides 
valuable information on acceptability of interventions, user preferences, requirements, 
barriers and facilitators (Pope & Mays, 2006). The UCD framework was used to select 
the appropriate method for the ‘requirements gathering’ stage. The most commonly-
used UCD methods for requirements gathering are interviews and focus groups to gain 
a more detailed understanding of an area or specific requirements (Maguire, 2001; 
Noyes & Baber, 1999).  
A focus group is a form of interview but in a group context, which allows the collection 
of a broad range of viewpoints from participants within a short time (Lazar et al., 2010; 
Robson & McCartan, 2016). However, scheduling a focus group with DSNs was difficult 
due to constraints of time and location, and participants’ unique points of view can be 
explored in detail using individual interviews. Face-to-face interview with DSNs was 
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chosen to gain insight into individuals’ perceptions, viewpoints and challenges. The 
goal was to obtain a sample of nurses’ needs and preferences for mobile apps within 
their work context and to identify emergent themes to inform the next stage of this 
research. Any possible misunderstandings between the interviewer and the 
participants could be identified and immediately addressed. All the interviews were 
semi-structured and guided by an interview schedule. Semi-structured interviews have 
a flexible structure with a fixed set of open-ended questions in order to allow the 
interviewee’s responses to direct the flow of the interview rather than the questions 
themselves, and to keep the discussions within the boundary of the research objective. 
This is a pragmatic choice, because semi-structured interviewing allows for depth of 
questioning with probing and detailed exploration of individual statements (Lazar et 
al., 2010; Robson & McCartan, 2016). Additionally, one-to-one interviews fit better 
within the busy schedule of nurses. The method for the interview study is outlined in 
Chapter 7. 
Usability testing 
Usability testing is another common method that can be used at the end of a design 
cycle for the ‘evaluation’ stage. It involves inviting a number of end-users to attend a 
testing session and asking them to perform a series of tasks using the design and 
talking aloud as they use it. The session can be audio or video taped and a moderator 
may take notes of any difficulties encountered. It represents an excellent method to 
identify functionality, the most likely usability problems, and user attitudes at early 
stages. Undertaking usability testing in a group setting is considered important to 
create a space that stimulates discussion and elicits ideas, in particular, around the 
app’s design and features. Usability testing requires some form of design to be 
available to test - whether a fully working version of the software or a paper 
prototype. It focuses primarily on gathering verbal feedback on the software 
design. However, collection of numerical performance measures, such as time taken to 
complete a task, is possible during usability testing (Lazar et al., 2010; Noyes & Baber, 
1999).  
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The DSNs tested the app in controlled conditions, performing representative tasks 
using case scenarios, to evaluate the app qualitatively with another group of potential 
users (Chapter 9, section 9.2.3). The nurses were asked to follow the ‘think-aloud’ 
protocol, i.e. verbalise what they are doing while they are doing it. 
Satisfaction questionnaires 
As part of the controlled experiment, participants completed a qualitative 
questionnaire. A questionnaire is a widely used method for the ‘requirements 
gathering’ and ‘evaluation’ stages (Lazar et al., 2010; Noyes & Baber, 1999; Robson & 
McCartan, 2016). 
A satisfaction questionnaire is a type of exploratory questionnaire comprising open-
ended questions to capture users’ subjective impressions following their experiences 
using a piece of software or a prototype. It is often group-administered, typically at the 
end of an experiment, to provide subjective data to complement and support the 
objective data collected. It can be administered on paper or electronically, e.g. online, 
and provides a simple, quick and inexpensive way of obtaining subjective feedback 
from users with a high response rate (Lazar et al., 2010; Maguire, 2001). 
Questionnaires were given to junior doctors who participated in the experimental 
group. They were instructed to complete the questionnaires as comprehensively as 
possible (Chapter 9, section 9.2.2). 
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Chapter 4  Systematic review method 
Chapter overview 
This chapter outlines the methods used in conducting two systematic reviews, 
quantitative and qualitative: research design; aim and objectives; rationale; criteria for 
considering studies for the reviews; search methods for identification of studies; data 
collection and analysis.  
4.1   Research design 
Two systematic reviews were undertaken, a quantitative review with meta-analysis of 
randomised controlled trials (RCTs) and a qualitative review. Their results are 
presented separately in Chapters 5 and 6, respectively.  
The reviews were carried out in conjunction with five co-authors: Dr Paul Sutcliffe, 
academic supervisor; Dr Krishnarajah Nirantharakumar, academic supervisor 
(University of Birmingham); Dr Yen-Fu Chen, Xiaofei Gao and Qing Fang. 
The protocol for the systematic reviews has been completed and registered at the 
PROSPERO website on April 2014 (available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014009211). 
PROSPERO is an international database of registered systematic reviews in health and 
social care funded by the National Institute for Health Research, England, the 
Department of Health, Public Health Agency, Northern Ireland and the National 
Institute for Social Care and Health Research, Welsh Government. 
4.2 Review aim and objectives 
The review’s aim was to systematically assess quantitative and qualitative evidence on 
mobile apps for diabetes care and management, to provide patients, clinicians and 
decision-makers with a robust evidence base concerning the effectiveness and impact 
of mobile apps.  
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The objectives of the quantitative review were to identify, appraise and summarise 
available research evidence on the effectiveness of mobile apps in diabetes care and 
management, identifying outcomes in the literature and areas for further 
consideration. 
The objectives of the qualitative review were to identify, appraise and synthesise 
qualitative research studies that have explored patients’ and HCPs’ use of, and 
perspectives on, mobile apps for diabetes care and management, to identify HCPs’ 
needs and requirements. 
4.3 Rationale for undertaking the two systematic reviews 
A growing body of literature is examining the use of mobile apps in diabetes 
management, making a systematic review of their impact very timely. Due to the rapid 
advances in technology, early mobile devices quickly become out-dated. In this fast-
changing field, existing systematic reviews of mobile apps require updating. The 
rationale for conducting a systematic review with a broad scope of selection criteria 
was due to the scarcity of studies when developing the protocol. The current review: 
▪ Closes gaps within the literature by focusing specifically on smartphone and 
tablet apps and including studies of apps designed to support people with any 
type of diabetes and HCPs 
▪ Provides an up-to-date review, including studies up to December 20151 
▪ Combines evidence from quantitative and qualitative research to strengthen 
and add value to the limited evidence base (Pope & Mays, 2006) 
▪ Avoids the weaknesses in quality found in past reviews by applying a high-
quality and rigorous methodology following the Cochrane Collaboration 
standards for the conduct and reporting of systematic reviews and the Centre 
for Reviews and Dissemination (CRD) guidance for undertaking reviews in 
healthcare (Higgins & Green, 2011; Tacconelli, 2010). 
                                                     
1 An updated search is being conducted and the result will be published (see Chapter 10, Section 10.5) 
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Previous reviews differ from this one by considering a broader definition of mobile 
apps; being limited to patient-directed self-management apps; primarily reviewing 
effects on glycaemic control; and being conducted some years ago. 
4.4 Criteria for considering studies for these reviews  
A complete list of all inclusion and exclusion criteria for study selection is presented in 
Table 4.1. 
4.4.1 Types of studies 
Eligible study designs included: 
▪ Randomised controlled trials (RCTs), including randomised crossover studies 
and cluster randomised trials 
▪ Quasi-experimental studies, including interrupted time series (ITS) studies 
▪ Controlled before and after (CBA) studies 
▪ Observational studies, including cohort, case-control and cross-sectional studies 
▪ Pilot single group studies 
▪ Qualitative studies e.g. interviews, focus groups 
▪ Partially published work, e.g. conference abstracts, only if it was linked to a full-
text report. 
Non-RCTs and pilot studies were included because the initial scoping search revealed 
that most identified trials were small-scale pilot studies, and to understand how 
variations in trial design and duration may influence their results. 
4.4.2 Types of participants 
Eligible populations include: 
1. Individuals with diagnosed diabetes mellitus (T1D, T2D or gestational), or their 
parents or caregivers. Studies examining mobile apps for a broad population of 
patients, e.g. those with chronic diseases, with subgroup analysis for patients 
with diabetes, were included. 
   
48 
2. HCPs involved in diabetes care (e.g. general practitioners (GPs), consultants, 
DSNs and diabetes dieticians). 
No participant was excluded on the basis of any socio-demographic characteristic (e.g. 
age, gender; ethnicity; marital status; geographic location; employment status; 
education; income or health status) in any care setting. 
4.4.3 Types of interventions 
Definition of the intervention 
The intervention (mobile apps) was defined in Chapter 1 (section 1.3.1). 
Studies which examined a broad range of interventions, e.g. ICT-based apps, for 
diabetes management, with subgroup analysis for mobile apps, were included. The 
review was restricted to studies of mobile apps that support one of the following 
aspects: 
1. Telemonitoring: facilitating remote monitoring of patients with HCPs at a 
distance, involving information exchange, i.e. two-way communication 
between patient and provider. Care provider feedback may include (but is not 
limited to) treatment recommendations, medication adjustment, reminders, 
advice, encouragements and corrections to lifestyle. 
2. Self-care: developing or supporting at least one of the seven diabetes self-care 
behaviours as defined by the American Association of Diabetes Educators 
(AADE7) (Tomky et al., 2008): 
a. Healthy eating 
b. Being physically active 
c. Self-monitoring of BG and other biometrics 
d. Medication adherence 
e. Problem solving skills  
f. Risk reduction behaviours and preventive care  
g. Healthy coping skills and maintaining motivation. 
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Apps in this domain may include one or more functions designed to initiate or 
reinforce those behaviours without the help of HCPs at a distance.  
3. Clinical practice: Medical apps that target HCPs engaged in diabetes care in a 
clinical setting. These include apps that provide on-demand, and instant clinical 
support in treatment, diagnosis and decision-making at the point of care, or 
facilitate care coordination between the care team. 
4.4.4 Comparisons 
The review considered studies comparing mobile apps with:  
▪ Usual care or any other control intervention; or 
▪ Other intervention variant.  
Studies without comparators were eligible for inclusion. 
4.4.5 Types of outcome measures 
All reported outcomes related to patients or HCPs were considered. No study was 
excluded based on the reported outcomes. 
Examples of outcomes related to patients include (but are not limited to): 
glycated haemoglobin (HbA1c), BP, cholesterol level, body mass index (BMI), QoL, 
hypoglycaemic episodes, hospital admissions, knowledge, self-efficacy and adherence. 
Examples of outcomes related to HCPs include (but are not limited to): adherence to 
clinical guidelines, prescription errors and time spent with patients. 
Examples of outcomes related to both patients and HCPs include (but are not limited 
to): usability, satisfaction, acceptability, accessibility, preferences, perceptions and 
experiences.  
Outcomes measured at the completion of the intervention or at any subsequent time 
points (follow-up) were included; short-term follow-up was defined as within 30 days 
of the completion of the intervention, medium-term as 30 days–6 months, and long-
term more than 6 months after the completion of the intervention. 
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4.4.6 Settings 
All settings were considered, with no restrictions by country or healthcare system type. 
Table 4.1 Inclusion and exclusion criteria for study selection. 
 Inclusion 
 
Exclusion 
Study design 
▪ RCTs, including randomised 
crossover studies and cluster 
randomised trials; 
▪ Quasi-experimental studies, 
including ITS studies; 
▪ CBA studies; 
▪ Observational studies, including 
cohort, case-control, and cross-
sectional studies; 
▪ Qualitative studies. 
▪ Systematic review/meta-analysis; 
▪ Literature review/review paper; 
▪ Descriptive paper, e.g. studies that 
describe a design or prototype of a 
mobile app with no testing on 
individuals; 
▪ Editorial or commentary paper; 
▪ Conference abstracts with no full-
text report; 
▪ Full-text article was not available. 
Populations 
1. Individuals with diagnosed 
diabetes mellitus (T1D, T2D or 
gestational);  
2. Parent of, or caregiver for, a 
person with diabetes; 
3. HCPs involved in diabetes care 
▪ Individuals with pre-diabetes; 
▪ Medical and nursing students 
Interventions 
Mobile apps that support one of the 
following aspects: Telemonitoring, Self-
care and Clinical practice 
▪ Mobile apps as co-intervention, i.e. 
another primary intervention 
besides the app; 
▪ Mobile apps as a secondary 
intervention or a minor component 
of a broader intervention 
programme; 
▪ Mobile web-based apps that can 
only can be accessed online through 
a web-browser, even though it was 
accessed using a smartphone or 
tablet; 
▪ Mobile apps with adapter attached 
to the smartphone/tablet; 
▪ Artificial Pancreas (AP) technology, 
since this is still under development 
and no AP is commercially available; 
▪ Mobile apps on ordinary 
mobile/cellular phone or if not clear 
whether the app was functioning on 
mobile phone or smartphone; 
▪ Apps on PDAs, netbooks, laptops or 
desktop computers; 
▪ Smartphone-based interventions 
other than apps, e.g. SMS, Internet, 
and social networks; 
▪ Insufficient details of the 
intervention or the trial; 
▪ Mobile apps for medical training or 
continuing medical education; 
▪ Mobile apps for complementary or 
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 Inclusion 
 
Exclusion 
alternative medicine; 
▪ Mobile apps for preventive care. 
Comparisons 
▪ Usual care or any other control 
intervention; 
▪ Other intervention variant; 
▪ No comparison. 
None 
Outcomes 
All outcomes related to patients or 
HCPs  
Technical evaluation, or validation of the 
accuracy of a mobile app 
Settings Any setting None 
4.5 Search methods for identification of studies  
All searches were limited to studies published from 2008, due to the relatively new 
innovation of smart devices and apps. The first-generation Apple iPhone was 
introduced in 2007 and the first mobile app store, the iOS App Store, was launched in 
July 2008 (Gröger et al., 2013). Since then, mobile apps became available to the public 
to download and use. Prior to that, mobile software applications were distributed 
directly by manufacturers.  
4.5.1 Electronic database search 
The following databases and journals were searched for relevant studies from 2008 
onwards: 
▪ The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane 
Library) 
▪ MEDLINE (OVID) 
▪ EMBASE (OVID) 
▪ PsycINFO 
▪ IEEEXplore 
▪ Web of Science 
▪ Journal of Medical Internet Research (JMIR) 
▪ Journal of Mobile Technology in Medicine (JMTM) 
▪ Journal of Diabetes Science and Technology (JDST). 
There were no language restrictions. 
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Initially, a detailed search strategy was devised for MEDLINE and then was adapted as 
appropriate for other databases. The search strategies were checked and refined by an 
academic support librarian. The detailed search strategies and the results for all 
databases and journals are in Appendix 1. 
Auto Alerts was set up to send weekly or monthly updates for new literature in most 
databases.  
4.5.2 Searching other resources   
Grey literature was searched through the following sources:  
▪ Google Scholar 
▪ ProQuest Dissertations 
▪ EThOS - Electronic Theses Online Delivery Service 
▪ DART-Europe Portal 
▪ Conference Proceedings: Conference Papers Index (ProQuest), Papers First, 
Proceedings First, Web of Science Core Collection – Proceedings Paper, Zetoc. 
Also, databases of completed and ongoing trials were searched in the following 
resources (2008-present without language restrictions): 
▪ NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/) 
▪ Current Controlled Trials (http://www.controlled-trials.com/) 
▪ The WHO International Clinical Trials Registry Platform (ICTRP) 
(http://www.who.int/ictrp/en/). 
Grey literature sources only allow for simple and short searches (Appendix 1).  
Additional studies were sought by searching the reference lists of retrieved primary 
trials, systematic reviews and meta-analyses. 
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4.6 Data collection and analysis 
4.6.1 Selection of studies 
To determine the eligibility of studies, one author (HA) assessed all titles and abstracts 
retrieved from electronic searches. A second author (QF) independently assessed a 
random sample comprising 20% of all identified studies due to the vast amount of 
potentially relevant literature. Agreement on inclusion was calculated using the 
Cohen’s kappa statistic to ensure consistency, and disagreement about any particular 
study was resolved by discussion. Next, HA investigated the full-text of all papers 
identified at the abstract sift and the reasons for exclusion were recorded. A third 
author, the academic supervisor (PS), was sought for their opinion about any 
uncertainty about inclusion.  
4.6.2 Data extraction and management 
Two review authors (HA and XG) each extracted data from half the included studies, 
and checked the extraction of the other author’s half for accuracy. Standard data 
extraction templates were used, with any disagreements resolved by discussion and, 
when required, by a third party. In the case of duplicate publications and companion 
papers of a primary study, to maximise yield of information, all available data were 
extracted simultaneously. Examples of data extraction sheets for quantitative and 
qualitative studies are in Appendices 2 and 3, respectively. 
4.6.3 Quality Assessment of included studies  
Quality assessment was independently undertaken by two review authors, HA and XG, 
and were compared, with any disagreements resolved by discussion, or with 
consultation of a third party.  
4.6.3.1 Assessment of risk of bias in included RCTs 
To evaluate the methodological quality of included RCTs, the Cochrane Collaboration’s 
Risk of Bias Tool was used (Higgins & Green, 2011). This method uses the following bias 
criteria: 
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▪ Random sequence generation (selection bias) 
▪ Allocation concealment (selection bias) 
▪ Blinding of participants and personnel (performance/detection bias) 
▪ Blinding of outcome assessors and data analysers (performance/ detection bias) 
▪ Incomplete outcome data (attrition bias) 
▪ Selective outcome reporting (reporting bias) 
▪ Other possible sources of bias, e.g. baseline imbalance, intention-to-treat 
analysis, possible contamination between groups, validity and reliability of 
outcome measures. 
Risk of bias criteria were judged as low, high or unclear risk, using a template. Where 
insufficient information was available about a specific domain, that domain was judged 
as ‘unclear.’ An example of the risk of bias assessment sheet is in Appendix 4. 
The risk of bias was described and illustrated in each study using a 'Risk of bias graph' 
and a ‘Risk of bias summary’ figure. This was followed by an overall assessment of the 
risk of bias for each of the criteria across all included studies with the possible impact 
on the overall effect size. 
4.6.3.2 Quality assessment of other study designs 
A Downs and Black checklist (Downs & Black, 1998) (Appendix 5) was used to assess 
the methodological quality of other quantitative, non-randomised studies (non-RCTs). 
Where a study used a mixed-methods approach, only the quantitative element was 
assessed using this instrument. The validity and reliability of this instrument meet 
accepted standards. The checklist contains 27 items distributed across five sub-scales, 
and provides an overall numeric score for study quality out of a possible 28 points. 
Each item is scored: yes=1, no=0, unable to determine=0, partially=0.5, except one 
item in the reporting subscale, which is scored: yes=2, no=0, unable to determine=0, 
partially=1. The five sub-scales are (Downs & Black, 1998): 
1. Study reporting –10 items to assess if sufficient information was provided in the 
paper to enable unbiased evaluation of findings 
2. External validity –3 items to assess generalisability of findings to the wider 
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population 
3. Internal validity (study bias) –7 items to address potential bias in the 
intervention and outcome measures 
4. Internal validity (confounding) –6 items to address potential selection bias 
5. Power of the study –1 item to determine if the findings are due to chance. 
The assessment for all included non-RCTs is illustrated in a graph with an overall score 
for each study and a profile of scores for all sub-scales, along with commentary about 
each sub-scale.  
4.6.3.3 Quality assessment of qualitative studies  
For the appraisal of qualitative research, the quality criteria defined by Critical 
Appraisal Skills Programme (CASP) was used (Appendix 6). This is a widely-used tool in 
appraising primary qualitative studies. Where a study used a mixed-methods 
approach, only the qualitative element was appraised using this tool. The checklist 
contains ten items to systematically assess a study reporting methodology, reflexivity, 
ethical issues and overall value. There are three possible answers for each item: ‘yes’, 
‘no’, and ‘can’t tell’ but studies were not given a weight based on this assessment 
(Critical Appraisal Skills Programme (CASP), 2013).  
All included studies were assessed and the relative value of insights was described in 
the synthesis process. 
4.6.4 Measures of treatment effect   
Dichotomous data were reported as odds ratios (OR) or risk ratios (RR) with 95% 
confidence intervals (CIs). Continuous data were reported as a mean difference (MD) 
or standardised mean difference (SMD) with 95% CI, depending on whether the 
outcomes were reported on similar measurement scales or not.  
This review looked at a broad range of outcomes to help understand the nature and 
extent of examined outcomes. As the review was carried out, it emerged that 
outcomes have not been measured and reported in a standard way across all studies. 
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Many of the included studies had missing data, poor reporting of data, or uncertainty 
in the treatment effect estimates. 
It was not possible to standardised data for any outcome. Data were used according to 
the study report. 
4.6.5 Dealing with missing data   
Study authors were contacted in order to obtain relevant missing data whenever 
possible, however, none was obtained, so they were calculated, e.g. standard 
deviation (SD) using parametric data such as standard error (SE), CI, and p-values, or 
the interquartile range (IQR) for non-parametric data, using a tool (template in 
Microsoft Excel), comprising formulae presented in the Cochrane Handbook (Higgins & 
Green, 2011), or imputed using baseline and follow-up scores using a formula reported 
in Follmann et al. (Follmann et al., 1992). A statistician was also consulted. 
4.6.6 Assessment of heterogeneity  
Heterogeneity describes differences among studies in a systematic review. There are 
three different types of heterogeneity; clinical, methodological, and statistical. Clinical 
heterogeneity comprises variability in the participants, interventions and the outcomes 
studied; methodological heterogeneity refers to variability in study design and risk of 
bias; and statistical heterogeneity refers to variability in the observed intervention 
effects in the different studies (which may be a consequence of clinical or 
methodological heterogeneity or both) (Higgins & Green, 2011). 
The degree of statistical heterogeneity across studies was identified through 
inspection of the forest plots and employing the I2 statistic (Higgins & Thompson, 2002; 
Higgins et al., 2003), where an I2 statistic greater than 50% indicates a considerable 
level of inconsistency (Higgins & Green, 2011). When heterogeneity was identified, the 
potential reasons for it were sought by examining individual study and subgroup 
characteristics. The impact of clinical, methodological and statistical heterogeneity on 
the review is described in the Chapter 5. 
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4.6.7 Assessment of reporting biases   
Reporting bias arises when the nature and direction of study results influence the 
likelihood of it being disseminated, e.g. publishing only results with positive significant 
findings. This may include, but is not limited to, rejected or delayed publication of 
results and selective reporting of some outcomes in a study.  
To detect reporting biases, a number of strategies were undertaken, including 
searching the trials registries and conference abstracts to identify studies that have 
been registered/presented but not published; and assessment of selective outcome 
reporting. The original study protocol was sought for all included studies to compare 
the reported methods and outcomes against the original plan. If this was not possible, 
and the missing data were suspected to introduce serious bias, a sensitivity analysis 
was used to investigate the impact of excluding such studies from the overall results. 
When appropriate, if 10 or more studies were pooled (Sterne et al., 2011), publication 
bias was assessed through visual inspection of funnel plots with respect to plot 
asymmetry and use of linear regression tests, and a regression slope of zero was 
interpreted as no publication bias. There are a number of explanations for the 
asymmetry of a funnel plot and thus, results should be carefully interpreted (Lau et al., 
2006; Sterne et al., 2001). 
4.6.8 Data synthesis 
4.6.8.1 Meta-analysis 
To pool the effect of the intervention in measures of clinical outcomes in diabetes, 
such as BG control, the study design was restricted to RCTs. Depending on the level of 
heterogeneity; a meta-analysis was conducted for any of the outcome measures 
where at least two studies were identified. Heterogeneity, in terms of study design, 
reported outcomes, outcome measures, intervention function and age group, 
prevented the conduct of meta-analysis for several outcomes. The number of meta-
analyses was determined by discussion amongst review authors. Where appropriate, a 
meta-analysis was performed according to the statistical guidelines for meta-analyses 
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of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins & Green, 
2011). Subject to the level of heterogeneity, pooling was carried out using an inverse 
variance random-effects model. Statistical analysis was performed using RevMan 5.3 
(The Nordic Cochrane Centre, 2014). 
4.6.8.2 Narrative synthesis 
Where meta-analysis was considered unsuitable due to the heterogeneity and/or the 
small number of studies, a narrative overview of the findings of included studies was 
presented, with tabular summaries of extracted data where appropriate. Narrative 
synthesis can be applied to both quantitative and qualitative reviews (Rodgers et al., 
2009).  
For the quantitative evidence synthesis, a narrative synthesis was carried out for all 
included quantitative studies. Study design, intervention, population and outcomes 
were summarised in text and tables. Outcomes were grouped into clinical, 
psychosocial, behavioural, knowledge, patient-reported, HCP-related and 
miscellaneous outcomes. Data were presented in tables, graphs and text primarily split 
by outcome group and stratified by diabetes type and/or study design, and the results 
for each outcome were presented in text individually and linked in text and summary 
tables.  
The choice of synthesis approach is highly dependent on the purpose of the review (in 
this case, to summarise and integrate all the available qualitative evidence in relation 
to mobile apps for diabetes) and the number of relevant studies and the nature of the 
available evidence (Pope & Mays, 2006). Planning the synthesis approach at the 
protocol stage is very important to help the review authors to avoid highlighting some 
findings above others, even unintentionally. At the protocol stage, the qualitative 
analysis was planned using the thematic synthesis approach, although during the 
review, the organisation and presentation of the data, and method of synthesis, 
evolved based on the findings into a narrative synthesis for studies that used 
qualitative methods of data collection and analysis, whether stand-alone studies or 
part of mixed-methods studies (Thomas & Harden, 2008). Narrative synthesis arranges 
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studies into homogenous groups and then summarises their primary data in a 
structured format and lastly puts into context the extracted data. Therefore, studies 
assessing the same outcome were first grouped together. Study characteristics, 
setting, quality and findings were reported in text and summary tables, with 
similarities and differences compared across studies. Information was structured 
according to the population (patients or HCPs) and then stratified according to the 
type of diabetes and/or intended purpose of the intervention (self-care, 
telemonitoring or clinical practice).  
4.6.9 Other factors relating to data synthesis 
Where it was possible to pool the data from included studies in a meta-analysis, 
subgroup and sensitivity analyses were both considered. 
4.6.9.1 Subgroup analysis  
When considerable heterogeneity was found (I2>50%), the following subgroup 
analyses were considered to explore further the effect of certain variables on the 
pooled intervention effects: 
▪ Diabetes types (T1D or T2D) 
▪ Purpose of intervention (telemonitoring, self-care) 
▪ Follow-up duration (3, 6 or 9 months) 
▪ Age groups (18-50 years, >50 years). 
4.6.9.2 Sensitivity analysis   
Sensitivity analyses examined the influence of the following factors on the pooled 
effects of the intervention: 
▪ Excluding studies with a high or unclear risk of bias across various domains 
▪ Restricting the analysis to large studies to establish how much they dominate 
the results 
▪ Excluding studies with results which differ significantly from other studies. 
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Chapter 5  A quantitative systematic review and meta-analysis: 
Results and discussion 
Chapter overview 
This chapter describes the findings from the quantitative systematic review and meta-
analysis, including the search results, characteristics of included studies, risk of bias 
and quality assessment (using figures and tables), effects of interventions are 
presented (text, tables and meta-analysis). The discussion section summarises the 
results of the review, the quality of the evidence, comparison with relevant reviews, 
strengths and limitations, methodological considerations and the implications and 
impact of the review on future research.  
Design 
This systematic review adopted both meta-analysis and narrative approach (Chapter 
4). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
checklist was used to ensure systematic reporting of the review (Moher et al., 2009). 
5.1 Results  
5.1.1 Results of the search 
One search was undertaken for both the quantitative and qualitative systematic 
reviews, run between August and September 2014, covering studies published from 
2008 until September 2014. The electronic database search found 7253 records and an 
additional 1059 records were identified through grey literature search. The reference 
management software EndNote (Thomson Reuters Corporation, 2013) was used to 
combine and de-duplicate the search results, leaving 5435 records to be screened at 
title and abstract level. A random sample of 1088 records was screened by two 
reviewers independently and the strength of agreement on inclusion was found to be 
‘very good’ (kappa=0.800; SE=0.033; 95% CI: 0.735 to 0.865). Next, 646 records were 
assessed for eligibility at full-text level.  
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An additional 6016 records were received through databases’ Auto Alerts considering 
publications until December 2015.2 These records were screened against inclusion 
criteria in a similar way. Finally, 80 records fulfilled the selection criteria and were 
included, comprising 34 quantitative studies and 20 qualitative studies. Figure 5.1 
shows an adapted PRISMA study flow diagram for the selection of studies in both 
reviews.  
The quantitative studies were published in the following formats:  
▪ three studies each had one individual thesis or dissertation (Min, 2013; Nielsen, 
2013; Sarala, 2014);  
▪ two each had a thesis plus one published journal article (Årsand, 2009; Årsand 
et al., 2010; Williams, 2015; Williams & Schroeder, 2015);  
▪ one had a thesis plus two published articles (Tatara, 2013; Tatara et al., 2013a; 
Tatara et al., 2013b);  
▪ one had three published articles (Holmen et al., 2014; Ribu et al., 2013; 
Torbjørnsen et al., 2014); 
▪ five each had one published article plus one published abstract (Cafazzo et al., 
2012a; Cafazzo et al., 2012b; Franceschi et al., 2014; Humble et al., 2014; 
Humble et al., 2015; Miele et al., 2015; Waki et al., 2015; Waki et al., 2011; 
Waki et al., 2013; Waki et al., 2014);  
▪ one had two published articles plus one published abstract (Frøisland et al., 
2011; Frøisland & Årsand, 2015; Frøisland et al., 2012);  
▪ one had two published articles plus three published abstracts (Holl et al., 2014; 
Neubauer et al., 2014a; Neubauer et al., 2015; Neubauer et al., 2014b; Spat et 
al., 2013);  
▪ one had three published articles plus five published abstracts (Gibson et al., 
2013; Hirst et al., 2015a; Hirst et al., 2014; Hirst et al., 2015b; Loerup et al., 
2013; Loerup et al., 2014a; Loerup et al., 2014b; Mackillop et al., 2014);  
                                                     
2 An updated search is being conducted and the result will be published (see Chapter 10, Section 10.5) 
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▪ one study had four published articles plus three published abstracts (Benhamou 
et al., 2010; Charpentier et al., 2011; Franc et al., 2012a; Franc et al., 2014; 
Franc & Charpentier, 2015; Franc et al., 2012b; Penfornis et al., 2010);  
▪ and the remaining 18 studies each had individual published articles (Alanzi et 
al., 2014; Chomutare et al., 2013; Conway et al., 2015; Dobson & Hall, 2015; 
Drion et al., 2015; Hong et al., 2015; Hsu et al., 2015; Hunt et al., 2014; 
Istepanian et al., 2014; Kim et al., 2014; Kim et al., 2015; Kirwan et al., 2013; 
Logan et al., 2012; Pellegrini et al., 2015; Rao et al., 2010; Tiefengrabner et al., 
2014; Wayne et al., 2015; Wayne & Ritvo, 2014).  
Several studies were published by the same authors or groups, for example, Årsand 
2010, Frøisland 2012, Tatara 2013, Chomutare 2013 and Holmen 2014 were all 
affiliated with the Norwegian Centre for Integrated Care and Telemedicine, University 
Hospital of North Norway, Tromsø, Norway (Årsand et al., 2010; Chomutare et al., 
2013; Frøisland et al., 2012; Holmen et al., 2014; Tatara, 2013).  
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Additional records identified through 
other sources  
(n=1059) 
 
Records identified through database 
searching  
(n=7253) 
Duplicated records removed 
(n=2877) 
Records screened  
(n=5435) 
 Records excluded at title and abstract level  
(n=4789) 
Records excluded at full-text level  
(n=571)  
- Descriptive design (n=146) 
- Review, systematic review, or meta-
analysis (n=124) 
- Excluded on intervention (n=179) 
- Excluded on population (n=29) 
- Unable to obtain full report (n=11) 
- Other (n=82) 
Abstracts excluded for being unable to find the 
full report  
(n=27) 
 
Records included 
(n=48)  
5 theses, 21 full-text papers, 22 abstracts 
Total records included 
(n=80)  
8 theses, 50 full-text papers, 22 abstracts 
Additional records were received through 
database Auto-Alert, or identified from 
reference lists, and were assessed for eligibility  
(n=6018) 
 Records included (n=32) 
3 theses, 29 full-text papers 
Records included in quantitative 
synthesis or meta-analysis  
(n=48) 
1 thesis, 32 full-text papers, 15 
abstracts 
Mixed method records included in 
both quantitative & qualitative 
synthesis (n=18) 
5 theses, 9 full-text papers, 4 
abstracts 
 
Records included in qualitative 
synthesis  
(n=14) 
2 theses, 9 full-text papers, 3 
abstracts 
Full-text records assessed for eligibility  
(n=646) 
Filtered 
Records included  
(n=75) 
Filtered 
Figure 5.1 Flow diagram illustrating selection of studies for inclusion in quantitative and qualitative reviews. 
Filtered 
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5.1.2 Excluded and ongoing studies 
Many studies did not fit the design inclusion criteria at full-text level and, thus, were 
excluded, mostly because studies were descriptive in nature, including those which 
described a design or prototype of a study-specific mobile app with no testing on 
individuals (n=146) or reviews of mobile apps (84 narrative overview/literature review; 
25 systematic review/meta-analysis; 15 reviews of commercial apps).  
Ineligible interventions were: 11 text messages; 44 telemedicine/telemonitoring 
systems; 16 computer/web apps; 14 PDA apps; 63 apps not functioning on smart 
devices or device unclear; 11 not specific to apps or no separate result for apps; 16 
Artificial Pancreas (AP) technology (i.e. continuous glucose measurement systems 
linked to an insulin pump where the smartphone was used as a hub running the closed 
loop control algorithm); and four studies tested an app that utilised a device camera or 
wearable computing device, e.g. smartwatch, as the primary intervention, whereas the 
app was a secondary component. 
Few studies were excluded based on their population (21 not specific to diabetes or no 
separate result for diabetes; 8 targeted pre-diabetes). Other reasons for exclusion 
included study outcomes that were not related to the user, e.g. studies which tested a 
mobile app’s accuracy or its technical validation (n=14); studies with insufficient 
reporting of the result for outcomes of interest or insufficient information on the 
intervention or the trial itself (n=24); studies with outcomes that were assessed only at 
baseline with no further assessment at the end of the study (n=1); duplicated records 
(n=44); studies in which the full-text report was unavailable (n=11), or study abstracts 
where no full paper was found (n=27).  
Online trials registers were searched on September 2014 and a list of all identified 
ongoing and completed trials is in Appendix 7. 
5.1.3 Included studies  
48 quantitative records and 18 mixed-methods records were included, comprising 34 
studies, published 2009–2015, with a notable increase in more recent studies. Table 
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5.1 presents the distribution of the included studies by different variables. 
Characteristics of included studies tables are in Appendix 8, including country, design, 
description of the mobile app and its purpose and function, comparator, sample size, 
mean age, study duration and outcomes.  
Table 5.1 Distribution of the included studies by different variables. 
 No of trials, n Percentage, % 
Study design 
RCT 
Crossover, repeated measures design 
Pre-post design with control 
Pre-post design without control 
Single group post-only design 
Cross-sectional 
Case report 
 
9 
1 
1 
6 
10 
6 
1 
 
26 
3 
3 
18 
29 
18 
3 
Sample size  
< 70  
≥ 70 
 
25 
9 
 
74 
26 
Study duration 
< 6 months 
≥ 6 months 
 
23 
11 
 
68 
32 
Country 
USA & Canada 
Europe (UK, Norway, Netherlands, France, Italy, Austria, 
Denmark) 
Southeast Asia (Korea, Japan, India) 
Middle East (Iraq, Saudi Arabia) 
Australia 
 
12 
13 
 
6 
2 
1 
 
35 
38 
18 
6 
3 
Study setting  
Primary care 
Secondary care (outpatient and inpatient) 
Tertiary care 
Community and non-medical setting  
 
6 
15 
3 
10 
 
18 
44 
9 
29 
Age group 
Younger age group < 18 
Older age group ≥ 18 
 
3 
31 
 
9 
91 
Population 
Patients 
HCPs 
 
32 
2 
 
94 
6 
Type of diabetes 
T1D 
T2D 
T1D/T2D 
GDM 
 
7 
18 
8 
1 
 
21 
53 
23 
3 
Intervention purpose 
Self-care 
Telemonitoring 
Clinical practice 
 
18 
14 
2 
 
53 
41 
6 
Study focus 
Disease management 
Behaviour change 
Adherence 
 
11 
9 
0 
 
32 
26 
0 
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Education 
Usability 
App utilisation 
Current use of apps and preferences 
Clinical decision-support 
0 
4 
3 
5 
2 
0 
12 
9 
15 
6 
5.1.3.1 Study design 
The 34 included studies were: 
▪ interventional studies:  
➢ RCTs (Charpentier et al., 2011; Drion et al., 2015; Holmen et al., 2014; Hsu 
et al., 2015; Istepanian et al., 2014; Kirwan et al., 2013; Logan et al., 2012; 
Waki et al., 2014; Wayne et al., 2015), of which two (Charpentier et al., 
2011; Holmen et al., 2014) were 3-armed but the third arm was not eligible 
as it involved a co-intervention combined with the mobile app; one study 
(Istepanian et al., 2014) was not described as an RCT, but met RCT criteria 
and was classified as an RCT within this review; and  
➢ non-RCTs: pre-post design with control (Kim et al., 2014) or without control 
(Cafazzo et al., 2012a; Chomutare et al., 2013; Frøisland et al., 2012; 
Pellegrini et al., 2015; Sarala, 2014; Wayne & Ritvo, 2014), post-only design 
(Alanzi et al., 2014; Årsand et al., 2010; Mackillop et al., 2014; Miele et al., 
2015; Min, 2013; Neubauer et al., 2015; Rao et al., 2010; Tatara, 2013; 
Tiefengrabner et al., 2014; Waki et al., 2015), crossover repeated measure 
design (Hunt et al., 2014) and case report (Hong et al., 2015); and 
▪ cross-sectional observational studies (Conway et al., 2015; Dobson & Hall, 
2015; Humble et al., 2015; Kim et al., 2015; Nielsen, 2013; Williams & 
Schroeder, 2015).  
5.1.3.2 Sample sizes 
The RCTs (n=9) included a total of 670 participants. Study sizes ranged from 12 to 121 
(mean=74.4, median=72, SD=35.85). All RCTs used power calculations except one pilot 
feasibility study (Istepanian et al., 2014) with 12 participants.  
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The non-RCTs (n=17) comprised a total of 343 participants. Study sizes ranged from 5 
to 73 (mean=20.2, median=14, SD=19.15). Only one study (Kim et al., 2014) involved a 
comparison group. Most (n=14) were pilot studies with very small sample sizes (n<25). 
Two other non-RCTs (Neubauer et al., 2015; Sarala, 2014), with HCPs as the main user 
of the intervention (102 HCPs and 99 patients), were analysed and discussed 
separately.  
A total of 1058 participant were included in the observational studies (n=6). Study sizes 
ranged from 42 to 588 (mean=176.3, median=75, SD=214.17).  
5.1.3.3 Participants 
The participants in 31 studies were aged 18-65 years (mean 35 years for T1D and 55 
years for T2D participants); a few studies clearly targeted adults but did not report the 
age distribution (Mackillop et al., 2014; Min, 2013; Sarala, 2014; Williams & Schroeder, 
2015); and three non-RCTs (Cafazzo et al., 2012a; Frøisland et al., 2012; Miele et al., 
2015) involved a total of 47 children and young adults with T1D (aged 4–18 years; 
mean=13, SD=4.40).  
Patients were the target population in nearly all studies, except two non-RCTs 
(Neubauer et al., 2015; Sarala, 2014) involving HCPs, of which one also included 
patient participants. 
More studies targeted patients with T2D only (n=16) than T1D only (n=7), whereas 
GDM only was studied in one non-RCT (Hirst et al., 2015b; Mackillop et al., 2014). Eight 
studies included both T1D and T2D; although four of them (Humble et al., 2015; Kim et 
al., 2015; Logan et al., 2012; Nielsen, 2013) did not identify the diabetes type. In total, 
the patient-directed studies (n=32) involved 2070 participants (T1D=493, T2D=1106, 
GDM=59, NR=412).  
5.1.3.4 Interventions 
In the 28 included interventional studies, 53% of studies examined apps aiming to 
support diabetes self-care, 41% examined apps aiming to facilitate patients’ 
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telemonitoring, whilst only 6% considered apps supporting clinical practice. Nine key 
functionalities of mobile apps were identified, summarised in Table 5.2.  
Table 5.2 Key apps’ functionalities identified in the included studies. 
Functionality Description 
Diabetes-related data 
collection 
Enables users to track and monitor their condition by collecting various 
biometrics (e.g. BG & BP readings), symptoms, medication, weight, diet, 
physical activity, or healthy behaviours  
Insulin/medication 
management 
Helps users to adhere to their medication regimen and independently 
initiate or adjust insulin doses  
Diet evaluation and 
management 
Helps users to modify their diet and build healthy eating habits by using 
different techniques 
Communication and 
remote monitoring  
Allows care providers to monitor patients and give personalised feedback 
(e.g. treatment recommendations, medication adjustment, reminders, 
advice, encouragements and corrections to lifestyle) remotely, and enables 
patients to communicate with HCPs 
Coaching Allows care providers to provide patients with active coaching through 
virtual interactions with the primary purpose of behaviour change, 
motivation, and education 
Reminder Reminds users to engage in daily management activities; e.g. taking 
medications, self-monitoring or behaviour change 
Education Provides patients with diabetes-related education pertinent to disease 
outcomes, self-monitoring, interpretation of measurements, benefits and 
risks of healthy behaviors, and medication and side effects 
Social Support Involves use of social media to enable users to communicate with other 
users, with similar health status, about health-related information or sharing 
self-management progress, to engage family members and friends 
Clinical decision-
support 
Utilises clinical guidelines and patient’s clinical parameters to generate 
personalised recommendations that assist HCPs in making informed 
decisions 
Studies varied in their main focus, with most (n=11; RCT=7; non-RCT=4) focusing on 
disease management; specifically, two (Charpentier et al., 2011; Hsu et al., 2015) 
focused on medication management. Other studies emphasised behaviour change 
(n=9; RCT=2; non-RCT=6; cross-sectional=1), with one study (Pellegrini et al., 2015), in 
particular, focusing on increasing physical activity. Another area of focus was the app 
usability and user satisfaction (non-RCT=4), app utilisation and usage trends (non-
RCT=3), and clinical decision-support (non-RCT=2). None of the included studies 
focused essentially on patient education or adherence to the management regimen. 
Most of the studies examined a study-specific mobile app, except five studies which 
tested a freely-available diabetes self-management app, or did not report sufficient 
details of the app. Two studies featured multi-faceted interventions (Kirwan et al., 
2013; Sarala, 2014). In Sarala (2014) the patients received an intervention package, 
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including a nurse coordinator and counselling services besides the mobile app and, 
thus, outcomes specific to the patients were excluded and only the HCPs’ outcomes 
relating to the app use were included. However, in Kirwan et al. (2013) the participants 
in the intervention arm used a separate text messaging software to communicate with 
a diabetes educator and received regular feedback and therefore this was treated as a 
telemonitoring study. 
Most studies (n=20) provided participants in the intervention group with a smartphone 
or tablet, while few studies (n=3) required smartphone ownership for inclusion. In 
some studies (n=15), participants were also provided with additional equipment 
necessary to use the app, e.g., glucometer, Bluetooth adapter, BP monitoring device, 
wireless scale, pedometer or accelerometer to allow collection of various health-
related parameters. Data entry, in most studies, was automatic from the connected 
devices; in particular, data were often transmitted wirelessly using Bluetooth 
technology. Few studies explicitly reported covering the cost of the mobile service 
during the trial. Some studies placed no restrictions on the use of the intervention, 
whereas others specified a required frequency for use. Some intervention group 
participants were trained on how to use the app, while other studies did not report 
offering any training or instructions. 
Frequently-applied techniques in diabetes-related apps were diaries, visual graphs, 
trend reports and information export, while gamification and rewards were the least-
implemented techniques. Studies, particularly those involving remote monitoring, 
used a web interface linked to the app. This involved a secure, web-based 
dashboard/portal which allowed care providers to review and monitor patients’ data 
remotely. Patient-provider communication was mostly achieved through text 
messages, except in a few studies where phone calls or virtual video visits were used.  
Table 5.3 Design techniques applied in the studied mobile apps. 
Technique Description 
Electronic diary/logbook Allows users to log health data automatically or manually and save them 
for later review 
Visual graphs and trend 
reports 
Provides summary graphs and reports based on logged health data to 
support users in problem-solving and decision-making  
Information export Allows users to export logged health data via email or other means of 
communication  
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Technique Description 
Web-based 
dashboard/portal 
Allows care providers to review a patient’s logged health data remotely 
and provide feedback accordingly 
Automated feedback Provides users with automatically-generated feedback based on logged 
health data, e.g., feedback on how a patient’s values compare with a 
clinical guideline 
Alerts Enables users to set pre-determined or customisable reminders 
triggered by logged health data 
Text messages Involves the delivery of messages to users on a recurring basis for 
various purposes, including delivery of educational and motivational 
messages 
Goal setting Allows users to set individualised goals/targets for treatment or 
behaviour change to motivate them to engage better with their 
management 
Food database Allows users instantly to browse a large amount of food and retrieve 
information on nutritional composition, reference intake or portion size 
Estimation of food 
nutritional value 
Allows users to upload photographs of meals (using a phone camera) 
and receive instant automatic dietary assessment and advice 
Other dietary management 
techniques 
Additional techniques to support diet management including nutrition 
quizzes, calorie counter, and healthy recipes 
Calculator Uses validated algorithms to help users perform calculations using 
logged health data, such as bolus calculator  
Gamification Uses games or game-like elements to condition users to perform 
particular tasks 
Rewards Integrates incentives (points or collectibles) to help sustain user 
engagement with their management tasks 
Observational studies (n=6) did not involve an intervention, and mainly included 
surveys to explore patients’ current use and preferences for mobile apps in diabetes 
self-management, except one (Kim et al., 2015) which explored the role of apps in 
patients’ behaviour change. Two studies (Dobson & Hall, 2015; Humble et al., 2015) 
explored the use of mHealth technology more broadly, however, the mobile apps’ 
result was analysed and reported separately. 
5.1.3.5 Comparator 
The RCTs compared the intervention group, generally access to a mobile app in 
addition to usual care, with a control group of usual care, with or without a standard 
paper diary/logbook. Control participants in one study (Wayne et al., 2015) 
additionally received Health Coach Support for selecting and progressing toward goals. 
Another study (Hsu et al., 2015) gave control participants access to high standard care 
at the clinic in initiating and titrating insulin, with interim face-to-face visits, as well as 
telephone/fax communication with educators and clinicians. Logan et al. (Logan et al., 
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2012) provided control participants with an identical-appearing home BP device 
without built-in Bluetooth capability for home BP monitoring.  
Two non-RCTs involved a comparison group; in one (Kim et al., 2014), control 
participants received usual care, while in the other (Hunt et al., 2014), they received a 
paper journal to log diabetes self-management activities. The remaining non-RCTs did 
not have a control group. 
5.1.3.6 Outcomes 
The most common primary outcome in both RCT and non-RCTs (n=17) was glycaemic 
control. Other frequently-studied outcomes included body composition, self-
management behaviour, QoL, self-efficacy and usability/utilisation of the intervention. 
Assessed outcomes in each study were all included and presented in this review, 
grouped as described below. 
Clinical outcomes 
All examined patient-related clinical outcomes; these included glycaemic control 
measures including HbA1c level, average BG level, fasting BG level, proportion of 
patients reaching the HbA1c target, and frequency of hypoglycaemic episodes. Other 
clinical outcomes included: BP, proportion of patients reaching the BP target, 
cholesterol levels, body composition (weight, BMI, waist circumference), and change in 
medication. 
Psychosocial outcomes 
This set included: QoL, depression and anxiety, diabetes-related distress, diabetes-
related self-efficacy, positive and negative affect, satisfaction with life, satisfaction 
with diabetes treatment, and comfort with self-monitoring. 
Behavioural outcomes 
This group included: Diabetes self-management, frequency of self-monitoring, logging 
behaviour, lifestyle change (physical activity, dietary habits), and performance of 
physical activity. 
   
72 
Knowledge outcomes 
This was knowledge about diabetes and diabetes management. 
Patient-reported outcomes 
This included satisfaction and usability of the intervention, and (primarily in the 
observational studies) participant’s current use of apps, preferences, attitudes, and 
intention to use apps. 
HCP-related outcomes  
Few HCPs’ outcomes were reported, including user errors and workflow anomalies, 
usability of intervention and compliance with given recommendation. 
Miscellaneous outcomes 
This group contained outcomes not included in any other group, e.g. number of GP 
visits, time spent on consultation visits, and utilisation and compliance with 
intervention use.  
Few studies (n=4) addressed adverse events, and this was mainly in the discussion, 
rather than as an outcome (Frøisland et al., 2012; Holmen et al., 2014; Kirwan et al., 
2013; Neubauer et al., 2015). 
Studies varied in duration from a week to 12 months (mean for RCTs=6.6 months 
[range=3–12 months]; non-RCTs=4.6 months [range=1 week–12 months]); three non-
RCTs (Alanzi et al., 2014; Min, 2013; Rao et al., 2010) did not report the duration of 
intervention use or follow-up. 
Outcomes studied are outlined in the ‘Characteristics of included studies’ tables in 
Appendix 8. 
5.1.3.7 Settings 
The included studies took place in the USA (n=6), Canada (n=6), Norway (n=5), UK 
(n=2), Austria (n=2), Netherlands (n=1), France (n=1), Denmark (n=1), Italy (n=1), 
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Australia (n=1), Korea (n=3), Japan (n=2), India (n= 1), Saudi Arabia (n=1) and Iraq 
(n=1). 
Settings included primary, secondary and tertiary care and in the community. Most 
RCTs (n=5) were set in secondary care, specifically in diabetes outpatient clinics. Of the 
four remaining studies, three (Istepanian et al., 2014; Logan et al., 2012; Wayne et al., 
2015) were in primary care and one (Hsu et al., 2015) was in a tertiary centre 
specialising in diabetes care. 
Similarly, most non-RCTs (n=10) were in secondary care, two were in primary care 
(Sarala, 2014; Wayne & Ritvo, 2014), and two were in tertiary care (one in an inpatient 
setting of a tertiary care hospital (Neubauer et al., 2015) and the other in a pregnancy 
and diabetes clinic (Mackillop et al., 2014)). The remaining studies (n=5) were set in 
the community or other non-medical settings. 
Four observational studies were conducted in non-medical settings and recruitment 
was primarily either online (noticeboards, health websites, social networks) or national 
diabetes registries. Of the remaining two studies, one (Dobson & Hall, 2015) was set in 
a community-based organisation providing diabetes education and the other (Humble 
et al., 2015) was in primary care. 
5.1.4 Risk of bias in included RCTs 
Risk of bias assessments were based on published reports only. The domains being 
sequence generation and allocation concealment (selection bias), blinding of 
participants and personnel (performance bias), blinding of outcome assessment 
(detection bias), incomplete outcome data (attrition bias), selective reporting 
(reporting bias), and other potential sources of bias. All of the included RCTs featured 
some bias. Figure 5.2 summarises the risk of bias for each domain across all included 
studies and Figure 5.3 summarises the domains for each included study.  
Seven studies used adequate sequence generation, using computer-generated block 
randomisation, shuffled envelopes, or a schedule randomly arranged and administered 
by a person not directly involved in the study. In two studies (Hsu et al., 2015; 
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Istepanian et al., 2014), sequence generation was not reported. Five studies reported 
adequate allocation concealment (using sealed, non-transparent envelopes kept by an 
independent researcher, or varied blinded block sizes and blinded allocation order 
within blocks) with the remaining studies not providing information on this domain. 
All studies were at high risk of bias in the domain of blinding of participants and 
personnel except two (Hsu et al., 2015; Istepanian et al., 2014), which did not provide 
information on blinding. Participants could not be blinded in any of the studies due to 
the nature of the intervention, which required apparent participation. The blinding of 
personnel was discussed in some studies and was considered unfeasible, as 
participants may use the device during visits to their care providers. Thus, HCPs who 
delivered the intervention knew participants’ allocated groups. Blinding of outcome 
assessors was not discussed in most studies and, therefore, studies were assessed 
based on their primary outcome. In seven studies, this was change in glycaemic control 
(assessed by HbA1c), which was generally measured by a pathology laboratory and 
forwarded to the research team, so was unlikely to be influenced by the lack of 
assessors’ blinding. The primary outcomes in the remaining two studies (Drion et al., 
2015; Logan et al., 2012) were change in QoL, measured by a validated tool, and 
change in mean daytime ambulatory systolic BP, respectively, both considered unlikely 
to be influenced by the lack of assessors’ blinding. 
Four studies were free of attrition bias (one study had no missing data; one had one 
withdrawal but an intention-to-treat analysis (ITT) was carried out to account for the 
missing data; in two studies, missing data was imbalanced between groups but an ITT 
analysis gave comparable results to completers-only analysis and an adequate 
description of missing participants was provided). In the remaining five studies, the risk 
of bias was assessed as ‘high’ due to high and uneven dropout rate; many withdrawn 
participants and data presented for completers only; insufficient information provided 
to assess whether an ITT analysis was carried out; or no attempt made to describe or 
investigate missing participants. 
Six studies had a trial protocol, whereas published protocols were unavailable for the 
remaining three (Drion et al., 2015; Istepanian et al., 2014; Waki et al., 2014). Four 
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studies were judged as free of selective outcome reporting. All primary and secondary 
outcome measures were pre-specified in their trial protocols and they presented all 
outcomes outlined in their protocol. One study (a conference paper), was assessed as 
having a high risk of selective reporting; the study protocol was not found and only the 
result of the primary outcome (HbA1c) was reported, while other outcomes were only 
summarised. The remaining four studies were judged unclear with study protocols not 
identified or incomplete results for some outcomes. 
Six studies had an unclear risk of other sources of bias, including potential concerns 
about imbalance in baseline characteristics, lack of adjustment for confounders, recall 
bias, intervention group compliance, technical issues and poor study reporting.  
 
Figure 5.2 Risk of bias graph: risk of bias for each domain (percentages across all included RCTs). 
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Figure 5.3 Risk of bias summary: domains for each included RCT. 
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5.1.5 Quality assessment of other study designs 
For the Downs and Black assessments (Figure 5.4), the non-RCTs, including the 
observational studies, scored a median of 16/28 overall (range 8–22). High scores 
indicate good quality, but only one study scored >20/28; 21 studies scored 10–20 and 
three scored <10. 
For study reporting, median was 7/11 (range 4–11). Nearly all had a clear 
hypothesis/aim/objective and main outcomes and clearly described the intervention. 
However, the characteristics of participants and the distributions of principal 
confounders were partially described in many studies. Only eight studies provided 
sufficient information to enable unbiased evaluation of their findings.  
For internal validity, the median was 4/7 (range 2–5) for bias and 2/6 (0–4) for 
confounding. No study scored highly in these two sub-scales, representing a high 
potential for bias/confounding. For external validity, the median was 1/3 (0–3) and 
seven studies scored 0, indicating limited generalisability of results. 
For power, the median was 0 (0–1)/1; only one study was sufficiently powered to 
detect a clinically important effect, whereas the remaining pilot/feasibility studies 
lacked the power to detect any difference.   
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Figure 5.4 Quality assessment result of non-RCTs: sub-scale and overall score by study. 
5.1.6 Effects of intervention 
This section presents the effect of mobile apps including a meta-analysis of RCTs and a 
narrative synthesis of the evidence from all the study designs for all the outcomes, 
grouped into categories.  
5.1.6.1 Clinical outcomes 
Glycaemic control 
Only HbA1c was reported in enough RCTs (Charpentier et al., 2011; Drion et al., 2015; 
Holmen et al., 2014; Hsu et al., 2015; Istepanian et al., 2014; Kirwan et al., 2013; Waki 
et al., 2014; Wayne et al., 2015) for meta-analysis (n=549 participants: T1D=232, 
T2D=317; intervention=271, control=278) (Figure 5.5). Data extracted included the 
sample size, mean change of HbA1c or mean±SD HbA1c at baseline and endpoint. 
Where data points were missing, values were estimated. A random-effects model was 
used as clinical heterogeneity was expected, and p<0.05 was considered statistically 
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significant. Heterogeneity was examined with I2 test, and I2>50% and p for 
heterogeneity<0.10 were considered significant heterogeneity. 
There was a statistically significant effect of mobile apps on glycaemic control versus 
usual care (mean difference [MD] -0.45%, 95% CI: -0.85 to -0.04%; P=0.03; I2=76%). 
Although the evaluation favoured apps, there was substantial heterogeneity in the 
effect.  
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Figure 5.5 Forest plot for HbA1c level of diabetes patients who used a mobile app. 
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There was a statistically significant difference in the reduction of HbA1c favouring the 
intervention group in 4/8 of the RCTs (Charpentier et al., 2011; Hsu et al., 2015; Kirwan 
et al., 2013; Waki et al., 2014). Only two of the seven non-RCTs that measured HbA1c 
(Hong et al., 2015; Wayne & Ritvo, 2014) found that mobile apps were associated with 
a significant reduction in HbA1c, whereas three studies (Årsand, 2009; Chomutare et 
al., 2013; Kim et al., 2014) reported positive but non-significant improvement, and two 
(Cafazzo et al., 2012b; Frøisland et al., 2012) reported no difference (Appendix 9).  
Other measures of glycaemic control were assessed in some studies: percentage of 
subjects reaching the HbA1c target in two RCTs (Charpentier et al., 2011; Hsu et al., 
2015) (no statistical difference between the groups); percentage of BG values in the 
target range in one study (Neubauer et al., 2015) was increased when using the mobile 
app and was significantly higher (P=0.001) than the criterion value derived from a 
recent best-practice study (Umpierrez et al., 2013). Two non-RCTs (Hong et al., 2015; 
Waki et al., 2014) measured fasting BG level which significantly declined (P=0.015) in 
one study and increased in the other. Average BG reduced in two studies (1 RCT; 1 
non-RCT) (Hsu et al., 2015; Mackillop et al., 2014; Neubauer et al., 2015) and one non-
RCT (Mackillop et al., 2014) found positive significant change for women with new 
diagnoses of GDM and non-significant result for women with previous GDM. The 
frequency of hypoglycaemic episodes did not differ between groups for the duration of 
study was reported in two RCTs (Charpentier et al., 2011; Hsu et al., 2015).  
For some non-RCTs, several data points were missing or had only descriptive results of 
changes in BG after using the intervention. For instance, one study (Hunt et al., 2014) 
aimed to evaluate HbA1c but only collected baseline values and no further measures 
were available during the study period. 
Subgroup analyses 
As considerable heterogeneity was found (I2=76%), subgroup analysis was performed 
to assess whether changes in HbA1c differed by type of diabetes (T1D/T2D; Figure 5.6), 
intervention purpose (telemonitoring/self-care; Figure 5.7), and follow-up duration 
(3/6/9 months; Figure 5.8).  
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Apps significantly reduced HbA1c for patients with T1D (MD -0.69%; 95% CI: -1.28 to -
0.09%; P=0.02; I2=71% but not T2D (-0.29%; 95% CI: -0.75 to 0.18%; P=0.23; I2=67%). 
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Figure 5.6 Forest plot for HbA1c level according to type of diabetes. 
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Telemonitoring apps reduced HbA1c (MD -0.59%; 95% CI: -1.06 to -0.11%; P=0.02; 
I2=80%), but self-care apps did not (-0.07%; 95% CI: -0.52 to 0.38%; P=0.76; I2=0%).  
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Figure 5.7 Forest plot for HbA1c level according to purposes of intervention. 
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The effect of apps on HbA1c was not significant at any individual time point but was 
significant when pooled together. 
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Figure 5.8 Forest plot for HbA1c level according to follow-up durations. 
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In all these subgroup analyses, there was no statistically significant difference between 
the subgroups (p for heterogeneity: 0.30; 0.12; 0.84, respectively). 
A sensitivity analysis was performed to investigate possible reasons for heterogeneity, 
excluding one study at a time and checking the changes in values of I2 and P. However, 
no notable change was observed on the total pooled effect or the heterogeneity. 
BP 
In 1 RCT and 1 non-RCT (Kim et al., 2014; Waki et al., 2014), systolic and diastolic BP 
remained similar without significant difference between the groups. However, one RCT 
(Logan et al., 2012) found a significant decrease in mean daytime systolic (P<0.0001) 
and diastolic (P<0.005) BP only in the intervention group. Additionally, they reported 
that 51% of intervention subjects achieved the guideline-recommended target BP 
versus 31% of controls (P<0.05). 
Cholesterol levels 
In three studies (RCT=2; non-RCT=1) (Istepanian et al., 2014; Kim et al., 2014; Waki et 
al., 2014), there were no changes in total cholesterol, triglycerides, or high- or low-
density lipoprotein.  
Body composition 
Of the studies that assessed at least one body composition measure (weight, BMI or 
waist circumference), four (2 RCTs; 2 non-RCTs) (Hong et al., 2015; Waki et al., 2014; 
Wayne et al., 2015; Wayne & Ritvo, 2014) reported improvements of varied 
magnitude; the other three (2 RCTs; 1 non-RCT) (Holmen et al., 2014; Hsu et al., 2015; 
Kim et al., 2014) found no difference between groups. 
Change in medication 
Changes in medication from baseline were evaluated in 4 RCTs (Charpentier et al., 
2011; Hsu et al., 2015; Logan et al., 2012; Waki et al., 2014), which reported no 
between-group differences in the total number of medicines or in their dosages. Only 
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the case report (Hong et al., 2015) showed that the medication dose was reduced at 3 
months follow-up and it was stopped at 6 months. 
5.1.6.2 Psychosocial outcomes 
QoL was assessed in six studies (RCT=5; non-RCT=1) using the Diabetes Quality of Life 
(DQOL) (Kirwan et al., 2013), the Diabetes Health Profile (DHP) (Charpentier et al., 
2011), the RAND 36-Item Short Form Health Survey (SF-36) (Drion et al., 2015), the 
Short-Form Health Related Quality of Life-36 (SF-36) (Holmen et al., 2014), the Short 
Form Health Survey-12 (SF-12) (Wayne et al., 2015) and the Diabetes Quality of Life for 
Youths (DQOLY) (Cafazzo et al., 2012a). One study (Wayne et al., 2015) found 
improvements in QoL for both intervention and control groups, but the remaining five 
studies found no influence of the diabetes diary app on QoL (Appendix 9).  
Three RCTs evaluated depression and anxiety using the Hospital Anxiety and 
Depression Scale (HADS) (Wayne et al., 2015), the Centre for Epidemiological Studies 
Depression Scale (CES-D) (Holmen et al., 2014) or the Anxiety Sensitivity Index (ASI) 
with HADS (Logan et al., 2012). The change in depressive symptoms did not differ 
significantly between the groups in one study (Holmen et al., 2014). Another study 
(Wayne et al., 2015) reported similar improvements for both intervention and control 
groups in the HADS depression subscale. In the third study (Logan et al., 2012), a trend 
toward worsening using the HADS depression was detected in the intervention group, 
with a significant between-group difference (P=0.032). This study also found a 
worsening in participants’ comfort with BP self-monitoring in both groups. One RCT 
(Drion et al., 2015) found no difference between groups in diabetes-related distress 
using the Problem Areas in Diabetes (PAID) questionnaire (Appendix 9).  
One RCT (Wayne et al., 2015) found significant between-group differences favouring 
the intervention group (p=0.007) for the negative affect subscale of the Positive and 
Negative Affect Schedule, and significant within-group improvements in life 
satisfaction were found in both groups on the Satisfaction with Life Scale. One RCT 
reported a statistically significant difference (p=0.01) between groups on the Diabetes 
Treatment Satisfaction Questionnaire (DTSQ) (Hsu et al., 2015). One non-RCT (Hirst et 
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al., 2015b) demonstrated that women’s overall satisfaction on the Oxford Maternity 
Diabetes Treatment Satisfaction Questionnaire (OMDTSQ) was high; 45 of 49 women 
agreed their care was satisfactory and felt it had been the best for them, and 47 
agreed they had a positive relationship with the maternity diabetes team, particularly 
the diabetes midwife. 
Diabetes-related self-efficacy was assessed in four studies (RCT=1; non-RCT=3) using 
the Short Form Diabetes Empowerment Scale (DES-SF) (Chomutare et al., 2013; Kirwan 
et al., 2013), the Diabetes Management Self-efficacy Scale (DMSES) (Hunt et al., 2014) 
or the Diabetes Family Responsibility Questionnaire (Cafazzo et al., 2012a). One study 
(Cafazzo et al., 2012a) found slight improvements in both the parent and adolescent 
scores. No significant changes were reported in self-efficacy in the remaining studies 
(Appendix 9).  
5.1.6.3 Behavioural outcomes 
Six studies (RCT=3; non-RCT=3) assessed diabetes self-management using the 
Summary of Diabetes Self-Care Activities (SDSCA) (Kim et al., 2015; Kirwan et al., 
2013), Diabetes Self-care Activities-Revised (SDSCA-Revised) (Hunt et al., 2014), the 
Japanese version of SDSCA (Waki et al., 2014), the Health Education Impact 
Questionnaire (HeiQ) (Holmen et al., 2014) or the 14-Item Self-care Inventory (Cafazzo 
et al., 2012a). Significantly improved self-care activities for at least one item were 
reported in two studies (Holmen et al., 2014; Kim et al., 2015). Non-significant 
improvements in exercise were found in an additional study (Cafazzo et al., 2012a). In 
the remaining studies, participants’ scores remained similar between the two groups 
(Appendix 9).  
In one non-RCT (Cafazzo et al., 2012a), the daily average frequency of BG self-
monitoring was significantly increased (p=0.006), whilst it did not differ significantly 
between groups in the two RCTs (Charpentier et al., 2011; Drion et al., 2015). In one 
non-RCT (Hunt et al., 2014), self-management activity logs stayed the same, whereas 
another non-RCT (Tiefengrabner et al., 2014) reported varying percentages of increase 
in logging behaviour for the different parameters. 
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In one RCT (Holmen et al., 2014) using self-reported questionnaires, there were no 
statistically significant differences between groups in physical activity or diet. One non-
RCT (Årsand et al., 2010) reported an increase of 20% in step count during the study. 
Another non-RCT (Pellegrini et al., 2015) showed significant changes in sedentary 
behaviour and physical activity during the one-month follow-up, with 87.5% of 
participants reducing sedentary time and increasing light-intensity physical activity. 
5.1.6.4 Knowledge outcome 
One non-RCT (Frøisland et al., 2012) found the knowledge test scores on a 27-item 
questionnaire based on the Norwegian National Health Informatics’ diabetes quiz 
remained nearly the same before and after the study. One RCT (Istepanian et al., 2014) 
found the level of knowledge on a questionnaire adapted and translated into Arabic 
from The Diabetic Knowledge Test [Michigan Diabetes Research and Training Centre] 
was significantly increased after the intervention.  
Figure 5.9 summarises the narrative synthesis results for the commonly-studied 
outcomes, demonstrating the distribution of outcomes according to diabetes type and 
intervention effects. Statistically significant positive effect indicates significant 
between-groups improvement or significant pre/post improvement; at least in one 
measure or subscale, while positive effect indicates non-significant improvement or 
pre/post improvement but not significant; at least in one measure or subscale. No 
effect indicates no difference between-groups or no change in a single group. Negative 
effect indicates any negative impact between-groups or pre/post, either significant or 
not. 
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Figure 5.9 Distribution of frequently studied outcomes according to diabetes type and intervention effects. 
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5.1.6.5 Patient-reported outcomes 
Five studies (RCT=1; non-RCT=4) used custom-made questionnaires including items on 
satisfaction, convenience willingness to use the app in the future and to recommend it 
to others. In the RCT (Charpentier et al., 2011), 77% of intervention participants were 
satisfied/very satisfied with the app and 67% were willing to continue using it. User 
satisfaction was high in two non-RCTs (Cafazzo et al., 2012a; Hirst et al., 2015b); 88% 
of participants in the former study would continue using the app, while the remaining 
12% suggested that it needed to be integrated with their insulin pump to continue 
using it. In the latter study, 48 of 49 women agreed that the app plus associated 
equipment was both convenient and reliable, even though four had problems 
transferring their readings automatically due to poor network coverage. The remaining 
two studies (non-RCT=1; cross-sectional=1) showed high user satisfaction, and 
improvements in HbA1c or self-management activities were greater in the satisfied 
group (Kim et al., 2014; Kim et al., 2015). In one study, 27 of 35 participants were 
satisfied, while 8 were less satisfied, with most complaints related to data transfer 
errors (Kim et al., 2014). In the other, almost 87% were satisfied with app structure 
and nearly 97% were willing to continue use and to recommend it to others (Kim et al., 
2015). 
App usability was assessed in ten studies (RCT=2; non-RCT=8) using the System 
Usability Scale (SUS) (Årsand, 2009; Chomutare et al., 2013; Drion et al., 2015; 
Frøisland et al., 2012; Hong et al., 2015; Min, 2013; Tatara, 2013), the Questionnaire 
for User Interaction and Satisfaction (QUIS) (Alanzi et al., 2014), or custom-made 
questionnaires (Rao et al., 2010; Waki et al., 2014) (Appendix 9). SUS scores range 
from 0–100, with a score ≥70 considered acceptable and <70 is below average (Bangor 
et al., 2009). SUS scores range from 72–92.5, indicating high satisfaction with usability, 
ease or learning and user-friendliness. Still, many usability problems were reported 
with apps, including inconvenience of manual data input, short battery life, and 
problems with the touch screen. Studies using QUIS indicated a positive impression 
and good levels of satisfaction. In studies using custom-made questionnaires 
(composite ease of use score across eight parameters (Rao et al., 2010) or frequency of 
   
94 
participants in agreement with statements given (Waki et al., 2014)), apps were easy 
to use, useful and requiring least time.  
Other self-reported outcomes, primarily explored in observational studies, included 
participants’ current use of apps for diabetes management, preferences, attitudes and 
intention to use them. Six studies assessed these outcomes (non-RCT=1; cross-
sectional=5) using custom-made questionnaires. All studies were targeting both T1D 
and T2D, apart from one (Dobson & Hall, 2015) aiming at T2D. Results from one study 
(Rao et al., 2010) indicated that ease of use and connectivity with a glucometer were 
the most desirable features in BG tracking apps (frequencies 100% and 90%, 
respectively). Use of diabetes apps, specifically glucose tracking apps, among Latinos 
was investigated in another study (Williams & Schroeder, 2015). They found that only 
3.1% (18/588) used diabetes apps, 50% of them reported that tracking of oral 
medications and reminders were the most frequently used functionalities, followed by 
tracking of BG (44%). In a third study (Conway et al., 2015), mHealth preference scores 
were skewed into high (7-10) preference category, nearly 70% of respondents agreed 
or strongly agreed that a smartphone app to manage diabetes would be a positive 
development and approximately 55% would prefer to use apps to manage their 
diabetes. The most preferred feature was password protection (56%), whereas social 
media was the lowest rated functionality (20%). Diabetes type influenced respondents’ 
preferences, with people with T1D showing a higher preference for a ratio wizard, 
logging of insulin and glucose monitoring; age, gender and diabetes type were 
significant confounders for mHealth preferences in diabetes management. Use of, and 
interest in, mobile apps were also assessed in underserved populations with less 
access to technology (Humble et al., 2015). High interest in using apps to help manage 
diabetes was found (57%) but only 36% thought that they would be extremely helpful 
in diabetes management. Users showed a greater preference for apps providing BG, 
BP, exercise tracking and reminders. Younger patients were more often smartphone 
owners and were more interested in using apps to manage their diabetes. In Denmark 
(Nielsen, 2013), 75% of patients surveyed were using apps to support diabetes control, 
with carbohydrate counting as the most-used functionality (75%), followed by 
insulin/medication tracking (21%), BG (17%), and BP monitoring (13%). Seventy-five 
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per cent of users were interested in sharing their collected data with their doctors and 
receiving feedback on their progress, and stated that they would feel safe if the app 
was recommended by their HCPs. On the users’ general perception of apps, 50% would 
trust the technology, and 63% did not have any concerns about confidentiality of their 
data. In another study (Dobson & Hall, 2015), 92% were not using their mobile phones 
in managing their diabetes, however 58% indicated their intention to use apps in the 
future. Most respondents expressed interest for tracking BG (90%), dietary planning 
(87.5%), and communication with HCPs about their diabetes (85.7%), and again 
younger people had more favourable attitudes and intentions to use apps in diabetes 
self-management.  
5.1.6.6 HCP-related outcomes  
One non-RCT assessed usability of a decision-support app using a custom-made 
questionnaire, with two samples of clinical staff (trial 1: nurses=12; physicians=6); trial 
2: nurses=51; physicians=14). Most participants in both trials (95% & 91%) felt safe and 
confident in using the app to support the glycaemic management of their patients; 
95% and 85% stated that glycaemic control was more efficient when using the app; 
100% and 80% reported that using the app helped prevent errors associated with 
insulin dosage or drug prescription; 89% and 89% believed that the app was practical 
to use in daily clinical routine; 95% and 86% stated that the app supported 
independent clinical decision-making and, thus, physicians were consulted less often. 
HCPs had mixed views about workload when using the app, 55.5% and 20% indicated 
workload was increased; 16.7% and 50.8% indicated workload was decreased; 27.8% 
and 18.2% indicated no change in the workload, while the remaining 11% in trial 2 did 
not answer the question. In general, the app was highly acceptable to HCPs on 
different clinical wards. 
HCPs’ compliance with given recommendations from the decision-support apps was 
assessed in two non-RCTs (Neubauer et al., 2015; Neubauer et al., 2014b; Sarala, 
2014). Adherence rates to the suggested insulin doses by physicians and nurses was 
very high in one study (range 95–98%). However, in the other study, 73% of 
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prescriptions in both the community health centres and the outpatient departments 
matched app recommendations, versus 63% at specialist clinics.  
HCPs’ errors and workflow anomalies were evaluated in one retrospective study (Spat 
et al., 2013). The study used real-life data from a previous clinical trial, including 1190 
decision-support action points, for simulation with the app. They compared the results 
generated by the app with those in the clinical study using a paper-based algorithm. 
Only four errors by the app were identified, versus 144 errors by physicians and nurses 
in the paper-based study, as well as ten workflow anomalies, such as adjustment of the 
daily insulin dose without any BG measurement. 
5.1.6.7 Miscellaneous outcomes 
The number of GP and specialist visits was assessed in one RCT only (Logan et al., 
2012), collected from medical records and patient self-reporting, which revealed no 
significant difference between groups in GP visits or combined visits to GPs and 
specialists.  
The time spent on consultation visits was evaluated in two RCTs. In one study (Hsu et 
al., 2015), the duration of virtual visits in the intervention group was electronically 
tracked whilst, for the control group, face-to-face interaction time was obtained from 
the subjects’ medical records. The intervention group required less total interaction 
time (average 65.7 minutes, excluding app training time, versus 81.6 minutes for 
controls). Still, the intervention group required additional time for training to use the 
mobile device. For the other study (Charpentier et al., 2011), the duration of visits was 
recorded as well as the time spent by participants coming for hospital visits. There was 
no difference between groups for the total time spent on visits, whether face-to-face 
or by telephone. However, face-to-face visits required more than half a working day 
traveling to and from the hospital, versus no additional time for the app. 
App utilisation and compliance with its use were reported in 12 studies (RCT=4; non-
RCT=8), using data logged in the app server, e.g. number and value of transmitted BG 
readings, inputted diet and exercise data, date and time. The extent and frequency of 
app use clearly varied among participants across the studies, some used it regularly or 
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as instructed, whereas others used it less frequently. A number of studies 
demonstrated high usage and excellent compliance with the app. In one study 
(Mackillop et al., 2014), 85% of women were compliant with the recommended 
frequency of BG monitoring (≥18 measurements/week). Two studies (Waki et al., 
2015; Wayne et al., 2015) reported relatively high compliance, ranged between 81-
90%, for both BG measurements and diet input but not for exercise. The rate of use 
was also very good in another study (Charpentier et al., 2011; Franc et al., 2014) with 
the insulin dose being calculated with the app for an average of 67% of meals 
throughout the study period. In a few studies, the data were extracted from the logs of 
the database and analysed for the purpose of identifying participants’ usage trends 
and patterns. A study (Tatara, 2013) confirmed a statistically decreasing (P<0.05) usage 
trend among participants. They concluded that individual usage patterns varied and 
changed over time with different magnitudes. BG measurement rate and input rate for 
diet and exercise declined to around 50% or more by the end of one study (Waki et al., 
2014), with the exception of morning BG measurements which stayed over 70%. 
Another study (Kirwan et al., 2013) also reported a decline with time in the number of 
BG logs and the number of text messages sent to the diabetes educator. By contrast, 
use in another study (Holmen et al., 2014) was low during the first month, then 
increased during the second month and remained about the same until the end-point. 
However, only 39% of participants were substantial users. The degree of usage for 
each app function was diverse too. One study (Kirwan et al., 2013) indicated that 54% 
of logged data were related to BG levels, followed by insulin (33%), whilst exercise was 
the least (1%). BG monitoring was the highest in another study also, with an average 
use of 3 times/day (Chomutare et al., 2013). Usage of the social networking 
functionality was generally very low (Cafazzo et al., 2012a; Chomutare et al., 2013). 
Gamification and reward techniques were used in one study (Cafazzo et al., 2012a) 
where they helped to sustain participants’ use and engagement with the app. Lastly, 
two studies (Miele et al., 2015; Pellegrini et al., 2015) did not aggregate the usage 
data. 
Very few studies (RCT=2; non-RCT=2) addressed adverse events and this, mainly, was 
in the discussion, rather than as an outcome (Frøisland et al., 2012; Holmen et al., 
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2014; Kirwan et al., 2013; Neubauer et al., 2015). Those that did report adverse events 
stated that, for the participants, there were no unintended effects related to the app 
use or the study overall. One study (Holmen et al., 2014) explained that some 
participants incurred high mobile costs for using the app while travelling abroad, 
however, participants were informed of this risk before starting the trial. 
5.1.7 Summary of findings  
The outcome matrix summarising the narrative synthesis of all studied outcomes, the 
number of supporting trials for the intervention effects, and a summary of the results 
of the outcomes that were reported in at least three studies in the review are provided 
in Appendix 9 (Tables 1–8).  
5.2 Discussion  
5.2.1 Summary of results 
The present review focuses on identifying, appraising and summarising all the available 
evidence about the use of mobile apps with respect to all reported outcomes. The 
result shows that the extent of the evidence for mobile apps in diabetes management 
and care is inadequate and weak. It is not possible to draw any conclusion thus far on 
their impact as an intervention either for patients or HCPs.  
A wide range of outcomes was reported in the included studies. HbA1c level was the 
most commonly assessed outcome. Evidence from meta-analysis showed that mobile 
apps may have a positive impact on HbA1c, as the pooled effect significantly favoured 
apps versus usual care. Subgroup analyses were conducted to investigate possible 
sources of the high heterogeneity found, but without finding significant differences in 
effects between the subgroups.  
Limited evidence of added benefits or mixed results were found for other clinical 
outcomes, psychosocial, behavioural or knowledge outcomes. Still, for the majority of 
outcomes when positive results were indicated, there were no significant differences 
found between groups or pre/post. 
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Utilisation of apps in diabetes management among participants is low, despite having 
access to the required technology. Both patients and HCPs have mixed views toward 
app usability, but generally scores were high. They expressed some satisfaction with 
apps and are willing to use them in routine care. 
Most studies focused on adults with T2D and patient-related outcomes. Evidence of 
the effectiveness of mobile apps for HCPs in clinical practice and for women with GDM 
is much more limited. 
5.2.2 Quality of evidence 
The review identified, appraised and summarised available evidence about the use of 
mobile apps, and found that the evidence base in diabetes management is inadequate. 
Findings should be interpreted with caution as the included RCTs had a high or unclear 
risk of bias across many domains, and many of the non-RCTs were uncontrolled with 
very small sample sizes (n≤25). In particular, there were studies with high risks of 
performance, attrition and reporting bias, and many had missing data, selectively 
presented data, or high or unclear dropout rates. Double-blinding was absent in all 
studies: as with most lifestyle interventions with modern technology, blinding of 
participants is not feasible; the open character may have introduced bias. 
Consequently, the decline in HbA1c, or any other observed effects, may not be 
attributable to the mobile app. Instead, it could be attributed to the special attention 
the participants may have received from their care providers when joining the study. 
By contrast, blinding of personnel may have been possible; specifically in those studies 
that examined self-care apps, as personnel may be masked to treatment group. With 
remote monitoring apps, personnel involved have to use a linked web portal to review 
participant’s data and provide feedback accordingly.  
Sample sizes in the RCTs were small (range 12–121) often leading to inadequate power 
to detect differences. 
Generally, non-RCTs scored low on the Downs and Black checklist (median 16/28). 
Most included non-RCTs were small (n=5–21) uncontrolled studies investigating the 
feasibility, acceptability, and the preliminary effectiveness of the apps. Nearly all 
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reviewed non-RCTs were neither statistically nor methodologically robust. This 
indicates limited generalisability to the wider population.  
Changes in technology over time 
Although the current review excluded studies that examined apps functioning on 
ordinary mobile phones, many of the included studies provided participants with first 
or second-generation smartphones when the technology was less developed than 
today. Advances in technology have occurred since their publication, which may make 
their results less relevant today. The smartphones provided in those studies, for 
example, were not integrated with Bluetooth technology or motion sensors. They 
required the use of supporting devices to help collecting certain health data. Thus, 
participants were provided with additional devices, such as Bluetooth adapters and 
external accelerometers, which posed challenges for participants owing to the 
requirement for multiple devices. 
Technical problems were reported by many participants across the studies, including 
trouble with the Bluetooth pairing, data transfer errors and difficulties in using the 
devices. This may have led to less satisfaction and decreased use of the app in the 
earlier studies. Therefore, this needs to be taken in consideration when evaluating the 
evidence. 
Mobile technology is rapidly evolving and, with developments through the years, smart 
devices have become smarter, and every new phone has superior features than the 
previous generation phone. Still, there is a great expectation for future possible 
development in the next generation of smart devices. Hence, findings are very likely to 
change after future research. This fact may limit the applicability of the findings from 
these studies. 
Wider settings 
The generalisability of findings from the included studies is quite limited. The patients, 
providers and practices in these studies were variable. The study durations, ranging 
between 1-12 months, were inconsistent as well, which may had an impact on the 
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glycaemic control measures reported across the included studies. Most studies took 
place in high-income countries, and all were published in English. Therefore, the 
applicability of their results to wider settings is questionable.  
Participants’ compliance 
Only one third of the studies tackled participants’ compliance with app use by using 
logged data; the remaining two thirds did not evaluate compliance. This raises 
uncertainties about whether detected effects were attributable to the use of the app.   
Overall, despite multiple trials examining the use of mobile apps in diabetes 
management, the standard of the evidence to date is poor. This highlights the need for 
large-scale, high-quality experimental research conducted in this area. 
5.2.3 Comparison with other reviews 
As outlined in the discussion on existing systematic reviews and meta-analyses 
presented earlier in this thesis (Chapter 2, section 2.2.1), several recent reviews have 
addressed the use of mobile apps in diabetes management but their approaches 
differed. 
The present review conducted a meta-analysis with a pooled effect on HbA1c reduction 
of -0.45% (95% CI: -0.85 to -0.04%; p=0.03; I2=76%), indicating a moderate benefit on 
glycaemic control, consistent with some earlier meta-analyses (Bonoto et al., 2017; Cui 
et al., 2016; Hou et al., 2016). One study (Cui et al., 2016) was restricted to T2D and 
showed that the pooled effect on HbA1c reduction was -0.40% after the use of self-care 
apps. In a second study (Hou et al., 2016), the pooled effect on HbA1c reduction for 
T2D was -0.49%, whereas for T1D was -0.36%. Another study (Bonoto et al., 2017) 
reported a mean decrease in HbA1c of -0.44%. These results were mostly associated 
with considerable heterogeneity. 
Subgroup analysis was performed according to diabetes type in two of these review 
(Bonoto et al., 2017; Hou et al., 2016), and both T1D and T2D showed non-significant 
HbA1c reduction with apps. Unlike those reviews, this review found a significant effect 
favouring T1D (P=0.02). This could be attributable to the younger age of people with 
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T1D (mean age 35 years vs. 55 years for T2D); this is in accordance with a study (Hou et 
al., 2016) which indicated that younger patients were more likely to benefit from apps 
(HbA1c reduction 1.03% for ≤55 years versus 0.41% for >55 years). 
The subgroup analysis showed a larger and significant reduction in HbA1c for apps that 
involved interaction with HCPs. This provides some support for previous claims that 
apps are more effective when combined with feedback from HCPs (Cui et al., 2016; 
Garabedian et al., 2015; Hou et al., 2016). A possible rationale for this is the added 
benefit of closer monitoring, even outside the clinic, in addition to the facilitated 
interaction at any time between patients and HCPs. Yet, the exact relationship 
between apps, feedback and positive outcomes is not clear. People with diabetes 
expressed interest and willingness to use apps that involve interaction with HCPs. 
Subgroups by follow-up duration did not differ significantly, possibly due to insufficient 
number of studies at each time-point. Other studies found a non-significantly larger 
reduction in HbA1c with a shorter follow-up duration (<6 months) than with a longer 
duration (>6 months) (Garabedian et al., 2015; Hou et al., 2016; Kitsiou et al., 2017). 
Existing reviews did not distinguish between the different functionalities of mobile 
apps (e.g. helping patients adjust insulin doses, track BG levels or support healthy 
lifestyles) despite the differences in the intervention components in both diabetes 
management and the use of design techniques. One exception is a study which 
performed subgroup analysis by the number of functions available in the app. 
However, both subgroups showed significant favourable results in HbA1c control 
(Bonoto et al., 2017). Within the included studies, various functionalities of apps were 
not always shown to support glycaemic control. It was not feasible to carry out a 
subgroup analysis by app functionality due to the small number of included RCTs. The 
functionality of apps needs to be standardised in future research to enable the 
assessment of their impact. 
On other outcomes, there appear to be early indications of improvement from the use 
of apps but the final results tended to be insignificant and inconclusive (Bonoto et al., 
2017; Cui et al., 2016; Deacon & Edirippulige, 2015; Hood et al., 2016). Some of the 
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past reviews examined mobile interventions more generally, rather than apps 
specifically, with significant heterogeneity existing among the trials included. 
Unlike the previous reviews, the present review addresses the use of apps by HCPs in 
clinical practice and decision-making, and apps that support women with GDM.  
5.2.4 Strengths and limitations of review 
There is no standard definition of a diabetes mobile app and studies may have defined 
it differently. This review made a clear definition of a mobile app before commencing 
the study, which may be considered as a strength. The present review is the first to 
evaluate the impact of mobile apps, functioning on smartphones and tablets. It 
expands the evidence base by bringing together studies of apps designed to support 
people with diabetes or HCPs in diabetes care and by assessing both clinical and non-
clinical outcomes. It also contributes to the emerging literature of mHealth app 
usability and acceptability. It further highlighted the lack of research with HCPs and 
women with GDM. 
The breadth of review scope, with a wide range of participants, settings and all 
reported outcomes, is a strength of this review, although this heterogeneity in study 
objective, design, age range, diabetes type and variation in app functionality all made 
clear comparisons difficult. 
This review was not limited to the English language. Moreover, a broad search strategy 
was carried out using variety of terms. As well as searching the main medical and 
computer science databases, searches were also carried out in the grey literature and 
trial registers. Additionally, setting up the Auto Alert in most databases enabled the 
inclusion of many more studies that were published after the search was conducted. 
Two authors were involved in making the decisions for study selection and for data 
extraction and quality assessment in order to avoid bias and improve reliability. 
This review had several limitations too. Problems were encountered regarding the 
selection of studies for inclusion, since some studies did not describe their intervention 
clearly, in particular, whether or not it was functioning on a smartphone/tablet, 
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causing a problem about deciding whether they should be included. As a result, there 
is a chance of missing a number of trials. Contacting study authors for clarification on 
their interventions was attempted in a few instances to ensure that the inclusion 
criteria were adhered to thoroughly. In addition, authors were contacted for missing 
data whenever possible. One weakness of evidence is that it was not always clear if the 
measured effect was entirely attributable to the use of apps since compliance with its 
use was not ensured in all studies; or perhaps, it could be attributed to other factors 
such as HCPs feedback. 
The main limitation of the meta-analysis was the substantial heterogeneity between 
the included studies. Thus, it only provided an overall estimate that suggests areas for 
future research. Data for other outcomes could not be pooled in a meta-analysis. Due 
to the inconsistencies in the outcome measures among the included studies in this 
review, it was not possible to standardise all the data for any single outcome. Although 
a number of studies assessed the same outcome, they were measuring it in different 
ways; for instance, QoL was assessed in many studies but using different instruments 
with varying numbers of scales and sub-scales. Therefore, a narrative synthesis was 
carried out for other outcomes by grouping them into categories which was deemed 
the most appropriate way to present such huge and variable data to allow the reader 
easily to capture the extent of the evidence base and the variability among the 
different studies and their measures.  
The findings from this review would have been more useful if the studies were 
classified into groups by app functionality to allow reliable comparison and help 
identify the most effective app functionality. However, a subgroup analysis by app 
functionality and stratifying the results of synthesis by app functionality was found to 
be infeasible due to the small number of RCTs included and the significant 
heterogeneity among studies. 
5.2.5 Methodological consideration 
Two of the included RCTs (Charpentier et al., 2011; Holmen et al., 2014) had three 
arms and for the purposes of this review, only two arms, the mobile app group and the 
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control group, were included for comparison. Any statistical analysis undertaken in 
these studies was between the three groups rather than between the two groups of 
interest. For that reason, it is important to recognise that any between-group 
comparisons presented are representative of a difference between all three groups 
and not precisely between the two groups. 
5.2.6 Implications of the review and future research 
The findings of the present review did not provide adequate evidence about mobile 
apps’ effectiveness. Therefore, the main implications of this review arise from the 
dearth of evidence in relation to apps.  
Need for additional research  
Small-scale pilot and feasibility studies with post-only, or pre-post with no control 
designs were the dominant forms of apps trials. This indicates scope for further 
research, requiring large scale and good quality as the central characteristics of any 
future studies, especially methodologically rigorous and adequately-powered RCTs 
with longer follow-up. Further empirical research is needed to examine the 
effectiveness and costs of introducing apps for both patients and HCPs. Additionally, 
research exploring the impact of apps on clinical practice outcomes is needed. 
Future research should also consider the use of apps by adolescents and women with 
GDM. Most teenagers are ‘technology savvy’; they are more inclined to use apps than 
adults and, thus, are anticipated to benefit more. Apps may also have high potential to 
contribute to the care of GDM due to the short-term nature of the condition that 
occurs during pregnancy. Given that the purpose and functionality of apps were 
diverse across the heterogeneous studies included, establishing standardised app 
functionalities may assist in identifying the most effective functionality and facilitate 
the interpretation of future research findings.  
Implications for app developers 
Not all studies agreed on the most desired app functionalities and features. However, 
in general, diabetes education was the least offered functionality in diabetes apps at 
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present, but was rated the highest, whereas social support was the least utilised 
functionality. Other repeatedly recommended functionalities included automatic data 
input, reminders and glucometer connectivity. Incorporating these functionalities and 
features into diabetes apps may maximise their potential benefits.  
In some studies, the app mainly supported one task of diabetes management, while in 
others it supported multiple tasks. Due to the lack of integration in apps’ functionality, 
some users were using more than one app, each with a specific task, to supplement 
each other. This may underline a need for more comprehensive apps that help 
patients manage different aspects of their condition. However, with multiple tasks 
app, their usability may be negatively impacted.  
Apps targeting patients’ remote monitoring were more likely to be effective. This 
suggests that HCPs feedback is a key functionality in future diabetes apps, helping to 
achieve greater improvements in glycaemic control and compliance.  
Implications for practice  
Mobile apps can potentially add to diabetes care in clinical practice. The lack of robust 
evidence makes implications for clinical practice difficult to determine. Before 
widespread implementation of mobile apps into practice to complement the care for 
the growing number of people with diabetes, more research on the effectiveness, cost-
effectiveness and acceptance by both patients and HCPs is needed.  
Patients and HCPs in the included studies generally expressed interest and satisfaction 
with apps, so increasing patients' and HCPs’ awareness of the available diabetes apps 
with their potential benefits is important. There remains a need for patients, clinicians 
and policy-makers to understand whether the use of apps should be considered for 
diabetes care and management. As the mHealth field matures, policies that integrate 
mobile apps into healthcare management and services will become more likely.   
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Chapter 6  A qualitative systematic review: Results and 
discussion 
Chapter overview 
This chapter describes the findings from the qualitative systematic review, including 
the search results; characteristics of included studies; quality assessment; narrative 
synthesis (text and tables); summary of the results; discussion on the quality of the 
evidence; a comparison with relevant reviews; strengths and limitations; 
methodological considerations; and the implications and impact of the review on 
future research.  
Design 
This systematic review adopted a narrative approach to synthesise the findings of 
qualitative studies. This deductive method allows an exploratory analysis which fits 
well with the aim of describing the literature on how mobile apps are perceived and 
experienced. The ENTREQ checklist (Enhancing Transparency in Reporting the 
Synthesis of Qualitative Research) was used to ensure systematic reporting of the 
review (Tong et al., 2012). 
6.1 Results  
6.1.1 Results of the search 
Detailed description of the search results and the flow diagram for the selection of 
studies were provided in the previous chapter (Chapter 5, section 5.1). Eighty records 
fulfilled the selection criteria, comprising 34 quantitative studies and 20 qualitative 
studies, the latter of which were published in the following formats: 
▪ four studies were represented by individual theses or dissertations (Min, 2013; 
Nielsen, 2013; Sarala, 2014; Skinner, 2015); 
▪ two had one thesis and one published journal article (Årsand, 2009; Årsand et 
al., 2010; Harris et al., 2010; Le, 2008); 
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▪ one had one thesis and two published articles (Tatara, 2013; Tatara et al., 
2013a; Tatara et al., 2013b); 
▪ three had one published article and one published abstract (Cafazzo et al., 
2012a; Cafazzo et al., 2012b; Franceschi et al., 2014; Miele et al., 2015; Waki et 
al., 2015; Waki et al., 2011); 
▪ one had two published journal articles and one published abstract (Frøisland et 
al., 2011; Frøisland & Årsand, 2015; Frøisland et al., 2012); 
▪ one had two published articles and three published abstracts (Hill & Masding, 
2013; Pulman et al., 2012; Pulman et al., 2013a; Pulman et al., 2013b; Pulman 
et al., 2013c); and 
▪ the remaining eight studies were represented by individual published articles 
(DeShazo et al., 2010; Garnweidner-Holme et al., 2015; Hsu et al., 2015; 
Lehocki et al., 2012; Owen et al., 2015; Pellegrini et al., 2015; Pludwinski et al., 
2015; Scheibe et al., 2015). 
6.1.2 Included studies 
The 20 studies (published 2008–2015) fell within two broad design approaches: nine 
were entirely qualitative and 11 utilised mixed-methods designs. Table 6.1 presents 
the distributions of the included studies by different characteristics. Details of included 
studies (country, data collection method, intervention purpose and functionality, 
sample size, study aim/objectives and analysis method) were extracted and 
summarised in the tables 'Characteristics of included studies' in Appendix 8 (Table 4).  
Table 6.1 Distribution of the included studies by different variables. 
  No of trials, 
n 
Percentage, % 
Data collection method 
Interview 
Focus Group 
Questionnaire 
Think-aloud  
Field-testing and user feedback 
  
18 
3 
5 
2 
1 
 
90 
15 
25 
10 
5 
Country 
USA & Canada 
Europe (UK, Norway, Slovak Republic, Italy, Germany, 
Denmark) 
Southeast Asia (Japan, India) 
 
 
8 
10 
2 
 
40 
50 
10 
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Study setting  
Primary care 
Secondary care (outpatient and inpatient) 
Community and non-medical setting (Non – clinical) 
Tertiary care  
  
4 
7 
8 
1 
 
20 
35 
40 
5 
Age group 
Younger age group <18 
Older age group ≥ 18 
  
4 
16 
 
20 
80 
Population 
Patients 
Children/adolescents patients with/without parents  
HCPs 
  
16 
4 
2 
 
80 
20 
10 
Type of diabetes 
Type 1 
Type 2 
Type 1 & 2  
GDM 
  
8 
7 
4 
1 
 
40 
35 
20 
5 
Intervention purpose 
Self-care 
Telemonitoring 
Clinical practice 
  
13 
6 
1 
 
65 
30 
5 
6.1.2.1 Data collection methods 
Qualitative elements of the included studies used five data collection methods, with 
several studies combined multiple methods. Interview (semi-structured, structured, in-
depth, ethnographic and structured written) was the most frequently-used method (18 
studies) (Årsand, 2009; Cafazzo et al., 2012a; Frøisland et al., 2012; Garnweidner-
Holme et al., 2015; Harris et al., 2010; Hsu et al., 2015; Miele et al., 2015; Min, 2013; 
Nielsen, 2013; Owen et al., 2015; Pellegrini et al., 2015; Pludwinski et al., 2015; Pulman 
et al., 2013a; Sarala, 2014; Scheibe et al., 2015; Skinner, 2015; Tatara, 2013; Waki et 
al., 2015). Focus group was employed by three studies (Årsand, 2009; DeShazo et al., 
2010; Tatara, 2013), whereas questionnaire was utilised within five studies (Årsand, 
2009; DeShazo et al., 2010; Nielsen, 2013; Pellegrini et al., 2015; Tatara, 2013). Two 
studies used think-aloud method (Garnweidner-Holme et al., 2015; Harris et al., 2010) 
and one study employed field-testing and user feedback (Lehocki et al., 2012). 
6.1.2.2 Sample sizes 
The studies (n=20) included a total of 357 participants (287 adult patients, 50 
children/adolescent patients with their parents, and 20 HCPs; study sizes ranged from 
5–52 [median=13]).  
   
110 
6.1.2.3 Settings 
Studies were conducted in the USA (n=5), Canada (n=3), Norway (n=4), UK (n=2), 
Germany (n=1), Italy (n=1), Denmark (n=1), Slovak Republic (n=1), Japan (n=1) and 
India (n=1). 
Studies were conducted in primary care (Harris et al., 2010; Lehocki et al., 2012; 
Pludwinski et al., 2015; Sarala, 2014), secondary care (Cafazzo et al., 2012a; Frøisland 
et al., 2012; Garnweidner-Holme et al., 2015; Miele et al., 2015; Min, 2013; Pulman et 
al., 2013a; Waki et al., 2015), tertiary care (Hsu et al., 2015), and community and non-
medical settings (Årsand, 2009; DeShazo et al., 2010; Nielsen, 2013; Owen et al., 2015; 
Pellegrini et al., 2015; Scheibe et al., 2015; Skinner, 2015; Tatara, 2013). 
6.1.2.4 Participants  
Participants in four studies (Cafazzo et al., 2012a; Frøisland et al., 2012; Miele et al., 
2015; Skinner, 2015) were children or adolescents with, or without, their parents; the 
remaining 16 studies included adult patients, and of these, two studies (Nielsen, 2013; 
Sarala, 2014) included both patients and HCPs.  
More studies targeted patients with T1D only (n=8), followed by T2D only (n=7), while 
only one study examined women with GDM (Garnweidner-Holme et al., 2015). Four 
studies considered both T1D and T2D (DeShazo et al., 2010; Harris et al., 2010; Nielsen, 
2013; Scheibe et al., 2015), of which two (Nielsen, 2013; Harris et al., 2010) did not 
report the distribution of diabetes type.  
6.1.2.5 Interventions 
Different types of mobile apps were examined: six studies explored apps aiming to 
facilitate patients’ telemonitoring (Hsu et al., 2015; Lehocki et al., 2012; Miele et al., 
2015; Nielsen, 2013; Pludwinski et al., 2015; Waki et al., 2015), whilst only one 
considered an app supporting clinical decision-making (Sarala, 2014). The remaining 
studies (n=13) examined apps supporting diabetes self-care. Studies varied in their 
main focus, functionalities and applied design techniques.  
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Other studies did not involve an intervention; generally they explored participants’ 
perceptions, needs and views on apps for diabetes management. 
6.1.2.6 Evaluation 
Studies evaluating the same outcome were grouped together. 
1. Patients’ experience with intervention components 
This group of studies commonly employed mixed-methods designs and, thus, involved 
app trialling followed by exploration of participants’ experiences with the intervention 
components (e.g. acceptability, accessibility, satisfaction, and use and utilisation). 
2. Patients’ perception on the use of apps 
Studies explored participants’ perceptions and views on the use of apps to support 
diabetes management.  
3. Patients’ needs and requirements for apps 
These studies identified, from participants’ experience with diabetes and their views, 
the needs and requirements of the target users in order to assist in the early design 
and development of an app. This also included participants’ preferences and desired 
apps features and, thus, some studies further provided a number of ideas and 
suggestions for apps functionalities and enhancements to help guide app developers. 
4. Usability of apps 
These studies evaluated the usability of an initial design of the app (second step of 
design phase) to identify potential issues in workflow and further refine the design. 
5. Factors influence patients’ acceptance of apps 
This group identified factors influencing participants’ acceptance and use of diabetes 
apps. 
6. HCPs’ experience and/or perspective on the use of apps 
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These studies explored HCPs’ experiences with intervention components or 
perspectives on the use of apps to support diabetes management. 
Table 6.2 shows studies in to each group. 
Table 6.2 Classification of included studies into groups according to their main focus of evaluation. 
Evaluation Study reference 
Patients’ experience with intervention 
components 
Årsand 2009, Frøisland 2012, Tatara 2013, Sarala 
2014, Miele 2015, Pludwinski 2015, Hsu 2015, 
Owen 2015, Pellegrini 2015 
Patients’ perception on the use of apps Nielsen 2013 
Patients’ needs and requirements for apps 
Harris 2010, Deshazo 2010, Cafazzo 2012, Min 
2013, Pulman 2013, Skinner 2015, Garnweidner-
Holme 2015 
Usability of apps 
Harris 2010, Deshazo 2010, Lehocki 2012, Tatara 
2013, Waki 2015, Garnweidner-Holme 2015 
Factors influence patients’ acceptance of apps Scheibe 2015 
HCPs’ experience and/or perspective on the use 
of apps 
Nielsen 2013, Sarala 2014 
6.1.3 Quality of included studies 
The application of CASP critical appraisal tool across the 20 studies showed variable 
results. In all studies, a clear statement of the research aims was provided and 
qualitative methods were considered appropriate to address their aims and objectives. 
All except four studies (Miele et al., 2015; Scheibe et al., 2015; Tatara, 2013; Waki et 
al., 2015) gave sufficient description of the sampling strategy and/or recruitment 
process but only five provided some rationale for the selection of participants (Lehocki 
et al., 2012; Nielsen, 2013; Owen et al., 2015; Sarala, 2014; Skinner, 2015). Only five 
studies reported potential reasons for non-participation (Nielsen, 2013; Pellegrini et 
al., 2015; Pludwinski et al., 2015; Skinner, 2015; Tatara, 2013). Data collection method 
was reported in all studies but with variation in the degree of detail given. The setting 
was described in nine studies (Årsand, 2009; Frøisland et al., 2012; Garnweidner-
Holme et al., 2015; Harris et al., 2010; Min, 2013; Nielsen, 2013; Sarala, 2014; Scheibe 
et al., 2015; Skinner, 2015), while who carried out the data collection was stated in ten 
studies (Årsand, 2009; Cafazzo et al., 2012a; DeShazo et al., 2010; Garnweidner-Holme 
et al., 2015; Lehocki et al., 2012; Min, 2013; Nielsen, 2013; Pellegrini et al., 2015; 
Sarala, 2014; Skinner, 2015). Only five studies provided justification for the selection of 
data collection methods (Min, 2013; Nielsen, 2013; Pulman et al., 2013a; Scheibe et 
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al., 2015; Skinner, 2015). Data saturation was only discussed in four studies (Cafazzo et 
al., 2012a; Pludwinski et al., 2015; Sarala, 2014; Skinner, 2015). 
Reflexivity was adequately discussed in three studies (Årsand, 2009; Min, 2013; Sarala, 
2014) where they critically examined researchers’ roles and any potential influence 
and bias in the formulation of research question, sampling, data collection or analysis. 
An additional six studies (Harris et al., 2010; Lehocki et al., 2012; Nielsen, 2013; 
Scheibe et al., 2015; Skinner, 2015; Tatara, 2013) partly reflected on potential bias of 
researchers at some stages of the study.  
Five studies (Lehocki et al., 2012; Miele et al., 2015; Nielsen, 2013; Owen et al., 2015; 
Pulman et al., 2013a) did not report details on ethical approvals from research ethics 
committees or participants’ consent. An additional three studies (DeShazo et al., 2010; 
Harris et al., 2010; Scheibe et al., 2015) did not explicitly discuss either the approval or 
the consent, whereas the remaining (12 studies) sufficiently discussed obtaining 
approvals and written consent from all participants before the commencement of any 
data collection. Only four studies (Owen et al., 2015; Pellegrini et al., 2015; Sarala, 
2014; Skinner, 2015) described how the study was explained to participants. Likewise, 
four studies (Owen et al., 2015; Pludwinski et al., 2015; Sarala, 2014; Tatara, 2013) 
discussed how confidentiality was maintained. 
Half of the studies (n=10) provided adequate description of data analysis method but 
the extent of information given was variable (Cafazzo et al., 2012a; Frøisland et al., 
2012; Min, 2013; Nielsen, 2013; Pellegrini et al., 2015; Pludwinski et al., 2015; Sarala, 
2014; Scheibe et al., 2015; Skinner, 2015; Tatara, 2013). An indication of involvement 
of multiple researchers in the analysis process was given in only four studies (Cafazzo 
et al., 2012a; Frøisland et al., 2012; Harris et al., 2010; Min, 2013). Sufficient primary 
data, i.e. quotations from participants, were presented to support findings in ten 
studies (Årsand, 2009; Frøisland et al., 2012; Nielsen, 2013; Owen et al., 2015; 
Pludwinski et al., 2015; Pulman et al., 2013a; Sarala, 2014; Scheibe et al., 2015; 
Skinner, 2015; Tatara, 2013). Findings in most (15) studies were explicit and clearly 
discussed in relation to other published research, but five studies (DeShazo et al., 
2010; Hsu et al., 2015; Lehocki et al., 2012; Miele et al., 2015; Pulman et al., 2013a) 
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were very limited in their presentation of findings. Only six studies considered the 
credibility and validity of their findings (Årsand, 2009; Frøisland et al., 2012; Nielsen, 
2013; Pulman et al., 2013a; Sarala, 2014; Tatara, 2013). The assessment result for all 
studies is in Appendix 10.  
6.1.4 Synthesis of findings 
A narrative overview of the findings of studies, using the above classification by main 
study focus, is shown with illustrative quotations from the primary studies. 
6.1.4.1 Patients’ experience with intervention components  
Although nine studies (presented in Table 6.2) explored participants’ experience 
following a completion of an intervention trial, these interventions were diverse in 
their main functionality, purpose and design. Three studies (Årsand, 2009; Frøisland et 
al., 2012; Tatara, 2013) examined different versions of the same app ‘Few Touch’; yet, 
the studies were different in their focus and population.  
Disease management was the main focus in four studies (Frøisland et al., 2012; Hsu et 
al., 2015; Owen et al., 2015; Pludwinski et al., 2015). Of these, two (Frøisland et al., 
2012; Owen et al., 2015) examined apps supporting self-care for patients with T1D, 
whereas the other two (Hsu et al., 2015; Pludwinski et al., 2015) examined apps 
involving remote monitoring of patients with T2D. Of these four, one (Frøisland et al., 
2012) explored adolescents patients’ experience, while the remaining targeted adults. 
Behaviour change was the primary focus in two studies (Årsand, 2009; Pellegrini et al., 
2015) which examined apps supporting self-care in patients with T2D. Understanding 
and describing app usage patterns and utilisation was the focus in two studies (Miele 
et al., 2015; Tatara, 2013). One targeted remote monitoring of children with T1D 
(Miele et al., 2015), while the other supported self-care for patients with T2D (Tatara, 
2013). 
Similarities emerged between studies’ findings. In three studies (Frøisland et al., 2012; 
Owen et al., 2015; Pludwinski et al., 2015), the app enabled participants to capture 
relevant health-related information in the form of images. Integrating trend graphs 
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and/or a photo-based diary gave young people and adults a better visual 
understanding of their diabetes and how physical activity, food intake and insulin 
dosage interact and affect BG levels (Årsand, 2009; Frøisland et al., 2012; Hsu et al., 
2015; Owen et al., 2015; Pludwinski et al., 2015; Tatara, 2013). This assisted individuals 
in trend spotting, self-reflection, and self-awareness of habitual behaviours. 
‘That one gets it visually – the combination of all the efforts you do – it’s 
incredibly important for further motivation.’ (Årsand, 2009) 
‘Before, I really thought that the blood sugar was one thing and giving insulin 
was one thing and eating was one thing, but now I see more all three of them as 
a whole, that they all belong together.’ (Tom, Frøisland et al., 2012) 
‘I understand the reasons behind the decision (of changing insulin dose) much 
better.’ (Hsu et al., 2015) 
In addition, capturing and saving meals’ pictures gave them a visual understanding of 
their own unhealthy diet (Frøisland et al., 2012), and increased awareness of portion 
size and carbohydrate intake (Pludwinski et al., 2015). Image capture was more likely 
to be used in unusual events and during moments of change as it enabled in 
understanding the impact of new factors (Owen et al., 2015).  
‘I just photographed the food I usually eat, but I thought during the process that I 
should apply more healthy eating habits, because I saw I had a lot of unhealthy 
canteen food in school.’ (Erik, Frøisland et al., 2012) 
‘If I can see a picture of what I have eaten it gives me a better idea of what my 
blood sugars are doing and why… I had a couple of hypos and I looked back at the 
photographs and saw that I had a coffee and a muffin and had really 
overestimated the insulin.’ (Holy, Owen et al., 2015) 
In studies that involved any type of interactions with care providers, participants 
described the app as a ‘sought-after’ tool that gave them a feeling of access and 
security (Frøisland et al., 2012). Additionally, the involved HCPs were perceived as 
always watching them (Pludwinski et al., 2015).  
‘The fact that you have someone to support you—someone who knows the 
subject, and if you get into difficulties you can get an answer—it gives a certain 
feeling of security.’ (Oda, Frøisland et al., 2012) 
‘(Smartphone) was my watcher. Somebody is watching you through your eyes . . . 
it was so interesting’ (Participant #9, Pludwinski et al., 2015) 
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In a similar way, participants in studies that involved telemonitoring (Hsu et al., 2015; 
Pludwinski et al., 2015) shared positive experiences about the interaction with their 
HCPs, and they felt that the connectivity with their HCPs helped reduce anxiety and 
the feeling of isolation, and the feedback received was specifically identified as 
motivating.  
‘It’s comforting to know that they [clinician coaches] are always there.’ (Hsu et 
al., 2015) 
‘I think this study helped me emotionally a lot, more than physical, I feel 
emotionally happy. That is important to me’ (Participant #9, Pludwinski et al., 
2015) 
Participants felt empowered through the connectivity with their HCPs, e.g. in making 
insulin adjustments (Hsu et al., 2015). Others became more critical of their own 
behaviours related to food and exercise (Pludwinski et al., 2015) 
‘I feel more equal with the coach in making decision about my health.’ (Hsu et al., 
2015) 
The use of apps appeared to have increased participants’ sense of control and 
confidence to deal with, and interpret, their information in meaningful way (Owen et 
al., 2015; Pludwinski et al., 2015; Tatara, 2013). Some participants reported notable 
changes to their management regime (Owen et al., 2015). One stated that the use of 
the app helped reduce his medication (Årsand et al., 2010): 
‘Even though I admit that the blood glucose measurement system made me 
stressed, I also see that when using it, I reduced my medication by one tablet a 
day.’ (Årsand et al., 2010) 
Another participant said:  
‘I did not eat so much sweet food in the Christmas season. Instead, I ate a lot of 
fruits and a little bit of cake every now and then.’ (P03 at Meeting 3, Tatara, 
2013)  
Participants in studies that were supporting lifestyle changes (Årsand et al., 2010; 
Pellegrini et al., 2015; Tatara, 2013) reported that they were motivated by the 
challenge to trying to reach their own goal; i.e. achieve a smiley face for attaining food 
habit goal or the red line for reaching the target daily steps. 
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‘The motivation increased again when we got the step counter. I have tried not to 
take the bus, but instead walked back and forth to my work.’ (Årsand et al., 2010) 
Moreover, they found the diet tracking functionality useful, particularly as a learning 
resource; however, they reported that the need to manually record food intake several 
times a day was tiring (Årsand et al., 2010). 
‘This is a tool that can help you to learn more about yourself, but sometimes I 
become tired of recording what I eat each day.’ (Årsand et al., 2010) 
Participants who underwent an intervention aiming to increase physical activity 
(Pellegrini et al., 2015) stated that the app made them more aware of their sitting time 
and motivated them to stand up and take more breaks from sitting. 
‘It would remind me that I had been sitting for a period of time, without having to 
think about it.’ (Pellegrini et al., 2015) 
Two studies described patterns of use among participants (Miele et al., 2015; Tatara, 
2013). One study (Miele et al., 2015) concluded that one size does not fit all, pointing 
to the fact that users have heterogeneous needs and, thus, no-one used all the 
provided functions and nobody used only a single function. The second (Tatara, 2013) 
concluded that there were significant variations in usage patterns and level of 
engagement and they changed over time. They explained that motivation to use the 
app is a result of balance between efforts required to use it and benefits attained. In 
general, participants’ usage and interactions with the app decreased over study 
periods and the novelty of using the app wore off with time (Owen et al., 2015). Tatara 
(2013) outlined two main reasons for the decrease in usage: 1) attrition of motivation 
after obtaining a sense of control over diabetes, and 2) experience of problems in 
using the app. 
‘I have not used the application in the last four months since the summer 
holidays. But the HbA1c went down from the last time. I believe that I have gained 
a better understanding about myself, and now I don’t have to use it daily as I did 
before. I was eager at the beginning. Even though I don’t use it, I think over what 
I eat and things like that anyways.’ (P11 at Meeting 6, Tatara, 2013)  
In terms of overall experience across studies, positive experiences indicated in the 
majority of studies as participants generally were satisfied and found apps to be highly 
usable and useful. 
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‘The program is a big motivation in my life… it’s a positive thing for me… with all 
that’s going on I need positive things.’ (Participant #6, Pludwinski et al., 2015) 
Contrary to that, participants encountered some technical problems that required 
resolution; mostly related to WiFi/network connectivity (Frøisland et al., 2012; Hsu et 
al., 2015). Other participants experienced malfunctions with the supporting devices 
such as a glucometer or a step counter (Årsand, 2009; Pellegrini et al., 2015; Tatara, 
2013).  
‘Yes, the project was tailored to me, but it could have been better on the glucose 
transmission [from the glucometer to the phone] because it didn’t work all the 
time.’ (David, Frøisland et al., 2012) 
Few participants, particularly those with highly structured and predictable routines, 
struggled to integrate the app into their management routine. The reported reasons 
were either that the app interrupted their habits and routines (Owen et al., 2015) or 
that there was a mismatch between app design concepts and reality (Tatara, 2013). 
‘I think it takes a bit more time for something like this to become part of a 
routine, I have been using paper and an insulin pump since 2001.’ (John, Owen et 
al., 2015) 
Participants expressed some concerns around the use of photo capture or data entry 
during social situations (Owen et al., 2015; Tatara, 2013). 
‘I entered results every time, except when it was rude to get my phone out then I 
would retrospectively add them.’ (Sarah, Owen et al., 2015) 
Sarala 2014 (Sarala, 2014) was distinct from others, that it interviewed 33 patients 
with T2D who underwent an intervention; a smartphone-based decision-support app 
used by HCPs. The study explored their experience and how they perceived the use of 
a ‘smart phone’ by nurses and physicians in the middle of the consultations. The app 
gained high acceptance among patients; the majority felt the smartphone was of use 
to them and the recording of their data through the app was useful. A 46-year-old 
female patient was of the opinion that: 
‘The nurse enters data into the phone in front of me. I think recording data is for 
patient care.’ (Sarala, 2014) 
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6.1.4.2 Patients’ perception on the use of apps 
Only one study (Nielsen, 2013) explored patients’ perceptions and preferences on the 
use of smartphone apps to enhance adherence to remote diabetes monitoring and 
self-management. The study showed that most people with diabetes in Denmark are 
using apps to support the monitoring and self-management. The overall perception 
was positive; participants have already adopted and accepted the technology. They 
believe that it could be used as a tool to help change their lifestyle and improve 
diabetes control, though different social group of users have variable meanings and 
opinions about the use of apps. The potential risks related to safety and security of 
apps do not seem to prevent respondents using apps for diabetes management.  
Most participants are willing to engage their HCPs in the monitoring and self-
management of diabetes through using apps. However, there is controversy on the 
extent that they should involve HCPs in their diabetes control. They do not perceive 
apps as a replacement for face-to-face visits with their doctors; they prefer a 
combination of both personal and digital interaction with their doctors. They stated 
that they would feel safe if apps were recommended by their physicians.  
Despite the satisfaction with some of the available apps’ features and functions, 
respondents expressed a lack of interest in using certain functionalities. Some users 
are not interested in the alert functionality which allow them to set reminders, for 
instance, to take medication. In addition, few participants are interested in social 
media networking with respect to their diabetes. The author interpreted this as ‘one-
size-does-not-fit-all’ with regards to apps’ features and functions, meaning that users 
have different preferences as individuals. Most participants would prefer an ‘all-in-
one-place’ app. Yet, most participants tend to use more than one app to complement 
each other.  
On the negative side, lack of synchronisation with other devices, such as the 
glucometer, or with their doctor’s system, and with other websites, were indicated as 
limitations of currently available apps.  
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6.1.4.3 Patients’ needs and requirements for apps  
Users’ needs and requirements were explored in seven studies to inform more patient-
centred design and development of apps supporting diabetes management. Of these, 
four (DeShazo et al., 2010; Garnweidner-Holme et al., 2015; Harris et al., 2010; Min, 
2013) targeted the needs of adults with T1D, T2D or GDM. Two (Cafazzo et al., 2012a; 
Skinner, 2015) targeted children and adolescents with T1D and their families, while the 
remaining one targeted young people aged 18–21 with T1D (Pulman et al., 2013a).   
Participants expressed their need to share diabetes-related information with close 
family members (Min, 2013; Skinner, 2015). Although most have social network 
accounts, i.e. Facebook, Twitter, etc., they further explained that they are not 
interested in discussing diabetes matters with online communities (Min, 2013). 
Children and teens are willing to share their data with parents (Cafazzo et al., 2012a; 
Skinner, 2015), and parents valued the idea of sharing information through an app; 
they felt this would make them comfortable and more secure (Skinner, 2015). For 
example, one parent stated: 
‘I think it would be cool, because then especially when he’s not around, I can 
know and then I can check in with him or not bug him if I don’t need to.’ (Parent 
2, Skinner, 2015) 
Children and teens liked the idea of an app that connect them with their friends and 
allow them to share data to compare progress and provide support (Cafazzo et al., 
2012a; Skinner, 2015).  
‘I feel like it would be useful, and it would be fun to like communicate with others 
and learn more about it.’ (Child 2, Skinner, 2015) 
However, one parent stated that even though connecting with peers with similar 
condition would be helpful, she expressed concerns about her child using social media 
and talking with strangers (Skinner, 2015). 
‘When your kids are younger, the fact that you want them talking to social media 
with people that you don’t know and they don’t know from all over is a scary 
thought.’ (Parent 4, Skinner, 2015) 
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Ease of logging data and the summary of data graphics were the most-liked features by 
most participants across several studies (Cafazzo et al., 2012a; Harris et al., 2010; Min, 
2013; Pulman et al., 2013a; Skinner, 2015).  
‘It’s just easy to log in your information, and it keeps it all for you. You don’t have 
to worry about paper or pencil. You just punch it in. It’s as easy as sending a text 
or writing a text or email. It’s just all very convenient and in one spot.’ (Parent 4, 
Skinner 2015) 
‘Cause again that’s something then you’re looking at that’s more visual, that you 
can see oh ok, maybe it’s not as good as I thought, whereas just doing it, doing 
your sugars once every day and just seeing the numbers…’ (Pulman et al., 2013a) 
Recording of data was regularly described as exhausting and time-consuming, 
therefore, participants reported that the key parameters that they needed to track are 
BG, carbohydrates, insulin and activities. Additionally, they requested that the app 
provides real-time feedback on their BG levels (Garnweidner-Holme et al., 2015), 
specifically, receiving a notification of abnormally high or low readings is helpful (Harris 
et al., 2010; Min, 2013). Moreover, participants showed a strong desire towards an 
app that connects them with their HCPs (Harris et al., 2010). One study explored 
participants’ needs for mobile games that deliver diabetes education, however, some 
participants thought games should be targeting the younger population (DeShazo et 
al., 2010). An additional requirement outlined by some participants is the need for 
individualised app content (Garnweidner-Holme et al., 2015; Pulman et al., 2013a).  
‘No one, no two people are the same with diabetes, everybody is different.’ 
(Pulman et al., 2013a) 
Adolescents, in particular, expressed a need for automated and fast transactions that 
only takes seconds in order to avoid social embarrassment when testing in public 
places (Cafazzo et al., 2012a). They further asked for decision-support prompts and 
alerts for testing BG to support accurate and timely management of their condition. 
One parent emphasised the need for the app to be engaging to increase the likelihood 
of being used by adolescents; otherwise, the novelty of a new app will wear off with 
time (Skinner, 2015). 
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‘I think it’s going to be like anything – in the beginning it’s going to be a novelty, 
and they’re doing to do it right away.’ (Parent 4, Skinner, 2015) 
Skinner (2015) suggested several features for apps’ design to best benefit young 
people (Skinner, 2015). This includes the ability to synchronise data between multiple 
accounts and devices and to their medical records. Another important feature was 
having customisable settings, and this is because families have children at different 
ages and, thus, their needs would be different. Furthermore, Pulman (2013) provided a 
list of apps’ ideas and enhancements to improve currently available apps 
functionalities based on young people views and experiences (Pulman et al., 2013a).  
6.1.4.4 Usability of apps 
Six studies (DeShazo et al., 2010; Garnweidner-Holme et al., 2015; Harris et al., 2010; 
Lehocki et al., 2012; Tatara, 2013; Waki et al., 2015) carried out usability testing to 
examine an initial design of the apps and identify usability impediments, then use the 
collected feedback to refine the design. Participants in most studies were provided 
with the devices, smartphones or tablets, to test the app and, therefore, participants 
expressed preference to use their own devices with which they would be more familiar 
(Lehocki et al., 2012). 
Most participants perceived the wireless upload of BG readings through the app as 
convenient and easier than their current practice (Garnweidner-Holme et al., 2015; 
Harris et al., 2010; Lehocki et al., 2012; Tatara, 2013) 
‘This is way easier, so I mean it would take me, what, five seconds?’ (Harris et al., 
2010) 
A woman with GDM made the following statement:  
‘I think it is very good. You get inspired to do things right. It’s pretty easy, yes, 
because you have your phone with you all the time. I always forget about the 
registration booklet and have to find a pen.’ (Garnweidner-Holme et al., 2015) 
Most participants in one study felt that receiving more than 2–4 reminder messages 
per day for compliance to self-management activities was annoying (Lehocki et al., 
2012). Participants in another study felt that the automated messages were irrelevant 
to them (Harris et al., 2010). They thought receiving 1–2 messages per day is 
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reasonable, and suggested adding an option allowing them to turn off automated 
messaging.  
‘I don’t need a stock answer. I need somebody to say okay, this person is in 
trouble. I need to call her.’ (Harris et al., 2010) 
In terms of mobile games that deliver nutritional education, participants generally 
found the information relevant to them and reported that they enjoyed playing 
(DeShazo et al., 2010). However, they suggested shorter games since this type of game 
is usually played to pass time while waiting for something or commuting. Participants 
in a study that examined the usability of meal-photo input function (Waki et al., 2015), 
which provides patients with real-time feedback for diet modification, appreciated the 
app and described it as convenient, helpful, quick and easy to use. 
‘I could know nutritional values of my meal immediately after I input extract 
images.’ (Waki et al., 2015) 
In general, positive feedback was reported on design interface, navigation structure 
and data presentation in most studies (Lehocki et al., 2012; Tatara, 2013; Waki et al., 
2015) except one where confusion was reported respecting the use of language and 
small picture sizes (Garnweidner-Holme et al., 2015). Other frequent usability 
problems included the short battery life; touch-screen or camera did not function well, 
or connectivity issues with other devices (Harris et al., 2010; Tatara, 2013). Finally, 
Tatara (2013) identified five major factors associated with usability of the app over 
time (Tatara, 2013): integration with everyday life with a minimal effort; automation of 
data transfer; balance between accuracy and meaningfulness of data with manual 
entry; intuitive and informative feedback; and rich learning materials, especially about 
foods. 
6.1.4.5 Factors influence patients’ acceptance of apps  
Only one study (Scheibe et al., 2015) identified several factors that influence the 
acceptance of diabetes apps among people aged ≥50. The study identified seven 
acceptance factors which were classified into two categories; the main impact factors 
are: perceived ease of use and perceived additional benefit, while the secondary 
impact factors include: previous knowledge and experiences, available support, 
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current state of health, trust in own technical abilities/insecurities in utilisation, 
perceived data security and expected reliability/fault tolerance and joy of use.  
Low degree of apps’ usability was shown among participants in the study as they 
encountered difficulties understanding the menu labelling and navigation. The main 
barriers were related to the small font size and representations plus the low colour 
contrast. This target group were generally not aware of the additional benefits 
provided by using apps compared to their current management practice. Hence, a 
diabetes app should provide users with written statements of the advantages of using 
the app.  
‘As long as the alternative doesn´t provide me with a technical advantage or true 
advantage, I won´t put any efforts into mastering this, I mean, a smartphone 
requires a certain amount of practice, so yeah, I haven´t gotten around to doing 
this as I don´t see the personal advantage.’ (Scheibe et al., 2015) 
Participants with no prior experience in using smartphones and tablets required more 
assistance during the session and this was identified as negatively influencing the 
group intention to use apps. This group of users needs support in using modern 
technology; therefore, having a personal contact person available to answer their 
technical questions is important. Family members, in particular children, grandchildren 
and partners, were their first choice. Most participants were concerned regarding the 
protection of their health data or incorrect data input, for example, one participant 
stated: 
‘…an inhibitional threshold where one could make a mistake and that data, 
personal data, could get lost, or that any involuntary payments might be 
necessary that were hidden somehow.’ (Scheibe et al., 2015) 
Health status was a factor impacting on perceived additional benefits and, thus, the 
acceptance of apps. For example, patients with insulin therapy may gain more benefit 
from using an app than patients with oral medications. The lack of interest and joy in 
using new technologies also emerged as a factor influencing app utilisation among the 
target group. 
Finally, the authors concluded that the needs of elderly users with diabetes are 
considerably variable due to the variations in their level of knowledge, age, type of 
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diabetes and treatment. As a result, they recommended that diabetes apps should be 
adaptable to individual needs in order to raise acceptance among target users. 
6.1.4.6 HCPs’ experience and/or perspective on the use of apps  
Two studies (Nielsen, 2013; Sarala, 2014) explored HCPs’ experiences or views on the 
use of apps for diabetes management. Sarala (2014) (Sarala, 2014) examined the 
feasibility of a smartphone-based decision-support app for clinical practice, and then 
explored opinions and satisfactions of the involved HCPs with regard to app use.  
Participants reported that using the app helped in making patient evaluation more 
systematic, and reduced the chance of missing important patient data such as clinical 
parameters or medical history. A Medical Officer stated: 
‘One change I can see is that we are ruling out the chance of missing any 
comorbidities.’ (Sarala, 2014) 
Another Medical Officer said: 
‘The software takes care of these medical updates and that way the new system 
is very useful.’ (Sarala, 2014) 
With respect to HCPs’ compliance to the given clinical management plan by the app, 
Medical Officers admitted that they were sometimes unable to follow the 
recommendations generated from the app, mainly due to the mismatch in the 
availability of medicines in drug supply or the affordability of medicines for patients. 
For example, a nurse stated: 
‘Our doctor writes mostly the drugs as per the guideline. For poor patients he 
gives drugs available in the supply which is free rather than advising medicines 
suggested by the software.’ (Sarala, 2014) 
However, specialist physicians were deviating from the suggestions more often as 
most of their patients have complications or comorbidities, therefore, they tended to 
prescribe newer and expensive medicines. They felt that the given recommendations 
were incompatible with their complicated patients and asked for more advanced 
version of the app.  
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Lastly, participants indicated that the small screen size of the smartphone was a 
limitation and suggested using a tablet as alternative. A specialist physician said: 
‘Probably you should give these girls a notebook or tablet, because it is difficult 
for them to feed data into phone from large number of patients. There is too 
much strain to the eyes. After two years, she will be wearing big spectacles. 
Nowadays tablets are very cheap. You will get it for 12000, 15000 rupees. That 
would be a better option.’ (Sarala, 2014) 
Nielsen (2013) (Nielsen, 2013), on the other hand, interviewed one Endocrinologist to 
explore his perception and opinion about the use of apps for remote monitoring of 
diabetes patients. His general perception is positive as he expressed interest in using 
apps for monitoring and interacting with patients, and acknowledged that he 
recommends such apps for his patients. The Endocrinologist further reported that 
receiving patient data from an app potentially improves treatment options as 
suggested in the following statement: 
‘We already have patients sending mails with their glucose measurements, and it 
provides us with improved treatment options. Integrating an app in our system 
would improve this further.’ (Nielsen, 2013) 
He believed that information received from apps would not represent a burden to 
HCPs’ daily workflow. Additionally, he thought that the risk of issues related to safety 
and security of apps will not undermine the utilisation of the technology in diabetes 
care. 
‘There is always some resistance to change – but I also think there would be a lot 
of interest in such a new app. Depending on HCP personality.’ (Nielsen, 2013) 
6.2 Discussion  
6.2.1 Summary of results 
This systematic review identified, appraised and summarised available literature on 
how mobile apps were perceived and experienced by patients with diabetes and their 
HCPs. Twenty primary studies met the inclusion criteria and were reported using a 
narrative synthesis approach. Studies were grouped according to their main focus of 
evaluation: patients’ experience with intervention components, patients’ perception 
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on the use of apps, patients’ needs and requirements for apps, usability of apps, 
factors influence patients’ acceptance of apps, and HCPs’ experience and/or 
perspective on the use of apps. 
Although studies were very heterogeneous in term of their aim, population, 
intervention purpose and main functionality, the findings of the studies were closely 
linked whether they were exploring experiences, perceptions or needs. The general 
perceptions on the use of apps of both patients and HCPs were positive. Yet, app users 
have different preferences and needs as persons and patients. The results indicate a 
need for more individualised app design, where users can customise apps according to 
their personal preferences and needs.  
The most appreciated and desired app features and functionalities among diabetes 
patients were the wireless automatic transfer of BG readings, visual summary graphs 
and connectivity with their HCPs. Apps that integrated visual elements helped diabetes 
patients in their self-management, enabling them to see their glucose levels as a 
historical trend graph on their smartphones or tablets. Implementing a visualisation 
tool is an important contribution for people with diabetes, facilitating reflective 
learning and helping patients better understand the link between their food choices, 
physical activity and insulin dosage and its impact on BG levels.  
Apps provided a convenient tool to capture and analyse contextual information about 
their condition. Thus, the use of apps had a motivational effect on some users. 
However, patients were engaging in the app use for various reasons and in different 
ways. Generally, patients decreased use over time, suggesting that apps might be 
more suitable for the short term.   
It is impossible to draw a definite conclusion on apps’ impact as an intervention either 
for patients or HCPs. Most studies focused on patients’ experiences and perspectives. 
Evidence on HCPs’ use of apps in clinical practice and for women with GDM is limited. 
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6.2.2 Quality of evidence 
All studies had a clear description of research aims and design but few gave explicit 
rationales for the sampling strategy. Data collection methods were reported in all 
studies, but only half clearly and sufficiently described the analysis method. Not all 
studies addressed obtaining ethical approval and participants’ written consent. Most 
studies did not include any consideration of reflexivity, however, findings in most 
studies were presented clearly.  
Studies which sufficiently met most quality criteria were either theses or dissertations 
where the word limit is much more compared to the restricted limits in journal 
publications. This certainly limits the degree of detail provided in journal articles, 
especially for studies that were part of mixed-methods research, since they need to fit 
in both quantitative and qualitative results. The CASP tool assesses the reported 
quality of studies rather than their actual quality; therefore, a study could be of good 
quality but poorly reported.  
6.2.3 Comparison with other reviews 
To the best of the authors’ knowledge, this review is the first to consider qualitative 
research exploring patients’ and HCPs’ use of, and perspectives on, mobile apps for 
diabetes care and management. As mHealth apps is an emerging field in diabetes 
management, the only identified reviews examining the effectiveness of apps in 
diabetes management were quantitative.  
6.2.4 Strengths and limitations of review 
The present review considered the impact of using apps functioning specifically on 
smartphones and tablets. It brought together the existing qualitative evidence on the 
use of apps by both people with diabetes and HCPs in diabetes care. It highlighted the 
lack of research with HCPs and women with GDM. The breadth of review scope, with a 
wide range of participants and all perspectives and experiences, is a strength of this 
review. However, this may be considered as a limitation as well, due to the variations 
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between included studies in study aim, participant’s age range, diabetes type and 
differences in apps main functionality; all made synthesis of findings more challenging. 
A comprehensive electronic database search was conducted including the main 
medical and computer science databases. Moreover, searches were also carried out in 
the grey literature. The search was not limited to the English language. Additionally, 
Auto Alert was set up in most databases which enabled the inclusion of more studies 
that were published after the search was conducted. Two authors were involved in 
making the decisions for study selection, data extraction and quality assessment to 
avoid bias and improve reliability. 
This review had limitations too. The main weakness is that most included studies were 
poorly reported, although no study was excluded based on its quality. Problems were 
also encountered in the selection of studies for inclusion due to the insufficient 
reporting of study details. As a result, eligible studies might have been missed. In the 
study protocol, a thematic synthesis approach was planned. However, the qualitative 
research literature was too heterogeneous to permit identifying any consistent 
themes. Therefore, it was necessary to change the method of synthesis to fit with the 
nature of the available evidence.  
6.2.5 Implications of the review and future research 
The findings of the current review provided inadequate evidence about the impact of 
using apps due to the scarcity of qualitative evidence in relation to apps.  
Need for additional research  
There is scope for further qualitative research in the area. Little is known with respect 
to app use in clinical practice. In particular, researchers need to consider HCPs’ 
acceptance of apps and whether they are interested in interacting with their patients 
by use of apps, as this would involve change in their workflow, specifically, regarding 
time and resources. There is a demand to identify HCPs’ needs and requirements for 
apps’ use, tasks that would be best served by apps, and any potential obstacles to 
integrating apps into diabetes care. Future research should also consider the 
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perspectives and preferences of women with GDM. The different social groups, young 
people, adults and elderly, have different perceptions and preferences of apps. Most 
patients with chronic conditions today are older people. They require an app design 
that is compatible with their needs. Therefore, another implication for future research 
involves discovering whether apps are accessible and acceptable to elderly patients.  
Implications for app developers 
This review highlighted the needs and preferences of people with diabetes and the 
highly-appreciated and desired functionalities and features. Also, it provided target 
users’ suggestions for apps’ ideas and enhancements to existing apps. Integrating 
these ideas, features and functions into diabetes apps may increase their acceptance 
and adoption. 
Implications for practice  
The lack of valuable qualitative evidence makes the implications for clinical practice 
difficult to define. Before there is widespread implementation of mobile apps into 
practice to complement care for people with diabetes, more research on the 
perspectives and acceptance by both patients and HCPs is needed.   
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Chapter 7  Diabetes specialist nurses’ interview study  
Chapter overview 
This chapter presents the interview study aim and objectives, research design, setting, 
ethics and research governance approval, methods (eligibility criteria, sampling/ 
recruitment of participants, interview process and data analysis approach), results 
(participant characteristics and key themes) and discussion (comparison with other 
relevant studies, methodological strengths and weakness and implications).  
7.1 Aim and objectives 
This chapter addresses the third objective of this thesis, relating to the ‘requirements 
gathering’ stage of the applied UCD approach (Chapter 3, section 3.1). The overall aim 
is to explore DSNs’ experiences and views on the use of mobile apps in clinical practice 
to draw on their clinical experience and vision to help design and develop an app that 
supports them in managing patients with diabetes. 
Specific objectives are to:  
▪ Explore how apps are currently being used among DSNs 
▪ Explore DSNs’ perceptions and preferences for mobile clinical support apps with 
particular attention to decision-support 
▪ Identify potential benefits and barriers of using apps at the point of care 
▪ Investigate current challenges facing DSNs in managing patients with diabetes 
that might be assisted by the use of apps 
▪ Explore DSNs’ willingness to use apps in the clinical setting. 
7.2 Research design and setting 
This was an exploratory qualitative study using face-to-face semi-structured interviews 
with DSNs from hospitals and community health centres across West Midlands. Details 
on the interview method and justification for its selection were provided previously 
(Chapter 3, section 3.2.2.2). 
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7.3 Ethics approval 
Research ethical approval was granted from the Biomedical and Scientific Research 
Ethics Committee (BSREC) at the University of Warwick (reference number REGO-
2014-786). As this study involved undertaking research on the premises of NHS 
organisations with NHS staff, it was necessary to obtain Trusts’ permission before 
carrying out any interview. Several NHS Trusts across West Midlands were 
approached, including: University Hospitals Coventry & Warwickshire NHS Trust, 
Sandwell & West Birmingham Hospitals NHS Trust, Walsall Healthcare NHS Trust, 
Shropshire Community Health NHS Trust, The Dudley Group NHS Foundation Trust, 
Heart of England NHS Foundation Trust and South Warwickshire NHS Foundation 
Trust. However, most considered this study as service evaluation and therefore did not 
require any further approval or permission. Only two Trusts classed this study as 
research and thus applications were submitted and NHS Trusts’ permissions were 
obtained from these Trusts, and letters of access were issued. The ethical approval 
letter along with the obtained access letters are in Appendix 11. 
7.3.1 Ethical considerations 
Nurses were fully informed of the study by given the ‘participant information leaflet’ 
and the ‘participant consent form’ (see Appendix 12). Filled consent forms were 
collected from nurses who agreed to participate at the beginning of each interview. 
Nurses’ contact information was not collected unless they were willing to take part in 
the second phase of this research. To ensure the confidentiality of participant, each 
nurse was anonymised. Participants had the right to withdraw from the study freely at 
any time, however, nobody did. 
Collected study information (including recorded interviews and consent forms) was 
only accessed by the research team. The study information was retained securely by 
the researcher; electronic copies of the interviews were stored on university-owned 
computers with access passwords, while paper records of the consent forms were 
stored in a locked cabinet in the office at the University of Warwick. Data will be 
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retained for a period of 10 years in line with the University of Warwick’s policy on 
published data. 
7.4 Eligibility criteria 
To be eligible, DSNs were required to have a minimum of two years’ experience of 
working with people with diabetes. This criterion was indicated in the invitation of 
potential participants. For practical reasons, only DSNs living in the West Midlands 
were considered. However, variations in socio-demographic characteristics such as age 
and gender, and the years of experience were desirable. There were no further 
restrictions on DSNs’ eligibility for participation. 
7.5 Sampling and recruitment of participants 
Convenience sampling was used in this study: DSNs who work at local NHS facilities 
were selected because they are accessible. It is the most common method of sampling 
because it is fast, easy and inexpensive (Green & Thorogood, 2009). Although the use 
of convenience sample has many disadvantages, such as the lack of transferability of 
findings to the entire population and the high risk of selection bias (Farrokhi & 
Mahmoudi-Hamidabad, 2012), yet, it was used for practical reasons. 
One main approach was undertaken in recruiting DSNs. Once the NHS Trusts’ 
permissions were obtained, an email was sent by the researcher to the Research & 
Development Department in each trust asking for a list of emails for all DSNs. Next, 
invitation emails were sent by the researcher to the provided mailing lists of DSNs with 
two documents attached: the ‘participant information leaflet’ and the ‘participant 
consent form’ (Appendix 12). Nurses interested in taking part were invited to contact 
the researcher by using the contact information given at the bottom of the information 
leaflet or by replying directly to the email. Follow-up emails were sent in some 
instances when no response was received. Moreover, two diabetes and endocrinology 
consultants were approached who were able to help circulate the invitation to all DSNs 
in their department, either via email or via word-of-mouth, to encourage participation.  
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DSNs who participated in the study were given a £20 Amazon.co.uk voucher as a 
reimbursement of their time, and were eligible to claim any travel expenses that they 
incurred through participating in this study. 
7.6 Participants 
The study was intended to include a variety of HCPs involved in diabetes care. 
However, due to the limited timeframe of this research, DSNs were chosen as the 
study population because they have more direct responsibility for diabetes clinical 
care, education and on-going support. Their role involves working closely with patients 
and their families and spending more time caring for them. 
A sample size estimate of ten DSNs was provided on the ethical approval application 
with intention to continue sampling until saturation point. Data saturation occurs 
when additional interviews do not add ‘new’ insights or themes relating to the study 
objectives (Green & Thorogood, 2009; Strauss & Corbin, 1990). According to Bowen 
(2008) (Bowen, 2008):  
“Saturation is reached when the researcher gathers data to the point of diminishing 
returns, when nothing new is being added.”  
Saturation was reached in the study within all interview questions after 15 interviews 
and, thus, the recruitment was discontinued. 
7.7 Interview process 
Once eligibility of a potential participant was confirmed, an interview was scheduled at 
a convenient date/time and location. Interviews lasted an average of 24 minutes 
(range 15–33 minutes). Fourteen interviews took place in a meeting room/office at the 
hospital or practice where the nurses work. One nurse was interviewed in her home. 
All interviews were recorded using a digital recorder. Participants were informed and 
consented to be recorded.  
A semi-structured, but flexible, discussion guide was used in all interviews (Appendix 
12). The interview topic guide was prepared with six open-ended questions concerning 
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the use of mobile clinical support apps that assist nurses in managing aspects of 
diabetes, with particular attention to decision-support apps. Open questions were 
supported with a number of possible probes that could be explored further. At the 
beginning of each interview, a brief description of mobile apps and the concept of 
decision-support, along with some examples, were provided. Then, some demographic 
questions, such as age and gender, along with other relevant questions (e.g., medical 
profession, level of clinical experience in years, and smartphone/tablet ownership), 
were included. Questions related to previous experience of using mobile apps, 
perceived value and subjective norms, benefits and barriers of using apps, challenges 
in clinical diabetes management that might be supported by the use of apps, and 
intention to use apps at the point of care. At the end, the interview concludes with one 
generic question; ‘is there anything else you would like to add before we end?’ as a 
prompt for further ideas related to the topic. 
7.8 Qualitative data analysis 
The analysis of interview data began during the data collection phase, to inform 
ongoing interviews and to help in determining when the saturation point was reached. 
Interview recordings were transcribed verbatim by the researcher. Computer-assisted 
qualitative data analysis software NVivo (QSR International, 2012) was used to assist in 
the analysis process. 
Thematic analysis is the most common approach for analysing qualitative research in 
healthcare (Pope & Mays, 2006), and was used. The process of data analysis was 
iterative, involving several cycles. The first cycle involved reading and re-reading all the 
transcripts for the purpose of familiarisation with the data. The next cycle involved 
coding and re-coding data items for emerging patterns. Coding methods applied in the 
analysis process followed the guidance provided in the coding manual for qualitative 
research (Saldaña, 2013). Once the coding scheme was produced, codes were then 
grouped, linked and sorted under categories or themes. Next, an initial set of recurring 
themes were identified, and repeatedly refined. Completion of further interviews led 
to a confirmation or adjustment to these themes. Data were mostly approached 
inductively; that is, themes emerged gradually from the data, and less often 
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deductively, where themes were anticipated or predetermined. As this was an 
exploratory study, the analysis proceeded by simply reporting and describing themes, 
with attempt to examine how the themes may be related by mapping them into a 
diagram to facilitate interpretation. In attempt to minimise bias in the interpretation of 
the data, Dr Antje Lindenmeyer (University of Birmingham), who is an experienced 
qualitative researcher, was consulted on the conduct and analysis of this research. The 
codes and themes were checked by her and discussed until consensus was achieved.  
7.9 Results  
7.9.1 Participant characteristics 
Fifteen DSNs were interviewed from four hospitals and two community health centres 
across West Midlands. All were female; 11 were aged 40-60 three aged 30-39 and one 
aged 20-29 years. Two were paediatric DSNs, one was diabetes service lead and the 
remaining 12 were DSNs. Most participants (n=9) were working in both the community 
and hospital settings, whilst four were hospital-based and two community-based only. 
The period of clinical experience ranged between 2 and 18 years of working with 
diabetes patients. Eleven were nurse prescribers; that is qualified to prescribe 
medicines for patients with diabetes, and four were not (see Table 7.1). 
Device ownership 
Nearly all nurses (n=14) own a personal smartphone (Apple iPhone=11; Samsung=2; 
Blackberry=1), and all had a personal tablet (Apple iPad=12; Samsung=2; Kindle HD=1). 
However, NHS Trusts did not all provide their nurses with smart devices. Five nurses 
were only provided with basic mobile phone, one was not provided with any device, 
while the remaining nine nurses were provided with at least one smart device or both 
(Table 7.1).  
Table 7.1 Characteristics of participants (N=15). 
Factor                                                                                                                                                                      N 
Gender 
Male  
Female 
 
0 
15 
Age group (years) 
Range  
 
29–57 
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Factor                                                                                                                                                                      N 
Mean  
20–29  
30–39  
40–49  
50–59 
44.8 
1 
3 
6 
5 
Work experiences with diabetes (years) 
Range 
Mean 
2–5  
6–10  
11–15  
16–18  
 
2–18 
9.5 
4 
5 
5 
1 
Profession 
Paediatric DSN  
DSN 
Diabetes service lead 
 
2 
12 
1 
Work setting  
Community-based 
Hospital-based 
Both 
 
2 
4 
9 
Prescribing qualification 
Nurse prescriber 
Not qualified 
 
11 
4 
Device ownership 
Smartphone 
Tablet 
 
14 
15 
Trust devices 
Provided with basic mobile phone only 
Provided with smartphone only 
Provided with tablet only 
Provided with smartphone and tablet 
Not provided with any 
 
5 
3 
3 
3 
1 
The following sections present the themes arising under the four main areas that 
addressed the objectives of this study: 
▪ Experience of using apps 
▪ Perceptions and views towards using apps in clinical setting 
▪ Difficulties that might be supported by the use of apps 
▪ Willingness to use apps at the point of care (Figure 7.1). 
7.9.2 Experience of using apps 
Nearly all nurses had prior experience in using mobile apps but only for personal 
purposes such as news, weather, games, travel and shopping. This indicates that 
nurses are experienced in using apps, For example: 
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‘I use quite a lot of apps for personal purposes…’ (Nurse 1) 
‘I do use apps, mobile applications on my phone for personal use.’ (Nurse 7) 
On the contrary, nurses had limited experience in using apps for clinical purposes, 
although this experience was recent, they generally were satisfied with their use.  
‘I am very much a novice, so in terms of my work life, I don’t use them at all, 
except for the BNF app on my own private iPhone.’ (Nurse 8) 
‘Um at work I have had experience with using apps for diabetic ketoacidosis in 
the wards, and also for patient information in respects to diet… um very limited in 
terms of what I have used within the workplace.’ (Nurse 15) 
DSNs who were provided with the smart devices by their trust reported that apps were 
not utilised on these devices at all. Provided iPads were exclusively used for accessing 
the hospital local system for referrals and retrieving/documenting patient information. 
 ‘I have an iPad but we haven't downloaded any app.’ (Nurse 5) 
 ‘…now with the iPhones when we’re in hospital, we can access patient 
information, some patient information systems, so you got that for the iPhone, 
you got it for the iPad. It is certainly easier to view on the iPad. We can look at 
patient’s blood test results, we can look at the observations, they are on the 
ward, so I can sit here, log in and look at my patient’s blood glucose levels that 
have been measured in the ward.’ (Nurse 14) 
By contrast, provided smartphones were mainly used for the purpose of 
communication with their patients using phone calls, texts or emails, in addition to the 
facility to access the local system. They were very satisfied with their use and reported 
that providing them with the smartphones enabled them to access the Internet and 
app stores when patients ask about some apps. 
 ‘I use the smartphones and tablet is mostly to communicate with patients usually 
through emails, texts or phoning them that’s what I use that for. Mostly it’s with 
emails and text when I’m on the go. Just for communication, it’s not for apps or 
anything like that I don’t use that at the moment… For me personally it’s made a 
difference having the smartphone and the tablet mainly easy communication 
with both patients, their carers and other healthcare professionals.’ (Nurse 12) 
Generally speaking, nurses had experience with using apps for personal purposes but 
lack the experience in using apps for clinical practice. Consequently, three main 
themes were arising here: the lack of experience in using clinical support apps, the lack 
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of knowledge and awareness of available apps that support HCPs and the tendency 
towards recommending apps for patients. 
7.9.2.1 Lack of experience in using clinical support apps 
Most nurses reported no experience at all in using work-related apps.  
‘…we just have no experience with them at the moment… I haven't had any 
experience using apps at all for work.’ (Nurse 2) 
‘Um but nothing for work to be honest. Personal really.’ (Nurse 4) 
This lack of experience among DSNs was due to several reasons that were identified 
from the discussions. Lack of resources, e.g. smart devices or WiFi, was the most 
frequently stated reason, specifically by those nurses who were not provided with the 
devices by their trust.  
‘…unfortunately, in the clinical setting because the trust doesn't supply 
smartphones with apps, obviously we don't use them.’ (Nurse 1) 
‘I haven't got access to them.’ (Nurse 5) 
Moreover, nurses were not willing to use their personal devices for work-related tasks. 
‘Clinical, we don't use mobile apps. I don't have a smartphone for work…. 
Because it's personal. I wouldn't pay and charge myself.’ (Nurse 2) 
 ‘Oh, never use my personal ones for work, no. No, there’s boundary’s.’ (Nurse 14) 
Some nurses described themselves as not being technology-minded and this was 
attributed either to their older age or to the lack of interest and knowledge in using 
technology. They further pointed out that nurses are experienced clinically, but may 
not be experienced in technology. 
‘Probably I'm just old school and we just know what we know really…’ (Nurse 4, 
40-49) 
‘I don't, I'm not, to be fair, I'm not of a generation where I'm used to using loads 
of apps and loads of technology.’ (Nurse 5, 40-49) 
‘None at the moment. We use no mobile applications because I can’t figure them 
out.’ (Nurse 12, 40-49) 
‘…when I was at school they didn’t; we didn’t do computers. So it’s like a self-
learning thing with the apps and the mobile phones.’ (Nurse 13, 50-59) 
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In the same context, the next theme is the lack of knowledge and awareness of 
available apps that support HCPs. 
7.9.2.2 Lack of knowledge and awareness of available apps that support HCPs 
Most nurses were only aware of apps that support patients in self-care and monitoring 
of their diabetes. Most nurses lack knowledge about available apps in the market that 
may support them in clinical work. 
‘I don't know if there's any app out there to use them.’ (Nurse 3, 50-59) 
‘I wasn't aware that there were this sort of thing, and then when you mentioned 
about wanting to meet to discuss today, I just thought, oh ok, so I had a little 
look... I know that there are lots of patient ones, I wasn't aware that there were 
more out there for professionals… But I did have a little bit of a search to see, and 
I did come across some other ones, which I felt um I found quite useful, actually.’ 
(Nurse 7, 30-39) 
Few nurses were unable to envisage how an app could fit around their work or what it 
is capable of.  
‘I don't really know how my work would fit around an app… I just don't know 
what there is in an app that I'm going to use in clinic.’ (Nurse 5, 40-49) 
‘…I don’t really know what they are capable of, um so I think it would be just, for 
me, a greater awareness really.’ (Nurse 8, 50-59) 
As a result, nurses suggested that there is a need to advertise the existing clinical 
support apps and raise HCPs’ awareness and encourage their use. 
‘I think having an awareness of it to advertise it that would be needed to be 
done.’ (Nurse 3) 
‘Just sort of um raise the fact that or advertise the right word, or put it out there 
that these are available.’ (Nurse 12) 
7.9.2.3 Tendency towards recommending apps for patients 
Most nurses tend to recommend the use of trusted apps to their patients. The 
commonly recommended app was the Carbs & Cals, which supports in carbohydrate 
counting. Other apps included Fitness Pal and Health Fabric; both for tracking exercise, 
and Dafne which is a patient education program for T1D. In return, nurses would 
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expect some feedback around the app from their patients so they could pass the 
information to other patients.  
‘I do direct patients to use apps themselves.’ (Nurse 1) 
‘We recommend Carbs & Cals to our Type 1 for carbohydrate counting.’ (Nurse 4) 
Other nurses exercised extreme caution in recommending any app unless it was 
certified by recognised body such as Diabetes UK. 
‘I am quite cautious about recommending apps for patients...’ (Nurse 8) 
Nurses also noted that some patients, specifically the younger population, were asking 
for apps to use in supporting self-management. 
‘It's something that the teenagers always ask us, you know, if there are any apps 
that can help them.’ (Nurse 2) 
7.9.3 Perceptions and views towards using apps in clinical setting 
There were mixed views towards the use of apps in clinical practice. For instance, time 
was perceived as a benefit in some cases, by helping clinicians to save time, and a 
barrier in other situations mostly due to the limited consultation’s time. However, in 
general, DSNs believed that the benefits of having a good app may outweigh its 
hindering. 
‘That would be both, a bit of both really. More beneficial. But it's again, if I'm 
somewhere on a ward and I'm struggling to get a signal, that's a hinder a 
limitation...’ (Nurse 4) 
‘…so it's mixed, but overall, I would say, it's far more powerful to have an 
effective app working for you.’ (Nurse 6) 
Three subthemes derived under the perceptions and views of DSNs: perceived 
benefits, perceived barriers/limitations and perceived concerns of using apps in clinical 
setting. 
7.9.3.1 Perceived benefits of using apps  
Nurses have clear ideas about several potential benefits of using apps in clinical 
practice. The commonly reported benefit was the convenience and accessibility of 
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apps due to the mobility of these devices, in particular for nurses working in the 
community since part of their work involves going to patients’ homes and schools. So 
they can access them wherever they are and all times; they would not be dependent 
on a computer or a workstation. It could also save them from carrying around loads of 
papers or materials.  
‘…it just makes things really accessible to you quickly… We work in the 
community as well so; my job takes me to schools and home visits and things. So, 
obviously when I'm out in the community, I don't have my computer with me so, I 
don't have access to that.’ (Nurse 2) 
‘Mobile apps, access to them at all times morning, noon, and night...’ (Nurse 3) 
‘I have always got my phone in my pocket, I don’t have to carry around bits of 
paper… It is more of a convenience than anything.’ (Nurse 9) 
In particular, nurses value the potential of apps to save them some time in many 
different ways, instead of wasting time in seeking assistance or retrieving information. 
‘It's quick, it's accessible immediately, you know, because we are not always 
hospital-based, that would be a huge benefit… So, it would be a bit of a time-
saver for us as well maybe.’ (Nurse 2) 
‘I think it can potentially speed up the consultation processes of patients.’ (Nurse 
9) 
‘It does definitely saves time… If you can access information there at your 
fingertips...’ (Nurse 14) 
One nurse pointed out to one advantage of using apps over other written materials; 
that is the ability to update its content easily.  
‘I think when it comes to the app they probably would be updated a bit more 
quicker than say anything that’s written down in paper… So that would be 
another advantage with the app...’ (Nurse 12) 
More generally, nurses foresee a potential for apps to help improve patients care; 
particularly to help HCPs in providing standardised care to all patients. 
‘…you'd all be giving the same information… you're all going to be giving the 
same advice and so yeah, quality of care, consistent advice as well.’ (Nurse 2) 
‘So from that point of view, again I guess it standardises care...’ (Nurse 11) 
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7.9.3.2 Perceived barriers/limitations to the use of apps  
Lack of resources, including the smart devices, funding and Internet access, was 
further reported as a barrier that needs to overcome in order for nurses to be able to 
use apps. 
‘Out in the community, if you couldn't access the app, if you didn't have Internet, 
that would be a bit of a downfall.’ (Nurse 2) 
‘We need to have the equipment. You know, I'm not using my own mobile phone 
to download apps for work. You know, I'd want a separate device specifically for 
work.’ (Nurse 5) 
Other limiting factor stem from the fact that nurses had experienced technical issues 
related to WiFi connection, network coverage and poor signal in the hospital.  
‘Sometimes it's hard to get a signal on some of the areas because there's blind 
spots.’ (Nurse 4) 
‘Um getting a good signal… there’s one of the wards where the Wi-Fi pick up isn’t 
so good.’ (Nurse 14) 
The cost of the app itself could be a hurdle as one nurse noted: 
‘And if there’s a cost implication. Because if it’s freeware obviously it’s okay, but 
if they have to pay for it. That might be a bit of a turning off point.’ (Nurse 12) 
The busy schedule for nurses and their limited time in clinic setting may introduce time 
as a barrier rather than a benefit, as exemplified by the following comments from one 
nurse: 
‘I suppose haven’t got the time in my consultations to spend looking at the app.’ 
(Nurse 8) 
Interest in technology and the ability or intellect to use technology, especially with 
older people, were reported as possible barriers to the use of apps. 
‘Um some of the older consultants might not even want to use it. You can't have 
that happening.’ (Nurse 1) 
‘Um I mean there’s always resistance to technology with a cohort of people.’ 
(Nurse 11) 
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Related to that is the small screen size of some devices made it inappropriate to be 
used by people with visual impairment, as another nurse stated that: 
‘It’s the screen size with me really, cause my eyesight.’ (Nurse 13) 
However, some reported no barriers at the present time to their use in clinical 
practice. 
‘I don’t think there will be barriers now. I notice there is quite a lot of hand held 
devices, certainly in this Trust.’ (Nurse 15) 
7.9.3.3 Perceived concerns of using apps  
Confidentiality and information governance were on top of the list of concerns, in 
particular, around apps that involve storing or accessing patients’ data. 
‘I would be concerned about accessing patient records, because of the 
confidentiality… if you put patient's information on there, it would be, that would 
be the main concern, because you are out and about with it.’ (Nurse 14) 
Nurses were keen to ensure, before using or recommending any app, that it came 
from a reliable source, and that it was validated and safe to use. They emphasised that 
despite the availability of loads of apps to download from app stores, they would never 
use any random app unless it was endorsed by a recognised agency.    
‘I’d like to see if it was approved by somebody within the medical profession...’ 
(Nurse 12) 
‘You want to know that it’s come from a neutral source and it’s not linked in with 
any pharmaceutical companies and buyers…’ (Nurse 13) 
‘Very important that you want to know, that it was trustee… I suppose you would 
want to have some sort of approval, that you know, it is approved by the NHS, if 
you know what I mean. You would want to know that it is reliable.’ (Nurse 15) 
IT is always a potential source of concern; therefore, some nurses expressed their 
concern in placing too much trust in technology. They indicated that they should not 
count on apps to work correctly all the time as they may fail to work or crash and 
stored data might be lost. 
‘If the app crashed or maybe it failed for whatever reason… that would be a bit of 
a negative.’ (Nurse 2) 
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‘…when you rely on systems, you rely on the fact that they are going to work and 
everything is going to be running right at the time for you that you needed.’ 
(Nurse 15) 
With regard to patients’ perception, nurses expressed some feelings that using the 
mobile devices in clinical setting may not be socially acceptable. Patients may not be 
aware that they were used for work-related tasks. 
‘I hope people don't think I'm sitting playing on my phone, because I'm actually 
not. So maybe it's not quite, so socially acceptable to just whip out your phone 
and start fiddling about, maybe people don't understand that you're actually 
using it for professional use, not playing on your phone.’ (Nurse 7) 
Another nurse pointed out to the importance of having eye contact with patients, and 
how the use of apps during the consultation may break this communication. 
‘I hate it when people are looking at screens and not making eye contact and 
listening. Um in most the communication is non-verbal and you pick so much up, 
if one tapping on an app, or even on a tablet, you know into a consultation, I am 
breaking that, I'm putting barriers up to them sort of communicating with me. I 
tend to do most of my inputting after the consultation.’ (Nurse 8) 
Safety of the equipment was brought up as another concern. Smartphones and tables 
are small, portable and expensive devices, as a result, there is high potential to be lost, 
broken or even stolen.   
‘There maybe some places where you don’t want to be taking out things, 
expensive piece of equipment. It might not be a safe area.’ (Nurse 14) 
‘… that it doesn’t get stolen and then it doesn’t get broken and things like that. So 
there is also issues with regard to the mobile as well.’ (Nurse 15) 
Nurses worry about the possibility that some apps may have an out-dated content. 
They demanded that clinical support apps should be updated regularly to correspond 
with the latest evidence-based clinical guidelines. 
‘…who would be responsible for keeping the apps updated. Um making sure that 
the information that we had access to on the app was current and you know, 
wasn't out of date… because it's you know, guidelines and things that's 
constantly changing.’ (Nurse 2) 
Another concern among nurses was that they may become very much reliant on 
technology on daily basis and thus, they may lose their clinical skills and judgements. 
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‘My worry would be maybe people would get a little bit deskilled in making that 
decision process for themselves, relying on an app... I think it's important that we 
still keep up our skills in being able to make decisions as professionals ourselves.’ 
(Nurse 2) 
‘It's an obvious concern isn't it, that people rely so much on technology, that they 
lose the common sense to make a decision.’ (Nurse 5) 
One nurse, who described apps as self-learning tools, stated that she would be 
concerned about the potential of misunderstanding or misinterpreting the given 
advice or recommendation and acting upon them. 
‘There would be a slight concern because we all when we're self-learning, can 
misunderstand and misinterpret things, sometimes incorrectly... It says do this, or 
they've read it wrong, or they've done it wrong.’ (Nurse 3) 
7.9.4 Difficulties in diabetes management that might be supported by the use 
of apps 
Clinical challenges facing DSNs were discussed in the context of those that might be 
assisted by the use of apps. Nurses expressed positive views towards the potential of 
apps to help overcome several difficulties, and they proposed a number of app’s ideas. 
As the focus of this study was mainly around decision-support, challenges and 
suggestions were specifically considered in this context. Nurses admitted that clinicians 
are extremely busy and certainly do not have the time to read lengthy guidelines and 
thus, they welcomed the idea of decision-support app which they described as an 
abbreviated and interactive version of the clinical guidelines. They considered such 
apps to be a promising alternative to help HCPs in making a proper clinical decision 
and improve patient’s safety by promoting the correct procedures and protocols that 
need to be followed. 
‘People haven't got time these days to sit down and read guidelines… at the 
moment, people don't even look at the guidelines that are already written to 
follow instructions.’ (Nurse 5) 
‘I think it would maybe reduce drug errors. It would probably, possibly reduce 
length of stay, or any complications that diabetes can bring in hospital...’ (Nurse 
7) 
‘Um I guess there is a place for sort of care pathways and decision-making and so 
on.’ (Nurse 11) 
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Most nurses were prescribers, and they use the British National Formulary (BNF) to 
look up drug prescriptions and support decisions regarding treatment compatibility. 
‘Because at the moment when I’m looking up prescribing medication, I look in the 
BNF to see is this medication going to be okay with the other medications...’ 
(Nurse 11) 
Decision-support apps were considered useful in some settings, particularly in hospital 
wards. They potentially reduce the number of referrals received from all over the 
hospital, and may help prompt nurses to ask the right questions.  
‘I think that would probably help us, maybe we wouldn't get such irrelevant 
referrals, if there was actually a mobile app that they could use, that could assist 
on caring for their patients...’ (Nurse 7) 
‘… it gives help to make your decision quicker, rather than you looking up the 
information, and it would help also in prodding you to um when asking questions. 
To ask the right questions in the shortest period of time…’ (Nurse 12) 
One of the nurses’ biggest challenges is the volume of patients with diabetes versus 
the small number of DSNs. To overcome this challenge, a major part of DSNs’ role is to 
train others, such as district nurses, in specialist care. Therefore, it was suggested that 
decision-support apps might be of great help in particular for practice nurses, district 
nurses, junior doctors, GPs and professionals from other specialties who do not 
necessarily have specialist diabetes knowledge.  
‘We’re a specialist diabetes team so our nurses have got a wealth of experience 
but obviously you’ve got other health care professionals who are treating people 
with diabetes but they aren’t themselves are not necessarily specialists in 
diabetes. So for example, the district nurses. So they’ve got knowledge of 
diabetes but not specialist knowledge. So I guess if there was something to help 
them, not necessarily make the call with regards to prescribing, but perhaps 
when to refer, whom to refer to. That could be useful.’ (Nurse 11) 
‘I think as well for the practise nurses that are prescribing and doing a lot more 
diabetes and GPs really it would be useful.’ (Nurse 13) 
‘I think, certainly to help with maybe juniors who are not so familiar with 
protocols.’ (Nurse 15) 
Many nurses expressed their interest in having educational apps, specifically, nurses 
working in the community as they described their job role as educator. They are 
educating patients or carers and school staff to help them to understand the condition. 
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‘…because we do go out at home visits and school visits, um we would like to 
create a kind of e-learning package. And we've put in for funding for an iPad or 
tablet of some description that we would be able to carry that out with us into 
the community.’ (Nurse 2)  
‘… um but I think I probably would see myself using it more as an education sort 
of tool in terms of helping patients to understand their condition rather than a 
decision-making one for myself.’ (Nurse 8) 
Nurses highlighted several clinically relevant apps’ suggestions that might help such as 
dose adjustments, insulin titration, medication prescribing including the timing for 
medication and hypo management. 
‘…we have another patients at home who have insulin delivered by district 
nurses. So, at the moment the district nurses have to faxing information to us 
about blood sugars, insulin if they want us to titrate up the dose. So, if there is an 
app that the district nurse could access when she is out in the home, that would 
be a good one.’ (Nurse 1) 
‘I think dose titration information would be really beneficial on the wards, 
especially for like, junior doctors, or you know, the doctors on the ward as well, 
because we get a lot of our referrals are for like, simple dose titration of insulin… 
that could just be done on the ward, without us having to go up and advise. And 
prescribing information as well. So the timings that the medication should be 
given, because that's another big issue that we come across on the wards, if 
medication's being prescribed at the wrong times, it's causing problems with the 
hypos, etc.’ (Nurse 7) 
‘Dosing maybe, so insulin dosage. So I would use a wide base dose if I was 
starting somebody on insulin, but if a doctor was prescribing maybe in a GP 
practise or in a ward or in a nursing home, they might do it slightly differently… 
and the other thing is converting… Swapping people from say a BD mixture to 
three times a day or swapping people from a BD to basal bolus.’ (Nurse 9) 
Nursing home was specifically deemed as a big area for decision-support as they may 
lack the speciality in diabetes, which is critical in most cases that they deal with. 
‘…having something that they can regularly use with a very structured app, I 
think would be very good to have for the nurses in the care homes. They're very 
good at the nursing care, but the diabetes side, they're much more nervous 
about. I'm not saying they're not good at it, but they're a lot more anxious about, 
and knowing the difference from the Type 1 and Type 2 is quite fundamental in in 
getting the balance right of the insulin…’ (Nurse 6) 
‘…they are complex care patients, and actually they are being cared for by people 
again who don’t necessarily have specialist knowledge of diabetes. So whilst we 
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go into nursing homes and undertake training for the staff that is a real area 
which I think could be massively supported by decision-making apps.’ (Nurse 11) 
Decision-support apps that provide high-level advice on the management of diabetes 
patients with comorbidities was suggested. For instance, nurses indicated that many of 
their patients have renal problems, which is challenging to decision-making since new 
drugs are always coming out, and they need to remember renal cut-off points specific 
for each drug. 
‘…we have got quite a large diabetic renal population here. They are quite a 
challenging group… they need to monitor a lot, so not just blood sugars, but 
blood pressure and pulses as well.’ (Nurse 9) 
‘With a lot of our patients certainly that we see in our clinics, they have other 
health problems as well… so apps that may be, could be flexible in terms of not 
just covering diabetes, but other long-term conditions as well, all built into one… I 
do diabetic renal clinic, so an app with you know, with hypotensive medications 
and sort of protocols for diabetic renal disease would be really useful for me to 
have personally.’ (Nurse 15) 
The following themes arose among DSNs: 
7.9.4.1 Poor understanding of the concept of decision-support tools 
Although nurses were given a brief description of decision-support tools with examples 
at the beginning of each interview, some nurses were still unable to envisage how apps 
could support their clinical decision-making process. They generally presumed that 
decision-support apps meant to replace the presence of human being, and that they 
will make a definite decision to be taken forward. However, clarification was given that 
these apps will only provide some suggestions based on clinical guidelines, and the 
clinical judgement of HCPs will still be needed; the app will not eliminate this. At the 
end, HCPs may agree with the given advice or just discard it, so those apps are only 
used as a mean of reinforcement. 
‘Oh do you mean people can't work it out for themselves; is it going to prompt 
you to make a decision? I don't think so really… Well, nothing can teach you to 
look after patients, you need that exposure and you need that experience, that 
clinical experience… And if you're always relying on technology, where's your 
experience, where's your clinical skill going to go?’ (Nurse 5) 
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‘… it is more as an aid isn’t it? Rather than telling you what to do… um but I think 
you’ve just gotta be careful not to rely on it and not lose your own clinical 
judgement.’ (Nurse 13) 
7.9.4.2 Basic requirements for clinical support apps 
Most nurses urged for apps that are simple, short and to the point. Clinical support 
apps need to work across multiple mobile platforms, and not to require WiFi 
connection in order to suit the setting where nurses work, whether it was in the 
hospital, which got poor signal reception, or in the community where they had no 
Internet access. Further, clinical apps need to be approved by, for example, the wider 
NHS, and their use must be restricted to NHS staff. Nurses prefer a small app that does 
one specific task rather than having one big and complicated app that does multiple 
tasks. 
‘… when it comes to the app rather than having a lot of information on one app it 
would probably be split into certain sections so you might have an app which tells 
you section about drugs to use for certain conditions and then another one which 
tells you about how to treat a hypo and stuff like that. So you don’t have a big 
app which tells you a lot of information. But just small… Quick and easy to get to.’ 
(Nurse 12) 
Clinical apps need to be customised locally, e.g. based on local guidelines, rather than 
having a generic app, which would be less relevant. 
‘You know, it's no good giving me a generic thing because then it's not going to 
be locally recognised.’ (Nurse 3) 
‘If it is a clinical app, it has to follow local or national guidelines in respect to the 
information that it is giving.’ (Nurse 15) 
And lastly to be visual, interactive and does not require inputting too much details.  
‘Pictorial, would be better... I'm happy to input information as long as I don't 
have to write an essay.’ (Nurse 5) 
7.9.5 Willingness to use apps at the point of care 
Overall, nurses expressed strong willingness to use apps in clinical practice. However, 
willingness was very much dependent on the benefits they get, and the simplicity of 
the app. 
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‘Yeah, very likely. As long as it was user friendly…’ (Nurse 2) 
‘As long as it's just simple, simple information, I think that people are more likely 
to use it.’ (Nurse 7) 
‘Um just ease of use bearing in mind the time restrictions.’ (Nurse 11) 
‘Just make it really simple, mobile app for dummies.’ (Nurse 14) 
Nurses are not willing to embrace change in work routine that requires many efforts, 
unless it supports their job role, and makes better use of it.  
‘I guess change is always a little bit difficult to implement in your working routine 
when you're used to doing things a certain way… I think yeah, absolutely, we 
would use mobile apps. I think we've got to embrace the change.’ (Nurse 2) 
‘If it's going to do a job and it's helping me do what I need to do, then fair 
enough.’ (Nurse 5) 
Willingness and adoption of apps may be impacted by user age. Nurses emphasised 
that young people are more into technology and very much interested in using apps, 
while older people are not much interested in technology and may encounter some 
difficulties in using them. 
‘It's whether you are of that generation that uses apps and are quite comfortable 
with using that technology. Quite a lot of older people are experienced clinically 
but not experienced in this technological age where they have a different way of 
working.’ (Nurse 5) 
‘I think, you know, in terms of like junior doctors. They are probably really familiar 
with using lots of apps and they use them all the time, so I think they would be 
more likely to be using that, but possibly if you were looking at older people who 
are not familiar with using apps… they might be a bit frightened about the 
technology or not know how to access things...’ (Nurse 15) 
When nurses asked whether they would prefer to use apps on a mobile device or on a 
traditional computer, nurses were generally more likely to use mobile-based apps but 
that depended on the situation. Nurses working in the community expressed 
preference for mobile apps due to the nature of their work, whereas nurses based in 
the hospital explained that when they are in the wards, they will have to keep going 
back to the office to use their own computer, or they will have to find a computer that 
is free, but then, getting hold of access to a computer is difficult sometimes within the 
clinical area. 
   
152 
‘Out in the community, definitely mobile… You know 50-60% of our job isn't 
based in the hospital so that would really, really help us.’ (Nurse 2) 
‘Mobile device definitely… most people have got the phone so the mobile will be 
better.’ (Nurse 12) 
‘I think certainly within a clinical area, it would better to be mobile, because 
getting hold of access to PC’s is difficult some times, within the clinical area…’ 
(Nurse 15) 
7.9.5.1 Mobile apps are the future 
Even though nurses indicated that there would be always resistance to technology 
and/or change with some people, mobile apps were conceived as the future. Nurses 
agreed that there is a place for apps in their clinical work. Nearly all thought that 
technology, specifically mobile apps, ought to be the way forward for NHS Trusts. They 
further believed that it is only a matter of time before mobile apps are integrated into 
their clinical practice as an essential tool. 
‘It is abnormal not to use them I would say… that's the way forward… I see that 
as the future.’ (Nurse 1) 
‘I think yeah, there is definitely a place for it… for us, we see the future is 
definitely going into mobile because that's where we are a lot of the time…’ 
(Nurse 2) 
‘I'm sure you know people have to move forward with the technology and that's 
the way it has to go… Everybody's always walking around like this, although with 
their phones.’ (Nurse 5) 
7.9.5.2 Apps are self-explanatory 
The majority of nurses reported having self-learning experience with apps. They think 
that apps do not require any training to use them. Some nurses stated that 
instructions contained within the app would definitely be sufficient. Others preferred 
to have someone in the first place to at least run through it, to make sure they will 
access it correctly and use it in the right way. 
‘I’m quite fine with using apps… I like to just work things out myself really. You 
know, when I get a new phone, I'll never read the instruction book, just press all 
the buttons until I find out how it works, and that's probably a bit how I would.’ 
(Nurse 1) 
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‘Surely apps are pretty self-explanatory.’ (Nurse 3) 
‘Well, I'm not that daft. I can probably manage to download an app and work my 
way through it.’ (Nurse 5) 
‘I don't think I would need training, no. I don't think most people need training; I 
think it's quite self-explanatory… I like to try… with new things I am a bit of a 
trier.’ (Nurse 7) 
Depending on the complexity of the app, nurses aged 45 and over were more likely to 
think that they may need training to use it. 
‘It depends on how complicated it is. Yeah, I probably just need a little bit. But if 
it's straightforward, that's okay.’ (Nurse 4, 40-49) 
‘Depends on how easy, you know, it would be good to have from the experts, an 
idea of what was expected of it, and how to deliver it.’ (Nurse 6, 50-59) 
‘Probably. Just to see how it works just at first.’ (Nurse 13, 50-59) 
7.9.6 One app does not fit all 
This theme emerged throughout the interviews but did not fit under any of the four 
main investigated areas. People have different needs and preferences, range of skills 
and varying degree of motivation. They will interact and engage with apps in different 
ways. No one particular app will fit all, as believed by most nurses. Having a good app 
design would not necessarily make it successful. Two apps might be doing exactly the 
same function, but only one becomes popular. It was clearly shown in this study that 
apps should meet DSNs’ needs in order to be adopted and used, but their needs and 
preferences varied according to their role. 
‘Not every app will fit all, and some will become quite popular.’ (Nurse 3) 
‘I think it's very specific to the person. It’s a broad spectrum of skills that people 
have and use them in in very different ways… which part of the app they may use. 
Some of them use all the functions; some may use just a specific part of it. But 
only if it's working for them.’ (Nurse 6) 
‘It’s not for everybody. You’ve got to choose the right person that, it’s the same 
with anything isn’t it, with a treatment, the way you deliver it. That’s just easy, 
yeah.’ (Nurse 10) 
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7.10 Discussion  
7.10.1 Summary of main findings 
This interview study addressed how mobile apps can support DSNs in clinical practice, 
and intended to provide end-user needs and requirements, which were essential for 
the design and development of the app described in the next chapter. The interviews 
with nurses identified varying themes related to four main areas; prior experience, 
perceptions and views, challenges in diabetes management and willingness to use 
apps.  
There were three key themes relating to the nurses prior experience of using apps; 
lack of experience in using apps, lack of knowledge and awareness of available clinical 
support apps, and the tendency towards recommending apps for patients. Nearly all 
nurses own personal smartphones and tablets, and some were provided with smart 
devices by their trusts. Nurses had prior experience in using apps for personal but not 
clinical purposes. There were no differences in the level of experience of using clinical 
support apps between nurses who were or were not provided with the devices by their 
trusts. Lack of experience was attributed to reasons including lack of resources, not 
being technology-minded or that apps did not meet their needs. Most nurses were 
only aware of the available apps that support patients in self-management, and some 
were not able to see how an app might fit within their work. Consequently, they 
suggested that there is a need to raise nurses’ awareness of the available clinical apps. 
On the other hand, some nurses tended to recommend the use of trusted apps to their 
patients, whereas others were cautious in doing that. 
The current study found that nurses have both positive and negative views around the 
use of apps in the clinical setting. Positively, nurses perceived many benefits, but most 
importantly, apps bring convenience, being described as straightforward, accessible, 
and time-saving. They appreciated the possibility that apps may improve patients’ care 
particularly through standardisation of care. On the negative side, nurses also 
perceived some barriers and concerns associated with their use. The limitations 
described were largely caused by the lack of resources and funding, technical issues, 
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interest in technology and the limited time in the clinic setting. A particular concern 
was in the form of privacy and confidentiality, but this concern reduced when they 
realised that most clinical apps do not require any form of patients’ identifiable data. 
Other concerns related to the source of the app, safety of the equipment, trust in 
technology, patient perception and overreliance on technology.  
Nurses thought that apps may offer a solution to some difficulties that they are 
currently facing in the diabetes management. Two main areas identified where nurses 
believed that apps would mostly assist in were patient education and decision-support. 
Nurses suggested that decision-support apps would be of great benefit, in particular 
for professionals from other specialties and for nursing homes, allowing them to make 
rapid decisions with reduced errors, reducing the number of referrals and prompting 
nurses to ask the right questions. The information most demanded was related to dose 
adjustment, insulin titration and medication prescribing, specifically for patients with 
comorbidities. There were two key themes relating to this area, poor understanding of 
the concept of decision-support and basic requirements for clinical support apps. 
Most nurses expressed strong willingness to use apps in clinical practice. Two factors 
were mostly emphasised by nurses that would impact their willingness: simplicity and 
usefulness of the app. Most nurses agreed that they would be more likely to use apps 
on mobile devices, particularly when they are in community or when ward computers 
were being used by other HCPs. There were two themes relating to the area of 
willingness, mobile apps are the future, and apps are self-explanatory. Nurses believed 
that it is only a matter of time before mobile apps are embraced and widely utilised in 
their clinical practice. They further explained that they had self-learning experience 
with apps and thus, the use of apps does not require any training. 
An additional theme emerged but did not fit under any of the four areas; one app does 
not fit all. It was clearly shown in this study that nurses’ needs and preferences varied 
according to their job role. Nurses considered the one-size-fits-all approach would not 
work with app design and development.  
   
156 
Themes appear to be interrelated and have overlapping elements. There was 
interconnection between the lack of experience and the perceived limitations of app 
use. Lack of resources was reported as a main reason for the lack of experience among 
nurses and as a major barrier for nurses’ use of apps in clinical setting. Lack of 
knowledge and awareness could be linked with the poor understanding of decision-
support; nurses who were mindful of the range of available clinical support apps were 
more familiar with this concept. Tendency towards recommending apps for patients 
was found to be associated with perceived concerns; nurses who expressed more 
concerns were less likely to recommend the use of apps. However, these perceived 
concerns were not enough to cease their willingness to use apps. Lastly, the perceived 
benefits of using apps were related to the theme apps are the future. The countless 
benefits they were anticipating from the use of apps have clearly influenced their 
willingness to use apps and their perception of apps as the future. All themes emerging 
in this study and their relationships are demonstrated in Figure 7.1. 
In the context of using a new technology such as apps, nurses thought that they would 
never use their personal devices for work-related tasks. It is not only about the 
provision of devices; nurses were not willing to use their personal accounts for app 
stores to download work-related apps and emphasised the need to have a separate 
work account. It is clear that nurses’ work and personal life are kept apart. This 
strongly emphasise the presence of work-personal life boundaries among nurses. 
Contrary to findings in the literature (Moyer, 2013), BYOD, short for “bring your own 
device”, was not acceptable among DSNs. Nurses demonstrated that this violates their 
Trusts’ regulations and policies, as they are not allowed to carry or use their own 
personal devices on the wards, for example, or during patient consultation. Besides, 
this may possibly violate professionalism. Moreover, nurses expressed a fear of 
possible disturbance to personal life when using personal devices for work related-
purposes. They are not willing to receive calls or messages during non-working hours 
or holidays. They further explained that they would not use their own devices and 
charge themselves as long as their Trusts do not offer any compensation or overtime 
pay. 
   
157 
Overall, mobile apps seem to have a potential to facilitate and support DSNs’ work 
whether in the community or in the hospital.  
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Figure 7.1 Themes identified in the study and their relationships 
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7.10.2 Comparison with other relevant studies 
The qualitative review (Chapter 6) identified that qualitative research on the use of 
mobile apps among HCPs in clinical practice is limited.  
Most studies in the area were experimental, assessing the effectiveness or feasibility of 
a study-specific app. Other related studies used quantitative instrument for data 
collection, most commonly a questionnaire. Most of these cross-sectional studies 
explored the prevalence of mobile devices and/or apps use among HCPs and their 
views and attitudes towards their use in clinical practice within a wide variety of 
clinical settings (Jamal et al., 2016; Johansson et al., 2014; Koehler et al., 2013; Liu et 
al., 2016; Moore & Jayewardene, 2014; Okazaki et al., 2012). Broadly speaking, the 
findings of the current interview study are not comparable with these studies. This is 
because they have applied statistical descriptive analysis and did not go beyond this. 
No qualitative exploration of HCPs’ perceptions or experiences in using clinical support 
apps have specifically addressed diabetes care and management. One interview study 
examined the experiences and views of nurses, in an acute care setting, on the use of 
iPhone to improve communication and decision-making processes at the point of care 
(Farrell, 2016). Overall there was good coherence with the findings of this study but 
there were no consistent themes. 
None of the previous offer congruence with the aim and objectives of the current 
study or the findings. Additionally, these studies were in different settings, and their 
sample consisted of HCPs with diverse specialties, not limited to those specialised in 
diabetes. 
Some elements found in this interview study were identified in previous studies. One 
of the perceived concerns found in this study was patient perception; this finding was 
consistent with related previous studies where nurses and other HCPs reported being 
perceived as unprofessional when using the device with the patient (Farrell, 2016; 
Johansson et al., 2014; Koehler et al., 2013). In the present study, nurses were not 
willing to embrace change in work routine that requires much effort. This has been 
shown in other studies where HCPs were more likely to use mobile devices if it could 
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fit into their workflow without requiring extra effort (Guo et al., 2015). Similar 
concerns around privacy and confidentiality during the use of apps have been 
documented in previous studies (Jamal et al., 2016; Koehler et al., 2013). Results from 
a number of studies were coherent with this study with respect to the benefits of using 
mobile devices and/or apps; most HCPs found them to be useful, accessible, time-
saving and to improve patient safety and quality of care (Farrell, 2016; Guo et al., 
2015; Johansson et al., 2014; Moore & Jayewardene, 2014). Nurses in another study 
had similar belief that this technology would evolve and be embraced by all nurses in 
the future (Farrell, 2016). A further study addressed the potential concern related to 
nurses’ overreliance on decision-support apps and not using their critical thinking skills 
(Sedgwick et al., 2016). Lastly, medical residents in another study reported self-
learning experience with mobile devices which is similar to the finding of this study 
(Jamal et al., 2016). 
On the other hand, the theme ‘one app does not fit all’ identified in this interview 
study was indicated in a number of patient-directed studies. Two studies (Miele et al., 
2015; Nielsen, 2013) pointed to this theme in their findings with regard to apps’ 
features and functions, summarising that patients have different preferences and 
needs. 
7.10.3 Methodological strengths and weaknesses 
To the best of the authors’ knowledge, this study is the first to thoroughly examine the 
use of mobile apps by DSNs in clinical settings to support diabetes management, with 
particular focus on decision-support. This study focused on the qualitative aspect 
where the nurses’ experiences and perspectives on apps use within this environment 
were explored. The study reached saturation and some of the findings were coherent 
with the wider literature.  
Qualitative data analysis is best carried out at least by two authors separately rather 
than an individual analyst. However, coding and analyses in the current study were 
mostly undertaken by the primary researcher and checked by academic supervisors 
through regular supervisory contact. The codes and themes were discussed until 
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consensus was achieved, to establish credibility and avoid bias in the interpretation of 
the data.  
The main weakness of this study was its use of convenience sampling which has many 
limitations. This includes the high potential of selection bias, and the lack of 
representation of the entire population. Though, it was deemed appropriate for 
exploratory studies, such as the current study, where little is known about the area of 
interest (Green & Thorogood, 2009). All participants were females, with four only were 
aged<39 years. Nonetheless, nursing is a profession that always perceived as a 
feminine one and thus, it does not have a balanced number of men and women; fewer 
men enter the profession. There were no male DSNs in all Trusts that were 
approached. 
7.10.4 Implications of study results 
This interview study intended to generate preliminary data to inform the next stage of 
this research; the development of an app, and any subsequent future works in this 
area.  
Need for additional research 
The present study contributes to the currently poor understanding of the role of 
mobile apps and experiences of using them in improving clinical practice among HCPs. 
The topic area is still under development, and there is a need for further qualitative 
research with robust design to fully realise the potential benefits of this technology. 
Future research should focus on both HCPs who specialise in diabetes and others from 
a wide range of clinical expertise.  
Implications for app developers 
This study provides a number of suggestions and end-user requirements for app 
developers interested in developing clinical apps supporting diabetes management. 
Apps will need to be simple, quick, assist with workflow and help save time compared 
with other traditional methods of support. In addition, app developers are 
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recommended to involve HCPs in app design and development in order for the app to 
meets their needs to increase the likelihood of being utilised. 
Implications for policymakers 
There is a lack of regulations around the use of mHealth apps. Policymakers need to 
regulate the use of apps for clinical practice and establish appropriate standards and 
policies within healthcare institutions. There is a need for an initiative to review, 
validate and assess the risk of the available clinical apps, developed by trustworthy and 
quality-assured companies, and then advertise them and promote their use among 
HCPs, e.g. establishing a library of approved clinical apps similar to the library launched 
by the NHS for approved patient-directed apps.  
Implications for practice 
Nurses are willing to use apps and certain that they will facilitate their work. However, 
they are very concerned to download and use any random app. They demanded that 
apps must be approved and recommended by their Trust to be able to use them. 
Mobile apps can be valuable tools for clinical practice due to their high accessibility. 
The challenges now lie with leaders and managers in clinical sectors to ensure that 
approved clinical apps that created by reputable organisations are utilised. It would be 
wise to arrange workshops or seminars to help disseminate the knowledge and share 
experiences with apps among clinical teams to promote safe use of them. These 
findings further suggest that it is feasible to provide nurses with access to decision-
support apps to promote best practice and improve quality and safety of patient care. 
Nevertheless, nurses should be warned of becoming over reliant on such apps and that 
they never be used as a substitute for clinical judgment.  
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Chapter 8  Design and development of a mobile-based clinical 
decision-support app 
Chapter overview 
This chapter describes the design and development process of the mobile app 
‘Diabetes & CKD’ that supports HCPs in clinical decision-making, including the rationale 
for the app design; functional, technical and medical requirements; the development 
process including the decision algorithms; and illustrates the final implemented design 
of the app with screen shots. 
8.1 Design rationale and requirements 
As discussed in the methodology chapter (Chapter 3, section 3.1), the UCD approach 
guided the design and development of the mobile app. This chapter addresses the 
fourth objective of this thesis, relating to the ‘design & development’ stage. ‘Diabetes 
& CKD’, a simple mobile clinical decision-support app for the management of adult 
patients (≥18) with T2D and CKD was designed and built for the study. CKD was 
selected taking into consideration the patterns of comorbidity that are most common 
in this population (Deshpande et al., 2008). As was pointed out in the introduction to 
this thesis (Chapter 1, section 1.1.3), multimorbidity significantly increases the use of 
health services, because people with multimorbidity are more likely to receive 
duplicated testing, contraindicated prescriptions or conflicting advice (Zulman et al., 
2014). Furthermore, as indicated in the findings of the systematic review (Chapter 5, 
section 5.1.3.5), only two studies were identified that reported development and 
evaluation of a decision-support app for diabetes management. This app aims to assist 
HCPs, e.g. diabetes specialist nursing staff, GPs, junior doctors, in decision-making 
process at the point of care, with key objectives of improving quality of care and safety 
of patients and better and timely management of diabetes. A more complex version of 
the app, incorporating all the common comorbidities of diabetes, is planned to be 
developed and tested in the future.  
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8.1.1 Source of requirements 
At the stage of ‘requirements gathering’, qualitative research was carried out to get 
insight into end-users needs and requirements. Interviews conducted with DSNs 
(Chapter 7) provided the main source of requirements. Identifying challenges that 
DSNs face helped to guide the development of the app. From the nurses’ feedback, it 
was found that they were interested in tools that support them in decision-making. 
Other requirements were gathered from the literature and from feedback and 
suggestions of two diabetes and endocrinology consultants. 
8.1.2 Functional requirements 
It is a single function app and hence, there is only one key requirement. The app 
needed to allow the user to enter patient’s parameters and convert them into 
recommendations. In other words, the app generates patient-specific advice to help 
clinicians in making informed decisions.  
8.1.3 Technical requirements 
The main non-functional requirements are as follows: 
▪ The app needed to work across all mobile platforms and with all smartphones 
and tablets running on all operating systems  
▪ The app needed to be downloadable on devices   
▪ The app needed to support offline mode; i.e. it does not require the use of WiFi 
or network connection, to suit the hospital environment in which some of the 
end-users are working which often have poor network coverage 
▪ The app may run within any evergreen browser; i.e. modern browser. This 
includes Google Chrome, Mozilla Firefox, Apple Safari and Microsoft Internet 
Explorer. However, no app feature is expected to make the app unusable in 
older versions of these browsers 
▪ No patient’s identifiable data are needed in the app 
▪ No user account or login data are needed to use the app 
▪ The number of data entries into the app kept to the minimum, including only 
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the data elements that impact on the management plan 
▪ Inputted data stored temporarily on the device’s memory and then wiped at 
the end of a session or upon reloading or exiting the app; they are not kept for 
future sessions. The server simply delivers the files necessary to run the app. 
8.1.4 Medical requirements 
The app needed to incorporate clinical management guidelines followed in the UK and 
best practices based on clinical guidelines, and to be updated regularly to reflect any 
update on the guidelines. The content of the app further needed to be verified by a 
number of diabetes and endocrinology consultants in order to ensure the accuracy of 
the given advice. 
8.2 Design considerations 
Two main factors informed the design of the app: first the needs identified from the 
interviews carried out with DSNs (Chapter 7) and second the management pathways 
presented in the next section. An iterative process of app design based on the 
specified user’s needs and requirements was undertaken. Several UCD development 
cycles are required, however, only the first iteration of an ongoing app design and 
development process was carried out. Further iterations of app design and 
development are planned in the near future. At this stage, the app was built for 
research purposes only, and was not released, as it requires obtaining a number of 
approvals before it becomes available for clinical use. An extended version of the app 
is also planned to be developed and evaluated in the future. 
8.3 Development process 
The app was built by a software developer (Medic Genie; https://medicgenie.com) - 
funded by the student’s scholarship - using an iterative development approach that 
involved frequent testing and modification by the developer. This process also involved 
consultation of a junior doctor to provide well-defined guidance and final verification 
of the management pathways’ correctness. Development process included two parts; 
design and coding part, and both parts were done by programming visually. 
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8.3.1 Prototype development 
Preliminary app sketches were drawn using pen and paper and given to the developer. 
The logical flow of the interface was designed in the following sequence: 
1. Collection of basic demographic and clinical parameters of patient; 
2. Summary of patient details; 
3. Treatment plan prompt. 
8.3.2 Management pathways (decision algorithms) 
The development of the app involved generating the management pathways using the 
National Institute for Health and Care Excellence (NICE) most recent guidelines on 
diabetes, CKD, and hypertension. This included developing algorithms for glycaemic 
control, management of hypertension, dose adjustments recommendations in CKD 
and monitoring and referral. Two diabetes and endocrinology consultants advised the 
selection of the NICE guidelines and technology appraisals. Text analysis of these 
guidelines was undertaken. Then, they were cross-referenced to bring together 
relevant recommendations for the multiple conditions and identify all relative 
synergies, cautions, and contradictions based on a few demographic and clinical details 
relevant to the patient. In addition, the clinical expertise of the consultants involved in 
this work, in areas where no or limited guidance has been found, was taken into 
account. 
8.3.2.1 Guidelines used in the development of the management pathways 
▪ NICE guidelines [NG28] Type 2 diabetes in adults: management, December 
2015 (National Institute for Health and Clinical Excellence, 2015a) 
▪ NICE guidelines [CG182] Chronic kidney disease in adults: assessment and 
management, July 2014 (National Institute for Health and Clinical Excellence, 
2014c) 
▪ NICE guidelines [CG127] Hypertension in adults: diagnosis and management, 
August 2011 (National Institute for Health and Clinical Excellence, 2011) 
▪ NICE guidelines [CG181] Cardiovascular disease: risk assessment and reduction, 
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including lipid modification, July 2014 (National Institute for Health and Clinical 
Excellence, 2014b) 
▪ NICE technology appraisal guidance [TA288] Dapagliflozin in combination 
therapy for treating type 2 diabetes, June 2013 (National Institute for Health 
and Clinical Excellence, 2013) 
▪ NICE technology appraisal guidance [TA315] Canagliflozin in combination 
therapy for treating type 2 diabetes, June 2014 (National Institute for Health 
and Clinical Excellence, 2014a) 
▪ NICE technology appraisal guidance [TA336] Empagliflozin in combination 
therapy for treating type 2 diabetes, March 2015 (National Institute for Health 
and Clinical Excellence, 2015b) 
▪ Clinical Practice Guideline on management of patients with diabetes and 
chronic kidney disease stage 3b or higher (eGFR <45 mL/min) (Guideline 
Development Group, 2015). 
The developed decision algorithms along with the table of dose adjustments in CKD 
are in Appendix 13. 
8.3.3 Implementation 
The app was built during the fall and early winter of 2016. The approached developer 
converted the algorithms into a simple decision-support app named as ‘Diabetes & 
CKD’. The initial version of the prototype, which had few elements for data entries, 
was tested by the developers for errors in the developed software codes and logic. The 
tested beta version software was further tested by two clinicians for the accuracy of 
the generated treatment plan, using a possible number of case scenarios. Once the 
app was finalised, a few individuals, not those included in the trial, tested it and 
comments received were used to make further amendments to the app. 
Of particular interest during the development stage was that the developer’s work was 
stored in a web server and thus, the work was accessible through the web browser 
regardless of location. The app was hosted by Medic Genie where the files stored on a 
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secure web server, but was by intention publicly accessible. No restricted access was 
required at this stage as it was built for research purpose only.  
The developer followed a process with various steps within the app development: 
▪ Familiarising with medical requirements 
▪ Investigating possible app structures that best meet the given pathways 
▪ Collection and translation of data (used as secondary input; to be combined 
with user input and transformed into expected outputs) 
▪ Automated tests to verify algorithmic correctness 
▪ User Interface (UI) design and User Experience (UX) considerations 
▪ Compilation, of the above, into a functional web app. 
8.3.3.1 Programming language 
There are various tools that can be used to develop a mobile app. Some mobile 
development tools are platform-specific, whereas others are cross-platforms. For 
purpose of deploying the app across multiple platforms, it was implemented using 
client-side web technologies; i.e. HyperText Markup Language (HTML), Cascading Style 
Sheets (CSS) and JavaScript.  
The algorithms were converted into the app logic most often using IF-THEN 
statements. This approach is not recommended for developing guideline-based 
decision-support tools, however, it was used due to the developer’s lack of skills and 
experience in other approaches and the limited time and resources of this research. An 
alternative method for developing computer-interpretable guideline is the knowledge-
based approaches, such as PROforma, PRODIGY, Prestige, etc., where the guidelines 
are coded as a set of rules. The use of such an approach will facilitate the validation 
process of the implemented guideline and speed up its update since clinical guidelines 
are continually updated. 
8.4 Final implemented design 
With the software developer, the app interface and layout were discussed and agreed. 
It was decided to be straightforward with an easy-to-follow look. The app was 
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implemented using a standard template with a plain white background and a header 
and navigation along the top of the screen and contained the app name on all pages. 
When possible, dropdown menus, predefined lists or checkboxes were considered in 
attempt to reduce the amount of typing required for data input. Error check for 
numerical variables was applied to ensure that the inputted value was in range. 
However, some features were not feasible to implement at this stage, such as 
integrating the app with electronic patient records, as this requires a significant time 
for development and involves complex technical and organisational solutions that 
were not practical to carry out in the timeframe for this thesis. When the final 
prototype design was implemented, the developer delivered compiled, bundled and 
minified files necessary to run the app. In addition, the source code was delivered to 
allow for future development.  
As indicated above, the key functionality of the app is to work out a personalised 
treatment plan based on patient’s parameters. Based on this, the app consisted of a 
number of integrated dynamic screens. They were classified into the following three 
main types of screens: 
Home screen 
Whenever the app launched or reloaded, it opens to the home screen. This page acts 
as a dashboard where the user can select one of the two management pathways: 
glycaemic control or BP management. The home screen is shown in Figure 8.1. 
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Figure 8.1 ‘Diabetes & CKD’ home screen. 
 
Data entry screens 
Once a pathway was selected, and for the sake of simplicity, the user asked to enter 
one parameter at a time in individual screen, and click the Next button in order to 
move to the following data entry screen, answer a few related questions and follow 
on-screen instruction. Examples of screens that were implemented for data entry are 
demonstrated in Figure 8.2.  
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Figure 8.2 Examples of data entry screens. 
 
Recommendation screens 
When data entries have been completed, treatment recommendation is given, with 
attached link for referral and monitoring advices. Drug names were clickable for 
further details including the recommended dose or adjusted dose. Samples of the 
recommendation screens are illustrated in Figures 8.3 and 8.4. 
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Figure 8.3 Examples of recommendation screens. 
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Figure 8.4 Additional examples of recommendation screens. 
The final developed app was prepared for user trial and usability testing, and the 
results are reported in Chapter 9. The app will be further refined following the 
feedback collected from end-users. 
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Chapter 9  Evaluation of the developed mobile app  
Chapter overview 
This chapter presents methods and results for the evaluation of the developed mobile 
app ‘Diabetes & CKD’, including aim and objectives, research design and setting, ethical 
approval and considerations, recruitment of participants, sessions process, data 
analysis approaches, results (participant characteristics and findings) and discussion 
(strengths, weakness and implications). 
9.1 Aim and objectives 
This chapter addresses the fifth objective of this thesis, relating to the ‘evaluation’ 
stage of the applied UCD approach (Chapter 3, section 3.1). The aim is to test the 
developed mobile app ‘Diabetes & CKD’ as an intervention for supporting HCPs in 
managing patients with diabetes and CKD in a controlled environment. 
Objectives are to:  
▪ Assess the effect of using the app on workflow and adherence to clinical 
guidelines 
▪ Explore how participants experienced the app and their suggestions for 
improvements 
▪ Test usability of the app. 
9.2 Research design and setting 
This study adopted the mixed-methods quantitative and qualitative design. Three main 
methods were undertaken and discussed below. More details on each method and 
justification for their selection were provided previously (Chapter 3, sections 3.2.2.1 & 
3.2.2.2). 
9.2.1 Pilot randomised controlled experiment 
A pilot randomised controlled experiment was carried out using case scenarios to 
investigate the feasibility and impact of introducing a clinical decision-support app. 
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Three case scenarios were prepared by a diabetes and endocrinology consultant from 
the University Hospitals Birmingham NHS Foundation Trust (see Appendix 14). 
Randomisation sequence was generated using the random number generator in 
Microsoft Excel Software. 
The evaluation of the app first design was conducted to assess how the app could 
support HCPs in terms of (a) workflow efficiency (measured by time to complete the 
tasks), and (b) adherence to clinical guidelines (measured by accuracy of decision 
made, compared to the use of paper-based guideline algorithms) (see Appendix 13).  
As indicated in Chapter 3 (sections 3.2.2.1), a controlled experiment tests a hypothesis 
about the effect of an intervention on some measurable outcomes in order to prove or 
disprove the null hypothesis which is an assumption that there is no difference 
between groups. The hypothesis here is that clinicians’ work will be greatly aided - 
shorter time to make a decision and more accurate decision - by an app intervention 
that can provide decision-support on the care of patients with diabetes and CKD.  
9.2.2 Satisfaction questionnaire 
All participants in the intervention group were invited at the end of the piloting session 
to provide qualitative feedback, using a questionnaire (Appendix 14) to assess their 
subjective satisfaction from working with the app. The questionnaire had six open-
ended questions relating to familiarity of respondents with the use of decision-support 
tools, overall satisfaction with the app, positive and negative aspects of the app, 
features to change/add, usability issues (if any), willingness to use the app in the 
future, and suggestions for improvements.  
9.2.3 Usability testing 
Usability testing session was undertaken to assess the app’s interface and functionality 
and users’ attitudes towards the app. Participants tested the app in controlled 
conditions, performing representative tasks using the case scenarios in Appendix 14. 
They were asked to follow the ‘think-aloud’ protocol which asks them to verbalise 
what they are doing while they are doing it, which slows participants down 
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considerably, therefore, measuring the time was considered not feasible in this 
session.  
9.3 Ethics approval 
Substantial amendments application for the previously granted ethical approval (see 
Chapter 7, section 7.3) was submitted to the University of Warwick’s Biomedical and 
Scientific Research Ethics Sub-Committee in order to include this study, and changes 
have been approved with a reference number (REGO-2014-786 AMO1). In addition to 
the previously obtained Trusts’ permissions (outlined in Chapter 7, section 7.3), the 
University Hospitals Birmingham NHS Foundation Trust was approached to obtain 
permission. However, they considered this study as service evaluation and did not 
require any permission. The amended ethical approval letter and access letter are in 
Appendix 11. 
9.3.1 Ethical considerations 
Participants were fully informed of the study by being given the ‘participant 
information leaflet’ and the ‘participant consent form’ (Appendix 14). Completed 
consent forms were collected from participants before the discussion started. 
Participants’ contact information was not collected; participants were anonymised and 
are not identifiable. Participants had the right to withdraw from the study freely at any 
time, however, nobody did. 
Collected study information (including recorded discussion and consent forms) was 
only accessed by the research team. Information was retained securely by the 
researcher; electronic copies of the discussion was stored on university-owned 
computers with access passwords, while paper records of consent forms were stored 
in a locked cabinet in the office at the University of Warwick. Data will be retained for 
a period of 10 years in line with the University of Warwick’s policy on published data. 
Participants were made aware that no major benefits or risks were anticipated as a 
result of participation in this study, since these were only simulation-based cases. All 
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case scenarios were prepared and tested by a diabetes and endocrinology consultant 
to ensure no incorrect information or decision is generated by the app.  
9.4 Participants 
Two types of end-users were considered as participants: 
1. Junior doctors on the Foundation Program (FY1 or FY2) 
2. DSNs from the interview study who expressed interest in taking part. 
9.5 Recruitment of participants 
Participants were recruited by two approaches: 
1. Junior doctors were recruited for the controlled experiment at the University 
Hospitals Birmingham NHS Foundation Trust as part of a teaching session on 
diabetes and renal complications (see Appendix 14 for the session agenda). 
Thirty-nine junior doctors were recruited in total, with a 100% recruitment rate. 
As it was a pilot study, the power of statistical tests was not calculated to help 
in deciding how many participants to recruit.  
2. Fifteen DSNs were invited to take part in the usability testing session, but only 
three were recruited at the Sandwell & West Birmingham Hospitals NHS Trust. 
Invitation emails were sent by the researcher to the mailing list of DSNs with 
two documents attached: the ‘participant information leaflet’ and the 
‘participant consent form’. Nurses interested in taking part were invited to 
contact the researcher by using the contact information given at the bottom of 
the information leaflet or by replying directly to the invitation email. DSNs who 
participated in the study were given a £20 Amazon.co.uk voucher as a 
reimbursement of their time, and were eligible to claim any travel expenses 
that they incurred through participating in this study. 
9.6 Session process 
The teaching session, where the pilot controlled experiment was undertaken, was 
carried out within the Hospital premises. During the piloting phase, junior doctors 
   
178 
were randomly divided into two groups using the software generated random 
numbers which were applied through a predefined sequence to alternating rows to 
ensure complete randomness of the assignment of a participant to each group. Those 
in the intervention group had access to the developed app ‘Diabetes & CKD’. Those in 
the control group had access to paper-based guideline algorithms that informed the 
app development (Appendix 13). Only participants in the intervention group were 
given a link to the app by opening their browser to the specified web page. However, 
for practical reasons, it was not possible to demonstrate the app to them. At the 
beginning, an example simulation-based case scenario was explained by the 
consultant. Next, both groups were asked to deal with two simulation-based case 
scenarios that lasted around half an hour. It was intended to time participants in both 
groups to compare how long it take them to complete the tasks, which is a good 
measure of efficiency, however, due to practical reasons, time measurement was not 
feasible. Decisions made in each group were written down on the provided answer 
sheets (Appendix 14). At the end, intervention participants were asked to complete 
the satisfaction questionnaires in as detailed a way as possible.  
For the usability testing, a seminar room at the hospital was booked for the session 
with a comfortable setting (i.e., seated around a table), to encourage maximum 
engagement from all participants. The session was run during informal time (dinner 
time) at the end of a working day. Group discussion lasted approximately one hour. 
The discussion was facilitated by the lead investigator of this research. The facilitator 
promoted turn-taking between participants to ensure that each participant 
contributed to all sections of the discussion. Also, participants were encouraged to talk 
to each other and not address themselves only to the facilitator. At the beginning of 
the session, a brief description of the app was provided, supplemented with a short 
demonstration. The researcher assisted nurses accessing the app on their own devices. 
During the testing phase, nurses were asked to perform tasks using the case scenarios 
and to verbalise what they are doing while they are doing it. Broad questions were 
asked to explore participants’ views and opinions based on use during the session. At 
the end of the discussion, participants were given the opportunity to raise any relevant 
uncovered topics. 
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9.7 Data analysis 
The answer sheets for both groups were blinded and scored against a model answer 
prepared in advance by the consultant (Appendix 14). In the used scoring scale, minor 
and major decisions were not scored equally; they were given varied weight. The 
scoring was carried out by an independent clinician not directly involved in the 
preparations of the case scenarios. Scores were compared and analysed using 
independent samples t-test/Mann-Whitney U-test for hypothesis testing as 
appropriate. Outcome measure was the accuracy of decision (whether the decision 
matched that expected based on the guidelines). Statistical analysis was carried out 
using SPSS software (IBM Corp, 2015).  
For the satisfaction questionnaire, basic analysis was undertaken. First, questionnaire 
responses were read carefully several times. Then, major patterns and trends were 
identified in the responses and were summarised for each question.  
The usability testing session was audiotaped and transcribed verbatim by a 
professional transcription company and analysed using a narrative synthesis approach. 
9.8 Results  
9.8.1 Participant characteristics 
Thirty-nine junior doctors were included in the controlled experiment (17 male, 22 
female). Of them, 17 were allocated to the intervention group (5 male, 12 female) and 
22 to the control group (12 male, 10 female). Minimal data were planned for collection 
at this stage, given that they all were junior doctors (FY1) and likely to be of similar 
ages. 
Three DSNs were included in the usability testing session. All were females, aged 30–
46 years. All were based in the hospital; however, all were also working in the 
community. Work experience with diabetes ranged from 6–16 years. Additionally, they 
all were provided with either a smartphone or tablet, or both, by their trust. 
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9.8.2 Findings 
9.8.2.1 Pilot randomised controlled experiment 
A Shapiro-Wilk’s test (P>0.05) (Razali & Wah, 2011; Shaphiro & Wilk, 1965) and a visual 
inspection of their histograms, normal Q-Q plots and box plots showed that the 
participants’ scores were approximately normally distributed for both intervention and 
control groups, with a skewness of -0.591 (SE=0.550) and a kurtosis of 0.419 
(SE=1.063) for the intervention group and a skewness of -0.147 (SE=0.491) and a 
kurtosis of 0.785 (SE=0.953) for the control group (Cramer, 1998; Cramer & Howitt, 
2004; Doane & Seward, 2011). 
As the intervention and control distributions were sufficiently normal, an independent 
samples t-test was performed. There was no significant difference in the scores 
between intervention group (mean=7.235, SD=2.4630) and control group 
(mean=7.386, SD=2.5632); t (37) = -0.186, P=0.854 (maximum score is 13). The 
frequency distribution of the scores for both groups is presented in Figure 9.1. These 
results suggest that, for the given two case scenarios in this small cohort of 
participants, no difference was observed on the accuracy of decision made using the 
app compared to the use of paper-based guideline algorithms.  
  
                Figure 9.1 Frequency of scores for control and intervention groups. 
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A score of 8 was determined as the minimum standard of safe care for the given two 
case scenarios. Nine doctors (%53) in the intervention group got score 8 or above, 
whereas only 7 doctors (%32) in the control group scored 8 or above. Yet, when 
comparing their scores for each case individually, nearly %77 doctors in both groups 
scored the minimum of 3 in case one, while %41 and %50 doctors in the intervention 
and control groups respectively got the minimum score of 5 in case two. 
9.8.2.2 Satisfaction questionnaire 
Seventeen questionnaires were completed, with a 100% response rate (app arm), but 
with a considerable number of missing answers for sub-sections. Nearly half of the 
junior doctors indicated prior experience using decision-support apps such as the BNF 
app and Medscape calculators. With regard to their overall impression, most were 
satisfied or somewhat satisfied with the app; with very few participants feeling that it 
did not meet their expectations and stated that the app needed more work. 
Respondents generally had good experiences using the app, with more positivity 
reported than negativity. On the positive side, ease and simplicity of the app were the 
most emphasised features. Participants used the following words/sentences more 
frequently to describe the app: easy to use, user-friendly, straightforward, quick, 
simple flow, good presentation, intuitive user interface, clear design, easy to input 
information, gives a good recommendation based on results, not too wordy, good font 
size and much easier to use than the algorithm.  
By contrast, the most common negative point was the ambiguity of the navigation 
between pages and/or recommendations, followed by the difficulty scrolling up and 
down. Regarding usability, some respondents reported that they encountered some 
problems during the session. The app crashed a few times with some participants, 
resulting in disappointment. 
In terms of suggestions for improvement, participants expressed the need for: easy 
and clear navigation, information on doses supported with links to evidence, additional 
information on drug side effects, e.g. weight loss or gain, hypos, etc., the possibility to 
save previous searches to go back to them easily, the ability to enter patient’s current 
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medications to help streamline the options at the end and more specific advice 
regarding which combinations of dual/triple therapy would be more appropriate. 
All participants thought that the app seems useful and, hence, they are willing to use 
such apps in their clinical practice, specifically for more complex patients when they 
are uncertain. They indicated that they would use it if it would help them save time 
compared to manually searching through guidance. They thought it would help them 
in the clinic and in ward care, especially overnight, but it would not be appropriate to 
use during consultation. They further pointed out that it might be hard to get the time 
to use the app, in particular, with those patients needing immediate management.  
9.8.2.3 Usability testing 
Consensus clearly emerged between the results of this usability testing and the 
satisfaction questionnaires. DSNs faced several usability problems as well when using 
the app. Once again, the ambiguity of the navigation between pages and/or 
recommendations was described as the most frustrating part of the app. Nurses found 
it unclear how to go back to the home screen and, when they wanted to go back to the 
last page, it took them back more or less to the beginning, and so they had to input the 
information in again. 
‘I am a bit scared to touch anything now in case it cancels everything again.’ 
(Nurse 2) 
‘Oh no it took me right back to the start. That would be annoying. So it's asking 
me to put everything in again.’ (Nurse 3) 
The app crashed once with a nurse as she became unable to move or type in any data, 
she said: 
‘Mines stuck a little bit I think, it won't let me answer questions.’ (Nurse 1) 
Some buttons within the app will only appear once the user typed in the data and, 
thus, they found this to be unclear and some users might miss it. 
‘When you say yes, that changes and it's not clear. I didn't realise it had 
changed.’  (Nurse 2) 
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The fact that users cannot skip any part and have to fill each section before they can 
move onto the next stage was described as unpractical.  
‘Sometimes in real life you might not get all the right information and then you 
can't move onto the next stage, because obviously you need all the information 
to get it.’ (Nurse 1) 
Nurses felt that some data items were irrelevant, for example, when the app asks for 
blood pressure while looking at glycaemic control. They thought it is not doing 
anything but adding more data to input. By contrast, they asked for adding some data 
item such as the BMI. They explained that the BMI is an important indicator which they 
use a lot in diabetes to make decisions. So patients with a higher BMI would go 
through a different pathway from the patients with a lower BMI.   
Nurses stated that some given advice would need further clarification. For instance, 
when the app recommends monitoring the patient, nurses wondered what sort of 
monitoring to do, and asked for some more information about how to monitor. They 
suggested giving guidance as to how often a patient need to be seen to check if the 
treatment they are on is adequate. In contrast, they were not happy with some of the 
given advice such as the recommendation to refer a patient to a nephrology. One 
nurse stated:  
‘I wouldn't accept a referral for her.’ (Nurse 1) 
Several suggestions were given by DSNs to improve the app. They indicated a 
preference to use other gestures when communicating with the app such as the swipe 
as opposed to just using the touch. Furthermore, nurses thought providing background 
information on the home page would be helpful. So giving links to basic guidelines on 
drugs, hypo or driving information to direct users for further education. Nurses 
explained that there are many different combinations of medications for diabetes, and 
there is not always a right or a wrong way. They have got to try one drug and see how 
it goes. Therefore, nurses asked for more information on their side effects, e.g. 
whether the drug is weight neutral or if the patient likely to gain weight – perhaps a 
shortened list of pros and cons for each drug – to help them make decisions quicker. 
Additionally, they asked for more details on drug doses, such as the starting dose and 
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maximum dose. Nurses further suggested that the app allow users to enter patient’s 
current medication because this obviously will reduce the given options. 
On the other hand, nurses indicated several positive aspects of the app. They liked 
having the button ‘how did I get here’ which allows them to check if they have 
inputted something incorrectly at any point. They also suggested having this screen 
compulsory in order to enable users to make sure their information was correct and 
that they have not omitted anything. Moreover, they found it very useful that they 
could click on the drug names to give them more information about them, because it 
saves them flicking through the system looking for this specific information. 
‘And obviously it gives you a caution box there. That's brilliant.’ (Nurse 3) 
DSNs stated that the app was a good idea, particularly from a practice point of view. 
Although usability issues were experienced with the app, they did not hinder the 
completion of tasks. The fact that the app was still under development will make it 
easy to overcome all the usability problems experienced by nurses in this study. 
9.9 Discussion  
9.9.1 Summary of main findings 
This feasibility study provided initial insights on the impact, usability and acceptability 
of an app supporting decision-making which was developed specifically for this 
research. The study employed multiple methods appropriate to address its objectives.  
A pilot randomised controlled experiment was undertaken in a controlled environment 
to assess whether the use of the app improved adherence to clinical guidelines. The 
experiment tested the difference in effect using the app and the paper-based version 
of the app’s algorithm, however, there was no difference between intervention and 
control groups (P=0.854). The scores were generally poor in both groups, with a mean 
around 7 (maximum score is 13). However, the number of safe doctors who scored 8 
or above was higher in the intervention group compared to the control group. 
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Junior doctors in the intervention arm did not make more accurate decisions, but since 
this was their first exposure to the app, the need to explore and learn to operate the 
app might explain these results. Another key point is that participants in the control 
group were given the paper algorithms that informed the app development as 
opposed to the lengthy guidelines, which enabled them to answer better. Significant 
efforts have been made, under a supervision of two diabetes consultants, to carefully 
build these algorithms as simply as possible. In real-life scenarios, no one will carry the 
paper algorithms with them but it could be made available electronically and, thus, 
results may become similar. A more comprehensive study would also compare how 
participants in both groups scored in regard to trivial and serious deviations from the 
care described in NICE guidance and the risk arising from scoring each one. 
The results from the satisfaction questionnaires showed that despite the reported 
negativity, most participants were satisfied with the app. They understood that it was 
still under development and, thus, they indicated there is room for improvement. They 
believed that the app would be a useful addition to their clinical practice and 
expressed their willing to use it when appropriate.  
The app is intended to provide a personalised recommendation tailored to the patient 
as a mean of support to HCPs’ clinical skills and judgment. Therefore, it should meet 
the needs of the target users in order to deliver its potential. The purpose of 
conducting the usability testing with DSNs, in conjunction with the controlled 
experiment, was to further evaluate the app qualitatively with another group of 
potential users. One important factor for the success of the app is to have a usable 
user interface. A think-aloud analysis was performed with DSNs to explore and identify 
potential usability problems. Nurses have experienced several usability issues during 
the session, though; they found learning to use the app is easy and straightforward. 
The findings suggest that the app was well-accepted by both DSNs and junior doctors. 
Clearly, encountering frequent crashes will certainly affect user’s satisfaction. Notably, 
however, the reported negative points could be attributed to the fact that the app is 
still immature. This highlights the need to provide participants with a well-functioning 
tool to increase their satisfaction and willingness to use the app. 
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9.9.2 Comparison with other relevant studies 
Research on mobile decision-support apps (mHealth DSS) in diabetes management is 
limited (see Chapter 5, section 5.1.6.6), as studies conducted thus far (Neubauer et al., 
2015; Neubauer et al., 2014b; Sarala, 2014) were neither randomised nor controlled. 
However, app piloting was carried out in a field setting in those studies. In addition, 
these studies mainly shed light on the impact of using the app on patient-related 
outcomes. 
Regarding HCP-related outcomes, one study assessed the usability of a decision-
support app using a quantitative questionnaire (Neubauer et al., 2015; Neubauer et al., 
2014b). Generally, the app was highly acceptable by HCPs involved in the trial. HCPs’ 
compliance with given recommendations from the decision-support apps was assessed 
in two studies (Neubauer et al., 2015; Neubauer et al., 2014b; Sarala, 2014). 
Adherence by physicians and nurses to the suggested advice was high in both studies. 
The study of Spat et al. (Spat et al., 2013) investigated HCPs’ errors and workflow 
anomalies retrospectively. They compared the results generated by the app with those 
generated in the clinical study using a paper-based algorithm. The number of errors 
made by the app was very much fewer than errors made by physicians and nurses in 
the paper-based study. 
The findings of the current study are not comparable with these studies. None of the 
studies described above have the same aim and objectives as the current study and, 
thus, the findings as well. This is because they have different designs, settings and 
reported outcomes. 
9.9.3 Methodological strengths and weaknesses 
This study, being a pilot not considering the statistical power required to detect a 
difference between groups, is unlikely to be generalisable to the entire population. The 
app was tested in a controlled setting which did not take into consideration the 
location. This may not give the same result as an assessment undertaken in the field 
within the intended context of the app, i.e. in clinical practice. Another aspect to 
consider is that blinding of participants to the intervention is impossible to conduct in 
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mobile app intervention trials. Furthermore, this was first-time use of the app for all 
participants. Therefore, the learning effect should be taken into account when 
interpreting the results. 
Some deviation from the protocol occurred. It was intended to demonstrate the use of 
the app for the example case scenario presented by the consultant. However, 
participants in the intervention arm did not receive any training or explanation prior to 
the piloting session. It was not possible to demonstrate the app due to Internet 
connectivity issue in the teaching room as the Trust had blocked the web page. This 
may have had a negative impact on completing the scenarios when using the app. 
Likewise, it was planned to assess and compare time to complete the tasks in both 
groups as a measure of workflow efficiency, but, due to practical reasons, time 
measurement was not feasible. Limitations also included difficulty of recruiting 
participants, specifically in group setting. This is because of the busy schedule of HCPs. 
Despite these limitations, this study has a few notable strengths. First, this was a ran-
domised controlled experiment with a 100% recruitment and completion rates. 
Second, the outcome assessor was blinded to group allocation. Moreover, it used 
multiple methods to investigate both quantitative and qualitative aspects of the app 
evaluation. Also, it was piloted with two different groups of targeted users. This pilot 
study was exploratory in nature which could be strength in generating future 
hypotheses. 
9.9.4 Implications of study results 
The results of the present study, although not conclusive, can be useful in providing 
initial insights into the situation and feed into future research. Previously, no decision-
support app interventions have undergone a robust assessment in diabetes 
management. Robust evaluations are needed to investigate whether such apps will 
improve workflow efficiency and lead to better adherence to guidelines in clinical 
practice. A better study would examine over a longer duration a large, controlled and 
randomly selected sample of HCPs involved in diabetes care and management. Future 
research should focus more on carrying out field trials, with a near-fully designed app. 
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Field trials can give better insight compared to studies conducted in a controlled 
environment. However, setting up such studies may involve higher cost and practical 
difficulties. Additionally, there is a need for future efforts to replicate the current study 
in a robust and large-scale trial but with a control group unaided by either apps or 
algorithms to anchor the scale in current practice and better understand its impact. 
It is crucial to develop an app that integrates end-users’ suggestions for improvements. 
The results from both the controlled experiment and usability testing will help further 
development and evaluation of a more user-friendly app. The app will be updated 
using the feedback and additional comorbidities will be considered for integration into 
the app to expand its usefulness.  
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Chapter 10  Overall discussion and conclusion for the thesis 
Chapter overview 
This chapter outlines key findings drawn from the quantitative and qualitative 
systematic reviews, interview study and app evaluation; summarises the contributions 
made to the field; discusses the limitations and challenges of the thesis as a whole; 
makes suggestions for further research; and ends with future plans and the thesis’ 
conclusions. 
10.1 Summary of main findings of the thesis 
This thesis had a primary aim of developing and evaluating a mobile app that supports 
in diabetes management, starting with reviewing quantitative and qualitative 
literature. Findings indicated the paucity of research around the use of apps by HCPs in 
clinical practice. So a qualitative study explored end-users’ views and needs for apps to 
support their clinical work. Interviews were conducted with DSNs (key workers in 
diabetes care), and the need and interest for apps was ascertained. Hence, a decision-
support app ‘Diabetes & CKD’ was developed based on clinical guidelines and input 
from diabetes consultants. Finally, the app was evaluated in a controlled environment 
with two of the main targeted users, junior doctors and DSNs.  
The UCD process (Chapter 3, section 3.1) was employed for the design, development 
and evaluation of the app. It involves three stages that guided the development and 
structure of the thesis objectives. The first stage is ‘requirements gathering’ and 
involved undertaking two systematic reviews, quantitative and qualitative, and the 
interview study. These studies addressed the first three objectives of this thesis. The 
second stage is ‘design & development’ which involved developing the decision 
algorithms and using programming languages to build the app. This stage addressed 
the fourth objective of this thesis. The final stage ‘evaluation’ involved testing the 
developed app using multiple methods and it addressed the fifth objective of this 
thesis. 
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The quantitative review and meta-analysis (Chapter 5) suggested that mobile apps 
might have a positive impact on glycaemic control in patients with diabetes, although 
the identified studies had considerable heterogeneity and methodological weaknesses, 
and most were small. Limited evidence of the added benefits or mixed results were 
found for other outcomes. The apps examined were different in two main ways: the 
combination of functionalities and the involvement of HCPs. It was not feasible to 
distinguish between the different functionalities in the calculation of the overall effect 
size. Thus, it is still unclear which app functionalities are most effective. 
In the qualitative review (Chapter 6), there was no general agreement about all topics. 
Participants were satisfied with some of the app’s features and functionalities and also 
they pointed out a number of negative aspects associated with its use. Apps involving 
HCPs’ feedback could be more effective in improving glycaemic control and adherence. 
Users also expressed a greater preference for apps that engage their HCPs in their 
diabetes management. The different points of view provide enriched feedback for 
better app designs. 
The two systematic reviews enabled full exploration of both quantitative and 
qualitative evidence on the impact of using apps to support people with diabetes and 
their HCPs. However, it was not possible to draw conclusions on their results either for 
patients or HCPs. Both reviews highlighted the dearth of research involving the use of 
apps with HCPs and women with GDM.  
DSNs (Chapter 7) were not currently using apps in their clinical practice, even though 
most of them were provided with work-related smart devices. Most nurses were not 
aware of the existing medical apps. Therefore, there is a need to advertise the 
available reliable clinical apps. They appreciated the potential benefits that apps may 
bring to their clinical practice. However, barriers and concerns about their use were 
expressed. The lack of official regulatory framework around apps that outlined in 
Chapter 2 (section 2.3) was also identified as a concern and barrier, prompting nurses 
to avoid their use. Despite this, nurses are strongly willing to use apps. They see app 
technology as an opportunity rather than a potential threat. There is a place for simple 
apps to support DSNs in clinical practice. 
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The qualitative review and the interview study were consistent in part of their 
conclusion. They showed that there is no ‘one size fits all’ app design. Participants’ 
varied responses indicate that every user is unique. This makes designing an app 
accommodating the needs of all individuals challenging. This highlights the need to 
develop either customisable apps or apps that are tailored specifically to one user 
group.  
Considerable effort has gone into developing the ‘Diabetes & CKD’ app (Chapter 8). 
The app was evaluated in a pilot randomised controlled experiment and usability 
testing session (Chapter 9). The pilot study showed feasibility but was not powered to 
demonstrate a difference in the accuracy of decision made between the intervention 
and control groups. Users, both junior doctors and DSNs, have mixed views toward app 
usability, but generally were positive. This was coherent with the findings regarding 
apps usability from the reviews undertaken in this thesis. 
10.2 Contributions to the field 
Petre and Rugg in 2010 (Petre & Rugg, 2010) state that: 
“Making a significant contribution means adding to knowledge or contributing to the 
discourse – that is, providing evidence to substantiate a conclusion that’s worth 
making.” 
Research on the use of mobile apps among HCPs in clinical practice is lacking. This 
thesis was driven by gaps in the existing knowledge relating to the impact of using 
apps in diabetes care and management and contributes to a better understanding of 
the role of apps in supporting HCPs in clinical practice.  
The following subsections highlight what makes the work carried out in this thesis an 
original contribution. 
10.2.1 Design contribution 
A key contribution of this thesis is the design and development of an innovative fully 
working mobile decision-support app ‘Diabetes & CKD’. It supports HCPs in decision-
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making for patients with diabetes and comorbidities. The app design took into 
consideration the needs and preferences of end-users in order to increase its 
acceptability and utilisation. Iterative development and refinement of the app will 
further enhance its design. It is hoped that the outputs from this thesis can inspire 
further ideas for developers and researchers for the design, development and 
evaluation of future diabetes apps.  
10.2.2 Methodological contribution 
The main methodological novelty was the application of a software development 
framework (UCD) for the entire thesis work. The UCD methods involved both 
quantitative and qualitative methods for data collection during the different design, 
development and evaluation stages of the thesis. The methodology chosen ensured 
thorough exploration of complex intervention such as the mobile app, particularly 
since it is still not fully mature.  
The pilot randomised experiment is the first attempt to test a mobile diabetes 
decision-support app for HCPs in a controlled environment using case scenarios. This is 
novel in the field of diabetes. The method may have been described before or possibly 
has been applied but in areas other than diabetes. 
10.2.3 Practical contribution 
A number of practical contributions were made. Firstly, the study has undertaken 
detailed quantitative and qualitative systematic reviews which appraised and 
summarised the key characteristics and findings of available studies. To the best of the 
authors’ knowledge, the qualitative review is the first to consider qualitative research 
studies that have explored patients’ and HCPs’ use of, and perspectives on, mobile 
apps for diabetes care and management. 
Secondly, the interview study contributes to scholarly mHealth literature since the 
qualitative aspects of HCPs’ use of clinical support apps in diabetes care and 
management is an under-studied area. This study is the only qualitative study of DSNs’ 
experiences and perspectives on apps use within this environment of which the 
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authors are aware. The findings provided valuable insights into end-users’ needs and 
requirements that can inform recommendations for the design and development of 
future diabetes apps, and future research in mHealth.   
Thirdly, through conducting the pilot controlled experiment and usability testing with 
junior doctors and DSNs, this study helped to develop a deeper understanding of HCPs 
and their views and attitudes towards decision-support apps. Therefore, the 
contributions of this research are the findings related to the feasibility, usability and 
acceptability of the app. This will further help to shape and guide the design of this and 
other chronic disease apps to facilitate and support decision-making among HCPs. 
10.3 Limitations and challenges 
This section discusses the limitations and challenges of the approach undertaken in the 
thesis as a whole (rather than those indicated in the individual chapters), which may 
affect the interpretations and application of the findings and, therefore, need be taken 
into consideration. 
With regard to external validity, the transferability/generalisability of findings to the 
entire population of HCPs in the interview study and the controlled experiment are 
limited due to the sampling method used and the absence of statistical power, 
respectively. Other groups of HCPs, e.g. male nurses or GPs, or another setting, might 
yield a different result. It was not possible to interview and evaluate the app with a 
varied group of HCPs involved in diabetes care. If this doctoral research had longer 
timeframe, a variety of HCPs could have been recruited. Undertaking further 
interviews including, for example, GPs and practice nurses, who have a central role in 
the care of diabetes, would enrich the findings and increase its validity.  
In terms of internal validity, conducting the interviews and analysis by the primary 
researcher only was a limitation. Bias may have occurred in interpretation of the 
results. Therefore, findings of the interview study may considered subjective and not 
definitive. However, working in a team was infeasible since doctoral research work 
needs to be undertaken independently. The iterative data collection in UCD process, 
and attempts to ensure neutral analysis through close monitoring by academic 
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supervisors and regular discussion of categories, codes and themes until consensus 
was achieved, hopefully enhanced credibility.  
There are also limitations with usability testing with an app still under development. A 
fully-developed app might have provided different results; possibly with reduced 
usability issues. Limitations also included time, resources and workforce available for 
the doctoral research. If more time had been available for the app development, 
without doubt, improvements could have been made, but this was not possible in the 
scope of this thesis. 
The main challenge of this research is the difficulty of recruiting HCP participants. 
Interviews and usability testing require a prolonged timeframe for recruitment. 
Another major challenge was developing the decision algorithms by the primary 
researcher, who does not have a clinical background. However, involvement of the two 
diabetes consultants into the iterative development process facilitated the work. 
Some decision-support apps may be considered a medical device and, thus, need to go 
through a regulatory approval process before they can be evaluated in a real-world 
setting. In particular, those involving interpretation of data, or some sort of complex 
calculation (as in this type of app) may pose risks to patients if they were unreliable. 
Undertaking an evaluation of such apps in field settings would be a challenge that 
needs to be taken into consideration when planning evaluation studies. 
10.4 Further research 
The findings of this thesis in relation to the evidence base are inconclusive. The 
technology is new and, thus, well-conducted studies are lacking. Therefore, the 
opportunities for conducting further research are broad.  
Results from the systematic reviews provide a baseline from which future research can 
move forward. These reviews indicated that patients experienced a variety of benefits 
from using diabetes apps. A logical next step would be to carry out high-quality 
research into apps’ impact in diabetes self-management and remote monitoring. 
Future research needs to be methodologically rigorous and avoid the weaknesses 
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identified in the studies included in the systematic reviews to ensure their contribution 
to the evidence base. In particular, studies need to be large-scale with longer follow-up 
and standardised outcome measures. Future research would certainly be facilitated if 
diabetes apps’ functionalities were standardised. This will help to discover what 
benefits can be gained and increase generalisability of findings to a wider variety of 
populations. Further research that is directed toward women with GDM, adolescents 
and older people, e.g. older than 65 years, is supported as these groups were barely 
considered in apps research. 
There is much scope for further research on the impact of using apps on clinical 
practice, given the increasing use of smart devices among HCPs. The mobility and 
convenience of apps may deliver benefits to workflow and patient care. Research is 
needed with robust designs and representative samples to evaluate the effectiveness 
of clinical apps to enhance care efficiency and patient outcomes and to explore 
experiences of using apps in improving clinical practice among HCPs. 
The findings of the interview study may provide a structure to guide future research in 
this area with a wider variety of HCPs. Opportunities are wide open for further 
research to extend the interview study with other group of HCPs such as GPs, practice 
nurses, district nurses and junior doctors, also using quantitative questionnaires, and 
covering other health conditions. This will help validate the findings of this study and 
explore broader perspectives which will increase transferability of findings to the wider 
population of HCPs and healthcare.  
Another effort for future research could involve undertaking app usability testing in 
real life for prolonged period of time. At the end, participants would be invited to 
provide feedback on the usability, satisfaction and acceptance of the app, which would 
be richer than feedback received upon initial introduction and use of the app. 
10.5 Future plans and prospects 
Since the systematic review search ended in late 2015, and given this fast-growing area 
of mHealth, an updated search was undertaken in MEDLINE in December 2017, 
covering studies published in 2016 and 2017. The search found 965 records screened 
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at title and abstract level. Next, 76 records are currently under assessment for 
eligibility at full-text level. The inclusion of these further studies is highly anticipated to 
change the findings from older literature. The result will be published in a journal 
article and the manuscript is currently in preparation (see Appendix 15). 
This thesis presents the first iteration of an ongoing app development process. Future 
plans include another iteration of app design and development with the end-users as 
the focus. This also involves updating the app using the feedback collected from the 
evaluation study undertaken in this thesis. This iterative data collection will further 
enhance the credibility of this research. Furthermore, common comorbidities of 
diabetes are to be included in the app. 
There is a great deal of room for improvements and research building on the findings 
of the thesis. The findings of the evaluation study need further validation in a 
randomised controlled trial applied in a real-world setting. The app will be evaluated 
for its impact on HCPs’ outcomes next, after regulatory approval if required, and 
eventually tested in a field setting. 
10.6 Conclusion 
This thesis explored available evidence on diabetes mobile apps; established a better 
understanding of end-user needs and requirements; translated those requirements 
into an app, and evaluated the final implemented design, although further work is 
needed in larger and longer studies.  
Previous research has explored extensively the use of mobile technology interventions, 
with limited consideration of apps according to the definition and criteria used in this 
thesis. Existing literature draws attention to the potential of apps for improving 
patients’ outcome, achieving treatment goals and improving quality of care. However, 
they are limited in showing apps’ effectiveness in diabetes self-management, remote 
monitoring and clinical practice due to concerns about their quality. Using apps for 
self-care is highly dependent on the individual’s motivation; without the patient’s 
willingness to be an active participant in their care, apps implementation will likely fail. 
A decision-support app, developed through an informative requirement gathering 
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process, was found to be acceptable. Such apps have a potential to enforce and 
encourage evidence-based practice. 
Despite the widespread use of smart devices, use of diabetes apps is still tentative. 
Utilisation of mobile apps is facing a number of challenges. These include, but are not 
limited to, poor evidence of effectiveness, lack of validation of diabetes apps and lack 
of integration with the healthcare system. The quote by David Schlanger, provided at 
the beginning of this thesis (p. xiv), pointed out to the lack of adoption of digital tools 
that may facilitate the delivery of healthcare. This thesis developed and evaluated one 
of the latest technologies that has a great potential to support HCPs in clinical practice. 
Yet, there still remains a need to understand further the benefits and the drawbacks of 
including apps within the care pathways for people with diabetes. 
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Appendices 
Appendix 1. Search strategy details and results for all electronic databases and 
journals and grey literature 
Limit: 2008 - Present  
No Limit for Language 
 
Database Link Search Date Hits 
Cochrane Central 
Register of Controlled 
Trials 
http://www.thecoc
hranelibrary.com/ 
 
#1   diabet* or "IDDM" or "NIDDM" or "MODY":ti,ab,kw or 
"hyperinsulin" or (insulin next sensitive*) or (insulin next 
resist*) or (insulin next depend*) or insulin?depend* or (non 
next insulin next depend*):ti,ab,kw or (noninsulin next 
depend*) or (non next insulin?depend*) or 
noninsulin?depend*:ti,ab,kw or (impaired next glucose next 
tolerance*) or (glucose next intoleran*):ti,ab,kw or (typ* next 
1 next diabet*) or (typ* next 2 next diabet*) or (typ* next I 
next diabet*) or (typ* next II next diabet*) or (gestational next 
diabet*):ti,ab,kw  
 
#2   (telephon* or phon*) and (mobil* or cell*) 
 
#3   (smartphone? or smart?phone?) or (window? next 
phone?) or (window? next mobile?) or "nokia" or ("palm" next 
"OS") or ("palm" next computer?) or "Symbian" or iphone? or 
ipad? or (ipod? next "touch") or ("personal" next "digital" next 
assistant?) "PDA" or android? or blackberry* or "apps" or 
applet? or ("mobile" next app*) or ("software" next app*) or 
("ehealth" or "e health" or "e-health" or e?health) or 
("mhealth" or "m health" or "m-health" or m?health) or 
("telehealth" or tele?health) or ("telemedicine" or 
tele?medicine) or (telemonitor* or tele?monitor*) or 
("remote" next (consult* or diagnos* or monitor* or treat* or 
"care")) or "mobile health" 
 
#4   #2 or #3 
 
#5   #1 and #4 
 
27/8/2014 180 
MEDLINE OVID 1. diabet*.ab,ti. 
2. IDDM.ab,ti. 
3. NIDDM.ab,ti. 
4. MODY.ab,ti. 
5. exp Diabetes Mellitus/ 
6. hyperinsulin.ab,ti. 
7. insulin sensitive*.ab,ti. 
8. insulin resist*.ab,ti. 
9. insulin depend*.ab,ti. 
10. insulin?depend*.ab,ti. 
11. non insulin depend*.ab,ti. 
12. noninsulin depend*.ab,ti. 
13. non insulin?depend*.ab,ti. 
14. noninsulin?depend*.ab,ti. 
15. exp Insulin Resistance/ 
16. impaired glucose tolerance*.ab,ti. 
17. glucose intoleran*.ab,ti. 
18. exp Glucose Intolerance/ 
28/8/2014 
 
1335 
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Database Link Search Date Hits 
19. typ* 1 diabet*.ab,ti. 
20. typ* 2 diabet*.ab,ti. 
21. typ* I diabet*.ab,ti. 
22. typ* II diabet*.ab,ti. 
23. gestational diabet*.ab,ti. 
24. or/1-23 
25. telephon*.ab,ti. 
26. phon*.ab,ti. 
27. 25 or 26 
28. mobil*.ab,ti. 
29. cell*.ab,ti. 
30. 28 or 29 
31. 27 and 30 
32. exp Cellular Phone/ 
33. (smartphone? or smart?phone?).ab,ti. 
34. (window? adj3 phone?).ab,ti. 
35. (window? adj3 mobile?).ab,ti. 
36. nokia.ab,ti. 
37. palm OS.ab,ti. 
38. (palm adj3 computer?).ab,ti. 
39. symbian.ab,ti. 
40. iphone?.ab,ti. 
41. ipad?.ab,ti. 
42. ipod? touch.ab,ti. 
43. personal digital assistant?.ab,ti. 
44. PDA.ab,ti. 
45. android?.ab,ti. 
46. blackberry*.ab,ti. 
47. exp Computers, Handheld/ 
48. apps.ab,ti. 
49. exp Mobile Applications/ 
50. applet?.ab,ti. 
51. (mobile adj3 app*).ab,ti. 
52. (software adj3 app*).ab,ti. 
53. *Medical Informatics Applications/ 
54. exp Decision Making, Computer-Assisted/ 
55. (ehealth or "e health" or e-health or e?health).ab,ti. 
56. (mhealth or "m health" or m-health or m?health).ab,ti. 
57. (telehealth or tele?health).ab,ti. 
58. (telemedicine or tele?medicine).ab,ti. 
59. exp Telemedicine/ 
60. (telemonitor* or tele?monitor*).ab,ti. 
61. (remote adj2 (consult* or diagnos* or monitor* or treat* 
or care)).ab,ti. 
62. "mobile health".ab,ti. 
63. or/31-62 
64. 24 and 63 
65. limit 64 to yr="2008 - Current" 
EMBASE OVID 1. diabet*.ab,ti. 
2. IDDM.ab,ti. 
3. NIDDM.ab,ti. 
4. MODY.ab,ti. 
5. exp Diabetes Mellitus/ 
6. hyperinsulin.ab,ti. 
7. insulin sensitive*.ab,ti. 
8. insulin resist*.ab,ti. 
9. insulin depend*.ab,ti. 
10. insulin?depend*.ab,ti. 
11. non insulin depend*.ab,ti. 
12. noninsulin depend*.ab,ti. 
13. non insulin?depend*.ab,ti. 
28/8/2014 
 
2479 
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Database Link Search Date Hits 
14. noninsulin?depend*.ab,ti. 
15. exp Insulin Resistance/ 
16. impaired glucose tolerance*.ab,ti. 
17. glucose intoleran*.ab,ti. 
18. exp Glucose Intolerance/ 
19. typ* 1 diabet*.ab,ti. 
20. typ* 2 diabet*.ab,ti. 
21. typ* I diabet*.ab,ti. 
22. typ* II diabet*.ab,ti. 
23. gestational diabet*.ab,ti. 
24. or/1-23 
25. telephon*.ab,ti. 
26. phon*.ab,ti. 
27. 25 or 26 
28. mobil*.ab,ti. 
29. cell*.ab,ti. 
30. 28 or 29 
31. 27 and 30 
32. exp Mobile Phone/ 
33. (smartphone? or smart?phone?).ab,ti. 
34. (window? adj3 phone?).ab,ti. 
35. (window? adj3 mobile?).ab,ti. 
36. nokia.ab,ti. 
37. palm OS.ab,ti. 
38. (palm adj3 computer?).ab,ti. 
39. Symbian.ab,ti. 
40. iphone?.ab,ti. 
41. ipad?.ab,ti. 
42. ipod? Touch.ab,ti. 
43. personal digital assistant?.ab,ti. 
44. PDA.ab,ti. 
45. android?.ab,ti. 
46. blackberry*.ab,ti. 
47. exp Microcomputer/ 
48. apps.ab,ti. 
49. exp Mobile Applications/ 
50. applet?.ab,ti. 
51. (mobile adj3 app*).ab,ti. 
52. (software adj3 app*).ab,ti. 
53. *Medical Informatics Applications/ 
54. exp Decision Support System/ 
55. (ehealth or "e health" or e-health or e?health).ab,ti. 
56. (mhealth or "m health" or m-health or m?health).ab,ti. 
57. (telehealth or tele?health).ab,ti. 
58. (telemedicine or tele?medicine).ab,ti. 
59. exp Telemedicine/ 
60. (telemonitor* or tele?monitor*).ab,ti. 
61. (remote adj2 (consult* or diagnos* or monitor* or treat* 
or care)).ab,ti. 
62. "mobile health".ab,ti. 
63. or/31-62 
64. 24 and 63 
65. limit 64 to yr="2008 - Current" 
PsycINFO http://search.pro
quest.com/psycinf
o 
 
#1  diabet* OR IDDM OR NIDDM OR MODY OR hyperinsulin OR 
insulin sensitive* OR insulin resist* OR insulin depend* OR 
insulin?depend* OR non insulin depend* OR noninsulin 
depend* OR non insulin?depend* OR noninsulin?depend* OR 
impaired glucose tolerance* OR glucose intoleran* OR typ* 1 
diabet* OR typ* 2 diabet* OR typ* I diabet* OR typ* II diabet* 
OR gestational diabet* 
2/9/2014 
 
239 
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Database Link Search Date Hits 
 
#2   (telephon* OR phon*) AND (mobil* OR cell*) 
 
#3 smartphone? OR smart?phone? OR (window? PRE/3 
phone?) OR (window? PRE/3 mobile?) OR nokia OR palm OS 
OR (palm PRE/3 computer?) OR Symbian OR iphone? OR ipad? 
OR ipod? touch OR personal digital assistant? OR PDA OR 
android? OR blackberry* OR apps OR applet? OR (mobile 
PRE/3 app*) OR (software PRE/3 app*) OR ehealth OR "e 
health" OR e-health OR e?health OR mhealth OR "m health" 
OR m-health OR m?health OR telehealth OR tele?health OR 
telemedicine OR tele?medicine OR telemonitor* OR 
tele?monitor* OR (remote PRE/2 (consult* OR diagnos* OR 
monitor* OR treat* OR care)) OR "mobile health" 
 
#4   1 AND (2 OR 3) 
 
#5   YR(2008-2014) 
IEEEXplore 
+ 
IEEE Conference 
Publications 
http://ieeexplore.i
eee.org/Xplore/ho
me.jsp 
 
#1  diabet* OR "MeSH Terms":Diabetes Mellitus OR Type 1 
Diabetes OR Type 2 Diabetes OR Gestational Diabetes OR 
Insulin OR Glucose 
 
#2   (telephone OR phone) AND (mobile OR cell*) 
 
#3  Smartphone OR iphone OR ipad OR ipod OR "PDA" OR 
android OR apps OR ehealth OR e-health OR mhealth OR m-
health OR telehealth OR telemedicine OR telemonitoring OR 
(remote AND (diagnos* OR monitor* OR treat* OR care)) OR 
"MeSH Terms":Cellular Phone OR Computers, Handheld OR 
Mobile Applications OR Decision Support System OR 
Telemedicine OR Mobile Health 
 
#4   1 AND (2 OR 3) 
 
#5   YR(2008-2014) 
3/9/2014 
 
1615 
Web of Science https://apps.web
ofknowledge.com
/ 
 
#1 diabet* OR IDDM OR NIDDM OR MODY OR hyperinsulin OR 
insulin sensitive* OR insulin resist* OR insulin depend* OR 
insulin?depend* OR non insulin depend* OR noninsulin 
depend* OR non insulin?depend* OR noninsulin?depend* OR 
impaired glucose tolerance* OR glucose intoleran* OR typ* 1 
diabet* OR typ* 2 diabet* OR typ* I diabet* OR typ* II diabet* 
OR gestational diabet* 
 
#2  smartphone? OR smart?phone? OR iphone? OR ipad? OR 
ipod? touch OR personal digital assistant? OR PDA OR 
android? OR blackberry* OR apps OR applet? OR ehealth OR e-
health OR e?health OR mhealth OR m-health OR m?health OR 
"mobile health" OR telehealth OR tele?health OR telemedicine 
OR tele?medicine OR telemonitor* OR tele?monitor* 
 
#3  (telephon* OR phon*) AND (mobil* OR cell*) 
 
#4  (remote NEAR/2 (consult* OR diagnos* OR monitor* OR 
treat* OR care))  
 
#5   1 AND (2 OR 3 OR 4) 
 
#6   YR(2008-2014) 
16/9/2014 
 
1405 
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Database Link Search Date Hits 
JMIR http://www.jmir.org
/ 
 
(diabetes or diabetic or diabetics or insulin or glucose or type 1 
diabetes or type 2 diabetes or gestational diabetes) and 
(smartphone or mobile phone or cell phone or app or apps or 
mobile application or mhealth or m-health or mobile health) 
 
4/9/2014 
 
58 
JMTM http://www.journal
mtm.com/ 
Searched across all issues 4/9/2014 
 
9 
Journal of Diabetes 
Science and Technology 
(DST) 
http://jdst.org/  
#1  smartphone or iphone in all fields or ipad or ipod in all 
fields or "PDA" or personal digital assistant in all fields or 
android or blackberry in all fields or pps or applet in all fields 
 
#2  mobile health or mhealth in all fields or ehealth or 
telehealth in all fields or telemedicine or telemonitoring in all 
fields 
 
#3  telephon* or phon* in all fields and mobil* or cell* in all 
fields 
 
#4   remote and diagnos* in all fields or remote and monitor* 
in all fields or remote and treat* in all fields or remote and 
care in all fields 
 
#5   decision support in all fields 
 
#6   1 or 2 or 3 or 4 or 5  
 
#7   yr(2008-2014) 
4/9/2014 
 
369 
Google Scholar http://scholar.googl
e.co.uk/ 
 
diabetes AND (smartphone OR apps OR mobile OR PDA OR 
iphone OR android OR mhealth OR ehealth  OR telehealth OR 
telemedicine) 
 
10/9/2014 
 
361 
 
50 
pages 
ProQuest Dissertations http://search.proqu
est.com/ 
 
#1  ab(diabet* OR insulin OR glucose) OR ti(diabet* OR insulin 
OR glucose) 
 
#2  all(smartphone? OR smart?phone? OR iphone? OR ipad? 
OR ipod? touch OR personal digital assistant? OR PDA OR 
android? OR blackberry* OR apps OR applet? OR ehealth OR e-
health OR e?health OR mhealth OR m-health OR m?health OR 
"mobile health" OR telehealth OR tele?health OR telemedicine 
OR tele?medicine OR telemonitor* OR tele?monitor*) 
 
#3  all((telephon* OR phon*) ) AND all((mobil* OR cell*)) 
 
#4 all((remote PRE/2 (consult* OR diagnos* OR monitor* OR 
treat* OR care)) ) 
 
#4   1 AND (2 OR 3 OR 4) 
 
#5   YR(2008-2014) 
9/9/2014 
 
55 
Other Conference 
Proceedings  
-- Conference Papers Index (ProQuest), Papers First, Proceedings 
First, Web of Science Core Collection – Proceedings Paper, 
Zetoc. 
15/9/2014 197 
Other Theses & 
Dissertations 
-- EThOS - Electronic Theses Online Delivery Service, DART-
Europe Portal 
16/9/2014 10 
ClinicalTrials.gov http://clinicaltrials.g
ov/ 
Condition: diabetes  
Intervention: smartphone application OR smartphone app OR 
11/9/2014 
 
30 
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Database Link Search Date Hits 
mobile application OR mobile app OR mHealth app 
Key words: cell phone OR PDA OR iphone OR android OR 
mhealth OR ehealth  OR telehealth OR telemedicine OR 
telemonitoring 
 
Current Controlled Trials  http://controlled-
trials.com/ 
diabetes AND (smartphone OR apps OR mobile application OR 
cell phone OR PDA OR iphone OR android OR mhealth OR 
ehealth  OR telehealth OR telemedicine OR telemonitoring) 
12/9/2014 
 
0 
WHO International 
Clinical Trials Registry 
Platform 
http://www.who.int
/ictrp/en 
 
diabetes AND (smartphone OR apps OR mobile application OR 
cell phone OR PDA OR iphone OR android OR mhealth OR 
ehealth  OR telehealth OR telemedicine OR telemonitoring) 
 
12/9/2014 
 
3 
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Appendix 2. Example of data extraction sheets for one RCT and one non-RCT  
Name of the reviewer: Hala Alhodaib                                                                    Date of review: 12/9/2015 
Study Details  
Study ID (EndNote): 12829 
Study Title: Diabetes Self-Management Smartphone Application for Adults With Type 1 Diabetes: 
Randomized Controlled Trial 
First author surname: Kirwan 
Year of publication: 2013 
Additional reference: No 
Publication type: Peer-reviewed journal  
Language: English  
Country of origin: Australia 
Study design: Parallel group, open-label RCT 
Study setting: Secondary care 
Method of recruitment: (1) An invitation letter sent to T1D patients registered with Diabetes Australia in 
New South Wales (n=3809) and Queensland (n=3207), (2) An advertisement in a T1D national 
newsletter (Yada Yada newsletter) emailed to more than 5000 recipients, and (3) Promotion in an online 
community forum (Reality Check Forum) 
Dates of recruitment: Original data collected November 2010 to November 2011 and analysed in 2012 
Duration of study: 9 months 
Intervention period: 6 months 
Follow up period: 3 months 
Funding: Non-commercial (University) - Central Queensland University, Australia 
Registered trial: Yes - Australian New Zealand Clinical Trials Registry: 
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=126120001328
42 
Aim of the study: 
To examine the effectiveness of a freely-available smartphone application combined with text-message 
feedback from a certified diabetes educator to improve glycemic control and other diabetes-related 
outcomes in adult patients with T1D 
Inclusion/Exclusion criteria 
Inclusion criteria: (1) Aged 18-65 years, (2) Diagnosed with T1D >6 months, (3) HbA1c >7.5%, (4) Treated 
with multiple daily injections or insulin pump, and (5) Own a smartphone (iPhone) 
Exclusion criteria: (1) Pregnant, or (2) Patients already using a smartphone application to self-manage 
their diabetes, or (3) Early indicators of diabetes related complications: retinopathy, neuropathy, 
nephropathy and heart-disease 
Ethical standards 
Was ethical committee approval obtained? Yes, study approved by Central Queensland University 
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Human Research Ethics Board. 
Informed consent obtained? Yes, written informed consent (via email) from the patient and their 
primary diabetes HCP (GP/endocrinologist) 
Participants  
Geographic location: Anywhere in Australia 
Main receiver of intervention:  Patient 
Age group: 18 ≤ Adult ≤ 65 
Type of diabetes: T1D 
Treatment: Multiple daily injections or continuous subcutaneous insulin injections (Insulin Pump) 
Severity of diabetes: NR 
Comorbidities: None 
Power calculation: Yes, calculated on the expected difference in mean (1.5%) in the primary outcome 
variable (HbA1c), and the logistically maximum available sample size was 36 patients per group based on 
part-time work status of the CDE. We allowed for a dropout of 11% (4 per group), consistent with 
dropout rates reported in recent reviews of similar studies, and variation in baseline (HbA1c=1.80) 
similar to previous studies. Based on these parameters, α=0.05 and 90% power, the estimated sample 
size was 68 in total and subsequently increased to 72 in line with the maximum caseload of the CDE 
Incentives for participation: NR 
Providers (Details of the healthcare worker(s) or systems responsible for providing or supporting the 
app) 
Who delivers the intervention? Certified Diabetes Educator (CDE) - The information logged in the 
Glucose Buddy application was reviewed by a CDE via a Web interface on a weekly basis 
Training offered in delivery of intervention? NR 
Intervention 
Name: Usual care plus a smartphone application named “Glucose Buddy” 
Hardware (device): iPhone   
Software (platform): iOS 
Purpose: Self-care 
Functions: (1) Manually enter BG levels, insulin dosages, other medications, diet (food item in grams), 
and physical activities (minutes), (2) View their data on a customizable graph and export this 
information via email 
Application type: Freely available diabetes self-management app on iTunes (Apple online store) since 
October 2008  
Any comparison (control): Usual care - a visit to their primary diabetes HCP (GP/endocrinologist) every 3 
months 
Any supporting intervention? Yes - Text-message feedback from a Credentialed Diabetes Educator on a 
weekly basis 
Phone provided (phone ownership): No 
Paid for mobile phone service? Yes - A text-messaging software program was used to text message 
patients 
Method of data transmission: Sync logs to online account 
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Feedback provided: Yes 
Type and nature of feedback: Personalised text-message - The content of the text messages sent to and 
received from patients fell into four categories: feedback on logs, diabetes questions, educational tips, 
and positive reinforcement 
Frequency of feedback: Intervention patients were sent a minimum of 1 personalised text-message per 
week for the first 6 months of the study, then stopped.  
Mode of data entry: Manual 
Data inputted: BG readings, carbohydrate consumption (grams), insulin dosages, other medications, and 
physical activities (minutes) 
Frequency of data input: No minimum amount of logging required 
Training offered: No education or training on how to use the Glucose Buddy smartphone application or 
website 
Mode of interaction: Patients could utilize the accompanying Glucose Buddy website to log diabetes 
parameters at their discretion besides the text-message communication with the CDE 
Require Internet access? No – Internet access required only to sync logs to the online account 
Security arrangements: NR 
Number of participants Overall Intervention Control 
Screened 197   
Excluded 125   
Randomised 72 36 36 
Lost to follow-up (LTFU) 3-months  4 0 
LTFU 6-months  4 4 
LTFU 9-months  3 4 
Dropout, n (%) 19/72 (26%) 11/36 8/36 
Included 53 25 28 
Patient’s baseline characteristics Overall Intervention Control 
Number of patients, n 72 36 36 
Age (years), mean (SD) 35.20 (10.43) 35.97 (10.67) 34.42 (10.26) 
Gender (Male/Female), n 28/44 19/17 9/27 
Diabetes duration (years), mean (SD) 18.94 (9.66) 19.69 (9.64) 18.19 (9.77) 
Insulin pump use, n 27/72 14/36 13/36 
HbA1c , mean (SD) 8.78 (1.07) 
Male  8.79 (1.31) 
Female  8.77 (0.90) 
9.08 (1.18) 
Male  9.10 (1.45) 
Female  9.07 
(0.84) 
8.47 (0.86) 
Male  8.17 
(0.65) 
Female  8.57 
(0.91) 
Healthy diet (days per week), mean (SD)  3.56 (1.70) 2.60 (1.98) 
Outcomes 
Primary outcomes: Change in glycaemic control (HbA1c) 
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Secondary outcomes: Diabetes-related self-efficacy, self-care activities, QoL, and engagement by 
intervention patients 
Timing of assessment (time points): Baseline, 3-month, 6-month, 9-month 
Technical issues: No privacy breaches or technical problems 
Method of assessing outcomes 
HbA1c level: Blood test collected by a pathology lab 
Diabetes-related self-efficacy: Online questionnaire - DES-SF 
Diabetes self-care activities: Measured using online questionnaire (SDSCA). Four scales used in this 
study: (1) general dietary behavior, (2) specific dietary behavior, (3) glucose monitoring, (4) exercise 
QoL: Measured using online questionnaire (DQOL). Three aspects of QoL directly related to diabetes: 
diabetes satisfaction, impact, and worry 
Engagement by intervention patients: Measured using the number of text messages sent to patients and 
the number of text-message responses, and the number of logs (BG, insulin, physical activity, and diet) 
entered by patients in the Glucose Buddy application during the 6-month study period 
Results                                                                              
HbA1c level, mean (SD) Overall Intervention Control 
Time Points: Baseline 8.78 (1.07) 9.08 (1.18) 8.47 (0.86) 
Time Points: 3-month 8.27 (0.86) 8.32 (0.84) 8.23 (0.89) 
Time Points: 6-month 8.22 (0.91) 7.97 (0.73) 8.43 (1.00) 
Time Points: 9-month 8.21 (1.05) 7.80 (0.75) 8.58 (1.16) 
Diabetes-related self-efficacy, mean (SD)  Overall Intervention Control 
Time Points: Baseline 3.62 (0.77) 3.62 (0.89) 3.62 (0.65) 
Time Points: 3-month 3.78 (0.64) 3.88 (0.61) 3.70 (0.65) 
Time Points: 6-month 3.73 (0.77) 3.82 (0.73) 3.64 (0.81) 
Time Points: 9-month 3.61 (0.72) 3.60 (0.71) 3.62 (0.74) 
Diabetes self-care activities, mean (SD) Overall Intervention Control 
General Diet 
Time Points: Baseline 3.81 (2.06) 3.42 (2.19) 4.19 (1.88) 
Time Points: 3-month 4.10 (2.00) 4.23 (1.86) 3.97 (2.13) 
Time Points: 6-month 4.36 (1.86) 4.59 (1.73) 4.16 (1.98) 
Time Points: 9-month 4.37 (1.83) 4.62 (1.80) 4.14 (1.85) 
Specific Diet  
Time Points: Baseline 3.08 (1.89) 3.56 (1.70) 2.60 (1.98) 
Time Points: 3-month 3.10 (1.63) 3.22 (1.48) 3.00 (1.76) 
Time Points: 6-month 3.68 (1.63) 3.80 (1.60) 3.56 (1.66) 
Time Points: 9-month 3.93 (1.61) 3.80 (1.82) 4.05 (1.43) 
Exercise  
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Time Points: Baseline 2.74 (2.09) 2.57 (2.08) 2.92 (2.12) 
Time Points: 3-month 2.45 (2.12) 2.36 (1.91) 2.53 (2.31) 
Time Points: 6-month 2.83 (1.95) 2.55 (1.92) 3.06 (1.97) 
Time Points: 9-month 2.96 (1.79) 3.12 (1.86) 2.82 (1.75) 
Glucose Testing  
Time Points: Baseline 5.46 (2.04) 5.40 (2.03) 5.51 (2.08) 
Time Points: 3-month 5.88 (1.64) 6.02 (1.64) 5.75 (1.65) 
Time Points: 6-month 6.10 (1.56) 6.20 (1.46) 6.02 (1.67) 
Time Points: 9-month 5.92 (1.62) 6.28 (1.06) 5.61 (1.95) 
QoL, mean (SD) Overall Intervention   Control 
Satisfaction 
Time Points: Baseline 3.14 (0.61) 3.20 (0.66) 3.09 (0.55) 
Time Points: 3-month 3.22 (0.61) 3.35 (0.67) 3.11 (0.54) 
Time Points: 6-month 3.32 (0.60) 3.43 (0.58) 3.23 (0.62) 
Time Points: 9-month 3.35 (0.66) 3.42 (0.68) 3.29 (0.65) 
Impact 
Time Points: Baseline 3.70 (0.53) 3.75 (0.52) 3.66 (0.54) 
Time Points: 3-month 3.81 (0.57) 3.89 (0.58) 3.75 (0.56) 
Time Points: 6-month 3.83 (0.61) 3.94 (0.62) 3.74 (0.61) 
Time Points: 9-month 3.85 (0.53) 3.93 (0.52) 3.77 (0.55) 
Worry   
Time Points: Baseline 3.98 (0.66) 4.06 (0.52) 3.90 (0.78) 
Time Points: 3-month 4.10 (0.70) 4.19 (0.61) 4.01 (0.77) 
Time Points: 6-month 4.16 (0.70) 4.35 (0.46) 3.99 (0.82) 
Time Points: 9-month 4.15 (0.63) 4.34 (0.36) 3.99 (0.76) 
The intervention group significantly improved glycemic control (HbA1c) from baseline (mean 9.08%, SD 
1.18) to 9-month follow-up (mean 7.80%, SD 0.75), versus the control group (baseline: mean 8.47%, SD 
0.86, follow-up: mean 8.58%, SD 1.16). No significant change over time was found in either group in 
relation to self-efficacy, self-care activities, and QoL 
Engagement by intervention patients Mont
h 1 
Month 
2 
Month 
3 
Month 
4 
Month 
5 
Month 
6 
Average number of text messages sent to 
patients, mean (SD) 
9.75 
(1.96) 
6.67 
(1.47) 
7.58 
(2.12) 
7.11 
(1.91) 
8.56 
(2.26) 
7.94 
(2.52) 
Median number of text messages sent to 
patients 
9 7 7 7.5 8 8 
Total number of text messages sent to 
patients 
351 240 273 256 308 286 
Average number of text messages received 
by CDE, mean (SD) 
6.47 
(3.92) 
2.36 
(2.82) 
2.03 
(2.52) 
1.11 
(1.30) 
2.22 
(2.84) 
1.33 
(2.46) 
   
228 
Median number of text messages received 
by CDE 
6 2 1 1 1.5 0 
Total number of text messages received by 
CDE 
233 85 73 40 80 48 
Glucose Buddy Logs, mean (SD) 187.5
3 
(137.4
1) 
137.22 
(143.3
9) 
92.03 
(109.6
6) 
96.02 
(129.0
6) 
89.03 
(107.1
4) 
84.83 
(153.4
7) 
Glucose Buddy Logs, total N 6751 4940 3313 3457 3205 3054 
Number of logs related to BG levels, n/N (%)  13,349/24,720 (54.00%) 
Number of logs related to insulin, n/N (%)  8158/24,720 (33.00%) 
Number of logs related to diet, n/N (%) 2966/24,720 (12.00%) 
Number of logs related to exercise, n/N (%) 247/24,720 (1.00%) 
Other outcomes Intervention 
Costs incurred Text messages Cost: $290.93 AUD ($8.08 per patient 
(n=36)) 
CDE Cost: The CDE spent on average 3 hours per week: 5 
minutes per patient (n=36) per week (72 hours in total 
over 6-month period). A CDE hourly rate is approximately 
$28.85; thus the total study cost was $2077.20 AUD  
Adverse events 
There were no unintended effects to the participants 
Author’s conclusion 
In adjunct to usual care, the use of a smartphone application combined with weekly text-message 
feedback from a health care professional led to a significant decrease in HbA1c compared to a control 
group receiving only usual care. Integrating a smartphone application into secondary care was effective 
in improving glycemic control in patients with T1D (a decrease of 1.1% in HbA1c level). This findings can 
be applied to adults with poorly controlled T1D that own a smartphone, though larger studies over a 
longer duration need to be conducted to validate this findings. There were no significant change in self-
efficacy, QoL, and self-care activities for either group over time 
Reviewer’s conclusion 
This RCT assessed the effectiveness of using a smartphone app on BG control and a number of other 
outcomes at different time points. The drop-out percentage considered high specifically in the 
intervention group 
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Name of the reviewer: Hala Alhodaib                                                                    Date of review: 27/10/2015 
Study Details 
Study title: Smartphone enabled health coach intervention for people with diabetes from a modest 
socioeconomic strata community: Single-arm longitudinal feasibility study 
First author surname: Wayne 
Year of publication: 2014 
Additional reference: No 
Publication type: Peer-reviewed journal 
Language: English 
Country of origin: Canada 
Study design: Single group pre-post test design 
Study setting: Primary care - (community health) 
Method of recruitment: Participants were recruited at the Black Creek Community Health Centre 
through health care provider referral and poster advertising 
Duration of study: NR 
Intervention period: 24 weeks 
Follow up period: 24 weeks 
Funding: Research funding was provided by Mitacs and Ministry for Research and Innovation (Province 
of Ontario) 
Aim of the study: 
To develop and test a smartphone-assisted intervention that improves behavioral management of T2D 
in an ethnically diverse, lower socioeconomic strata (SES) population within an urban community health 
setting 
Inclusion/Exclusion criteria 
Inclusion criteria: Patients over 18 years old, diagnosed with T2D, and able to read and speak English 
Exclusion criteria: Participants were excluded if baseline HbA1c > 9.5% 
Ethical standards 
Was ethical committee approval obtained? All study procedures were approved by the York University 
Human Participants Research Committee  
Informed consent obtained? Yes, participants signed an informed consent 
Participants 
Geographic location: Toronto, Ontario, Canada 
Main receiver of intervention: Patient 
Age group: Adult ≥ 18 
Type of diabetes: T2D 
Treatment: NR 
Severity of diabetes: NR 
Comorbidities: NR 
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Power calculation: NR 
Incentives for participation: NR 
Providers (Details of the healthcare worker(s) or systems responsible for providing or supporting the 
app) 
Who delivers the intervention? A graduate student trained in behaviour change techniques. Wellness 
plans were collaboratively created in multiple interactions focused on exercise instruction and reviews 
of electronic monitoring entries, with diet and medication guidelines set by primary care physicians and 
dieticians 
Training offered in delivery of intervention? NR 
Intervention 
Name: Health Coach app 
Hardware (device): Blackberry Curve 8900 
Software (platform): NR 
Purpose: Self-care, and telemonitoring 
Functions: Tracking health behaviours (exercise, diet), self-monitoring health data (BG, BP, weight, 
mood, pain), messaging, and reminders 
Application type: Study-specific 
Any comparison (control): No, single arm 
Any supporting intervention? No 
Phone provided (phone ownership): Yes, most participants (n=19) did not own a smartphone and were 
loaned a device for the trial duration, unless they possessed a smartphone (n=2) 
Paid for mobile phone service? Yes, full data access for the duration of the trial 
Method of data transmission: No transmission 
Feedback provided: Yes 
Type and nature of feedback: Messaging - two-way secure messaging between participant and health 
coach who can selectively promote healthy choices at pivotal times of client decision-making, providing 
support immediately after healthy behaviours have been logged, and/or addressing questions and/or 
sending relevant materials 
Frequency of feedback: NR 
Mode of data entry: Manual, except the photo capture of meals where the food tracker automatically 
triggers the smartphone’s camera 
Data inputted: Exercise, diet, BG, BP, weight, mood, and pain 
Training offered: NR 
Require Internet access? NR 
Security arrangements: Provider-client communications require two-way, certificate-based 
authentication and passwords stored in encrypted columns, with entered data recalled by client and 
health coach through a secure online portal 
Number of participants Intervention 
Screened NR 
Randomised/Included 21 
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Excluded NR 
Missing participants 2 - primary care physician failure to forward lab results 
 Withdrawals NR 
Patient’s baseline characteristics n (%) 
Number of patients, n 21 
Age (years), mean (SD) 55.6 (12.3) 
Gender  Male 9 (43%) 
Female 12 (57%) 
Marital status Single 5 (24%) 
Married or common-law 14 (67%) 
Widowed 2 (10%) 
Children Yes 18 (86%) 
No 3 (14%) 
Ethnicity Hispanic 3 (14%) 
African 3 (14%) 
Caribbean 3 (14%) 
South Asian 3 (14%) 
Caucasian 9 (43%) 
Educational background Less than high school 3 (14%) 
Completed high school 4 (19%) 
Some college/university 7 (33%) 
College diploma 6 (29%) 
University degree 1 (5%) 
Employment Full-time 12 (57%) 
Part-time 2 (10%) 
Not presently employed 7 (33%) 
Outcomes 
Primary outcomes: HbA1c 
Secondary outcomes: Weight, BMI, Waist circumference 
Timing of assessment (time points): Baseline, 24 weeks 
Technical issues: As the Health Coach app was version 1.0, periodic malfunctions hindered client 
communications during the trial. Due to the close relationship between the health coach and software 
production team, the feedback and user experience was communicated as received, resulting in 
upgrades installed on the server at frequent intervals. This feedback loop led to significant 
improvements in the software throughout the trial. Therefore, throughout the trial, the temporary 
software malfunctions and upgrades inevitably resulted in service disruptions 
Method of assessing outcomes 
HbA1c level: A clinical indicator collected by a lab 
Results                                                                              
Outcome n Baseline, Post, mean Mean P value 
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mean (SD) (SD) change, 
mean 
(SD) 
 
Entire sample 
HbA1c (%) 19 7.58 (1.13) 7.31 (0.95) −0.28 
(0.57) 
.05 
Weight (kg) 14 94.6 (16.8) 93.2 (15.8) −1.3 (1.9) .02 
BMI 13 34.4 (5.5) 33.9 (5.3) −0.4 (0.7) .05 
Waist circumference (cm) 11 109.4 (16.1) 112.1 (16.1) 2.7 (4.3) .06 
Baseline A1c≥7.0% 
HbA1c (%) 12 8.26 (0.80) 7.83 (0.78) −0.43 
(0.63) 
.04 
Weight (kg) 9 100.1 (18.0) 98.1 (17.1) −1.9 (1.7) .01 
BMI 8 36.2(5.8) 35.6 (5.7) −0.7 (0.7) .37 
Waist circumference (cm) 7 114.4 (17.1) 116.5(16.4) 2.1 (5.3) .33 
Baseline A1c<7.0% 
HbA1c (%) 7 6.43 (0.39) 6.41 (0.38) −0.01 
(0.32) 
.91 
Weight (kg) 5 84.6 (8.7) 84.4 (8.8) −0.2 (1.8) .81 
BMI 5 31.4 (3.7) 31.3 (3.8) −0.1 (0.7) .80 
Waist circumference (cm) 4 100.6 (11.0) 104.4 (10.0) 3.8 (1.6) .02 
Adverse events   
NR 
Author’s conclusion 
As mobile technology becomes more accessible, electronically assisted health coaching may emerge as a 
viable and effective means of managing chronic conditions through improved health behaviours across 
all SES 
Reviewer’s conclusion 
This pilot study supported the feasibility of smartphone-based health coaching for individuals from 
lower SES with minimal prior smartphone experience. It was intended to generate results guiding the 
eventual design of an RCT, which will assess the effectiveness of health coaching in T2D patients both 
with and without the use of smartphone technology at multiple sites with diverse populations 
The result of the RCT is reported in Wayne 2015, and a qualitative evaluation from subsample of the RCT 
is reported in Pludwinski 2015 
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Appendix 3. Example of data extraction sheet for one qualitative study 
Name of the reviewer: Hala Alhodaib                                                                         Date of review: 5/6/2016 
Study Details 
Study title: Participant experiences in a smartphone based health coaching intervention for type 2 
diabetes: A qualitative inquiry 
First author surname: Pludwinski 
Year of publication: 2015 
Additional reference: No 
Publication type: Peer-reviewed journal 
Country of origin: Canada 
Study design: Semi-structured interview 
Study setting: Community health (primary care) 
Method of recruitment: This qualitative evaluation was part of a larger T2DM self-management RCT 
undertaken at the Black Creek Community Health Centre (BCCHC) in Toronto, Canada. After completing 
the trial, individuals were invited by phone or in person to participate in qualitative face-to-face 
interviews. Efforts were made to reach n=26 intervention participants, and n=11 were contacted. All the 
participants who were reached were invited and they agreed to participate in the study 
Intervention period: 6 months 
Funding: Funding for this project was provided by the Public Health Agency of Canada and the Federal 
Development Agency of Southern Ontario 
Aim of the study: 
The objective was to compare the effectiveness of six months of smartphone use with health coaching 
vs. health coaching of equal intensity without smartphone support. Using in person, semi-structured 
interviews following study completion, participants reflected on their smartphone- based experiences in 
relation to the role of the health coach in the enhanced intervention arm. 
We investigated the experience of individuals diagnosed with T2D who participated in an intervention in 
which the key elements were the provision of a smartphone and self-monitoring software. The 
interviews focused on use of a smartphone and the effects on motivation for health behaviour change 
Inclusion/Exclusion criteria 
Inclusion criteria: Subsample of T2D patients who participated in a larger RCT 
Exclusion criteria: N/A 
Ethical standards 
Was ethical committee approval obtained? This study received ethical approval from York University’s 
Human Participants Review Subcommittee (HPRC)  
Informed consent obtained? All participants provided informed consent 
Participants 
Total number of participants: 11 
Sample attrition/drop out: N/A 
Geographic location: Lower income neighbourhood of Toronto, Ontario, Canada 
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Main receiver of intervention: Patient 
Age group: Males (mean age=63.5±4.9), females (mean age=55.8±8.8) 
Gender: 2 males, 9 females 
Ethnicity (ethnic groups): The catchment area of the health centre serves a high proportion of recent 
immigrants from ethnic minority backgrounds 
Education: NR 
Type of diabetes: T2D 
Severity of diabetes: NR 
Diabetes duration: NR 
Treatment: NR 
Comorbidities: NR 
Incentives for participation: NR 
Providers (Details of the healthcare worker(s) or systems responsible for providing or supporting the 
app) 
Who delivers the intervention? Health coach 
Training offered in delivery of intervention? Training and supervision were also more intense as health 
coaches received continuous supervision throughout the trial, totaling 100 hrs. per coach, delivered by a 
registered clinical psychologist  
Intervention 
Name: Health Coach app 
Hardware (device): NR 
Software (platform): NR 
Purpose: Telemonitoring, self-care 
Functions: Tracking health behaviours (exercise, diet), self-monitoring health data (BG, BP, weight, 
medication), messaging, and reminders 
Application type: Study-specific 
Phone provided (phone ownership): Yes 
Paid for mobile phone service? NR 
Method of data transmission: NR 
Feedback provided: Yes 
Type and nature of feedback: Counselling interactions using messages between participant and health 
coach 
Frequency of feedback: Smartphone and health coach contacts summating to one hour of contact 
weekly per patient 
Mode of data entry: Manual, except the photo capture of meals where the food tracker automatically 
triggers the smartphone’s camera 
Data inputted: Exercise, diet, BG, BP, and weight 
Training offered: NR 
Require Internet access? NR 
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Security arrangements: To maintain confidentiality, personal information was removed from transcripts 
and audio interview recordings were stored in a locked cabinet in locked offices. Transcripts were 
transferred between locked password protected computers, with encrypted USB Keys 
Data collection and analysis 
Method of data collection: In person, semi-structured interviews. Interviews were conducted by a 
trained interviewer, and reviewed by two additional members of the research team to ensure 
standardised technique. Interview questions were developed by the lead investigator from prior 
research and modified by other team members. Interviews were conducted, transcribed verbatim, and 
reviewed for accuracy by the entire investigative team. Saturation–the point where no new information 
is detected with additional interviews–was evaluated and agreed on by all research team members, in 
accord with study goals 
Duration of data collection: Each interview lasted approx. 30–40 min 
Method of data analysis: Coding and analyses were performed using NVivo employing a thematic 
analytic approach that thoroughly explored relevant themes surfacing during the interviews. Thematic 
analysis provides a systematic identification of emergent patterns, and logically organises qualitative 
data into broader common and representative themes.  Our analytic strategy of constant comparison 
included code development as the basic analytic unit (capturing important aspects of data) and, based 
on codes, the derivation of broader themes (team discussions) illustrating a coherent view of collected 
data 
Outcomes 
Participant perspectives and T2DM self-management experiences were explored in the context of 
changes in HbA1c levels, a reliable index of long-term glucose control 
Findings 
Key themes (1st order interpretations) 
Thematic analysis identified four major themes:  
1. Smartphone and software: Pertained to phone utility and self- activation through awareness, 
feedback, self-management and monitoring 
2. The health coach: Focused on participant experiences with smartphone interactions in relation 
to perceived health coach qualities, roles and influences on diet, BG monitoring and exercise 
3. Overall experience 
4. Frustrations managing chronic conditions 
Data extracts related to the key themes  
Theme 1: Smartphone and software 
Smartphone utility: 
‘I liked sending all the information to my health coach. I didn’t have to tell her’ (Participant #11 – change 
in HbA1c: –2.0%) 
‘I could just take a picture . . . a visual record of what I have eaten’ (Participant #1 – change in HbA1c: –
0.6%) 
‘It was not hard to use, the health coach explained everything’ (Participant #7 – change in HbA1c: –
1.7%) 
‘It was a helpful reminder of keeping a check on my blood . . . what I eat . . . what I shouldn’t’ 
(Participant #4 change in HbA1c: –1.1%) 
Self activation: 
‘I eat, I take the picture, and then . . . I poke myself . . . how high the sugar is . . .’ (Participant #7 – 
change in HbA1c: –1.7%) 
Theme 2: The health coach 
Overall health coach qualities 
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‘Very persistent (with) monitoring what I have been eating . . . as soon as I sent a picture they would call 
back immediately’ (Participant #5 – change in HbA1c: 0.5%) 
Health coach supportive role 
‘I think this study helped me emotionally a lot, more than physical, I feel emotionally happy. That is 
important to me’ (Participant #9 – change in HbA1c: –0.4%) 
Working together 
‘We talk about everything that is going on in my life. What happened? Why is (my sugar) . . . a little bit 
higher (or) lower’ (Participant #11 – change in HbA1c: –2.0%) 
‘It was like the doctor looking at you. I have to do this, I have to test my blood sugar, I have to test my 
pressure, how much exercise. ... Your meal, what you eat . . . you have this eye looking at you on the 
phone (Participant #6 – change in HbA1c: .0.1%) 
‘(Smartphone) was my watcher. Somebody is watching you through your eyes . . . it was so interesting’ 
(Participant #9 – change in HbA1c: –0.4%) 
Focal contact activities 
‘She teach me how to eat, what I had to eat’ (Participant #3 – change in HbA1c: –7.1%) 
‘We never discussed medication, I let (the health coach) know what I was taking, and brought them in’ 
(Participant #5 – change in HbA1c: 0.5%) 
‘(If) my sugar (is) high, (health coach) will explain . . . there can be things to eat or something to drink to 
make sure it’s okay’ (Participant #2 – change in HbA1c: –2.0%) 
‘The exercise was an important part of the treatment, so (the health coach) was very aware that I’m 
doing the right exercise, how many times, (Participant #10 – change in HbA1c: 0.2%) 
Theme 3: Overall experience 
‘When I first came here . . . I was in really bad shape. [My] sugar was very high. The A1c was high . . .’ 
(Participant #11 – change in HbA1c: – 2.0%) 
‘The program is a big motivation in my life . . . it’s a positive thing for me . . . with all that’s going on I 
need positive things’ (Participant #6 – Change in HbA1c: 0.1%) 
Theme 4: Frustrations in managing chronic conditions 
Medication and glucose measurement 
‘I used to feel weak. [Medication] is helpful, but to be honest, I don’t take it’ (Participant #7 – change in 
HbA1c: –1.7%) 
‘My sugar was sky high . . . I would eat half a sandwich and my sugar would double to 22 [mmol/l]’ 
(Participant #8 – change in HbA1c: –1.1%) 
Diet/weight loss 
‘Doctor just wants you to eat leaves and egg whites; I couldn’t handle it’ (Participant #8 – change in 
HbA1c: –1.1%) 
Comorbidities 
‘I have type 2 diabetes, high cholesterol, macular degeneration, and carpal tunnel. I have a lot on my 
plate’ (Participant #6 – change in HbA1c: 0.1%) 
Author’s explanations of the key themes (2nd order interpretations) 
Theme 1: Smartphone and software 
Two sub-themes: 
(a) Smartphone utility, or direct use in behavioral tracking with the smartphone 
Participants discussed exercise tracking, food tracking (via photo journaling), health coach 
communication and self-generated/coach-generated reminders 
Individuals emphasized the benefits of self-monitoring changes in BG, diet and exercise 
Participants viewed meal photographing as conveying helpful dietary feedback. Co-monitoring with the 
health coach was helpful in modifying portions 
Applications were viewed as user friendly, although most participants had never used a smartphone 
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that enabled behaviour tracking and feedback. Some participants described learning to use the system 
as a challenge, while others found it easy from the start 
Reminder messages could be programmed to appear on the patient’s smartphone at predetermined 
times, a function that was appreciated by several participants 
(b) Self activation, or processes related to personal monitoring, feedback, awareness and self-
management 
Processes identified by participants and associated with self-activation were: self-awareness, feedback, 
and self-management 
The smartphone increased self-awareness of habitual behaviours, especially dietary choices. Having 
pictures of their food increased awareness of portion size and carbohydrate intake. The application also 
helped them connect blood sugar levels to food choice 
Participants identified the feedback as motivating. When participants shared meal photographs, they 
received immediate feedback from coaches on where improvements could be made 
The smartphone supported self-management and monitoring, as individuals monitored patterns of 
behaviours, giving them a chance to ‘think twice’ about consumption 
Theme 2: The health coach 
All participants shared positive experiences about their smartphone interactions with health coaches, 
emphasising the understanding and encouragement received in the behaviour change process 
Four sub-themes: 
(a) Overall health coach qualities 
Various descriptions of the health coach included: strong, meticulous, confident, responsible, respectful 
and hardworking, especially in terms of monitoring and providing feedback. Appreciation was expressed 
in multiple forms, with representative descriptors being: best, nice, positive, generous, supportive, 
helpful and dedicated 
(b) Health coach supportive role 
Individuals described health coach support as having someone ‘always by their side’. This helped reduce 
feelings of isolation and being misunderstood. Trust was important in relationship strengthening as 
individuals discussed their diabetes management but also felt comfortable discussing personal struggles 
(c) Working together 
Good listening skills were mentioned by participants who felt ‘being heard’ by the health coach built 
trust and therapeutic alliance. Their logged behaviours on the smartphone provided the ability for 
participants and health coaches to communicate by phone and in person. This feedback was perceived 
valuable in meeting personal goals. For example, a photo-journalled meal allowed participants to pause, 
think, and communicate with the coach. On the health coach side, there could be reference to specific 
food pictures, specific BG readings and specific exercise sessions; a strong tie appeared to develop in 
relation to program specific activities (diet, exercise, glucose monitoring, medication) 
Some participants became more critical of their own behaviours related to food and exercise in ways 
that served productive discussions. Participants were activated by the co-monitoring with health 
coaches who were perceived as always watching (despite not being physically present) which increased 
the client’s feelings of accountability to follow through with change 
A few participants felt uncomfortable at the start because someone was ‘watching’ their diet and BG 
levels via smartphone. With time they realised benefits and became comfortable with health coach 
observation 
(d) Focal contact activities 
All participants agreed that the health coach assisted with diet, glucose testing, medication, and 
exercise. Individuals also discussed more specific ways in which their coach helped improve their self-
management 
In terms of diet, individuals worked on portion control, monitoring carbohydrate intake and ethnic 
specific food choices. Participants described how health coaches addressed various domains of diet, 
such as amounts/ types of food consumed in routine and celebrative situations 
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On the issue of medication, few subjects spoke in detail, explaining that medications were mostly 
discussed with their health coach at the start and thereafter the main emphasis was on healthy 
behaviours 
All participants discussed BG monitoring. Their conversations included daily glucose readings and 
insights on using food and exercise logs for interpretation 
Exercise was also part of participant conversations with health coaches, who encouraged participants by 
teaching techniques tailored to individual preferences and needs 
Theme 3: Overall experience 
Overall experience highlights factors that influenced participants after intervention completion. This 
theme reflects what participants ‘took away’ from the program. They described increased control and 
confidence in dealing with their condition and a substantial gain of knowledge about diabetes 
management 
When discussing the program, participants described it as helpful and were motivated to participate in 
other programs where financial costs and burdens were non-existent 
Theme 4: Frustrations in managing chronic conditions 
Three challenges: although they existed prior to joining the program 
 
(a) Medication and glucose measurement 
Both injection and oral medication were noted as a combined adherence challenge and the self-
administration of multiple medications was deemed frustrating. There was a common pattern of 
aversion to medications, as well as honest disclosures of adherence lapses 
Participants were further frustrated by having to check blood sugar levels in relation to medications and 
were not often confident their regulation was accurately reflected in readings 
(b) Diet/weight loss 
Participants struggled with modifications in diet and with weight loss goals, specifically mentioning 
cooking practices and diet restrictions, and their impact on family members 
(c) Comorbidities 
Individuals suffered comorbidities (e.g. chronic pain, mental health difficulties, hypertension) further 
hindering diabetes management 
Participants in this subsample had a clinically significant mean HbA1c reduction (–1.38%, SD= 2.08). 
However, positive views of smartphone functionality were expressed by individuals who did not achieve 
significant benefits, either in terms of glucose regulation or personal support, and negative views were 
expressed by individuals who demonstrated considerable benefits. These findings provide some 
confirmation that participants were not biased by their overall glucose regulation 
Recommendations made by authors 
In this qualitative study, it is evident that the smartphone monitoring software substantially enhanced 
the therapeutic alliance with patients who held their intervening coaches in high regard. Future studies 
can address how smartphone use enhances relationships and how different intensities and approaches 
to health coaching integrate effectively with smartphone use 
Reviewer’s conclusion 
This is a qualitative study, and so the outcome change in HbA1c is not extracted, as it’s a subgroup of 
the result from the RCT. The result of the RCT is reported in Wayne 2015, and a pilot feasibility study 
conducted before the RCT is reported in Wayne 2014 
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Appendix 4. Example of the Risk of Bias assessment for one RCT 
Name of the reviewer: Hala Alhodaib                                                                      Date of review: 26/2/2015 
First author surname year of publication: Kirwan 2013 
Bias domain Source of bias Support for judgment* Authors’ 
judgment** 
Selection bias Random 
sequence 
generation 
“The study coordinator randomized 
patients using a freely available online 
randomization program.” 
(www.randomization.com). 
Low risk 
Allocation 
concealment 
“A permuted block randomization design 
method was used during the 3-month 
rolling recruitment to ensure roughly equal 
numbers of patients were allocated to 
each comparison group.” 
In block randomisation, as long as the 
block size is not fixed and the order in 
which treatments were allocated in each 
block was random, and both the ordering 
of blocks and their respective size were 
blinded; this will ensure that the allocation 
process is not predictable 
Low risk 
Performance bias Blinding of 
participants and 
personnel 
There was no blinding of participants, they 
were told about the two groups – it was 
not possible to blind them, as one group 
got access to the smartphone app and the 
other group did not 
Insufficient information to to permit 
judgement of the blinding of personnel 
High risk 
Detection bias Blinding of 
outcome 
assessors to 
intervention 
allocation 
No blinding of outcome assessors, but 
HbA1c and its measurement is not likely to 
be influenced by the lack of assessors 
blinding 
“The primary outcome measure was 
change in glycemic control assessed by 
HbA1c which was collected by a pathology 
lab at the request of the patients’ general 
practitioner or endocrinologist as per usual 
care (every 3 months) and then forwarded 
to the research team.” 
“The secondary outcome measures, being 
diabetes-related self-efficacy, self-care 
activities, and quality of life, were collected 
via a Web-based survey.” 
Self-reported outcomes may introduce bias 
HbA1c - Low risk 
Other outcomes 
– High risk 
Attrition bias Incomplete 
outcome data 
The dropout rate is high and not even 
between groups, which may imply a 
problem with the intervention. 
“Dropout was 26% (11 males, 8 females, 
High risk 
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Bias domain Source of bias Support for judgment* Authors’ 
judgment** 
19/72) with logistic regression analysis 
revealing no significant difference in age, 
gender, diabetes duration, insulin pump 
use, and baseline HbA1c among those that 
completed the study and those that were 
lost to follow up.” 
“Due to the dropout of patients, the study 
may not have been powered sufficiently to 
detect differences between groups for the 
secondary outcome measures.” 
Reasons for subject attrition could not be 
determined as “patients could not be re-
contacted.” 
Analysis of missing data (ITT): 
 “Linear mixed model analysis allows for 
inclusion of cases with missing data, 
without replacement of missing values, 
and therefore includes all randomized 
patients.” 
They reported using the ITT, however, the 
result was presented per-protocol 
Reporting bias Selective 
reporting of the 
outcome, 
subgroups, or 
analysis 
All primary and secondary outcome 
measures were pre-specified in the trial 
protocol; however, the protocol was 
retrospectively registered in 30/01/2012. 
Low risk 
Other bias Bias due to 
problems not 
covered 
elsewhere; such 
as funding 
source, 
adequacy of 
statistical 
methods used, 
type of analysis 
[ITT/PP], 
baseline 
imbalance in 
important 
characteristics 
Imbalance in baseline characteristics:    
There were differences in glycemic control 
(HbA1c) and gender between groups at 
baseline - the intervention group had a 
significantly higher HbA1c at baseline 
(P=0.02) and thus had a greater potential 
to improve their glycemic control, and 
reported a healthier diet (P=0.03) than the 
control group. There were significantly 
more females (P=0.02) in the control 
group. 
Possible contamination:                   
“although patients in the control group 
were instructed not to use any mobile 
applications to self-manage their diabetes 
during the study period, it is possible they 
did.” 
High risk 
ITT=intention-to-treat; PP=per protocol 
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Appendix 5. Example of the Downs and Black quality assessment for one non-
RCT 
Name of the reviewer: Hala Alhodaib                                                              Date of review: 12/02/2016 
First author surname year of publication: Wayne 2014                              Total score: 16 
No Criteria Answer Second reviewer After discussion Score 
1 Is the 
hypothesis/aim/objective 
of the study clearly 
described? 
Yes, “The intent of the study was to 
develop and test a smartphone-
assisted intervention that improves 
behavioral management of type 2 
diabetes in an ethnically diverse, 
lower SES population within an 
urban community health setting.” 
Not clear, no clear 
definition of the 
population: Low 
SES or modest? 
Yes, the 
ambiguous target 
population should 
be assessed in 
another question 
that related to the 
population 
 
1 
2 Are the main outcomes to 
be measured clearly 
described in the 
Introduction or Methods 
section? 
Yes, in the method section. “The 
primary study outcome was 
glycosylated hemoglobin (HbA1c) 
assessed at baseline and 24 weeks. 
HbA1c is a clinical indicator of 
glucose regulation correlated with 
debilitating and costly diabetic 
complication.” 
Yes, though 
secondary outcome 
was not mentioned 
in the method 
section 
 
 1 
3 Are the characteristics of 
the patients included in 
the study clearly 
described? 
Yes, “Eligible participants were 
patients over 18 years old, 
diagnosed with type 2 diabetes, and 
able to read and speak English. 
Participants were excluded if their 
baseline HbA1c was greater than 
9.5%.” 
Yes, participants 
were recruited at 
the Black Creek 
Community Health 
Centre in Toronto, 
Ontario, Canada. 
Recruitment was 
through health care 
provider referral 
and poster 
advertising. 
Inclusion/exclusion 
criteria were clear 
 1 
4 Are the interventions of 
interest clearly described? 
Yes  
 
No, how could the 
coach make his 
decision? 
How could the 
patients receive the 
feedback - same 
device? What 
frequency? 
The decrease in 
HbA1c could be 
purely attributed to 
the coach feedback 
intervention rather 
than the mobile 
app 
Yes, the end-user 
interface was 
displayed and how 
the data input 
system worked, 
But not clear about 
the frequency, and 
how the coach 
interacted with the 
users 
1 
5 Are the distributions of 
principal confounders in 
Yes=age, gender, ethnicity, marital 
status, children, education, 
Yes  2 
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No Criteria Answer Second reviewer After discussion Score 
each group of subjects to 
be compared clearly 
described? 
employment. There is single group 
of patients 
6 Are the main findings of 
the study clearly 
described? 
 
Yes, “There was a mean reduction of 
0.28% (SD 0.57) (P=.05) found over 
the entire sample…” 
No, no description 
of BMI, weight, 
waist 
circumference 
 
No, other 
outcomes of 
interest were not 
reported in the 
result section. Only 
mentioned a 
subgroup outcome 
with significantly 
favourable result 
(high risk of 
reporting bias) 
0 
7 Does the study provide 
estimates of the random 
variability in the data for 
the main outcomes? 
Yes, SD was reported No  Yes 1 
8 Have all important adverse 
events that may be a 
consequence of the 
intervention been 
reported? 
No adverse events reported No  0 
9 Have the characteristics of 
patients lost to follow-up 
been described? 
2 participants were lost, “The 
primary reason for missing data was 
primary care physician failure to 
forward lab results (n=2).” 
No, only the reason 
reported 
 
Partial, did not 
provide details on 
their 
characteristics, 
such as “there 
were no significant 
difference 
between the drop-
out and those 
remained in the 
trial” 
0 
10 Have actual probability 
values been reported (e.g. 
0.035 rather than <0.05) 
for the main outcomes 
except where the 
probability value is less 
than 0.001? 
Yes Yes  1 
External validity    
11 Were the subjects asked to 
participate in the study 
representative of the 
entire population from 
which they were 
recruited? 
 
Yes  
 
 
Not sure whether 
representative of 
the entire 
population 
 
 
Not clear 
 
Due to the lack of 
definition and 
classification of 
SES. Plus, in the 
article title they 
said modest SES; 
but in the main 
body they targeted 
lower SES  
0 
12 Were those subjects who Yes   Not clear, is it Not clear 0 
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No Criteria Answer Second reviewer After discussion Score 
were prepared to 
participate representative 
of the entire population 
from which they were 
recruited? 
consistent with the 
demographic 
characteristics in 
that community? 
 
13 Were the staff, places, and 
facilities where the 
patients were treated, 
representative of the 
treatment the majority of 
patients receive? 
Yes, “Participants were recruited at 
the Black Creek Community Health 
Centre in Toronto, Ontario, Canada.” 
 
 
No, “Most 
participants (n=19) 
did not own a 
smartphone and 
were loaned a 
device for the trial 
duration.”” 
Nonetheless, as the 
costs of mobile 
technology 
decrease, mobile 
technology 
interventions will 
be increasingly 
feasible and useful 
at all SES levels.” 
Yes, the app 
considered as the 
intervention and 
the smartphone 
would not 
considered facility 
1 
Internal validity - bias    
14 Was an attempt made to 
blind study subjects to the 
intervention they have 
received? 
No, blinding is not feasible, it is not 
possible to blind subjects as they got 
access to the smartphone app 
No  0 
15 Was an attempt made to 
blind those measuring the 
main outcomes of the 
intervention? 
No blinding to the assessors was 
stated, however, the primary 
outcome HbA1c is a clinical indicator 
and the lab result was forwarded by 
their primary care physician, 
“Second, our experience with 
primary care providers involved their 
inconsistent provision of HbA1c 
tests.” 
No, but for Hb1Ac 
not necessary 
 0 
16 If any of the results of the 
study were based on “data 
dredging”, was this made 
clear? 
Yes, there is no unplanned analysis 
indicated 
Yes  1 
17 In trials and cohort studies, 
do the analyses adjust for 
different lengths of follow-
up of patients, or in case 
control studies, is the time 
period between the 
intervention and outcome 
the same for cases and 
controls? 
Yes, the follow-up was the same for 
all study patients 
Yes  1 
18 Were the statistical tests 
used to assess the main 
outcomes appropriate? 
Yes, “Differences in outcome 
variables (baseline to 24 weeks) 
were analyzed using a paired 
samples t test.” 
Yes, descriptive 
statistics are 
reported (means 
and standard 
deviations). 
Differences in 
 1 
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No Criteria Answer Second reviewer After discussion Score 
outcome variables 
(baseline to 24 
weeks) were 
analysed using a 
paired samples t 
test 
19 Was compliance with the 
intervention/s reliable? 
Yes  No, not mentioned 
  
Not clear 0 
20 Were the main outcome 
measures used accurate 
(valid and reliable)? 
Yes No  
 
Yes 1 
Internal validity - confounding (selection bias)    
21 Were the patients in 
different intervention 
groups (trials and cohort 
studies) or were the cases 
and controls (case-control 
studies) recruited from the 
same population? 
Single group One group N/A 1 
22 Were study subjects in 
different intervention 
groups (trials and cohort 
studies) or were the cases 
and controls (case-control 
studies) recruited over the 
same time? 
Single group, but the study did not 
specify the time period over which 
patients were recruited 
No, time was not 
specified 
 
N/A 1 
23 Were study subjects 
randomised to 
intervention groups? 
No randomisation; single group N/A No 0 
24 Was the randomised 
intervention assignment 
concealed from both 
patients and health care 
staff until recruitment was 
complete and irrevocable? 
No No  0 
25 Was there adequate 
adjustment for 
confounding in the 
analyses from which the 
main findings were drawn? 
“Participants were split into 
groupings according to baseline 
assessments (HbA1c≥7.0% and 
HbA1c<7.0%).” 
 
 
No, “A total of 21 
subjects consented 
and 19 participants 
completed the 6-
month trial; 12 had 
baseline 
glycosylated 
hemoglobin 
(HbA1c) levels 
>7.0% and these 
subjects 
demonstrated a 
mean reduction of 
0.43% (SD 0.63) 
(P<.05) with 
minimal changes in 
medication.” 
No 
 
Possible 
confounders: 
Changes in 
medications as no 
further description 
about what level 
was the minimal 
changes in 
medication 
 
Possibly the cohort 
were very 
proactive in 
improving their 
health status and 
hence 
communicated 
0 
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No Criteria Answer Second reviewer After discussion Score 
 
Medications? 
 
The effect from the 
coach intervention? 
 
 
 
with their GP to 
modify the 
medication. At 
least the study 
should have 
mentioned how 
they deal with this 
confounder before 
they put it in their 
final conclusion 
26 Were losses of patients to 
follow-up taken into 
account? 
Yes, the number and reason was 
reported, but they’re not included in 
the analysis 
Yes  1 
27 Did the study have 
sufficient power to detect 
a clinically important effect 
where the probability 
value for a difference 
being due to chance <5%? 
No, it is a pilot study, which was not 
powered to detect differences “This 
pilot study enrolled a small 
convenience sample with no control 
group, limiting the generalizability of 
intervention results.” 
No  0 
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Appendix 6. Example of the CASP methodological quality assessment for one 
qualitative study  
Name of the reviewer: Hala Alhodaib                                                                    Date of review: 4/6/2016                                                                                                                                                                           
First author surname year of publication: Pludwinski 2015 
No. Screening question Yes Can’t tell No 
1 Was there a clear statement of the aims of the 
research? 
✓   
“The objective was to compare the effectiveness of six months of smartphone use with health 
coaching vs. health coaching of equal intensity without smartphone support. Using in person, semi-
structured interviews following study completion, participants reflected on their smartphone- based 
experiences in relation to the role of the health coach in the enhanced intervention arm.” 
2 Is a qualitative methodology appropriate? ✓   
The study investigates the experience of individuals 
“The most precise quantitative assessments of smartphone- based health coaching must be derived 
through randomized controlled trials (RCTs), but RCTs only produce modest levels of patient 
feedback. We recently completed an RCT and, to provide more in-depth feedback, undertook semi-
structured interviews with n= 11 intervention participants.” 
Is it worth continuing? 
3 Was the research design appropriate to address the 
aims of the research? 
 ✓  
Face-to-face interview would be considered one of the best qualitative methods to explore 
individuals experience, but the author did not justify the choice of methodology 
Only justification for the choice of the qualitative approach  
“Nonetheless, the qualitative approach provides a detailed perspective on what some participants 
experienced during interventions.” 
4 Was the recruitment strategy appropriate to the aims of 
the research? 
✓   
Even though it’s not very detailed, what they reported is sufficient as their target population is a 
subsample of patients who participated in the RCT 
“After completing the trial, individuals were invited by phone or in person to participate in qualitative 
face to face interviews. Efforts were made to reach n= 26 intervention participants, and n= 11 were 
contacted. All the participants who were reached were invited and they agreed to participate in the 
study.” 
5 Was the data collected in a way that addressed the 
research issue? 
✓   
They reported sufficient details about the data collection method, which is in person, semi-structured 
interview and the setting. Also they provided the interview guide and discussed saturation 
“Interviews were conducted by a trained interviewer, and reviewed by two additional members of 
the research team to ensure standardized technique… Interview questions were developed by the 
lead investigator from prior research and modified by other team members. Interviews were 
conducted, transcribed verbatim, and reviewed for accuracy by the entire investigative team. 
Saturation–the point where no new information is detected with additional interviews–was evaluated 
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and agreed on by all research team members, in accord with study goals.” 
6 Has the relationship between researcher and 
participants been adequately considered? 
 ✓ partially  
I think the relationship is not adequately considered; the only method I thought maybe helpful in 
reducing the bias brought by the interviewers is the trained interviewer, but no further details or 
discussion are given.  
  
“Interviews (approx. 30–40min.) were conducted by a trained interviewer, and reviewed by two 
additional members of the research team to ensure standardized technique.” 
 
7 Have ethical issues been taken into consideration? ✓   
“This study received ethical approval from York University’s Human Participants Review 
Subcommittee (HPRC) and all participants provided informed consent. To maintain confidentiality, 
personal information was removed from transcripts and audio interview recordings were stored in a 
locked cabinet in locked offices. Transcripts were transferred between locked password protected 
computers, with encrypted USB Keys.” 
 
8 Was the data analysis sufficiently rigorous? ✓   
Sufficient details of the analysis process 
“Coding and analyses were performed using NVivo employing a thematic analytic approach that 
thoroughly explored relevant themes surfacing during the interviews. Thematic analysis provides a 
systematic identification of emergent patterns, and logically organizes qualitative data into broader 
common and representative themes.  Our analytic strategy of constant comparison included code 
development as the basic analytic unit (capturing important aspects of data) and, based on codes, the 
derivation of broader themes (team discussions) illustrating a coherent view of collected data.” 
9 Is there a clear statement of findings? ✓   
The findings were explicit and easy to follow and supported with evidences from the original sample 
10 How valuable is the research?  ✓  
They discussed some limitations of their research, compared it to other relevant research, 
recommended some future research 
But the sample size is small, and might not be representative of the whole population 
Other potential bias that were discussed are: 
 
“These findings provide some confirmation that participants were not biased by their overall glucose 
regulation.” 
 
“These participants are, of course, were willing to participate in two studies (the RCT and this 
interview study), which may differentiate them from other participants whose blood sugars were 
significantly dysregulated. In future studies, it may be possible to identify and recruit additional 
groups of patients and in doing so, derive results more representative of the general population of 
diagnosed patients.” 
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Appendix 7. Ongoing and completed trials identified from the online trials registers  
Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
A Smartphone 
Application to Improve 
Medication Adherence 
Among People With 
Type 2 Diabetes 
Mellitus in Singapore: A 
Randomized Controlled 
Trial 
Diabetes 
Mellitus 
Mobile 
application 
Medication  
adherence 
Singapore  
General  
Hospital, 
National  
University,  
Singapore 
August 2014 March 2015 Recruiting Hua Heng McVin 
Cheen 
+6563214110    
mcvin.cheen.h.h
@sgh.com.sg    
 
Audio Health 
Engagement Analysis in 
Diabetes: The AHEAD 
Study 
T1D CareCoach mobile 
application  
Diabetes 
management 
University of  
California, San  
Francisco 
October 2013 June 2015 Not yet recruiting Korey Hood 
hoodk@peds.ucsf
.edu 
Clinical Trial of Mobile 
Application to Enhance 
Diabetic Health Care 
Diabetes 
Mellitus 
Diabetes  
mobile  
application 
Change of  
diabetic  
retinopathy  
risk factors 
University of  
California, Los  
Angeles 
September 2012 December 2014 Recruiting Elaine Ngo 
Ngo@jsei.ucla.ed
u 
 
Marianne 
Bernardo 
Esguerra@jsei.ucl
a.edu 
Effect of Mobile Phone 
Telemedicine on 
Diabetes Care 
Diabetes  
Mellitus 
Diabetes  
Doctor 
Evidence for 
improved diabetic 
care with mobile 
phone application 
use 
University of  
Nebraska 
December 2012 June 2013 Unknown Jay Patel 
402-559-9013 
jay.patel@unmc.e
du 
Influence of a Mobile 
Phone Application on 
Quality of Life of 
Patients With Type 1 
Diabetes Mellitus: a 
T1D Dbees;  
diabetes 
 mobile  
 application 
QoL Medical  
Research  
Foundation,  
The  
Netherlands 
September 2011 April 2012 Completed Henk J. Bilo 
Isala clinics 
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
Randomized Controlled 
Trial 
Changing the 
Healthcare Delivery 
Model: A Community 
Health Worker/Mobile 
Chronic Care Team 
Strategy 
T2D Mobile health 
care  
application 
Goals/ 
behaviours met 
George  
Washington 
 University 
April 2014 April 2016 Not yet recruiting Linda Witkin 
202-741-3047    
lwitkin@mfa.gwu.
edu   
 
Carine Nassar 
202-877-0351 
carine.m.nassar@
medstar.net 
Assessment of the 
Clinical Efficacy and 
Acceptability of the 
Think Positive (T+) 
Diabetes Management 
System in Insulin 
Requiring Diabetes 
Diabetes  
Mellitus  
(Insulin-
requiring,  
T1D or T2D) 
 
Mobile phone 
telehealth 
application: Think 
Positive (T+) 
Blood sugar levels 
(HbA1c) 
University College 
London Hospitals 
June 2010 November 2011 Completed Justine Baron 
Data Driven Feedback 
as a Method to 
Improve Glycaemic 
Control in Type 1 
Diabetes 
T1D Few Touch  
application;   
Diastat 
Change in the 
frequency of 
hyper- and hypo-
glycemic events 
University  
Hospital of  
North Norway;   
University of  
Tromso;   The 
 Research  
Council of  
Norway 
March 2013 August 2013 Completed Stein Olav 
Skrøvseth 
STEP AND GO: A Study 
of Technology-based 
Exercise Promotion and 
Gaming Outcomes 
Cardiovascular Di
sease;    
Obesity; Cancer;    
Diabetes 
Game application 
loaded onto 
smartphone 
Change in 
physical activity 
The University of  
Texas,  
Galveston;    
American  
Heart  
Association 
September 2014 December 2014 Not yet recruiting Elizabeth J Lyons 
409-772-1917 
ellyons@utmb.ed
u  
 Eloisa Martinez 
409-266-9643    
esmartin@utmb.
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
edu   
A Randomized 
Controlled Study on the 
Use of Self-
management Tools to 
Improve Chronic Care 
T2D;    
Hypertension 
Mobile phone, 
software 
application, and 
assessment 
devices 
Change in  
HbA1c 
VTT Technical 
Research Centre 
of Finland 
May 2011 June 2012 Completed Sipoo Health Care 
Centre 
Motivation Psychology-
based Smart 
Engagement System for 
Improved Older Adult 
Chronic Disease 
Management 
Diabetes  
Mellitus 
Software 
application on a 
digital tablet 
device 
Improvement in  
HbA1c 
Baltimore  
Research &  
Education  
Foundation, 
 Inc. 
June 2014 March 2015 Not yet recruiting Nanette Steinle 
410-605-7432    
Nanette.Steinle@
va.gov    
Tammy Bremer    
410-605-7188    
Tammy.Bremer@
va.gov    
Interactive Tool to 
Support Self-
management Through 
Lifestyle Feedback, 
Aimed at Physical 
Activity of COPD/DM 
Patients (RCTIt'sLiFe!) 
COPD;   T2D Accelerometer, 
app on a 
smartphone; a 
server and a 
website 
Physical  
activity 
Maastricht  
University  
Medical Center;    
ZonMw: The 
Netherlands 
Organisation for 
Health Research 
and Development 
April 2013 October 2014 Active, not 
recruiting 
Luc de Witte 
Self-Management 
Using Smartphone 
Application for Type2 
DM in Real siTuation 
(SMART-DM) 
T2D Smartphone 
application 
Fasting  
serum 
glucose and  
HbA1c 
Inje University, 
Korea 
November 2012 October 2013 Completed  
 
Jongha Park 
 
 
Self-management in 
Type 2 Diabetes 
Patients Using the Few 
Touch Application 
T2D Few Touch 
application  
(FTA) 
Improved  
glycemic  
control 
University  
Hospital of  
North Norway; 
Oslo University C
ollege; European  
Commission;   The
March 2011 September 2013 Unknown Astrid Grøttland    
+47 976 95 111    
astrid.grottland@
telemed.no 
 
Gerd Ersdal 
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
 Research  
Council of  
Norway 
+47 915 71 915    
gerd.ersdal@tele
med.no 
 
Lis Ribu 
+4792206229    
Lis.Ribu@su.hio.n
o   
Feasibility of Using a 
Smart Phone 
Application for Self-
titration of Insulin on 
Glycemic Control in 
Patients With Type 2 
Diabetes 
Diabetes  
Mellitus 
Smart phone appl
ication 
Change in 
glycemic control 
(HbA1c) 
National  
University,  
Singapore; Duke-
NUS Graduate Me
dical School;   
Singapore  
General  
Hospital 
March 2013 March 2015 Recruiting Yong Mong Bee 
bee.yong.mong@
sgh.com.sg    
 
David Matchar 
(65) 6516 2584 
david.matchar@d
uke-nus.edu.sg 
Assessment of an 
Electronic Self-
Management Tool on 
Glycemic Control in 
Teens With Type 1 
Diabetes 
T1D Bant iPhone 
 application 
Changes in  
HbA1c 
The Hospital  
for Sick  
Children;    
Thrasher  
Research Fund; 
University  
Health  
Network,  
Toronto;    
York University 
July 2013 February 2016 Recruiting Mark R Palmert 
416-813-6217 ext 
206217 
mark.palmert@si
ckkids.ca 
 
Caitlin A Nunn 
416-813-7654 ext 
328158    
caitlin.nunn@sick
kids.ca    
 
Stephanie So 
416-340-4800 ext 
6843    
Stephanie.So@uh
n.ca    
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
A Randomised Pilot 
Trial to Compare 
Remote Blood Glucose 
Monitoring With 
Standard Clinical Care 
in the Gestational 
Diabetic Population 
GDM;  Pregnancy Blue tooth 
enabled glucose 
meter with smart 
phone application 
HbA1c  
University of  
Oxford 
 
September 2013 March 2015 Recruiting Lucy Mackillop 
+441865861165 
Lucy.Mackillop@
ouh.nhs.uk 
 
Jane E Hirst 
+441865221008 
jane.hirst@obs-
gyn.ox.ac.uk 
NEAT! Technology to 
Increase Breaks in 
Sedentary Behavior in 
Adults With Diabetes 
Diabetes 
Mellitus 
Accelerometer 
and NEAT app 
Evaluation of  
NEAT 
Northwestern  
University 
February 2013 October 2013 Completed Christine 
Pellegrini 
Is a Smartphone 
Application Effective as 
an Oral Medication 
Adherence Aid 
Hypertension;    
Diabetes;    
Dyslipidemia 
Medication 
adherence 
smartphone app 
Medication 
adherence 
University of  
Arkansas 
October 2013 October 2014 Recruiting Paul H Anderson 
5018128561 
panderson3@ua
ms.edu 
Prospective Study, 
Insulin Pump-RT 
Advisor (IPRA©): A 
Decision Support 
Software for Diabetic 
Patients Treated by 
Insulin Pump and Using 
Continuous Glucose 
Monitoring. 
Experimental Study. 
Evaluation by an Expert 
Patient Panel 
T1D Decision support 
smartphone 
application 
IPRA© 
Patient 
agreement with 
the IPRA© 
advices 
Rennes  
University  
Hospital 
June 2013 September 2013 Completed Isabelle Guilhem 
The Smart-phone as a 
Physical Fitness 
Monitor on a 
Population Level - 
T2D InterWalk 
smartphone app 
Amount of time 
during interval 
walking 
University of  
Copenhagen; 
Denmark 
March 2014 October 2014 Recruiting Laura Staun 
Valentiner 
+45 51173649 
lauravalentiner@
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
Validity and Sensitivity 
and Improtance of 
Individual Motivation 
for Doing Interval 
Walking With the 
InterWalk Application 
gmail.com 
 
Mathias Ried-
Larsen 
+45 21782087 
mathias.ried-
larsen@regionh.d
k 
Comparative Efficacy of 
iBGStar Glucose Meter 
vs. Traditional Glucose 
Monitoring in 
Improving Metabolic 
Control and 
Compliance Towards 
Self-Monitoring of 
Blood Glucose in Young 
Patients With Type 1 
Diabetes 
Diabetes  
Mellitus 
iBGStar Diabetes 
Manager app 
uploaded on 
iPhone 
Change in  
HbA1c levels 
 
Sanofi, Italy 
 
June 2012 April 2014 Active, not 
recruiting 
Clinical Sciences 
& Operations 
Role of Mobile 
Technology to Improve 
Diabetes Care in Adults 
With Type 1 Diabetes: 
the REMOTE-T1D 
Study, a Pilot Study 
T1D iBGStar  
meter 
Hypoglycaemia 
fear and QoL 
University of 
Colorado Denver 
School of 
Medicine Barbara 
Davis 
Center;  Sanofi;    
Colorado  
Prevention  
Center 
December 2012 November 2013 Completed Satish K Garg 
mHealth Skill 
Enhancement Plus 
Phone CBT for Type 2 
Diabetes Distress 
Medication 
T2D Phone CBT 
approach 
supported by a 
mobile phone 
CBT skills practice 
Acceptability  
questionnaire 
University of  
Pittsburgh;    
National  
Institutes of  
Health (NIH) 
May 2013 August 2014 Recruiting Judith A. Callan 
412-383-5321    
callanja@pitt.edu
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
Nonadherence: Pilot 
Study 
app Lisa Tamres 
412-624-1213    
ltamres@pitt.edu
   
Brief CBT Interventions 
Delivered by Nurse 
Care Managers to 
Improve Type 2 
Diabetes Outcomes: 
Pilot Study 
T2D CBT phone app Acceptability  
questionnaire 
University of  
Pittsburgh 
January 2013 July 2014 Recruiting Judith A. Callan 
412-383-5321    
callanja@pitt.edu
   
 
Lisa Tamres 
412-624-1213    
ltamres@pitt.edu
   
A Mobile Personal 
Health Record for 
Behavioral Health 
Homes (mPHR) 
Hypertension; 
Hyperlipidemia; 
Diabetes 
Mobile personal 
health record app 
Quality of  
general  
medical care 
Emory  
University;    
National  
Institute of  
Mental Health  
(NIMH) 
July 2014 June 2018 Not yet recruiting Gretl Glick 
404-712-8529 
gglick@emory.ed
u 
 
Silke von 
Esenwein 
404-712-8525 
svonese@emory.
edu 
 
Deborah Strotz    
770-499-2422 
The Mobile Health 
Platform - 
Development and 
Feasibility Evaluation 
Obesity;    
Hypertension;  
Diabetes 
The mobile  
health  
platform 
Change in the 
acceptance and 
use of technology 
survey 
Duke University, 
USA 
March 2014 July 2014 Recruiting Ryan J. Shaw 
919-684-9434 
Ryan.Shaw@duke
.edu 
 
Markedia Y. 
Mason 
   
255 
Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
919-660-0357 
markedia.mason
@gmail.com 
Webdia Study: Use of 
Smartphones to 
Improve Diabetes 
Control and Quality of 
Life in Children With 
Type 1 Diabetes - 
Randomized Crossover 
Study to Test the 
Impact of Using a 
Software for 
Smartphones and 
Tablets in Treating Type 
1 Diabetes 
T1D Webdia 
smartphone 
software 
Effect of 
Webdia use  
on HbA1c 
University  
Hospital,  
Geneva;    
Philippe Klee 
May 2014 December 2015 Recruiting Philippe Klee 
+41 79 55 33 476 
philippe.klee@hc
uge.ch 
 
Valérie M 
Schwitzgebel 
+41 22 372 45 92 
valerie.schwitzge
bel@hcuge.ch 
Electronically 
Connected Health 
Coaching in Improving 
Type 2 Diabetes Self-
Management - Phase III 
Trial 
T2D Lifestyle  
counselling  
with  
smartphone 
HbA1c York University;   
Public Health Age
ncy of  
Canada (PHAC) 
February 2012 June 2014 Recruiting Paul Ritvo 
4165808021 
pritvo@yorku.ca 
 
Noah Wayne 
4168897289 
noahwayne@gma
il.com 
Edmonton Automated 
Sugar Intelligence - 
Intelligent Diabetes 
Management, EASI-
IDM, App Program to 
Assist Diabetes Care 
T1D Edmonton 
Automated Sugar 
Intelligence (EASI) 
app 
Glucose  
control - HbA1c 
University of  
Alberta 
August 2014 December 2016 Recruiting Edmond Ryan 
idmuofa@ualbert
a.ca 
Randomised Controlled 
Trial of the Diabetes 
Self-Management 
T1D Glucose Buddy 
iPhone app 
improvement in 
glycaemic control 
 
Central 
Queensland 
January 2012 February 2013 Completed Morwenna 
Kirwan 
+61749232546 
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Study Title Condition Intervention Primary Outcome  Sponsor Study Start Study Completion Status Contact 
‘Glucose Buddy’ 
Smartphone Applicatio 
University, 
Australia  
 
m.kirwan@cqu.e
du.au 
Surveys for 
determining the clinical 
usefulness and user 
satisfaction of diabetes 
self-management 
system using a 
smartphone 
Diabetes  
Mellitus 
Diabetes self-
management 
smartphone app 
 
User satisfaction 
of diabetes self-
management 
smartphone app 
 
KyungHee 
University 
Hospital, Seoul, 
Korea 
April 2013 -- Recruiting Sang Youl  Rhee 
The effect of Mobile 
Program on Quality of 
life and Blood Glucose 
control in Patient With 
Type II Diabetes 
T2D Educational 
software installed 
on mobile phone 
QoL Kerman 
University of 
Medical Sciences, 
Iran 
December 2012 -- Completed Fariba Borhani  
00983413205220 
faribaborhani@m
sn.com 
 
Hadi  Ranjbar 
00983413205219 
hadiranjbar@kmu
.ac.ir 
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Appendix 8. Characteristics of included studies tables 
Table 1. Included RCTs 
Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
subjects 
Age (yrs) Duration  Outcomes 
Type 1 diabetes 
Charpentier 
2011, Franc 
2012, Franc 
2014, Franc 
2015 
 
 
Franc 2012, 
Benhamou 
2010, Penfornis 
2010 
(abstracts) 
France 3-armed, 
multicentre RCT 
Self-care   
 
Diabeo software: 
Insulin 
management,  
Diabetes-related 
data collection (BG 
level, medication, 
diet) 
 
Control group 
(G1):  Kept their 
paper logbook 
with two follow-
up visits at the 
hospital, after 3 
and 6 months 
Intervention 
group (G2): 
Received a 
smartphone 
loaded with the 
Diabeo software 
with face-to-face 
follow-up visits 
on month 3 and 
month 6 
G1: n=61 
 
G2: n=60 
 
 
G1: 
36.8±14.1 
 
G2: 
32.9±11.7 
 
 
6 months HbA1c level 
Proportion of patients reaching the 
HbA1c target of<7.5% 
Frequency of self-monitoring BG 
Frequency of hypoglycaemia 
episodes 
Insulin dose 
QoL and satisfaction measured 
using Diabetes QOL questionnaire & 
DHP 
Time spent on consultation 
Satisfaction with app  
App utilisation 
Kirwan 2013 Australia RCT Self-care, but with 
weekly feedback 
from diabetes 
educator 
 
Glucose Buddy 
app: Diabetes-
related data 
collection (BG 
Control group: 
Received usual 
care; a visit to 
their primary 
diabetes health 
care practitioner 
(general 
practitioner or 
endocrinologist) 
Intervention: 
n=36 
Control: n=36 
Intervention: 
35.97±10.67 
Control: 
34.42±10.26 
9 months HbA1c level 
Diabetes-related self-efficacy (DES-
SF) 
Self-management behaviours 
(SDSCA) 
QoL (DQOL) scale 
App utilisation 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
subjects 
Age (yrs) Duration  Outcomes 
level, diet, 
medication, 
physical activity) 
every 3 months 
Drion 2015 Netherlands RCT Self-care 
 
DBEES app: 
Diabetes-related 
data collection (BG 
level, diet, 
medication, 
physical activity) 
Control group: 
Used standard 
paper diary 
Intervention: 
n=31 
Control: n=32 
Intervention: 
33 [23] 
Control: 
35 [18] 
3 months HbA1c level 
QoL measured using RAND-36 
health survey 
Diabetes-related distress PAID 
Frequency of self-monitoring BG 
Usability of the app SUS 
Type 2 diabetes 
Holmen 2014, 
Torbjørnsen 
2014, Ribu 
2013 
Norway 3-armed RCT Self-care 
 
Few Touch App 
(FTA): Diabetes-
related data 
collection (BG 
level, diet, physical 
activity), Diet 
evaluation and 
management, 
Education 
Control group 
(G1):  Received 
usual care by 
their GP 
Intervention 
group (G2): 
Received the FTA 
diary in addition 
to the usual care  
G1: n=50 
 
G2: n=51 
 
 
G1: 
55.9±12.2 
 
G2: 
58.6±11.8 
 
 
1 year HbA1c level 
QoL (SF-36) 
Depressive Symptoms (CES-D) 
Self-management behaviours (HeiQ) 
Lifestyle Change (Physical activity, 
Dietary habits) measured using 
Physical activity (from HUNT) and 
motivation (transtheoretical model) 
Weight 
App utilisation 
Istepanian 
2014 
Iraq Pilot RCT Self-care and 
telemonitoring 
 
DIAR app:  
Diabetes-related 
data collection (BG 
level), 
Communication 
Control group: 
Followed their 
usual diabetes 
care pathway 
plan and follow-
up visits 
Intervention: 
n=6 
Control: n=6 
Intervention: 
54.8±12.7  
Control: 
55.2±10.1 
 
 
6 months HbA1c level  
Diabetic knowledge measured using 
Questionnaire adapted and 
translated into Arabic from The 
Diabetic Knowledge Test [Michigan 
Diabetes Research and Training 
Center] 
Cholesterol levels 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
subjects 
Age (yrs) Duration  Outcomes 
and remote 
monitoring, 
Reminders 
Waki 2014 
 
 
Waki 2013 
(abstract) 
Japan RCT Self-care and 
telemonitoring 
 
DialBetics app:  
Diabetes-related 
data collection (BG 
level, medication, 
diet, physical 
activity, BP, 
weight), 
Communication 
and remote 
monitoring, Diet 
evaluation and 
management, 
Reminders 
Control group: 
Would continue 
their self-care 
regimen, but 
they did not 
receive or use 
any devices to 
monitor their 
health data; they 
did not record 
their diet and 
exercise 
Intervention: 
n=27 
Control: n=27 
Intervention: 
57.1±10.2 
Control: 
57.4±9.4 
 
3 months HbA1c level 
Fasting blood sugar (FBS) 
BP 
BMI 
Cholesterol levels  
Change in medication 
Self-management behaviours (in 
terms of diet and exercise) 
measured using the Japanese 
version of the questionnaire 
Summary of Diabetes Self-care 
Activities 
Usability of the app and user’s 
satisfaction measured using custom 
questionnaires 
Compliance with app use 
Wayne 2015 Canada RCT Self-care and 
telemonitoring 
 
Health Coach app:  
Diabetes-related 
data collection (BG 
level, diet, 
medication, 
physical activity, 
BP, weight, mood), 
Coaching,  
Diet evaluation and 
Control group: 
Received Health 
Coach support in 
selecting and 
progressing 
toward goals 
without access 
to a smartphone 
Intervention: 
n=48 
Control: n=49 
Intervention: 
53±10.9 
Control: 
53.3±11.9 
6 months HbA1c level 
Weight 
BMI 
Waist circumference  
Satisfaction with life measured 
using Satisfaction with Life 
Scale 
Depression and anxiety (HADS) 
Positive and negative affect 
measured using Positive and 
Negative Affect Schedule (PANAS) 
QoL SF-12 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
subjects 
Age (yrs) Duration  Outcomes 
management, 
Reminders 
Compliance with app use 
Hsu 2015 USA RCT Self-care, 
telemonitoring 
 
Cloud-based 
diabetes 
management app: 
Insulin 
management, 
Diabetes-related 
data collection (BG 
level, medication), 
Communication 
and remote 
monitoring  
Control group: 
Received high 
standards of 
care from 
diabetes 
specialists and 
certified 
diabetes 
educators in a 
tertiary center 
specializing in 
diabetes care in 
initiating and 
titrating insulin, 
with interim 
face-to-face 
visits, as well as 
telephone/fax 
communication 
with educators 
and physicians 
as dictated by 
their HCPs 
Intervention: 
n=20 
Control: n=20 
Intervention: 
53.3 
Control: 
53.8 
12 weeks HbA1c level 
Average BG level 
Proportion of patients reaching the 
HbA1c target of<7% 
Frequency of hypoglycaemia 
episodes 
Weight 
Insulin dose 
Patient satisfaction measured using 
Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) 
Time HCPs and patients spent on 
managing the insulin titration 
Type 1 & 2 diabetes 
Logan 2012 Canada RCT Self-care and 
telemonitoring 
 
A custom app 
running on a 
Control group: 
Subjects were 
issued with an 
identical-
appearing home 
Intervention: 
n=55 
Control: n=55 
Intervention: 
63.1±9.0 
Control: 
62.7±7.8 
 
1 year Change in mean daytime 
ambulatory systolic BP 
Changes in 7 days of home BP 
readings 
Psychological questionnaire (ASI, 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
subjects 
Age (yrs) Duration  Outcomes 
BlackBerry 
smartphone: BP 
monitoring, 
Communication 
and remote 
monitoring  
BP device 
without built-in 
Bluetooth 
capability for 
Home BP 
monitoring 
during the study 
without self-care 
support 
HADS) and Comfort with self-
measurement of BP questionnaires 
Change in number of 
antihypertensive drugs 
Number of GP visits  
App utilisation 
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Table 2. Included non-RCTs 
Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
Type 1 diabetes 
Cafazzo 2012 
 
 
Cafazzo 2012 
(abstract) 
 
 
Canada Pre-post design 
with no control 
(Clinical pilot 
phase)  
 
Self-care 
 
Bant app: 
Diabetes-related 
data collection 
(BG), 
Insulin 
management, 
Social support 
 
-- 20 14.9±1.3 3 months HbA1c level 
Frequency of self-monitoring BG 
Diabetes-related self-efficacy 
measured using Diabetes Family 
Responsibility Questionnaire 
Self-management behaviours 
measured using 14-item Self-Care 
Inventory 
QoL (DQOLY) 
App utilisation  
Satisfaction with app 
Frøisland 2012, 
Frøisland 2015 
 
 
Frøisland 2011 
(abstract) 
Norway Pre-post design 
with no control 
 
Self-care 
 
DiaMob app: 
Diabetes-related 
data collection (BG 
level, medication, 
diet, physical 
activity), 
Reminders, 
Education  
-- 12 16.2±1.7 3 months HbA1c level 
Diabetic knowledge measured 
using 27-item questionnaire based 
on the Norwegian National Health 
Informatics’ diabetes quiz 
Usability of the app SUS 
 
Min 2013 Canada Post-only design  
(Usability 
testing phase) 
Self-care 
 
Bant app:  
Diabetes-related 
data collection (BG 
level, insulin, diet, 
physical activity, 
-- 7 -- -- Usability of the app and willingness 
to use it in the future SUS followed 
by a general post-session 
questionnaire 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
emotion) 
Miele 2015 
 
 
Franceschi 2014 
(abstract) 
Italy Post-only design  Telemonitoring 
 
TreC Diabetes app:  
Diabetes-related 
data collection (BG 
level, medication, 
diet, physical 
activity), Insulin 
management, 
Communication 
and remote 
monitoring, 
Reminders 
-- 15 4 to 12  3 months User’s usage trends and patterns 
 
Type 2 diabetes 
Årsand 2009, 
Årsand 2010 
Norway Post-only design  
 
  Self-care 
 
Few Touch App 
(FTA): Diabetes-
related data 
collection (BG, 
physical activity), 
Diet evaluation and 
management, 
Education 
-- 12 56.2 6 months HbA1c level 
Number of steps 
Usability of the app SUS 
Tatara 2013, Tatara 
2013, Tatara 2013 
Norway Post-only design  
(2-phases) 
Self-care 
 
Few Touch App 
(FTA): Diabetes-
related data 
collection (BG, 
-- Phase 1: n= 12 
Phase 2: n= 11 
Phase 1: 
55.1±9.6 
Phase 2: 
57.2±8.6 
Phase 1: 
1 year 
Phase 2: 
5 months 
User’s usage trends and patterns 
Usability of the app SUS 
questionnaire 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
physical activity), 
Diet evaluation and 
management, 
Education 
Chomutare 2013 Norway Pre-post design 
with no control 
 
Self-care 
 
Few Touch App 
(FTA) with 
extension: 
Diabetes-related 
data collection (BG, 
physical activity), 
Diet evaluation and 
management, 
Education, Social 
support 
-- 7 62.7±9.0 12 weeks HbA1c level 
Usability of the app SUS  
Diabetes-related self-efficacy 
measured (HeiQ) and the DES-SF 
App utilisation  
 
Sarala 2014 India Pre-post design 
with no control 
(Pilot phase) 
 
Clinical practice 
 
mPower Heart 
DSS: Clinical 
decision-support in 
computation of 
personalised 
patient’s 
management plan 
based on logged 
clinical parameters 
-- 19 HCPs -- 8 months 
 
Compliance with the DSS-based 
clinical management plan 
Wayne 2014 Canada Pre-post design 
with no control 
Self-care and 
telemonitoring 
 
Health Coach app:  
-- 21 55.6±12.3 6 months HbA1c level 
Weight 
BMI 
Waist circumference 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
Diabetes-related 
data collection (BG 
level, diet, 
medication, 
physical activity, 
BP, weight, mood), 
Coaching, 
Reminders 
Kim 2014 Korea Pre-post design 
with control  
 
Self-care and 
telemonitoring 
 
Mobile Smartcare 
app: Diabetes-
related data 
collection (BG, BP), 
Communication 
and remote 
monitoring  
Control group: 
Received usual 
care with no 
smartphone 
app 
Intervention: 
n=38 
Control: n=35 
Intervention: 
51.8±10.3 
Control: 
53.8±9.0 
 
3 months HbA1c level 
BP 
Cholesterol levels 
BMI 
Satisfaction with the app measured 
using a questionnaire survey on the 
smartphone app and number of 
complaints 
Hunt 2014 USA Crossover, 
repeated-
measures 
design 
Self-care 
 
Diabetes Buddy 
app: Diabetes-
related data 
collection (BG 
level, diet, 
medication, 
physical activity) 
Control group: 
Were given a 
paper journal 
to log diabetes 
self-
management 
activities 
G1: n=6 
G2: n=8 
Adult ≥ 19 3 months Diabetes-related self-efficacy 
DMSES 
Self-management behaviours 
measured using SDSCA-Revised 
questionnaire 
Logging behaviour 
Alanzi 2014 Saudi 
Arabia 
Post-only design  
(Usability 
testing) 
Self-care 
 
SANAD system:  
Diabetes-related 
-- 33 18 to 65 -- Users’ satisfaction with the app’ s 
usability measured using the 
questionnaire for user interaction 
satisfaction (QUIS) 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
data collection 
(BG), Social 
support, 
Cognitive 
behavioural 
therapy 
Hong 2015 Korea Case report Self-care 
 
Diabetes & 
Nutrition app:  
Diabetes-related 
data collection 
(BG), Diet 
evaluation and 
management 
-- 1 46 6 months HbA1c level 
FBS 
BP 
Cholesterol levels 
Weight 
BMI 
Waist circumference  
Change in medication 
Usability of the app SUS 
Pellegrini 2015 USA Pre-post design 
with no control 
Self-care 
 
NEAT! App:  
Tracking physical 
activity, Reminders 
-- 9 53.1±10.7 1 month App utilisation  
Changes in sedentary behaviour 
and physical activity 
Waki 2015 
 
 
Waki 2011 
(abstract) 
Japan Post-only design  
 
Self-care and 
telemonitoring 
 
DialBetics app:  
Diabetes-related 
data collection (BG 
level, medication, 
diet, physical 
activity, BP, 
weight), 
Communication 
-- 5 58.6±4.1 1 week Compliance with app use 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
and remote 
monitoring, Diet 
evaluation and 
management, 
Reminders 
Neubauer 2015, 
Spat 2013 
 
 
Neubauer 2014, 
Neubauer 2014, 
Holl 2014 
(abstracts) 
Austria Post-only design  Clinical practice 
 
GlucoTab app: 
Clinical decision-
support for 
standardised 
glycaemic 
management and 
insulin titration 
-- 99 patients 
 
65 HCPs 
 
18 HCPs 
67±11 
 
36±11 
 
32 ±11 
7.8±4.5 days Proportion of BG measurements in 
the target range of 70–140 mg/dL 
Average BG level 
Compliance with given 
recommendation  
Usability of the app measured using 
a questionnaire 
User errors 
Type 1 & 2 diabetes 
Rao 2010 USA Post-only design 
(Task analysis)  
 
Self-care 
 
3 top-rated apps - 
Diamedic Diabetes 
Logbook 
Blood Sugar 
Diabetes Control 
WaveSense 
Diabetes Manager: 
Diabetes-related 
data collection  
(BG), Diet 
evaluation and 
management, 
Insulin 
management 
-- 23 43.7 -- Usability of the apps (time taken 
per task, number of requests for 
help, and perceived ease of use for 
performing the tasks) 
Importance and desirability of app 
features 
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Study Country Design Intervention 
purpose & 
functionality 
Comparator Number of 
participants 
Mean age 
(yrs) 
Duration of 
intervention 
Key outcomes 
Tiefengrabner 2014 Austria Post-only design  Self-care and 
telemonitoring 
Diabetes diary:  
Diabetes-related 
data collection (BG 
level, medication, 
diet, physical 
activity), 
Communication 
and remote 
monitoring  
-- 9 25 to 65 2 weeks Logging behaviour 
 
Gestational diabetes 
Mackillop 2014, 
Hirst 2015, Hirst 
2015 
 
Loerup 2015, Hirst 
2015, Loerup 2014,  
Loerup 2014, Hirst 
2014, Loerup 2013, 
Gibson 2012 
(abstracts) 
UK Post-only design 
(2-phases) 
Telemonitoring 
GDm-health:   
Diabetes-related 
data collection (BG, 
medication), 
Communication 
and remote 
monitoring, 
Reminders 
GDM Phase 1: n=7 
Phase 2: n=52 
-- Average 13.1 
weeks 
Average BG level 
App utilisation  
Satisfaction (OMDTSQ) 
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Table 3. Included cross-sectional studies 
Study Country Design Diabetes type Number of 
participants 
Mean age (yrs) Key outcomes 
Type 2 diabetes 
Dobson 2015 Canada Cross-sectional 
survey 
Type 2 44 58.7±11.02 Users’ current use of technology in their self-
management 
Patient’s attitudes toward using mobile apps in 
self-management 
Users’ confidence and intention to use 
technological diabetes applications 
Type 1 & 2 diabetes 
Humble 2015 
Humble 2014 
(abstract) 
USA Cross-sectional 
survey 
Type 1 & 2 Practice 1: n=29 
Practice 2: n=31 
Practice 1: 
63.1±2.4 
Practice 2: 
61.9±2.2 
Users’ current use of smartphones and apps 
Users’ interest in mHealth support services for 
diabetes self-care 
Williams 2015, 
William 2015  
USA Cross-sectional 
survey 
Type 1 & 2 588 NR Latinos’ use of mobile phones and glucose tracking 
apps  
Conway 2015 UK Cross-sectional 
survey 
Type 1 & 2 234 46 to 65 Users’ current use of technology in diabetes self-
care  
Users’ preference for mHealth  
Preferred features/functionality of mHealth apps 
Kim 2015 Korea Cross-sectional 
survey 
NR 90 43.5±10.5 Satisfaction 
Diabetes related self-care activities after the use of 
the app (SDSCA)  
Nielsen 2013 Denmark Cross-sectional 
survey 
NR  
42  
 
18 to 60 Users’ perceptions and preferences of smartphone 
apps for remote monitoring and self-management 
of diabetes 
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Table 4. Included qualitative studies 
Study, Year Country Data collection 
method 
Intervention purpose & 
functionality 
Number of 
participants 
Study aims/objectives Analysis method 
Type 1 diabetes 
Frøisland 
2015 
Norway Semi-structured 
interview, field 
notes 
Self-care 
DiaMob app: Diabetes-related 
data collection (BG level, 
medication, diet, physical 
activity), Reminders, 
Education  
12 To evaluate adolescent patients’ experiences with 
two different mobile phone applications for 
diabetes care; adolescents to use their 
experiences to guide product developers by 
advising on further improvements 
 
Focuses on the user experiences related to patient 
empowerment (self-efficacy and self-treatment), 
and prospective nutrition-based mobile systems 
easing daily self-care 
Qualitative description, 
influenced by 
phenomenology and 
hermeneutics 
Cafazzo 2012 
 
Canada  Ethnographic 
interview (User-
centered design 
phase) 
 
Self-care 
Bant app: Diabetes-related 
data collection (BG), 
Insulin management, Social 
support 
6 
adolescents 
(with 1 
parent for 
each) 
Engaging adolescents with T1D, their families, and 
care providers in the design, development, and 
pilot evaluation of a home- and community-based 
diabetes telemanagement system 
Thematic analysis 
Lehocki 2012 Slovak 
Republic 
Usability testing 
(field testing 
and user 
feedback) 
Telemonitoring 
Mobile app for assisted 
diabetes management:  
Diabetes-related data 
collection (BG), 
Communication and remote 
monitoring, 
Insulin management, 
Diet evaluation module, 
Reminders, Foot care, 
Information export 
15 To highlight best practices in development of 
telemedicine services for self-management of 
patients with diabetes;  
to describe key characteristics and functionalities 
of the telemedicine system  
NR 
Pulman 2013 
 
UK Semi-structured 
interview 
Self-care 
 
-- 
9 Explore what young people aged 18–21 with T1D 
feel about their use of mobile and web-based 
technology and whether it might enable them to 
Thematic analysis 
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Study, Year Country Data collection 
method 
Intervention purpose & 
functionality 
Number of 
participants 
Study aims/objectives Analysis method 
engage better with the NHS and their own health 
to enhance health-related QoL. To build a few 
prototype mobile phone applications  
Min 2013 Canada  Interview 
(Requirements 
gathering 
phase) 
 
Self-care 
Bant app: Diabetes-related 
data collection (BG level, 
insulin, diet, physical activity, 
emotion) 
8 To design and develop a mobile application (bant 
for adults) that can help adult T1DM patients 
better manage their disease. UCD process 
emphasising data visualization, social 
communities, and (gamification) 
An affinity diagram 
Miele 2015 Italy Semi-structured 
interview 
generally with 
the parents 
Telemonitoring 
TreC Diabetes app:  Diabetes-
related data collection (BG 
level, medication, diet, 
physical activity), Insulin 
management, Communication 
and remote monitoring, 
Reminders 
15 An observational study to assess user acceptance 
of the system  
The analysis was 
quantitatively driven 
Owen 2015 UK Entry and exit 
interviews 
Self-care 
ConCap: Diabetes-related data 
collection (BG level, insulin/ 
medication) 
12  
To understand how mobile interventions can 
support management of health information;  
to discover user behaviours and needs  
NR 
Skinner 2015 USA Interview Self-care 
 
-- 
6 families 
(11 
participants) 
To understand users' needs to offer appropriate 
design guidelines for a mobile application to help 
daily management and adherence of children with 
T1D 
A critical ethnography 
epistemology approach 
Årsand 2010 Norway Focus groups, 
semi-structured 
interviews, 
tailor-made 
questionnaires 
  Self-care 
 
Few Touch App (FTA): 
Diabetes-related data 
collection (BG, physical 
activity), Diet evaluation and 
management, Education 
12 How tools can be designed for supporting lifestyle 
changes among people with T2D and how these 
were perceived by users 
NR 
Tatara 2013 Norway Questionnaires, Self-care Phase 1: Trial 1: to understand how a design solution Thematic analysis  
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Study, Year Country Data collection 
method 
Intervention purpose & 
functionality 
Number of 
participants 
Study aims/objectives Analysis method 
semi-structured 
interviews, and 
focus groups 
Few Touch App (FTA): 
Diabetes-related data 
collection (BG, physical 
activity), Diet evaluation and 
management, Education 
n=12 
Phase 2: 
n=11 
developed in a UCD was experienced by users 
 
Trial 2: to understand how the Few Touch 
application is used, experienced and perceived by 
target users  
Sarala 2014 India  In-depth 
interview 
(Design phase) 
Clinical practice 
mPower Heart DSS: Clinical 
decision-support  
19 HCPs 
 
33 Patients 
To pilot the smartphone-enabled hypertension 
and diabetes intervention package at primary 
healthcare facilities in India to identify barriers, 
synergies and health system strengthening 
requirements for feasibility and scalability of such 
an intervention 
Thematic analysis - the 
themes were based on the 
objectives of the evaluation 
Pellegrini 
2015 
USA Questionnaire, 
and interview 
Self-care 
NEAT! App: Tracking physical 
activity, Reminders 
9 Feasibility study to examine the acceptability of 
using NEAT! (a technology to interrupt prolonged 
sedentary time among adults with T2D 
Inductive thematic analysis 
Waki 2015 Japan Interview Self-care and telemonitoring 
DialBetics app: Diabetes-
related data collection (BG 
level, medication, diet, 
physical activity, BP, weight), 
Communication and remote 
monitoring, Diet evaluation 
and management, Reminders 
5 To test a more patient-friendly version of 
DialBetics; to determine if usability and 
compliance improved with the new, FoodLog-
assisted meal-input function 
 
NR 
Pludwinski 
2015 
Canada Semi-structured 
interview 
Self-care and telemonitoring 
Health Coach app: Diabetes-
related data collection (BG 
level, diet, medication, 
physical activity, BP, weight, 
mood), Personal goal setting, 
Communication and remote 
monitoring, Reminders 
11 To investigate the experience of individuals with 
T2D using a smartphone and self-monitoring 
software; interviews focused on use of a 
smartphone and the effects on motivation for 
health behaviour change 
Thematic analysis 
Hsu 2015 USA Exit interview Self-care, telemonitoring 
Cloud-based diabetes 
20 To explore users’ experience with the diabetes 
management system and interaction with their 
NR 
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Study, Year Country Data collection 
method 
Intervention purpose & 
functionality 
Number of 
participants 
Study aims/objectives Analysis method 
management app: Insulin 
management, Diabetes-
related data collection (BG 
level, medication), 
Communication and remote 
monitoring  
HCPs 
 Type 1 & 2 diabetes 
Harris 2010 USA 2-phase UCD: 
Design 
evaluation 
(modified think-
aloud), and 
Usability testing 
(interview) 
 
Self-care 
HealthReachMobile:   
Diabetes-related data 
collection (BG), Diet 
evaluation and management, 
Education 
Phase 1: 
n=6 
Phase 2: 
n=8 
To assess the feasibility and acceptability of using 
mobile phones as part of an existing Web-based 
system for collaboration between patients with 
diabetes and a primary care team; usability and 
workflow impediments 
Thematic analysis 
Deshazo 2010 USA 2-phase UCD: 
Focus groups, 
and Usability 
testing 
(questionnaire) 
Self-care 
3 mini-games Hangman 
QuizShow, and 
Countdown: Nutrition 
education 
 
Phase 1: 
n=11 
Phase 2: 
n=10 
To investigate game design (refined by focus 
groups) and usability for three mobile phone 
video games for diabetes education.  
NR 
Nielsen 2013 Denmark Questionnaire, 
and structured 
written 
interview 
Self-care and telemonitoring 
 
-- 
42 patients 
1 HCP 
To study users’ perceptions and preferences of 
apps for diabetes for adherence to remote 
monitoring and self-management; HCPs’ 
perspectives  
 
Survey: MAST (Model for 
Assessment of Telemedicine 
Applications) framework 
model was applied 
Interview: Analysed using 
SCOT (Social Construction of 
Technology) theoretical 
analysis 
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Study, Year Country Data collection 
method 
Intervention purpose & 
functionality 
Number of 
participants 
Study aims/objectives Analysis method 
Scheibe 2015 Germany Guided 
interview 
Self-care 
On Track Diabetes, and 
Glukose Monitor: Diabetes-
related data collection, 
Reminders, Information 
export 
 
32 To investigate factors influencing the acceptance 
of diabetes apps among patients aged 50 or older; 
current usage of mobile devices and apps, 
acceptance-promoting/-inhibiting factors, 
features of a helpful diabetes app, and contact 
persons for technical questions 
Structured content analysis 
by Mayring, which allows for 
an association between the 
deductive and inductive 
creation of categories 
Gestational diabetes 
Garnweidner-
Holme 2015 
Norway 2-phase UCD: 
Interview, and 
Usability testing 
(think-aloud) 
Self-care 
Pregnant+ app: Diabetes-
related data collection (BG), 
Diet evaluation and 
management, Education  
Phase 1: 10 
Phase 2: 11 
To document the process of designing and 
developing the smartphone Pregnant+ app that 
automatically transfers blood sugar levels from 
the glucometer and has information about 
healthy eating and physical activity 
A quotation count report 
was performed to analyze 
the interviews 
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Appendix 9. Summary of findings tables 
Table 1. Outcome Matrix: Narrative synthesis results indicating the number of supporting trials 
for the effects 
Outcome Number of 
trials that 
examined 
the 
outcome 
Significant 
positive 
effect1 
Positive effect2 No effect3 Negative 
effect4 
 
Clinical outcomes 
Glycaemic control 8 RCTs 
9 non-RCTs 
 
Kirwan 2013, 
Charpentier 
2011, Hsu 
2015, 
Waki 2014, 
Wayne 2014, 
Hong 2015 
 Wayne 2015, 
Årsand 2009 
Kim 2014, 
Chomutare 
2013, Mackillop 
2014, Neubauer 
2015 
Drion 2015, 
Holmen 2014, 
Istepanian 
2014, 
Cafazzo 2012, 
Frøisland 2012 
 
Percentage of 
subjects reaching 
the HbA1c target  
2 RCTs 
1 non-RCT 
 Neubauer 2015 Charpentier 
2011, 
Hsu 2015 
 
Frequency of 
hypoglycaemia 
episodes 
2 RCTs   Charpentier 
2011, Hsu 
2015 
 
BP 2 RCTs 
1 non-RCT 
Logan 2012  Waki 2014, 
Kim 2014 
 
Cholesterol levels 
(LDL-C, HDL-C, TG) 
2 RCTs 
1 non-RCT 
  Waki 2014, 
Istepanian 
2014, Kim 
2014 
 
Body composition 
(weight, BMI, 
waist 
circumference) 
4 RCTs 
3 non-RCTs 
Wayne 2015, 
Wayne 2014, 
Hong 2015 
Waki 2014 Holmen 2014, 
Hsu 2015, Kim 
2014 
 
Change in 
medication 
4 RCTs 
1 non-RCT 
Hong 2015  Charpentier 
2011, Waki 
2014, Logan 
2012, Hsu 
2015 
 
Psychosocial outcomes 
QoL 5 RCTs 
1 non-RCT 
 
 Wayne 2015 Kirwan 2013, 
Charpentier 
2011, Drion 
2015, Holmen 
2014, Cafazzo 
2012 
 
Depression and 
anxiety 
3 RCTs  Wayne 2015 Holmen 2014 Logan 2012 
Diabetes-related 
distress 
1 RCT   Drion 2015  
Diabetes-related 
self-efficacy  
1 RCT 
3 non-RCTs 
 Cafazzo 2012 Kirwan 2013, 
Hunt 2014, 
Chomutare 
2013 
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Outcome Number of 
trials that 
examined 
the 
outcome 
Significant 
positive 
effect1 
Positive effect2 No effect3 Negative 
effect4 
 
Positive and 
negative affect 
1 RCT Wayne 2015    
Satisfaction with 
Life 
1 RCT  Wayne 2015   
Satisfaction with 
diabetes 
treatment 
1 RCT Hsu 2015  
Hirst 2015 
  
Comfort with BP 
self-monitoring 
1 RCT    Logan 2012 
Behavioural outcomes 
Diabetes self-
management 
behaviours 
 3 RCTs 
3 non-RCTs 
Holmen 2014, 
Kim 2015 
Cafazzo 2012 Kirwan 2013, 
Waki 2014, 
Hunt 2014  
 
Frequency of self-
monitoring 
2 RCTs 
1 non-RCT 
Cafazzo 2012  Charpentier 
2011, Drion 
2015 
 
Logging behaviour 2 non-RCTs  Tiefengrabner 
2014 
Hunt 2014  
Lifestyle change 
(physical activity, 
dietary habits) 
 
1 RCT 
 
  Holmen 2014  
Performance of 
physical activity 
2 non-RCTs Pellegrin 2015 Årsand 2010   
Knowledge outcome 
Knowledge about 
diabetes and 
diabetes 
management 
 
1 RCT 
1 non-RCT 
 
Istepanian 
2014 
 Frøisland 2012  
1 Significant between-groups improvement or significant pre/post improvement; at least in one measure or subscale 
2 Non-significant improvement or pre/post improvement but not significant; at least in one measure or subscale 
3 No difference between-groups or no change in single group  
4 Any negative impact between-groups or pre/post; either significant or not 
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Table 2. Outcome Matrix: Narrative synthesis results indicating the number of supporting trials 
for each outcome 
Patient-reported outcomes 
Satisfaction with 
app 
1 RCT 
4 non-RCTs 
Charpentier 2011, Cafazzo 2012, Kim 2014, Kim 2015, Hirst 2015 
Usability of app 2 RCTs 
8 non-RCTs 
Drion 2015, Waki 2014, Frøisland 2012, Hong 2015, Chomutare 
2013, Alanzi 2014, Rao 2010, Min 2013, Årsand 2009, Tatara 2013 
Current use of 
apps, 
preferences, 
attitudes, or 
intention to use 
apps 
6 non-RCTs Dobson 2015, Williams 2015, Humble 2015, Conway 2015, Rao 
2010, Nielsen 2013 
HCP-related outcomes 
Usability of app 1 non-RCT Neubauer 2015/ 20141 
Compliance with 
given 
recommendation 
2 non-RCTs  
Sarala 2014, Neubauer 2015/ 20141 
User errors and 
workflow 
anomalies 
1 non-RCT Spat 2013 
Miscellaneous outcomes 
Number of GP 
visits 
1 RCT Logan 20122 
Time spent on 
consultation visit 
2 RCTs Charpentier 2011, Hsu 2015 
Utilisation and 
compliance with 
app use 
4 RCTs 
8 non-RCTs 
Kirwan 2013, Holmen 2014, Wayne 2015, Franc 2014, Chomutare 
2013, Miele 2015, Tatara 2013, Pellegrin 2015, Mackillop 2014, 
Cafazzo 2012, Waki 2014, Waki 2015 
1 Two-parts study; first part was published as a conference abstract, and the second was published as journal article 
2 No significant difference between-groups 
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Table 3. Mobile apps interventions and impact on HbA1c from non-RCTs only 
Study Study design Number of 
subjects 
Mean change, 
mean±SD 
P value 
Type 1 diabetes 
Cafazzo 2012 Pre-post design 
with no control 
20 - 0.4±1.27 0.11 
Frøisland 2012 Pre-post design 
with no control 
12 - 0.2±1.27 0.38 
Type 2 diabetes 
Wayne 2014 Pre-post design 
with no control 
21 - 0.28±0.57 0.05 
Kim 2014 Pre-post design 
with control 
Intervention: 38 
Control: 35 
- 0.2  -- 
Chomutare 2013 Pre-post design 
with no control 
7 - 0.18±0.97 -- 
Årsand 2010 Post-only design 
with no control 
12 - 0.1 -- 
Hong 2015 Case report 1 - 1.8 -- 
 
Table 4. Mobile apps interventions and impact on QoL 
Study Study design Number of 
subjects 
Impact on QoL Measurement tool 
Type 1 diabetes 
Kirwan 2013 RCT Intervention: 
36 
Control: 36 
No difference   DQOL 
Charpentier 2011 3-armed, 
multicentre 
RCT 
Intervention: 
61 
Control: 60 
No difference DQOL and DHP 
Drion 2015 RCT Intervention: 
31 
Control: 32 
No difference SF-36 
Cafazzo 2012 Pre-post design 
with no control 
20 No difference DQOLY 
Type 2 diabetes 
Holmen 2014 3-armed RCT Intervention: 
50 
Control: 51 
No difference SF-36 
Wayne 2015 RCT Intervention: 
48 
Control: 49 
Positive1 SF-12 
1 Within-groups significant improvement in one subscale 
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Table 5. Mobile apps interventions and impact on depression and anxiety 
Study Study 
design 
Number of 
subjects 
Impact on 
depression 
Measurement tool 
Type 2 diabetes  
Holmen 2014 3-armed 
RCT 
Intervention: 
50 
Control: 51 
No difference CES-D 
Wayne 2015 RCT Intervention: 
48 
Control: 49 
Positive1 HADS 
Type 1 & 2 diabetes 
Logan 2012 RCT Intervention: 
55 
Control: 55 
Negative2 ASI, HADS 
1 Within-groups significant improvement in one subscale 
2 Significant negative result in one subscale only 
 
Table 6. Mobile apps interventions and impact on diabetes-related self-efficacy 
Study Study design Number of 
subjects 
Impact on self-
efficacy 
Measurement tool 
Type 1 diabetes 
Kirwan 2013 RCT Intervention: 
36 
Control: 36 
No difference DES-SF  
Cafazzo 2012 Pre-post design 
with no control 
20 Positive1 Diabetes Family 
Responsibility Questionnaire 
Type 2 diabetes 
Hunt 2014 Crossover, 
repeated 
measure design 
Group 1: 6 
Group 2: 8 
No difference DMSES 
Chomutare 
2013 
Pre-post design 
with no control 
7 No difference HeiQ, DES-SF 
1 Slight improvement but not significant 
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Table 7. Mobile apps interventions and impact on self-management activities 
Study Study design Number of subjects Impact on self-management Measurement tool 
Type 1 diabetes 
Kirwan 2013 RCT Intervention: 36 
Control: 36 
No difference SDSCA  
Cafazzo 2012 Pre-post design with no 
control 
20 Positive2 14-item Self-Care Inventory 
Type 2 diabetes 
Holmen 2014 3-armed RCT Intervention: 50 
Control: 51 
Significant positive1 HeiQ 
Waki 2014 RCT Intervention: 27 
Control: 27 
No difference Japanese version of SDSCA 
Hunt 2014 Crossover, repeated-
measure design 
Group 1: 6 
Group 2: 8 
No difference SDSCA 
Type 1 & 2 diabetes 
Kim 2015 Cross-sectional survey 90 Significant positive1 SDSCA 
1 Significant improvement at least for one item 
2 Slight improvement but not significant in one item 
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Table 8. Mobile apps interventions usability results 
Study Study design Duration Usability score, mean±SD Measurement tool 
Type 1 diabetes 
Drion 2015 RCT 3 months 72±20 SUS*  
Frøisland 
2012 
Pre-post 
design with 
no control 
3 months 73.0±22.1 SUS* 
Min 2013 Post-only 
design with 
no control 
-- 80 or higher SUS* 
Type 2 diabetes 
Waki 2014 RCT 3 months Reported as the frequency of 
participants in agreement 
with given statements 
Waki 2014 
Hong 2015 Case report 6 months 92.5 SUS* 
Chomutare 
2013 
Pre-post 
design with 
no control 
3 months 84.6±13.2 SUS* 
Alanazi 2014 Post-only 
design with 
no control 
-- Reported as mean ratings of 
each individual item in all 
five parts 
Questionnaire for 
User Interaction and 
Satisfaction (QUIS) 
Årsand 2009 Post-only 
design with 
no control 
6 months 84.0±13.7 SUS* 
Tatara 2013 Post-only 
design with 
no control 
Halfway trial 1: 
6 months 
End of trial 1: 1 
year 
End of trial 2: 5 
months 
84.0±13.55 
86.0±10.08 
74.1±16.95 
SUS* 
Type 1 & 2 diabetes 
Rao 2010 Post-only 
design with 
no control 
-- Reported as time taken per 
task, number of requests for 
help, and composite ease of 
use score across eight 
parameters  
Custom-built 
questionnaire 
* SUS scores are ranged from 0 to 100; a score of 70 or greater considered acceptable, while a score less than 70 is 
below average 
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Appendix 10. Summary of methodological quality of included qualitative studies using CASP assessment tool 
Study 
Aims and 
methods 
Research design Sampling Data Collection Reflexivity Ethical issues Data Analysis 
Discussion of 
findings 
Value 
Frøisland 
2012, 
Frøisland 
2015 
 
Aims stated 
and 
qualitative 
methods 
appropriate  
Researchers 
justified their 
choice of mixed-
method design 
and the use of 
triangulation. 
Data collection 
method not 
explicitly justified 
Convenience 
sample  
No description 
of recruitment 
or selection of  
Semi-structured 
interviews.  No 
justification of data 
collection method. A 
topic guide was used. 
Interviews audio 
recorded and 
transcribed.  Field 
notes taken during 
interviews as an 
additional data source. 
Data saturation not 
discussed 
 
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis were not 
discussed  
 
No details on 
how study 
explained to 
participants. 
Confidentiality 
not discussed.  
Ethical 
approval was 
obtained from 
regional 
committee. 
All participants 
gave written 
consent. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
study 
Inductive 
analytic 
approach 
based on 
qualitative 
description, 
influenced by 
phenomenolog
y and 
hermeneutics. 
Deductive 
approach 
based on 
empowerment 
theory. Notes 
from 
interviews 
were used in 
identifying 
themes. 
Two 
researchers 
coded 
interview 
transcripts 
independently; 
discrepancies 
Findings 
explicit and 
clearly 
discussed in 
relation to 
other 
published 
research and 
research 
question. 
Discussion of 
credibility 
and validity 
of the 
research 
through 
researcher 
triangulation 
 
Briefly considered 
the contribution 
to existing 
knowledge and 
practice with 
some attempt to 
describe the 
findings in relation 
to relevant 
research-based 
literature. 
Provided 
recommendations 
for practice and 
education. 
Acknowledged 
limitations in 
transferability to 
other populations, 
and suggested 
areas for future 
research  
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resolved 
through 
consensus. 
Sufficient data 
presented to 
support  
findings but 
did not provide 
contradictory 
data 
 
 
Cafazzo 
2012 
 
 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researchers 
justified their 
choice of mixed-
method user-
centered design 
Data collection 
method not 
explicitly justified 
 
 
 
 
 
No description 
of how 
recruitment was 
undertaken or 
about selection 
of those who 
volunteered. 
No discussion 
about the 
reasons why 
some chose not 
to participate 
 
Ethnographic semi-
structured interview; 
each participant and 
parent interviewed 
individually, then 
together. Each 
interview conducted by 
research coordinator 
using an interview 
guide based on study 
objectives and a priori 
knowledge of diabetes 
management, 
behaviour change 
theory, and health care 
software design. 
Sessions recorded and 
transcribed verbatim. 
Data saturation 
discussed 
 
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis were not 
discussed  
 
Ethical 
approval 
sought, and 
informed 
consent 
obtained. No 
details on how 
study 
explained to 
participants. 
Confidentiality 
not discussed. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
study 
 
Data analysed 
thematically; 
general 
inductive 
method used. 
Transcripts 
read 
repeatedly and 
text segments 
coded for 
potential 
themes. As the 
coding 
framework 
developed, 
transcripts 
were 
reanalysed in 
light of new 
themes. One 
reviewer 
Findings 
were explicit 
and clearly 
discussed in 
relation to 
research 
question. No 
discussion of 
the 
credibility of 
findings 
Considered the 
contribution of 
the study to 
existing 
knowledge with 
some attempt to 
describe the 
findings in relation 
to relevant 
research-based 
literature. 
Acknowledged 
limitations in 
transferability to 
other populations, 
and suggested 
areas for future 
research  
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analysed the 
coding, which 
was validated 
through 
member 
checking of 
adolescent 
health and 
endocrinology 
specialists. 
No data 
presented to 
support 
findings 
 
Miele 2015 
 
 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Research design 
and data 
collection 
method was not 
justified 
 
15 young 
patients aged 4 -
12 years were 
recruited. No 
further details 
about the 
recruitment and 
selection 
process  
Semi-structured 
interviews were 
conducted generally 
with the parents.  No 
details about how and 
where the interviews 
were conducted. Data 
saturation was not 
discussed 
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis was not 
discussed  
 
Ethical 
approval and 
informed 
written 
consent not 
reported. No 
details on how 
the study was 
explained to 
participants. 
Confidentiality 
not discussed. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
Exact method 
used for 
analysis not 
specified.  
The analysis 
was 
quantitatively 
driven. No data 
presented to 
support 
findings. Did 
not consider 
researcher bias 
on analysis or 
selection of 
data 
 
Only a 
summary of 
findings was 
presented. 
No 
discussion of 
the 
credibility of 
findings 
Briefly considered 
the contribution 
of the study to 
existing 
knowledge. Did 
not make 
suggestions for 
future research.  
Transferability not 
discussed 
   
285 
study 
Owen 2015 
Aims clearly 
stated and 
research 
importance 
and 
relevance 
articulated. 
Qualitative 
methods 
appropriate  
Research design 
and data 
collection 
method was not 
explicitly justified 
 
Only 
experienced 
users of mobile 
phones were 
recruited.  
Choice of 
purposive 
sampling 
method was 
justified to avoid 
learning effects 
and general 
unfamiliarity 
with devices. 
12 participants 
with T1D were 
recruited 
through an 
email call to 
local Diabetes 
Support groups 
and sessions 
were organized 
either through 
similar 
correspondence, 
or through 
telephone 
conversations. 
Participants 
Entry and exit 
interviews conducted 
with all participants. 
The entry session 
elicited each 
individual’s existing 
attitudes and 
management practices 
of diabetes. The exit 
session was used to 
query participants 
regarding their usage 
of the app during the 
study period. No 
justification of why this 
data collection 
method. No details 
about how and where 
the interviews were 
conducted. Interviews 
audio recorded and 
field notes were taken 
during the interviews. 
Exact quotations 
transcribed from the 
relevant audio 
recordings. Data 
saturation not 
discussed 
 
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis were not 
discussed  
 
Brief 
discussion on 
confidentiality 
and how study 
explained to 
participants.  
Ethical 
approval and 
informed 
written 
consent were 
not reported. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
study 
Exact method 
used for the 
analysis is not 
specified.  
Notes from 
interviews 
taken into 
account in 
analysis. 
Sufficient data 
presented to 
support 
findings, but 
did not provide 
a description 
of how data 
presented was 
selected. 
No indication 
of involvement 
of multiple 
researchers in 
analysis.  
Did not 
consider 
researcher bias 
on analysis or 
selection of 
data 
 
Findings 
explicit and 
clearly 
discussed in 
relation to 
other 
research and 
original 
research 
question. No 
discussion of 
the 
credibility of 
findings 
except the 
use of logged 
information 
into the app  
during the 
study to 
verify 
participant’s 
reports 
 
 
Considered the 
contribution of 
the study to 
existing 
knowledge with 
some attempt to 
describe the 
findings in relation 
to relevant 
research-based 
literature. 
Provided a 
number of key 
design 
considerations. 
Did not make 
suggestions for 
future research.  
Transferability not 
discussed 
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received sum of 
£114 as an  
incentive for 
completing the 
study. No 
discussion about 
whether some 
people chose 
not to 
participate and 
their reasons 
Lehocki 
2012 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Research design 
and data 
collection 
method was not 
justified 
 
15 patients with 
T1D age 27-38 
were recruited. 
Physicians 
selected 
motivated 
patients to 
achieve 
maximum 
adherence. The 
goal was to 
obtain the 
quality feedback 
on usability and 
acceptability of 
the system. 14 
patients 
completed the 
study, one 
cancelled 
Field testing and user 
feedback, evaluated in 
free comments and 
discussions with 
patients either by 
authors or feedback 
received through 
physicians. Data 
collection method not 
explicitly described.  
Data saturation not 
discussed 
 
Authors are 
aware that 
patient selection 
might introduce 
potential 
selection bias in 
evaluation.  
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis not 
discussed  
 
No details on 
how the study 
was explained 
to participants. 
Confidentiality 
was not 
discussed.  
Ethical 
approval and 
informed 
written 
consent not 
reported. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
study 
No details 
about analysis 
methodology 
or process.  
No indication 
of involvement 
of multiple 
researchers in 
analysis. No 
data presented 
to support the 
findings. 
Contradictory 
data not 
presented. No 
examination of 
researcher’s 
role, potential 
bias and 
influence 
The findings 
were not 
explicit and 
poorly 
presented.  
Did not 
discuss 
credibility of 
findings 
 
Did not consider 
the contribution 
of the study to 
existing 
knowledge and 
practice. Limited 
attempt to 
describe the 
findings in relation 
to relevant 
research-based 
literature. 
Provided a 
number of design 
charecteristics. 
Identifies the need 
for research. 
No explicit 
discussion of 
transferability to 
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attendance due 
to purchase of 
new mobile 
phone running 
on different OS 
during analysis 
and in 
presentation of 
data 
other populations 
 
Pulman 
2013, 
Pulman 
2012 
 
Aims clearly 
stated and 
research 
importance 
and 
relevance 
articulated. 
Qualitative 
methods 
appropriate  
Use of qualitative 
design justified 
to allow for the 
development of 
a breadth and 
depth of 
understanding of 
the studied 
experience. Data 
collection 
method was 
explicitly justified 
 
Convenience 
sample of young 
people with T1D 
aged between 
18 and 21 years. 
Recruitment 
was conducted 
at a district 
hospital located 
in south west 
England (SWDC) 
and a local 
university, but 
unclear how 
many were 
approached and 
how many 
declined. 9 
participants 
were 
interviewed. 
Lacking details 
about how 
participants 
invited to 
participate 
4 semi-structured, in-
depth interviews and 5 
unstructured 
interviews were 
conducted. Choice of 
data collection 
methods explicitly 
justified. 
A semistructured 
interview guide was 
used.  Data saturation 
not discussed 
 
 
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis were not 
discussed  
 
No details on 
how study 
explained to 
participants. 
Confidentiality 
not discussed.  
Ethical 
approval and 
informed 
written 
consent not 
reported. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
study 
No details 
about analysis 
methodology 
or process.  
Interviews 
transcribed 
and loaded 
onto NVivo for 
theme 
identification.  
Does not state 
who conducted 
the analysis or 
if multiple 
authors 
involved.  
Sufficient data 
presented to 
support  
findings but 
did not provide 
contradictory 
data 
No 
discussion 
around 
identified 
themes. 
Many of the 
findings 
presented in 
terms of the 
proposed 
ideas, and 
clearly 
discussed in 
relation to 
other 
research and 
original 
research 
question. 
Some 
discussion of 
the 
credibility 
and validity 
of the 
research  
Considered the 
contribution of 
the study to 
existing 
knowledge with 
some attempt to 
describe the 
findings in relation 
to relevant 
research-based 
literature. 
Provided a 
number of 
suggestions for 
mobile apps 
design and 
development. 
Identified further 
research areas. No 
explicit discussion 
of transferability 
to other 
populations 
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Skinner 
2015 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researcher 
justified the 
choice of 
qualitative 
design as the 
interpersonal 
aspect of 
previous 
research is 
notably lacking. 
Data collection 
method was 
explicitly justified 
 
6 families living 
with T1D 
recruited using a 
personal letter 
to the director 
of a camp aimed 
at children living 
with T1D and 
their families, 
plus personal 
contacts made 
by the 
researcher at a 
diabetes clinic. 
A randomised 
sampling 
method was 
used to select 
the interested 
recruits and the 
order in which 
participants 
contacted, since 
it was not 
feasible to 
interview all 
interested 
volunteers. Did 
not report the 
number of 
volunteers, but 
General interview 
guide approach was 
conducted whether in 
person or via 
video/phone call. 
Interviews were 
recorded and 
transcribed. Data 
collection method was 
explicitly described.  
Data saturation was 
discussed 
 
Potential 
influence and bias 
of the 
interviewer’s 
status as having a 
brother with T1D 
has been critically 
examined  
 
 
Sufficient 
details on how 
the study was 
explained to 
participants. 
Ethical 
approval 
sought, 
informed 
consent 
obtained. 
Confidentiality 
not discussed. 
Lacking details 
on how 
researchers 
handled issues 
raised by the 
study 
 
Qualitative 
analysis 
following a 
critical 
ethnography 
epistemology 
approach 
within the 
cognitive 
ethnography 
frame. Each 
interview had 
been read 
enough times, 
and all ideas 
had been 
extracted and 
highlighted by 
color coding. 
Coded 
categories that 
emerged 
clustered 
together to 
form themes. 
Analysis 
method 
justified. No 
indication of 
involvement of 
multiple 
Findings 
were explicit 
and clearly 
discussed in 
relation to 
the original 
research 
question. No 
discussion of 
the 
credibility of 
findings  
Briefly considered 
the contribution 
of the study to 
existing 
knowledge and 
practice. Provided 
a number of 
design 
requirements for 
practice. 
Acknowledged the 
limitations in 
transferability to 
other populations, 
and suggested 
areas for future 
research  
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reported some 
reasons why 
some were 
removed from 
the list of 
potential 
participants 
researchers in 
analysis. 
Sufficient data 
presented to 
support  
findings but 
did not provide 
contradictory 
data 
Min 2013 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researcher 
justified the 
choice of 
qualitative 
design as to 
understand 
adults with T1D 
culture and to 
generate a 
theory about 
what their needs 
would be for a 
mobile self-
management 
support app. 
Data collection 
methods 
explicitly justified 
 
8 participants 
with T1D were 
recruited for the 
interview from 
Toronto General 
Hospital 
Diabetes Clinic.  
No description 
of how 
recruitment was 
undertaken for 
the interview or 
selection of 
those who 
volunteered. 6 
participants 
were recruited 
for usability 
testing initially 
by an RN in their 
circle of care 
either in person 
Semi-structured 
interviews at the 
Centre for Global 
eHealth Innovation; 
interview guide used. 
Interviews recorded 
and transcribed. 
Usability testing at The 
Centre for Global 
eHealth Innovation in 
the usability 
laboratories. 
Participants asked to 
complete a total of 
eight scenarios by 
interacting with a 
paper prototype of the 
mobile app. Data 
collection methods 
explicitly described.  
Data saturation not 
discussed 
Considered 
potential bias in 
data collection 
and analysis 
Ethical 
approval 
sought, 
informed 
consent 
obtained for 
both study 
phases. 
Confidentiality 
not discussed. 
Lacking details 
on how 
research 
explained to 
participants, 
but considered 
how 
researchers 
dealt with 
some issues 
raised by the 
study  
An affinity 
diagram was 
used to analyse 
data collected 
from the 
interviews.  
Members of 
the Interactive 
Media Lab 
were recruited 
to group 
related 
statement 
cards together 
to avoid 
potential bias. 
After data 
organised into 
category and 
sub-category, 
the groupings 
were 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question. No 
discussion of 
credibility of 
findings 
except the 
use of more 
than one 
analyst for 
the interview 
Considered the 
contribution of 
the study to 
existing 
knowledge and 
understanding.  
Provided a 
number of design 
principles that 
must be included 
in the app. 
Discussed the 
transferability of 
the findings and 
highlighted the 
limitations of the 
study. Further 
research areas 
suggested 
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or via a 
recruitment 
letter sent 
through email, 
but no details 
on how 
participants 
selected. No 
discussion about 
reasons why 
some chose not 
to participate 
 
 
 
 
 
translated into 
user 
requirements. 
In-depth 
description of 
the analysis 
process for 
interview and 
usability 
testing, but no 
data presented 
to support 
findings. 
Contradictory 
data was taken 
into account 
 
Pludwinski 
2015 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researcher 
justified choice 
of qualitative 
design to provide 
a detailed 
perspective on 
what participants 
experienced 
during 
interventions. 
Data collection 
method not 
explicitly justified  
After 
completing the 
trial, individuals 
with T2D at the 
Black Creek 
Community 
Health Centre in 
Toronto were 
invited by phone 
or in person to 
participate in 
interviews. 
Efforts were 
made to reach 
26 intervention 
Face-to-face semi-
structured interviews 
conducted by trained 
interviewer, and 
reviewed by two 
additional members of 
the research team to 
ensure standardized 
technique; interview 
guide used. 
Interviews recorded 
and transcribed 
verbatim. Data 
saturation discussed 
 
Potential bias in 
formulation of 
research 
questions, data 
collection and 
analysis not 
discussed  
 
No details on 
how study 
explained to 
participants. 
Confidentiality 
discussed.  
Ethical 
approval 
sought, 
informed 
written 
consent 
obtained. 
 
Data analysed 
using thematic 
analytic 
approach. 
Coding and 
analyses using 
NVivo. Analysis 
method 
justified. 
Sufficient data 
presented to 
support 
findings. 
Contradictory 
data not taken 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question. No 
discussion of 
the 
credibility of 
findings 
except the 
use of more 
than one 
Briefly considered 
contribution of 
study to existing 
knowledge. 
No explicit 
discussion of 
transferability to 
other populations. 
Highlighted some 
limitations of the 
study, and 
suggested few 
areas for future 
research  
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participants; 11 
contacted. All 
participants who 
were reached 
were invited and 
agreed to 
participate  
into account   
 
analyst for 
the interview 
 
Årsand 
2009, 
Årsand 
2010 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researcher 
justified choice 
of qualitative 
design to provide 
rich insights into 
design concepts. 
Data collection 
methods 
explicitly justified 
15 people with 
T2D recruited 
through letters 
to all members 
of the 
Norwegian 
Diabetes 
Association 
aged 40–70 
years. A few of 
these were also 
recruited at a 
members’ 
meeting. No 
details on how 
participants 
selected. No 
discussion about 
reasons why 
some chose not 
to participate 
 
 
 
Focus group meetings 
and semi-structured 
interviews. 
The focus groups were 
arranged in the NST’s 
assembly rooms; topic 
guide used. Focus 
groups/ interviews 
audio- and/or video-
taped and transcribed. 
Field notes taken and 
used as additional data 
source. During most of 
the meetings, three 
project members have 
participated, where 
two have mainly been 
responsible for asking 
questions, initiating 
discussions and 
managing the themes 
of the meeting, while 
the third participant 
has taken notes during 
Potential 
influence and bias 
of the 
researchers’ 
status as two of 
the members of 
the project group 
have T1D 
themselves. Using 
interviewers with 
in-depth 
knowledge of the 
subject may bias 
the questions and 
thus the results. 
Potential 
selection bias was 
also considered. 
The self-selected 
cohorts were 
heavily involved 
in the design of 
the tested app. 
Additionally, 
Ethical 
approval 
sought, 
informed 
written 
consent 
obtained. 
Confidentiality 
not discussed. 
Lacking details 
on how 
research 
explained to 
participants 
 
No details 
about analysis 
methodology 
or process. The 
analysis of user 
data done by 
one person 
only. The 
dataset and 
aggregated 
result files 
were made 
available 
internally and 
colleagues 
were 
encouraged to 
comment on 
them, and they 
did. Sufficient 
data presented 
to support 
findings. 
Contradictory 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question.  
There was a 
discussion of 
the 
credibility 
and validity 
of the 
research 
through use 
of a set of 
methods to 
achieve 
triangulation. 
Also, because 
time did not 
allow a full 
process 
Considered 
contribution of 
study to existing 
knowledge and 
practice.   
Discussed 
transferability of 
findings and 
highlighted 
limitations of the 
study. Further 
research areas 
suggested 
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 the discussions.  Data 
saturation not 
discussed 
 
recruitment of 
the informants 
was addressed to 
members of the 
Norwegian 
Diabetes 
Association 
resulting in a 
more motivated 
cohort than the 
general 
population with 
T2D 
data not taken 
into account   
 
 
 
where two or 
more 
investigators 
analysed the 
data and 
transcripts, 
sharing both 
raw and 
aggregated 
results 
considered 
as a quality 
assurance 
mechanism 
to prevent 
wrong 
interpretatio
n of the data 
Tatara 
2013, 
Tatara 
2013, 
Tatara 
2013 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researchers 
justified their 
choice of mixed-
methods design 
and the use of 
triangulation.   
Data collection 
methods were 
explicitly justified 
12 participants 
with T2D 
recruited in Trial 
1, but no details 
on how 
participants 
were recruited 
and selected.  
11 recruited in 
Trial 2 from the 
Motivation 
Group (a 
patient-oriented 
Questionnaires, semi-
structured interviews, 
and focus groups; topic 
guide used. All 
interviews and focus 
groups audio recorded. 
Data saturation not 
discussed 
 
Potential 
selection bias 
discussed; 
participants 
recruited from 
the Motivation 
Group considered 
highly motivated 
for self-
management 
 
Ethical 
approval 
sought, 
informed 
written 
consent was 
obtained. 
Confidentiality 
discussed. 
Lacking details 
on how 
research 
explained to 
Data analysed 
using thematic 
analysis 
following the 
framework 
suggested by 
Braun and 
Clarke in which 
codes and 
themes 
identified at 
semantic level 
using a 
Findings 
explicit and 
clearly 
discussed in 
relation to 
other 
published 
research and 
original 
research 
question. 
Discussion of 
credibility 
Considered 
contribution of 
study to existing 
knowledge and 
practice with 
some attempt to 
describe findings 
in relation to 
relevant research-
based literature. 
Acknowledged 
limitations in 
transferability to 
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learning course), 
but no details 
on how 
selected.  
Limited 
discussion about 
reasons why 
some chose not 
to participate; 
“due to both 
small population 
in towns of 
North Norway 
and 
inconvenience 
in 
transportation 
due to 
geography.” 
 
  
 
participants theoretical 
approach. 
Findings from 
thematic 
analysis 
investigated by 
collating 
results of 
questionnaires 
and analyses of 
usage data. 
Results used to 
explain 
mechanisms of 
participants’ 
engagement 
with the app 
over time and 
factors 
associated with 
usability. The 
researcher 
examined their 
own role 
during analysis 
process. 
Sufficient data 
presented to 
support the 
findings. 
Contradictory 
and validity 
of the 
research 
through 
researcher 
triangulation 
and having 
more than 
one analyst 
 
other populations, 
and suggested 
areas for future 
research  
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data not taken 
into account   
Sarala 2014 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researchers 
justified their 
choice of mixed-
methods design 
for evaluation of 
intervention 
design and 
implementation. 
Data collection 
methods 
explicitly justified 
33 patients with 
T2D recruited 
from 8 
outpatient 
departments in 
India for the 
interview.  
Posters and 
badges were 
used to inform 
patients about 
the project, but 
no details on 
how the 
participants 
were selected.  
18 healthcare 
professionals 
recruited during 
the design 
phase using 
purposive 
sampling to 
ensure that 
perspectives of 
individuals with 
In-depth interviews 
conducted in Hindi or 
English, in settings 
ensuring sufficient 
privacy and 
confidentiality, and 
digitally recorded. 
Topic guide was used. 
Interviews with 
patients conducted by 
a research staff 
member, trained using 
the interview guide and 
mock interviews.  
Interviews with 
healthcare team were 
conducted by Project 
Coordinator. Data 
saturation discussed 
Potential bias 
during data 
collection and 
analysis 
discussed. The 
principal 
investigator 
conducted most 
of the interviews, 
which could have 
brought bias in 
the interpretation 
of the results. 
However, close 
monitoring by the 
PhD supervisors 
helped minimise 
the bias in the 
interpretation 
No explicit 
discussion 
about ethical 
approval. 
Informed 
written 
consent 
obtained. 
Confidentiality 
discussed. 
Briefly 
considered 
how study was 
explained to 
participants 
Thematic 
content 
analysis 
approach used 
to explore the 
data. Themes 
for the 
interviews 
based on the 
objectives of 
evaluation. 
Interview 
notes and 
recordings 
reviewed on 
the same day, 
and themes 
and questions 
further 
developed 
using an 
inductive 
approach to 
condense raw 
information 
into a 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question. 
There was a 
discussion of 
the 
credibility 
and validity 
of the 
research 
through 
having more 
than one 
analyst 
 
Considered the 
contribution of 
study to existing 
knowledge and 
implications for 
practice with 
some attempt to 
describe findings 
in relation to 
relevant research-
based literature. 
Acknowledged 
limitations in 
transferability to 
other populations, 
and suggested 
areas for future 
research  
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varied roles in 
the healthcare 
organisation 
were assessed. 
On the pilot 
phase, the 
healthcare team 
who were 
assigned to 
implementing 
the intervention 
were all 
included. No 
discussion about 
reasons why 
some chose not 
to participate 
 
summary and 
to establish 
clear links 
between the 
research 
objectives and 
findings. 
Researchers 
have examined 
their own role 
during analysis 
process. 
Sufficient data 
presented to 
support the 
findings. 
Contradictory 
data not taken 
into account   
Pellegrini 
2015 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Research design 
and data 
collection 
methods were 
not justified 
 
9 participants 
with T2D 
recruited via 
flyers posted in 
the Chicago land 
community and 
online postings 
(e.g., Craigslist). 
1 did not 
complete the 
one-month 
intervention and 
Questionnaire and a 
brief 14-question 
interview with a staff 
member were 
conducted.  Data 
collection methods not 
explicitly described.  
Data saturation not 
discussed 
Potential bias in 
the formulation 
of research 
questions, data 
collection and 
analysis not 
discussed  
 
Ethical 
approval 
sought, 
informed 
written 
consent 
obtained. 
Confidentiality 
not discussed.  
Eligible 
participants 
attended a 
An inductive 
thematic 
analysis used 
to determine 
the pattern of 
responses to 
the interview 
on evaluation 
of app. 
Categories and 
themes 
derived 
Findings 
explicit and 
clearly 
discussed in 
relation to 
the original 
research 
question, but 
limited 
discussion 
around 
identified 
Considered 
contribution of 
study to existing 
knowledge and 
implications for 
practice with 
some attempt to 
describe findings 
in relation to 
relevant research-
based literature. 
Acknowledged 
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was unable to 
contact. 
Reported 
numbers who 
were screened 
and excluded, 
and reasons why 
 
 
 
baseline  
orientation 
session, in 
which they 
were given 
complete 
details about 
the study and 
learned about 
the technology 
used  
according to 
different 
questions from 
questionnaire 
and interview. 
The frequency 
of responses 
obtained from 
the 
questionnaire 
were 
examined. 
Limited data 
presented to 
support the 
findings. 
Contradictory 
data not taken 
into account   
themes.  No 
discussion of 
credibility of 
findings  
 
 
limitations in 
transferability to 
other populations, 
and suggested 
areas for future 
research  
 
Waki 2015 
 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Research design 
and data 
collection 
methods not 
justified 
 
5 participants 
diagnosed with 
T2D recruited; 
all had 
participated in 
previous 3-
month trial. No 
details on how 
participants 
recruited and 
selected. No 
discussion about 
Face-to face interview. 
Data collection method 
not described or 
justified.  Data 
saturation not 
discussed 
Potential bias in 
formulation of 
research 
questions, data 
collection and 
analysis not 
discussed  
 
Ethical 
approval 
sought, 
informed 
written 
consent 
obtained. 
Confidentiality 
not discussed. 
Lacking details 
on how 
research was 
No details 
about analysis 
methodology 
or process. No 
examination of 
researcher’s 
role, potential 
bias and 
influence 
during analysis 
and 
presentation of 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question. No 
discussion of 
credibility of 
findings 
Considered the 
contribution of 
study to existing 
knowledge. No 
explicit discussion 
of transferability 
to other 
populations. Did 
not make 
suggestions for 
future research 
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reasons why 
some chose not 
to participate 
 
explained to 
participants 
data. Limited 
data presented 
to support the 
findings. 
Contradictory 
data 
considered 
briefly 
Hsu 2016 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
 
Research design 
and data 
collection 
methods not 
justified 
 
Staggered 
recruitment in a 
tertiary diabetes 
centre. 20 
patients with 
T2D (+18 years 
of age) being 
started on basal 
insulin therapy 
were recruited, 
all trained by a 
diabetes 
educator before 
commencing 
therapy. A 
member of the 
study staff 
assessed patient 
interest in study 
after this 
diabetes 
educator 
meeting. No 
Intervention group 
underwent an exit 
interview. Data 
collection method not 
described or justified.  
Data saturation not 
discussed 
Potential bias in 
formulation of 
research 
questions, data 
collection and 
analysis not 
discussed  
 
Ethical 
approval 
sought, 
informed 
written 
consent 
obtained. 
Confidentiality 
not discussed. 
Lacking details 
on how 
research was 
explained to 
participants 
No details 
about analysis 
methodology 
or process. No 
examination of 
researcher’s 
role, potential 
bias and 
influence 
during analysis 
and in 
presentation of 
data. Limited 
data presented 
to support the 
findings 
Summary of 
findings 
presented, 
and clearly 
discussed in 
relation to 
original 
research 
question. No 
discussion of 
credibility of 
findings 
Considered the 
contribution of 
study to existing 
knowledge. No 
explicit discussion 
of transferability 
to other 
populations. Did 
not make 
suggestions for 
future research 
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details on how 
participants 
recruited and 
selected. No 
discussion about 
reasons why 
some chose not 
to participate 
Harris 
2010, Le 
2008 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researcher did 
not justify choice 
of qualitative 
design. Data 
collection 
methods partially 
justified 
6 participants 
with diabetes in 
phase 1 
recruited by 
email from 
patients 
enrolled in a 
past diabetes 
management 
pilot study at 
University of 
Washington. 
8 participants 
with T2D in 
phase 2 
recruited by 
phone. No 
details on how 
participants 
selected. No 
discussion about 
reasons why 
some chose not 
A modified think-aloud 
method used in phase 
1 for usability testing, 
and post-trial interview 
used in phase 2. Think-
aloud sessions and 
interviews were video 
and/or audio-recorded, 
and audio recordings 
transcribed using a 
commercial 
transcription service. 
All sessions were 
located at the UW 
Laboratory for Usability 
Testing and Evaluation 
(LUTE); which has 
equipment specifically 
designed to test and 
record user interaction 
with computers and 
personal devices. Data 
saturation not 
Potential 
selection bias in 
the recruitment 
strategy was 
discussed. It is 
considered that 
the sample was 
more highly 
motivated to 
manage their 
health and had 
higher levels of 
technical literacy 
than the general 
population of 
patients with 
diabetes 
No details on 
how ethical 
standards 
maintained.  
No explicit 
discussion 
about ethical 
approval. 
Briefly 
reported in 
one table that 
they presented 
consent forms 
and explained 
voluntary 
study 
withdrawal. 
Confidentiality 
not discussed 
No sufficient 
details about 
the analysis 
methodology 
or process.  
The transcripts 
of audio 
recordings 
were open 
coded by three 
researchers 
separately to 
identify salient 
themes using 
Weft QDA, an 
open sourced 
qualitative 
analysis tool. 
The sessions’ 
documents 
analysed in 
sequential 
order with 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question. No 
discussion of 
credibility of 
findings 
except use of 
more than 
one analyst  
Considered the 
contribution of 
study to existing 
knowledge and 
practice. Provided 
several key design 
recommendations
. Acknowledged 
limitations in 
transferability to 
other populations. 
Did not make 
suggestions for 
future research  
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to participate discussed respect to the 
session 
timeline, 
because some 
usability 
changes were 
introduced to 
hypoglycaemia 
messages after 
the 3rd session 
and analysing 
in order made 
it easier to 
differentiate 
the effect of 
those changes. 
Limited data 
presented to 
support 
findings. 
Contradictory 
data not taken 
into account   
Deshazo 
2010 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researcher did 
not justify the 
choice of 
qualitative 
design. Data 
collection 
methods 
explicitly justified 
6 participants 
with diabetes 
recruited for 
focus groups 
from a college 
campus and a 
local diabetes 
clinic. 
Two focus groups and a 
remote usability 
testing. 
Focus groups audio was 
recorded and 
professionally 
transcribed. 
A moderator facilitated 
Potential bias in 
formulation of 
research 
questions, data 
collection and 
analysis not 
discussed  
 
Ethical 
approval 
sought for 
usability 
testing, but no 
details for 
focus groups. 
No explicit 
No details 
about analysis 
methodology 
or process. 
Researchers 
examined their 
own role 
during analysis 
The findings 
were poorly 
presented, 
but were 
discussed in 
relation to 
the original 
research 
Considered the 
contribution of 
study to existing 
knowledge. 
Acknowledged 
limitations in 
transferability to 
other populations. 
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10 participants 
with diabetes 
recruited for 
remote usability 
testing via 
advertisements 
on online 
message boards 
specific to 
diabetes and 
local classified 
advertisements. 
8 websites used, 
and followed up 
with updated 
postings several 
days per week 
for two weeks. 
No details on 
how participants 
selected. No 
discussion about 
reasons why 
some chose not 
to participate 
each focus group with 
help of an assistant. 
Field notes taken and 
used as an additional 
data source. 
All aspects of usability 
testing were 
accomplished online. 
Participants were 
instructed to play the 
games as much or as 
little as they chose for 
one week, and then 
complete an 11-item 
online questionnaire 
with categorical and 
unstructured 
(narrative) responses. 
Open-ended narrative 
responses were 
obtained for favourite 
and least favourite 
aspects of games, as 
well as suggestions for 
improving the games. 
Data saturation not 
discussed 
discussion 
about 
informed 
written 
consent. No 
details on how 
ethical 
standards 
maintained.   
Confidentiality 
not discussed 
process. No 
data presented 
to support the 
findings. 
Contradictory 
data not taken 
into account   
  
 
question. Did 
not discuss 
credibility of 
findings 
 
Did not make 
suggestions for 
future research 
Scheibe 
2015 
Aims clearly 
stated and 
qualitative 
methods 
Researchers 
justified their 
choice of 
qualitative 
32 participants 
with diabetes 
recruited from 
diabetics’ self-
Guided interview 
conducted in open 
setting. 
It adopts a theory-
Briefly considered 
bias in data 
collection, but 
not in 
Ethical 
approval 
sought. No 
explicit 
Researchers 
started analysis 
in accordance 
with the 
Findings 
explicit and 
clearly 
discussed in 
Considered 
strengths and 
contribution of 
study to existing 
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appropriate  design to have an 
open approach 
toward this field 
of research, and 
to focus on 
relevant 
subjective 
aspects of 
participants. 
Data collection 
method explicitly 
justified 
help groups, 
diabetics’ 
associations, 
and specialty 
shops for 
diabetics, 
general medical 
practices, 
diabetologists’ 
practices, and 
pharmacies. No 
details on how 
participants 
selected. No 
discussion about 
reasons why 
some chose not 
to participate 
 
 
based and uniform 
interview guideline 
with open-ended 
questions. Interviews 
transcribed verbatim, 
and individual steps 
were processed with 
qualitative data 
analysis (QDA) 
software MAXQDA.   
Data collection method 
justified.  Data 
saturation not 
discussed 
formulation of 
research 
questions and 
data analysis  
discussion 
about 
informed 
written 
consent. No 
details on how 
ethical 
standards 
maintained.   
Confidentiality 
not discussed 
structure of 
the guideline.  
They used the 
structured 
content 
analysis by 
Mayring, which 
allows for an 
association 
between the 
deductive and 
inductive 
creation of 
categories. The 
analytical focus 
was on 
designing a 
system of 
categories and 
subcategories, 
as well as their 
characteristics, 
which in turn 
served as a 
structural 
dimension.  
Researchers 
did not 
examine their 
own role 
during analysis 
relation to 
original 
research 
question. No 
discussion of 
credibility of 
findings 
knowledge. 
Acknowledged 
few limitations of 
study. No 
discussion of 
transferability to 
other populations. 
Did not make 
suggestions for 
future research 
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process. 
Sufficient data 
presented to 
support the 
findings. 
Contradictory 
data not taken 
into account   
Nielsen 
2013 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researchers 
justified choice 
of qualitative 
design to 
understand 
human 
experiences and 
describe them. 
Data collection 
method explicitly 
justified 
The target group 
for the e-survey 
is social 
networks of 
diabetes 
patients on 
Facebook. 
Systematic 
selection 
strategy used to 
ensure 
representative 
sample of target 
group. There 
were 71 views 
to the survey, 
but the total 
respondents are 
42, of which 24 
are full answers 
and 18 
incomplete 
answers. 
Online survey and 
structured written 
interview.  
The survey was a 
combination of open 
and closed questions, 
constructed in English 
and translated to 
Danish.  The sequence 
of questions was 
controlled, so that 
respondents could not 
jump to the next 
without answering the 
current question. A 
written interview was 
used as it was not 
possible to interview 
the HCP personally. 
The interview guide 
became the interview 
itself. Data saturation 
not discussed 
Briefly considered 
bias in data 
collection and 
analysis, but not 
in formulation of 
research 
questions  
No explicit 
discussion 
about ethical 
approval and 
informed 
written 
consent. No 
details on how 
ethical 
standards 
maintained.   
Confidentiality 
not discussed 
Topics (i.e. 
themes) were 
pre-defined in 
the context of 
the problem. 
MAST 
framework 
model was 
applied to 
present the 
survey result. 
Interview 
result analysed 
using SCOT 
theoretical 
analysis. In 
order to 
confirm or 
discard any 
similarities, 
researcher 
crossed the 
results of the 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question 
Discussion of 
credibility 
and validity 
of findings 
through 
triangulation 
of methods 
Considered the 
contribution of 
study to existing 
knowledge.  
Acknowledged 
limitations in 
transferability to 
other populations.  
Did not make 
suggestions for 
future research 
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One HCP 
interviewed. 
No sufficient 
details about 
selection 
process 
 
 
 
survey and 
interview 
worked 
through the 
MAST model in 
the SCOT 
analysis. 
Sufficient data 
presented to 
support the 
findings. 
Researchers 
examined their 
own role 
during analysis 
process. 
Contradictory 
data not taken 
into account   
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Garnweidn
er-Holme 
2015 
Aims clearly 
stated and 
qualitative 
methods 
appropriate  
Researchers 
justified their 
choice of 
qualitative 
design to give 
useful insights in 
the first phase of 
designing and 
developing the 
app. Data 
collection 
methods not 
justified 
 
Participants 
purposively 
recruited at 
three outpatient 
clinics in the 
area of Oslo, 
Norway. 10 
women with 
GDM recruited 
for the 
interview, and 
11 for usability 
testing. Very 
limited details 
about 
recruitment and 
selection 
process. No 
discussion about 
why some chose 
not to 
participate 
Interview and think-
aloud method were 
conducted. The 
interviews were carried 
out at the outpatient 
clinics by the first 
author, a public health 
nutritionist, and 
occasionally 
accompanied by other 
project members. 
For usability testing, 
users were asked to 
speak aloud while 
performing six tasks on 
the second prototype. 
All interviews were 
audio taped and 
transcribed verbatim. 
Limited details on the 
data collection 
methods and settings. 
Data saturation not 
discussed 
Potential bias in 
formulation of 
research 
questions, data 
collection and 
analysis not 
discussed  
 
Ethical 
approval 
sought, 
informed 
written 
consent 
obtained. 
Confidentiality 
not discussed. 
Lacking details 
on how 
research was 
explained to 
participants 
A quotation 
count report 
was performed 
to analyse the 
interviews. No 
further details 
about analysis 
methodology 
or process. No 
sufficient data 
presented to 
support the 
findings. 
Researchers 
did not 
examine their 
own role 
during analysis 
process 
Findings 
explicit and 
clearly 
discussed in 
relation to 
original 
research 
question. No 
discussion of 
credibility of 
findings 
Considered the 
contribution of 
study to existing 
knowledge and 
practice. 
Acknowledged 
few limitations of 
study. No 
discussion of 
transferability to 
other populations. 
Did not make 
suggestions for 
future research 
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Invitation email 
 
Dear (diabetes specialist nurse),  
 
This letter is an invitation to consider participating in a study I am conducting as part of my 
Doctoral degree at Warwick Medical School at the University of Warwick under the supervision 
of Dr Paul Sutcliffe, Dr Krishnarajah Nirantharakumar, and Dr Sailesh Sankar. I am conducting 
interviews as part of the research study and I hope to interview at least 10 diabetes specialist 
nurses, in order to increase our understanding of how mobile applications (apps) is perceived 
and experienced by those in the field of diabetes care. As a diabetes specialist nurse who’s 
actively involved in the management of patients with diabetes, you are in an ideal position to 
give us valuable first-hand information from your own perspective.  
 
Participation in this research is completely voluntary. It will involve an interview which may 
take up to 45 minutes (but this depends on how much you have to say) and will take place in a 
mutually agreed location. However, the interview could be conducted online using Skype or 
telephone. If you decide to participate, the interview would be arranged at a convenient time. 
During the interview, you will be asked questions to capture your thoughts and perspectives 
on using mobile apps at the point of care. There are no right or wrong answers. What is 
important are your opinions. Your responses to the questions will be kept private and 
confidential. You may decline to answer any of the interview questions. Further, you may 
decide to withdraw from this study at any time. With your permission, the interview will be 
audio recorded, and later transcribed for analysis. The audio recordings will only be reviewed 
by members of the research team.  This study has been reviewed and received ethics 
clearance through the Biomedical and Scientific Research Ethics Committee (BSREC) at the 
University of Warwick.  
 
Your participation will be a valuable addition to the broader research community, and findings 
could lead to developing a mobile app that support you in clinical work. You will receive a £20 
Amazon.co.uk voucher as a thank you for taking part in this study. Additionally, we will cover 
any travel expenses you may incur through participating in this study. The result of the study 
may be published or presented at professional meetings, but your name will not appear in any 
thesis or report resulting from this study, however, with your permission anonymous 
quotations may be used. 
 
The participant information sheet and consent form have been attached to provide you with 
more information about this study and what your involvement would entail if you decide to 
take part. If you are interested in participating, please suggest a day and time that suits you 
and I will do my best to be available. If you have any further questions about the research, 
please feel free to contact me at the email or number listed below.  
 
I very much look forward to speaking with you and thank you in advance for your assistance in 
this research.  
 
Thank you,  
Hala Alhodaib 
Principal Investigator  
Doctoral Student  
University of Warwick 
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Appendix 12. Interview study materials 
Study Title: Perceptions, Perspectives and Experiences of Diabetes Specialist Nurses in Using Mobile 
Applications in a Clinical Setting: A Semi-Structured Interview 
Researcher: Hala Alhodaib 
 
You are invited to take part in an interview to help explore your perceptions, perspectives and 
experiences of using mobile applications (sometimes referred to as “apps”) at the point of care. My 
name is Hala Alhodaib, and I am a PhD student from the University of Warwick working on the use of 
mobile applications in diabetes management. Before you decide, you need to understand why the 
research is being done and what it would involve for you. Please take the time to read the following 
information carefully.  
Please ask the researcher if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
The purpose of the current study is to explore and understand diabetes specialist nurses’ views and 
experiences of using mobile applications in a clinical setting, and to find out the clinical areas of diabetes 
management that might be supported with mobile applications. 
This will help a further research to design and develop a mobile application that will provide tools to 
support diabetes specialist nurses in managing their patients. 
 
You have been invited to take part in an interview because you are a diabetes specialist nurse. 
 
It is entirely up to you to decide. We will describe the study and go through this information sheet, 
which we will give you to keep. If you choose to participate, we will ask you to sign a consent form to 
confirm that you have agreed to take part. You will be free to withdraw at any time, without giving a 
reason and this will not affect you or your circumstances in any way. 
 
Introduction 
What is the study about? 
Why have I been invited? 
Do I have to take part? 
What will happen to me if I take part? 
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If you decide to participate, you can contact the researcher using the contact information at the bottom 
of the leaflet to make an interview date/time at your preference. The interview will be face-to-face at a 
mutually agreed upon time and place. During the interview, you will be asked to complete a consent 
form (after reading this information sheet), and then you will be asked about your view and experience 
of using mobile applications in clinical work. The conversation will be audio recorded but your identity 
will be kept anonymised.  
 
No major benefits or risks are anticipated, but you will have to give up 30–45 minutes of your time. You 
will receive a £20 Amazon.co.uk voucher as a thank you for taking part in this study. Additionally, any 
travel expenses you may incur through participating in this study will be covered. The research result 
will benefit in developing a mobile application to support you in clinical work. 
 
Yes. We will follow strict ethical and legal practice and all information about you will be handled in 
confidence. All information which is collected about you during the course of the research will be kept 
strictly confidential. Our procedures for data handling, processing, storing and destruction comply with 
the United Kingdom (UK) Data Protection Act 1998.  
You will only be asked to provide basic information (age and gender) and your name will not be taken. 
During the study, data will be stored within a locked filing cabinet in the office at the Warwick Medical 
School and on university owned computers which require a user name and password by Hala Alhodaib. 
This data will be accessed only by Hala Alhodaib and the research team from the University of Warwick. 
After the study, the data will be kept for a period of 10 years in line with the University of Warwick’s 
policy on published data. 
It will not be possible to identify you from any published material arising from the study as anonymity 
will be ensured as all participants will be given a participant identification number. 
 
This study is covered by the University of Warwick’s insurance and indemnity cover.   
Any complaint about the way you have been dealt with during the study or any possible harm you might 
have suffered will be addressed.  Please address your complaint to the person below, who is a Senior 
University of Warwick official entirely independent of this study: 
Jo Horsburgh 
Deputy Registrar 
Deputy Registrar’s Office 
University of Warwick 
Benefits and risks 
Will my taking part in the study be kept confidential? 
What if there is a problem and who should I contact if I wish to make a complaint? 
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Coventry, UK, CV4 8UW. 
T:  +00 44 (0) 2476 522 713  E:  J.Horsburgh@warwick.ac.uk  
 
You may decide to stop being a part of the research study at any time without explanation. You have the 
right to ask that any data you have supplied to that point be withdrawn/destroyed. You have the right to 
omit or refuse to answer or respond to any question that is asked of you and there will be no 
consequences of withdrawal or changing your mind part way through. 
You have the right to have your questions about the study answered (unless answering these questions 
would interfere with the study’s outcome). If you have any questions as a result of reading this 
information sheet, you should ask the researcher before the study begins. 
 
All the information collected from the study will be examined and analysed. The study results will help 
to develop a mobile application, and will be submitted to a scientific journal for publication or 
conference presentation. The results will be used within the final PhD thesis. All data collected will be 
anonymous so no one can identify you as an individual. 
 
The researcher who is a PhD student at the University of Warwick is organising the study. There is no 
external funding for the study. 
 
This study has been reviewed and given favourable opinion by the University of Warwick’s Biomedical 
and Scientific Research Ethics Committee (BSREC): REGO-2014-786, 4th June 2014. 
 
I will be glad to answer your questions about this study at any time. You may contact me at: 
h.alhodaib@warwick.ac.uk  
Thank you for taking the time to read this participant information leaflet. 
  
What will happen if I don’t want to carry on with this research? 
Who has reviewed the study? 
What will happen to the results of the research study? 
Who is organising and funding the research? 
What if I want more information about the study? 
   
314 
 
   
315 
Interview Guide 
Research Questions 
• How do DSNs currently use mobile applications?  
• What are the DSNs’ perceptions and views towards the use of mobile applications in a clinical 
setting? 
• What are the challenges facing DSNs in diabetes management that might be supported by the 
use of mobile applications? 
• Are DSNs willing to use mobile applications at the point of care? 
• What are the potential benefits and concerns of using mobile applications in a clinical setting? 
 
Participant Details 
1. Age:  
2. Gender: 
3. Profession:  
4. Experience Level in Years: 
5. Mobile Phone/Smartphone/Tablet Ownership (Yes/No): 
a. If yes, for how long have you owned the Smartphone/Tablet? 
b. What is your Smartphone/Tablet brand? 
(Black- Questions to be ask participant, Red- possible probes, and my ideas that may be explored further) 
Discussion Questions 
1. Can you please tell me about your experience of using mobile applications (these are 
sometimes referred to as “mobile apps” or “apps”)?  
- Have you ever used an app for any purpose? For clinical purpose? Provide details. 
- What were the reasons for using the app that you mentioned? 
- Could you describe in as much detail as possible how satisfied you were with the app used? 
Why? 
 
2. In your opinion, how might mobile apps help diabetes professionals during clinical work?  
- E.g., access guidelines, treatment/diagnosis information, calculators, drug information, access 
to HER, and secure texting. 
 
3. What are the potential benefits of using mobile apps at the point of care?  
- E.g., time spent with patient, workflow, patient’s safety, and quality of care. 
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- Can you give examples of how mobile apps might benefit/facilitate your work? 
 
4. What are the potential limitations of using mobile apps at the point of care? 
- E.g. technological limitations, time limitations. 
- What if you were provided with the smartphone/tablet instead of using your own device? 
- What are the barriers of using mobile apps during a patient visit? 
- Can you tell me about any concerns you may have about the use of mobile apps (in your work)?  
E.g., confidentiality, patient perception. 
- How important is it for you to check the credibility of information source (content source, who 
created it) into a mobile app? 
 
5. Could you describe any challenges/difficulty you are facing in managing your patients where 
mobile apps may support you? 
- Examples may include, managing diabetes in a setting like nursing homes, diabetes with 
comorbidities, decision making. 
- Do you have further examples of this? 
- How do you feel about having a mobile app to support you in those areas?  
- Do you think there is a place for such a mobile app in clinical work?  
 
6. How likely would you be to use a mobile app? Why, why not?  
- What might be the challenges to adopting mobile apps? 
- Would you be more likely/less likely to use the application if this was on a mobile device or on a 
traditional computer?  
- Do you think you may need a training to use such a mobile app? If so, what in? 
- Are there any other features that you think should be considered to increase your willingness to 
use a mobile app?  
 
7. Thank you for all the information you have provided, is there anything else you’d like to add 
before we end? 
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(HbA1c>58 AND maximal 
oral anti-diabetic therapy) 
OR (BP>150/90 AND using 
>3 anti-hypertensive 
drugs) OR (6 ≤ K+<3.5 AND 
unexplained) 
Appendix 13. Decision algorithms and table  
      Algorithm for diabetes and CKD stage 1 – 2 (60 ≤ eGFR ≤ 90)  
Yes No 
Haematuria? 
AND NO 
microvascular 
disease? 
Yes 
Refer to Diabetes 
Renal Clinic 
Check eGFR and ACR annually AND Go 
to Glycaemic Control Algorithm OR 
Hypertension Management Algorithm 
according to their values 
Yes 
Yes 
Yes 
No 
No 
No 
ACR<30 
Haematuria? 
AND Age ≥ 45 
ACR ≥ 100 
No 
Refer to Nephrology 
Refer to Urology 
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Hypertension on 4 or more anti-
hypertensive drugs? OR Sustained 
decrease in eGFR of >25% over 12 
months and a change in CKD stage? OR 
Sustained decrease of eGFR >15 ml/min 
over 12 months? OR Renal anaemia (Hb 
<110 g/L, following exclusion of 
bleeding, deficiency states, or primary 
haematological problem)? 
ACR<100 
Haematuria 
AND No 
retinopathy or 
neuropathy? 
(HbA1c > 58 AND maximal oral 
anti-diabetic therapy) OR (BP > 
150/90 AND using > 3 anti-
hypertensive drugs) OR (6 ≤ K+<3.5 
AND unexplained) 
eGFR ≥ 30 
ACR ≥ 30 
eGFR<45 
Visible Haematuria? OR 
Symptoms of urinary tract 
obstruction? OR Accelerated 
progression of CKD? 
Algorithm for diabetes and CKD stage 3 – 5 (eGFR<60) 
 
  
Renal 
ultrasound 
Repeat eGFR at 3/12; 
then check eGFR and 
ACR yearly 
Check FBC yearly; iron deficiency 
anaemia is: ▪ diagnosed in stage 5 CKD 
with a ferritin <100 mcg/l ▪ considered in 
stage 3/4 CKD with a ferritin <100 mcg/l 
Refer to Diabetes 
Renal Clinic 
No Yes 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Refer to or discuss 
with Nephrology 
Yes 
Go to Glycaemic Control Algorithm OR 
Hypertension Management Algorithm 
according to their values 
 
Yes 
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Algorithm for glycaemic control 
Initial therapy: 
  
HbA1c > target HbA1c on 
lifestyle intervention 
Metformin 
contraindicated 
or not tolerated? 
? 
eGFR ≥ 45 
Standard-release Metformin with caution for 
those at risk of a sudden deterioration in 
kidney function and those at risk of eGFR 
falling below 45. Gradually increase the dose 
of standard-release metformin over several 
weeks to minimise the risk of gastrointestinal 
side effects  
Standard-
release 
Metformin 
tolerated? 
Go to initial therapy – 
Metformin contraindicated or 
not tolerated 
 
Stop Metformin eGFR ≥ 30 
HbA1c ≤ 
target HbA1c 
 
Go to first intensification 
 
Review the dose of 
Metformin 
Consider a trial of 
modified-release 
metformin 
Modified-
release 
Metformin 
tolerated? 
Yes 
Yes 
Yes 
Yes Yes 
Yes 
No No 
No 
No 
No 
No 
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Initial therapy – Metformin contraindicated or not tolerated: 
  
HbA1c > target HbA1c on 
lifestyle intervention 
Discuss the benefits and risks of the 
options available, and base the choice of 
drug treatment on: effectiveness in terms 
of metabolic response, safety and 
tolerability, individual clinical 
circumstances, individual preferences and 
needs, the licensed indications or 
combinations available, and cost 
Initial drug treatment with: 
• A DPP-4i, or  
• Pioglitazone1, or  
• Repaglinide, or  
• An Sulfonylurea 
 
Drug 
treatment 
tolerated? 
HbA1c ≤ 
target HbA1c 
 
Go to first intensification 
 
Yes 
1 Do not offer or continue Pioglitazone if the patient has any of the following:  
• heart failure or history of heart failure  
• hepatic impairment  
• diabetic ketoacidosis 
• current, or a history of bladder cancer 
• uninvestigated macroscopic haematuria. 
 
Yes 
No 
No 
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First intensification:   
HbA1c > target HbA1c on 
initial therapy 
Metformin 
contraindicated 
or not tolerated? 
Dual therapy with:   
• Metformin and a DPP-4i, or 
• Metformin and Pioglitazone, or   
• Metformin and an Sulfonylurea, or 
• Metformin and an SGLT-2i1; only if eGFR 
≥ 60 
 
 
 
Dual therapy with:2 
• DPP-4i and Pioglitazone, or  
• DPP-4i and an Sulfonylurea, or 
• Pioglitazone and an Sulfonylurea 
Drug 
treatments 
tolerated? 
HbA1c ≤ 
target HbA1c 
 
Go to second 
intensification 
 
1 Interrupt treatment with the SGLT-2i in patients who are hospitalised for major surgery or acute serious illnesses, and 
treatment may be restarted once the patient’s condition has stabilised 
2 No licensed combination containing Repaglinide that can be offered at first intensification 
No 
No 
No Yes 
Yes 
Yes 
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Second intensification:  
  
Insulin detemir 
 
No 
No 
No 
No 
No 
No 
1 An SGLT-2i in combination with insulin with or without other antidiabetic drugs is an option 
2 Interrupt treatment with the SGLT-2i in patients who are hospitalised for major surgery or acute serious illnesses, and treatment may be 
restarted once the patient’s condition has stabilised 
3 Adjust accordingly for people from black, Asian and other minority ethnic groups 
4 Liraglutide and Dulaglutide are licensed to be used only if eGFR ≥ 30, and all GLP-1 mimetic should be stopped if eGFR<30 
 
Yes 
Yes 
Yes 
Yes 
Yes 
HbA1c > target HbA1c on 
first intensification 
Metformin 
contraindicated 
or not tolerated? 
Insulin-based 
treatment1 
 
Triple therapy with:  
• Metformin, an Sulfonylurea and a DPP-4i, or 
• Metformin, Pioglitazone and an Sulfonylurea, or  
• Metformin, Pioglitazone and an SGLT-2i2 (not 
Dapagliflozin); only if eGFR ≥ 60, or 
• Metformin, an Sulfonylurea and an SGLT-2i2 (not 
Dapagliflozin); only if eGFR ≥ 60 
Metformin + start 
Insulin-based 
treatment 
 
 
 
Triple therapy not 
effective, not 
tolerated, or 
contraindicated? 
(BMI ≥ 353 AND specific 
psychological or medical problems 
associated with obesity) OR (BMI<35 
AND (Insulin therapy have significant 
occupational implications OR weight 
loss considered beneficial)) 
 
 
Is NPH 
appropriate 
for patient? 
Combination therapy with Metformin, a 
Sulfonylurea and a Glucagon-Like Peptide-1 
(GLP-1) mimetic4 
 
Reduction of at least 11 
mmol/mol (1.0%) in HbA1c 
AND weight loss of at least 
3% of initial body weight in 
6 months 
 
HbA1c ≤ 
target 
HbA1c 
 
NPH Insulin 
 
Insulin glargine 
 
Biphasic or other 
pre-mixed Insulin  
 
Yes 
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Algorithm for management of hypertension 
Step 1 treatment 
                                                                                     
Ethnic 
group=Black 
African 
Caribbean 
 
 
Pregnant or of 
child-bearing 
potential 
 
 
A once-daily, generic ACE inhibitor, but for a 
person with continuing intolerance to an ACE 
inhibitor (other than renal deterioration or 
hyperkalaemia), substitute an ARB for the 
ACE inhibitor 
 
BP > target BP OR ACR ≥ 3 OR 
eGFR<60 OR CVD indications 
Yes 
Pre-treatment 
serum potassium 
concentration > 5 
 
 
 
Investigate and 
treat other factors 
known to promote 
hyperkalaemia 
Stop the ACE or ARB, or reduce the 
dose to a previously tolerated lower 
dose and go to step 2 treatment if 
required 
 
Serum 
potassium 
concentration 
> 5 
 
 
 
Measure serum potassium 
concentrations and estimate the 
GFR between 1 and 2 weeks1 
 
Serum 
potassium 
concentration 
≥ 6 
 
 
 
Stop ACE or ARB and other drugs 
known to promote hyperkalaemia 
, and go to step 2 treatment 
Do not offer ACE or 
ARB, and go to step 
2 treatment 
1 If concurrent prescription of drugs known to promote 
hyperkalaemia, more frequent monitoring of serum 
potassium concentration is needed 
 
eGFR > baseline GFR – (25 * 
baseline GFR)/100 OR Serum 
Creatinine<baseline Serum 
Creatinine + (30 * baseline 
Serum Creatinine)/100 
 
 
Treat the 
other factor 
and retest 
 
ACE inhibitor plus either 
a diuretic or a generic 
CCB 
 
CCB 
Investigate other causes of 
deterioration in renal 
function such as volume 
depletion or concurrent 
medication e.g. NSAIDs 
 
Other 
causes 
found 
 
Do not modify the dose, and 
repeat the test in 1 - 2 weeks 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
Yes Yes 
Yes 
Yes 
Yes 
No 
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Step 2 & 3 & 4 treatment 
BP > target BP on 
step 1 treatment 
Add a CCB 
 
BP ≤ target 
BP 
 
 
 
Add a diuretic (usually a 
thiazide or thiazide-
related diuretic 
CBB not tolerated OR not 
suitable because of oedema 
OR there is evidence of heart 
failure OR a high risk of heart 
failure 
 
 
Add the other drug (that is, 
the CCB or diuretic) 
Add an alpha-blocker, a beta-blocker or 
a potassium-sparing diuretic (the last 
with caution if the individual is already 
taking an ACE inhibitor or an ARB) 
Seek expert advice 
Monitor BP every 4-6 
months 
BP ≤ target 
BP 
 
 
 
BP ≤ target 
BP 
 
 
 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
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Table 1. Dose adjustment recommendations in CKD (reproduced from Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease 
stage 3b or higher) 
 
Drug 
CKD-1 
(GFR≥90) 
CKD-2 
(60≤GFR≤89) 
CKD- 3a 
(45≤GFR≤59) 
CKD- 3b 
(30≤GFR≤44) 
CKD-4 
(15≤GFR≤29) 
CKD-5ND 
(GFR<15) 
CKD-5D 
(GFR<15) 
Biguanides Metformin No adjustments 1.5g-850 mg/day; do not initiate if 
eGFR <45 
To be avoided 
Sulfonylureas 
Glicazide Start at low doses and dose titration every 1-4 weeks (High risk of hypoglycemia) 
Glimepiride Reduce dosage to 1 mg/day (High risk of hypoglycemia) 
Meglitinides 
Repaglinide No adjustments Limited experience available 
Nateglinide No adjustments Start at 60 
mg/day 
To be avoided 
TZD’s Pioglitazone No adjustments 
DPP-4 inhibitors 
Sitagliptin No adjustments Reduce to 50 mg/once daily if eGFR 30-
50 
Reduce to 25 mg/once daily 
Vildagliptin No adjustments Reduce to 50 mg/once daily if eGFR <50 
Saxagliptin No adjustments Reduce to 2.5 mg/once daily 
Linagliptin No adjustments 
Alogliptin No adjustments Reduce to 12.5 mg/once daily  Reduce to 6.5 mg/once daily; and use with caution 
Incretin mimitics 
(GLP-1) 
Exenatide No adjustments Careful use if eGFR 30-50  To be avoided  
Liraglutide 
 
No adjustments To be avoided 
Lixisenatide 
 
No adjustments Careful use if eGFR 30-50 To be avoided – no information available 
Dulaglutide No adjustments To be avoided 
SGLT-2 inhibitors 
Dapagliflozin No adjustments To be avoided - ineffective 
Canagliflozin No adjustments Reduce to 100 
mg/once daily 
To be avoided 
Empagliflozin No adjustments Reduce to 10 
mg/once daily 
To be avoided 
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Appendix 14. App evaluation study materials 
Example Case Scenario: 
Mr. Patel 
Is an Indian male, 57 years of age, with Type 2 Diabetes first diagnosed 4 years ago, 
which had been uncontrolled with Metformin 1 g BD plus Gliclazide 80 mg BD. Basal 
NPH Insulin was initiated replacing Gliclazde and titrated over the last 3 months (the 
patient continued on Metformin). This resulted in a few mild hypoglycemia episodes 
not requiring assistance. As Insulin titration progressed, hypoglycemic episodes were 
more frequent but not severe. He has Stage 3 Chronic Kidney Disease (CKD) i.e. 
“moderate” renal impairment. He presents now for routine follow-up and is noted to 
have gained 3 kg weight over the past month. There is no retinopathy and no clinical 
evidence of congestive heart failure or peripheral vascular disease. Laboratory 
evaluation reveals trace protein on urinalysis, with albumin-to-creatinine ratio 
indicating a moderately increased albuminuria. He is also treated with an Angiotensin-
Converting Enzyme (ACE) Inhibitor for the past 2 years.  
Task 1: How will you manage his glycaemic control? 
Task 2: How will you manage his blood pressure? 
Measure Result Measure Result 
HbA1c 8.6% or 70 mmol/mol  Serum potassium  5 mmol/litre 
Blood pressure 
(measured twice) 
160/100 mmHg Weight 110 kg 
eGFR 47 mL/min/1.73 m2 Height 177 cm 
ACR 250 mg/mmol  BMI 35.1 kg/m2 
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Case Scenario 1: 
Mrs. Smith 
A white female, 65 years of age, who has had Type 2 Diabetes for approximately 8 
years and Hypertension for 5 years. She also has Stage 2 Chronic Kidney Disease (CKD). 
She presents after a recent ophthalmic examination that showed diabetic retinopathy 
with poor glycemic control despite receiving Metformin (2000 mg/d) plus a SGLT-2 
Inhibitor (Dapagliflozin 10 mg OD) for the last 12 months. On review of systems, she 
indicates no weight change.  She has mild Dyslipidemia controlled with a Statin and 
Hypertension treated with an Angiotensin II Receptor Blocker (ARB).  
How will you approach managing her glycaemic control? 
Measure Result Measure Result 
HbA1c 9% or 75mmol/mol ACR 110 mg/mmol  
Blood pressure 120/70 mmHg Serum potassium  3 mmol/litre 
eGFR 64 mL/min/1.73 m2 BMI 29 kg/m2 
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Case Scenario 2: 
Mr. John 
A white male, 46 years of age, who is registered as a new patient at the GP practice. 
His medical history included Type 2 Diabetes and Hypertension for the past 11 years. 
Previously he had been told that he had protein in his urine. He now presents at the 
clinic with peripheral neuropathy. The patient had evidence of both microvascular and 
macrovascular disease. He also had microscopic haematuria. His GFR had deteriorated 
by 10ml/min (26%) over the past year from G3b to G4. Renal ultrasound shows 
normal-size kidneys. He was referred for smoking cessation counselling and given 
advice on weight reduction. His current medications include Metformin 1 g BD, 
Gliclazide 160 mg BD and Sitagliptin 100 mg OD, a Thiazide plus an Angiotensin-
Converting Enzyme (ACE) Inhibitor. His blood lipids are well controlled on Atorvastatin 
10 mg daily.  
Task: How will you approach his glycaemic control management? 
Measure Result Measure Result 
HbA1c 76 mmol/mol (9.1%) ACR 200 mg/mmol  
Blood pressure 140/80 mmHg Serum potassium  3.5 mmol/litre 
eGFR 28 mL/min/1.73 m2 BMI 28 kg/m2 
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Feedback Sheet 
 
1. Do you have any prior experience of using a mobile-based platform as a 
decision-support tool?  
 
 
2. Your overall satisfaction with the app. 
 
 
3. Positive and negative things about the app. 
 
 
 
4. Usability issues if any was encountered during the session. 
 
 
 
5. Features to change/add. 
 
 
6. Your willingness to use the app in the future and why. 
 
• When appropriate to use the app? 
 
• When and why not appropriate to use the app?  
 
• Wishes/ suggestions for improvements. 
 
7. Any other thoughts about the app.  
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Study Title:  Design, Development and Evaluation of a Mobile-based Clinical Decision 
Support Application for the Management of Patients with Diabetes and Kidney 
Disease to Facilitate Evidence-based Care Delivery 
   Investigator:  Hala Alhodaib 
 
You are invited to take part in a session to test a study-specific mobile application (hereafter referred to 
as “app”) that assist in decision-making process. My name is Hala Alhodaib, and I am a PhD student from 
the University of Warwick working on the use of mobile apps in diabetes management. Before you 
decide, you need to understand why the research is being done and what it would involve for you. 
Please take the time to read the following information carefully.  
Please ask the researcher if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
The purpose of the current study is to test a mobile app as an intervention for supporting clinicians in 
decision-making in patients with diabetes and chronic kidney disease, and to explore how the app was 
experienced and any suggestions for improvements. 
This will help to further refine the developed app, and to plan and develop a more complex version of 
the app that includes all the common comorbidities of diabetes in the future. 
 
You have been invited to take part in this session because of your professional role. 
 
It is entirely up to you to decide. We will describe the study and go through this information sheet, 
which we will give you to keep. If you choose to participate, we will ask you to sign a consent form to 
confirm that you have agreed to take part. You will be free to withdraw at any time, without giving a 
reason and this will not affect you or your circumstances in any way. 
 
Introduction 
What is the study about? 
Why have I been invited? 
Do I have to take part? 
What will happen to me if I take part? 
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If you decide to participate, you can contact the researcher using the contact information at the bottom 
of the leaflet. The session will be held at a mutually agreed upon time and place. During the session, you 
will be asked to complete a consent form (after reading this information sheet). After that, you will be 
asked to deal with a number of simulation-based case scenarios, and then you will be given the option 
to join a group discussion around the overall satisfaction with the app to help identify positive and 
negative aspects of the app, features to change/add. The session will be audio recorded but your 
identity will be kept anonymised.  
 
No major benefits or risks are anticipated, but you will have to give up 60 – 90 minutes of your time. You 
will receive a £20 Amazon.co.uk voucher as a thank you for taking part in this study. Additionally, any 
travel expenses you may incur through participating in this study will be covered. The research result 
will benefit in evaluating the mobile app to support you in clinical work. 
Yes. We will follow strict ethical and legal practice and all information about you will be handled in 
confidence. All information which is collected about you during the course of the research will be kept 
strictly confidential. Our procedures for data handling, processing, storing and destruction comply with 
the United Kingdom (UK) Data Protection Act 1998.  
You will only be asked to provide basic information (age and gender) and your name will not be taken. 
During the study, data will be stored within a locked filing cabinet in the office at the Warwick Medical 
School and on University owned computers which require a user name and password by Hala Alhodaib. 
This data will be accessed only by Hala Alhodaib and the research team from the University of Warwick 
and the University of Birmingham. After the study, the data will be kept for a period of 10 years in line 
with the University of Warwick’s policy on published data. 
It will not be possible to identify you from any published material arising from the study as anonymity 
will be ensured as all participants will be given a participant identification number. 
 
This study is covered by the University of Warwick’s insurance and indemnity cover. If you have an issue, 
please contact the Chief Investigator of the study:  
Hala Alhodaib 
E: h.alhodaib@warwick.ac.uk 
 
Any complaint about the way you have been dealt with during the study or any possible harm you might 
have suffered will be addressed.  Please address your complaint to the person below, who is a Senior 
University of Warwick official entirely independent of this study: 
What are the possible benefits and risks of taking part in this study? 
Will my taking part in the study be kept confidential? 
What if there is a problem? 
Who should I contact if I wish to make a complaint? 
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Director of Delivery Assurance 
Registrar's Office 
University House 
University of Warwick 
Coventry, CV4 8UW 
T:  024 7657 4774 E: Complaints@Warwick.ac.uk  
 
You may decide to stop being a part of the research study at any time without explanation. You have the 
right to ask that any data you have supplied to that point be withdrawn/destroyed. You have the right to 
omit or refuse to answer or respond to any question that is asked of you and there will be no 
consequences of withdrawal or changing your mind part way through. 
You have the right to have your questions about the study answered (unless answering these questions 
would interfere with the study’s outcome). If you have any questions as a result of reading this 
information sheet, you should ask the researcher before the study begins. 
 
All the information collected from the study will be examined and analysed. The study results will help 
to develop a mobile app, and will be submitted to a scientific journal for publication or conference 
presentation. The results will be used within the final PhD thesis. All data collected will be anonymous 
so no one can identify you as an individual. 
 
The principal investigator who is a PhD student at the University of Warwick is organising the study, and 
she has received a scholarship, which covers the studentship and the research consumables. 
 
This study has been reviewed and given favourable opinion by the University of Warwick’s Biomedical 
and Scientific Research Ethics Committee (BSREC): REGO-2014-786 AMO1, 22nd March 2016. 
 
I will be glad to answer your questions about this study at any time. You may contact me at: 
E: h.alhodaib@warwick.ac.uk 
Or you may contact my academic supervisor, Dr Paul Sutcliffe at: 
T: 02476574505 E: P.A.Sutcliffe@warwick.ac.uk   
Thank you for taking the time to read this participant information leaflet.  
What will happen if I don’t want to carry on being part of the study? 
What will happen to the results of the research study? 
Who is organising and funding the research? 
Who has reviewed the study? 
What if I want more information about the study? 
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Answer Sheet 
To access the mobile app: https://diabetes.medicgenie.com 
Case Decision Time taken 
Case 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 2 
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Model Answer 
Case Answer Score 
Case 1 
Add-on Sulfonylurea or Pioglitazone or DPP-4i, or switch the 
patient to another dual therapy combination 
Switch Dapagliflozin to another SGLT-2i (according to NICE 
guidelines, only Canaglifozin and Empagliflozin are 
recommended as options in triple therapy regimens) 
Start Insulin 
No change 
 
+ 3 
 
 
+ 2 
 
 
 
 
- 1 
 
- 1 
 
Case 2 
 
Because the patient is currently CKD stage G4A3, Metformin 
should be stopped 
Reduce Sitagliptin dose (Pioglitazone should not be offered 
because the patient had microscopic haematuria) 
Start Insulin  
Refer the patient to a Nephrologist in view of the rapid 
decline in renal function, and to an Urologist to investigate 
the haematuria, given his age and smoking history 
 
 
+ 3 
 
 
 
+ 1 
 
 
+ 2 
 
 
+ 2 
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Appendix 15. Contributions to science and outputs from this thesis 
➢ Diapedia: The living textbook of diabetes 
Alhodaib, Hala. Information technology in DM [internet]. 2014 Aug 13; Diapedia 
81040851628 rev. no. 7. Available from: https://doi.org/10.14496/dia.81040851628.7 
Presentations 
▪ Presentation at the Cochrane UK & Ireland Annual Symposium 2014, University 
of Manchester titled: Mobile phone messaging for facilitating self-management 
for long-term illnesses. Awarded the 3rd prize in the student competition, and 
the entry is published on the Students 4 Best Evidence website. Available from: 
http://www.students4bestevidence.net/cochrane-evidence-useful-usable-used-
mobile-phone-messaging-for-facilitating-self-management-of-long-term-
illnesses/ 
▪ Poster session at WMG Doctoral Research and Innovation Conference 2014, 
University of Warwick titled: Telehealth for diabetes mellitus: Smartphone 
applications as a management tool. 
▪ Poster session at the 8th Saudi Student Conference 2015, Queen Elizabeth II 
Centre, London titled: Exploring the Potential of Using Mobile Applications in 
Diabetes Management: A systematic review. Available from: Proceedings of the 
Eighth Saudi Students Conference in the UK 
Manuscripts in preparation 
The following manuscripts are in preparation and will be submitted for publication 
within the next couple of months: 
1. Alhodaib, H. I., Gao, X., Nirantharakumar, K., Chen, Y-F., Fang, Q., Sutcliffe, P. 
Mobile Applications for the Management of Diabetes Mellitus: A Systematic 
Review and Meta-analysis, (in preparation). 
2. Alhodaib, H. I., Nirantharakumar, K., Sutcliffe, P., Lindenmeyer, A. Perceptions, 
Perspectives and Experiences of Diabetes Specialist Nurses in Using Mobile 
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Applications in a Clinical Setting: An Interview Study, (in preparation). 
3. Alhodaib, H. I., Sutcliffe, P., Hanif, W., Sankar, S., Nirantharakumar, K. Design, 
Development and Evaluation of a Mobile-based Clinical Decision Support 
Application for the Management of Patients with Diabetes and Kidney Disease 
to Facilitate Evidence-based Care Delivery, (in preparation). 
 
 
 
